{"534a301ea6a76eb47c8d42e30981088ac5603418": [["IntroductionCoxsackievirus B3 (CVB3) is a positive-sense RNA virus, belonging to the Picornaviridae family.", [["IntroductionCoxsackievirus B3", "ORGANISM", 0, 29], ["CVB3", "ORGANISM", 31, 35], ["Picornaviridae family", "PROTEIN", 85, 106], ["IntroductionCoxsackievirus B3", "SPECIES", 0, 29], ["CVB3", "SPECIES", 31, 35], ["IntroductionCoxsackievirus", "TEST", 0, 26], ["a positive-sense RNA virus", "PROBLEM", 40, 66]]], ["CVB3 commonly infects children, resulting in a self-limiting illness that can lead to the development of muscle, lung, and heart maladies.", [["muscle", "ANATOMY", 105, 111], ["lung", "ANATOMY", 113, 117], ["heart", "ANATOMY", 123, 128], ["illness", "DISEASE", 61, 68], ["muscle, lung, and heart maladies", "DISEASE", 105, 137], ["CVB3", "ORGANISM", 0, 4], ["children", "ORGANISM", 22, 30], ["muscle", "ORGAN", 105, 111], ["lung", "ORGAN", 113, 117], ["heart", "ORGAN", 123, 128], ["CVB3", "SPECIES", 0, 4], ["children", "SPECIES", 22, 30], ["CVB3", "SPECIES", 0, 4], ["a self-limiting illness", "PROBLEM", 45, 68], ["muscle, lung, and heart maladies", "PROBLEM", 105, 137], ["muscle", "ANATOMY", 105, 111], ["lung", "ANATOMY", 113, 117], ["heart", "ANATOMY", 123, 128], ["maladies", "OBSERVATION", 129, 137]]], ["Importantly, CVB3 infection can lead to myocarditis and endocarditis, and the virus is able to persist in cardiac tissue [1, 2] .", [["cardiac tissue", "ANATOMY", 106, 120], ["CVB3 infection", "DISEASE", 13, 27], ["myocarditis", "DISEASE", 40, 51], ["endocarditis", "DISEASE", 56, 68], ["CVB3", "ORGANISM", 13, 17], ["cardiac tissue", "TISSUE", 106, 120], ["CVB3", "SPECIES", 13, 17], ["CVB3 infection", "PROBLEM", 13, 27], ["myocarditis", "PROBLEM", 40, 51], ["endocarditis", "PROBLEM", 56, 68], ["the virus", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 18, 27], ["myocarditis", "OBSERVATION", 40, 51], ["endocarditis", "OBSERVATION", 56, 68], ["cardiac tissue", "ANATOMY", 106, 120]]], ["Currently, no antivirals are available for treating or preventing CVB3 infection; thus, the identification of novel antiviral targets is crucial to controlling infection.", [["CVB3 infection", "DISEASE", 66, 80], ["infection", "DISEASE", 160, 169], ["CVB3", "ORGANISM", 66, 70], ["CVB3", "SPECIES", 66, 70], ["antivirals", "TREATMENT", 14, 24], ["CVB3 infection", "PROBLEM", 66, 80], ["novel antiviral targets", "TREATMENT", 110, 133], ["controlling infection", "PROBLEM", 148, 169], ["infection", "OBSERVATION", 71, 80], ["infection", "OBSERVATION", 160, 169]]], ["Viral proteases, including enteroviral proteases, play crucial roles in the replication of RNA viruses [3] .", [["Viral proteases", "PROTEIN", 0, 15], ["enteroviral proteases", "PROTEIN", 27, 48], ["Viral proteases", "PROBLEM", 0, 15], ["enteroviral proteases", "TREATMENT", 27, 48], ["RNA viruses", "PROBLEM", 91, 102], ["RNA viruses", "OBSERVATION", 91, 102]]], ["Following virus entry, picornavirus RNA is directly translated via host ribosomes into a polyprotein, containing both structural and nonstructural proteins.", [["ribosomes", "ANATOMY", 72, 81], ["picornavirus", "ORGANISM", 23, 35], ["picornavirus RNA", "RNA", 23, 39], ["structural and nonstructural proteins", "PROTEIN", 118, 155], ["virus entry", "PROBLEM", 10, 21], ["picornavirus RNA", "PROBLEM", 23, 39], ["a polyprotein", "TREATMENT", 87, 100], ["picornavirus RNA", "OBSERVATION", 23, 39], ["nonstructural proteins", "OBSERVATION", 133, 155]]], ["This large protein is subsequently cleaved to generate functionally distinct viral proteins.", [["viral proteins", "PROTEIN", 77, 91], ["This large protein", "PROBLEM", 0, 18], ["functionally distinct viral proteins", "PROBLEM", 55, 91], ["large", "OBSERVATION_MODIFIER", 5, 10], ["protein", "OBSERVATION", 11, 18], ["distinct", "OBSERVATION_MODIFIER", 68, 76], ["viral proteins", "OBSERVATION", 77, 91]]], ["Importantly, the ability of viral proteases to cleave the viral polyprotein is essential for productive infection, as limiting viral protease activity significantly hinders virus infection.", [["infection", "DISEASE", 104, 113], ["infection", "DISEASE", 179, 188], ["viral proteases", "PROTEIN", 28, 43], ["viral protease", "PROTEIN", 127, 141], ["viral proteases", "TREATMENT", 28, 43], ["the viral polyprotein", "PROBLEM", 54, 75], ["productive infection", "PROBLEM", 93, 113], ["viral protease activity significantly hinders virus infection", "PROBLEM", 127, 188], ["viral polyprotein", "OBSERVATION", 58, 75], ["essential for", "UNCERTAINTY", 79, 92], ["productive", "OBSERVATION_MODIFIER", 93, 103], ["infection", "OBSERVATION", 104, 113]]], ["Modulation of protease activity, however, can also alter antiviral susceptibility [4] .", [["protease", "PROTEIN", 14, 22], ["Modulation of protease activity", "PROBLEM", 0, 31], ["protease activity", "OBSERVATION", 14, 31]]], ["Additionally, viral proteins cleave several host proteins, including translation factors, immune effectors, and signaling molecules [5] [6] [7] [8] [9] [10] , to establish a proviral environment.Infection and Enumeration of Viral TitersCVB3 (Nancy strain) was derived from the first passage of virus in Vero cells (NR-10385), which were obtained through BEI Resources, National Institutes of Allergy and Infectious Diseases, National Institutes of Health (NR-10385).", [["Vero cells", "ANATOMY", 303, 313], ["NR-10385", "CHEMICAL", 315, 323], ["Allergy and Infectious Diseases", "DISEASE", 392, 423], ["NR-10385", "CHEMICAL", 456, 464], ["[5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 132, 156], ["Viral TitersCVB3", "ORGANISM", 224, 240], ["Nancy strain", "ORGANISM", 242, 254], ["Vero cells", "CELL", 303, 313], ["NR-10385", "CELL", 315, 323], ["viral proteins", "PROTEIN", 14, 28], ["host proteins", "PROTEIN", 44, 57], ["translation factors", "PROTEIN", 69, 88], ["immune effectors", "PROTEIN", 90, 106], ["signaling molecules", "PROTEIN", 112, 131], ["Vero cells", "CELL_LINE", 303, 313], ["Viral TitersCVB3 (Nancy strain", "SPECIES", 224, 254], ["viral proteins cleave several host proteins", "PROBLEM", 14, 57], ["translation factors", "PROBLEM", 69, 88], ["signaling molecules", "PROBLEM", 112, 131], ["Infection", "PROBLEM", 195, 204], ["Viral TitersCVB3", "PROBLEM", 224, 240], ["virus in Vero cells", "PROBLEM", 294, 313], ["NR", "TEST", 315, 317], ["host proteins", "OBSERVATION_MODIFIER", 44, 57], ["Viral", "OBSERVATION_MODIFIER", 224, 229], ["Infectious", "OBSERVATION_MODIFIER", 404, 414]]], ["For all infections, DFMO and diethylnorsmperidine (DENSpm) were maintained throughout infection as designated.", [["infections", "DISEASE", 8, 18], ["DFMO", "CHEMICAL", 20, 24], ["diethylnorsmperidine", "CHEMICAL", 29, 49], ["DENSpm", "CHEMICAL", 51, 57], ["infection", "DISEASE", 86, 95], ["DFMO", "CHEMICAL", 20, 24], ["diethylnorsmperidine", "CHEMICAL", 29, 49], ["DENSpm", "CHEMICAL", 51, 57], ["DFMO", "SIMPLE_CHEMICAL", 20, 24], ["diethylnorsmperidine", "SIMPLE_CHEMICAL", 29, 49], ["DENSpm", "SIMPLE_CHEMICAL", 51, 57], ["all infections", "PROBLEM", 4, 18], ["DFMO", "TREATMENT", 20, 24], ["diethylnorsmperidine (DENSpm)", "TREATMENT", 29, 58], ["infections", "OBSERVATION", 8, 18], ["infection", "OBSERVATION", 86, 95]]], ["Viral stocks were maintained at \u221280 \u2022 C. For infection, the virus was diluted in serum-free DMEM for a multiplicity of infection (MOI) of 0.1 on Vero cells, unless otherwise indicated.", [["serum", "ANATOMY", 81, 86], ["Vero cells", "ANATOMY", 145, 155], ["infection", "DISEASE", 45, 54], ["infection", "DISEASE", 119, 128], ["Viral", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["Vero cells", "CELL", 145, 155], ["Vero cells", "CELL_LINE", 145, 155], ["Viral stocks", "TEST", 0, 12], ["infection", "PROBLEM", 45, 54], ["the virus", "PROBLEM", 56, 65], ["serum", "TEST", 81, 86], ["infection", "PROBLEM", 119, 128], ["Vero cells", "TREATMENT", 145, 155], ["infection", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 119, 128]]], ["The viral inoculum was overlain on cells for 10 to 30 min, and the cells were washed with PBS before replenishment of media.", [["cells", "ANATOMY", 35, 40], ["cells", "ANATOMY", 67, 72], ["cells", "CELL", 35, 40], ["cells", "CELL", 67, 72], ["The viral inoculum", "PROBLEM", 0, 18], ["PBS", "TREATMENT", 90, 93], ["replenishment of media", "TREATMENT", 101, 123], ["viral inoculum", "OBSERVATION", 4, 18]]], ["Supernatants were collected from CVB3 24 hpi and 48 hpi.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["CVB3", "ORGANISM", 33, 37], ["CVB3", "SPECIES", 33, 37]]], ["Dilutions of cell supernatant were prepared in serum-free DMEM and used to inoculate confluent monolayer of Vero cells for 10 to 15 min at 37 \u2022 C. Cells were overlaid with 0.8% agarose in DMEM containing 2% NBCS.", [["cell supernatant", "ANATOMY", 13, 29], ["serum", "ANATOMY", 47, 52], ["monolayer", "ANATOMY", 95, 104], ["Vero cells", "ANATOMY", 108, 118], ["Cells", "ANATOMY", 147, 152], ["NBCS", "CHEMICAL", 207, 211], ["cell", "CELL", 13, 17], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["monolayer", "CELL", 95, 104], ["Vero cells", "CELL", 108, 118], ["Cells", "CELL", 147, 152], ["agarose", "SIMPLE_CHEMICAL", 177, 184], ["NBCS", "SIMPLE_CHEMICAL", 207, 211], ["Vero cells", "CELL_LINE", 108, 118], ["cell supernatant", "PROBLEM", 13, 29], ["serum-free DMEM", "TREATMENT", 47, 62], ["confluent monolayer of Vero cells", "TREATMENT", 85, 118], ["C. Cells", "TEST", 144, 152], ["cell supernatant", "OBSERVATION", 13, 29], ["Vero cells", "OBSERVATION", 108, 118]]], ["CVB3 samples incubated for 2 days at 37 \u2022 C. Following appropriate incubation, cells were fixed with 4% formalin and revealed with crystal violet solution (10% crystal violet; Sigma-Aldrich, St. Louis, MO, USA).", [["samples", "ANATOMY", 5, 12], ["cells", "ANATOMY", 79, 84], ["formalin", "CHEMICAL", 104, 112], ["formalin", "CHEMICAL", 104, 112], ["CVB3", "ORGANISM", 0, 4], ["cells", "CELL", 79, 84], ["formalin", "SIMPLE_CHEMICAL", 104, 112], ["St. Louis", "ORGANISM", 191, 200], ["CVB3", "SPECIES", 0, 4], ["CVB3 samples", "TEST", 0, 12], ["crystal violet solution", "TREATMENT", 131, 154]]], ["Plaques were enumerated and used to back-calculate the number of plaque forming units (pfu) per milliliter of collected volume.Mutant CVB3 PropagationVero cells were treated with DFMO for four days prior to infection with CVB3 at MOI 0.1.", [["Plaques", "ANATOMY", 0, 7], ["plaque", "ANATOMY", 65, 71], ["Vero cells", "ANATOMY", 150, 160], ["plaque", "DISEASE", 65, 71], ["DFMO", "CHEMICAL", 179, 183], ["infection", "DISEASE", 207, 216], ["DFMO", "CHEMICAL", 179, 183], ["CVB3", "ORGANISM", 134, 138], ["Vero cells", "CELL", 150, 160], ["DFMO", "SIMPLE_CHEMICAL", 179, 183], ["CVB3", "ORGANISM", 222, 226], ["Vero cells", "CELL_LINE", 150, 160], ["CVB3", "SPECIES", 134, 138], ["CVB3", "SPECIES", 222, 226], ["Plaques", "PROBLEM", 0, 7], ["collected volume", "TEST", 110, 126], ["Mutant CVB3 PropagationVero cells", "PROBLEM", 127, 160], ["DFMO", "TREATMENT", 179, 183], ["infection", "PROBLEM", 207, 216], ["CVB3 at MOI", "TREATMENT", 222, 233], ["plaque", "OBSERVATION", 65, 71], ["CVB3", "OBSERVATION", 134, 138], ["Propagation", "OBSERVATION_MODIFIER", 139, 150], ["Vero cells", "OBSERVATION", 150, 160], ["infection", "OBSERVATION", 207, 216]]], ["After 24 h, 1/10th of the cell culture volume was used to inoculate the next virus passage.", [["cell", "ANATOMY", 26, 30], ["cell", "CELL", 26, 30], ["the cell culture volume", "TEST", 22, 45]]], ["This process was continued for ten passages, at which time RNA was purified from the cellular supernatant, reverse transcribed, amplified using CVB3-specific primers, and Sanger sequenced.", [["cellular supernatant", "ANATOMY", 85, 105], ["cellular", "CELL", 85, 93], ["CVB3", "ORGANISM", 144, 148], ["CVB3-specific primers", "DNA", 144, 165], ["CVB3", "SPECIES", 144, 148], ["CVB3-specific primers", "TREATMENT", 144, 165]]], ["Sequences were aligned to CVB3 parental genome and mutants were confirmed by manual chromatogram verification.Drug TreatmentsDifluoromethylornithine (DFMO; TargetMol, Boston, MA, USA) and N1,N11-Diethylnorspermine (DENSpm; Santa Cruz Biotechnology, Dallas, TX, USA) were diluted to 100\u00d7 solution (100 mM and 10 mM, respectively) in sterile water.", [["Difluoromethylornithine", "CHEMICAL", 125, 148], ["DFMO", "CHEMICAL", 150, 154], ["N11-Diethylnorspermine", "CHEMICAL", 191, 213], ["DENSpm", "CHEMICAL", 215, 221], ["Difluoromethylornithine", "CHEMICAL", 125, 148], ["DFMO", "CHEMICAL", 150, 154], ["N1,N11-Diethylnorspermine", "CHEMICAL", 188, 213], ["DENSpm", "CHEMICAL", 215, 221], ["CVB3", "ORGANISM", 26, 30], ["Difluoromethylornithine", "SIMPLE_CHEMICAL", 125, 148], ["DFMO", "SIMPLE_CHEMICAL", 150, 154], ["N11-Diethylnorspermine", "SIMPLE_CHEMICAL", 191, 213], ["DENSpm", "SIMPLE_CHEMICAL", 215, 221], ["CVB3 parental genome", "DNA", 26, 46], ["CVB3", "SPECIES", 26, 30], ["manual chromatogram verification", "TEST", 77, 109], ["Drug TreatmentsDifluoromethylornithine (DFMO", "TREATMENT", 110, 154], ["TX, USA)", "TREATMENT", 257, 265]]], ["For DFMO treatments, cells were trypsinized and reseeded with fresh medium supplemented with 2% serum.", [["cells", "ANATOMY", 21, 26], ["serum", "ANATOMY", 96, 101], ["DFMO", "CHEMICAL", 4, 8], ["DFMO", "CHEMICAL", 4, 8], ["DFMO", "SIMPLE_CHEMICAL", 4, 8], ["cells", "CELL", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["DFMO treatments", "TREATMENT", 4, 19], ["cells", "TREATMENT", 21, 26], ["fresh medium supplemented", "TREATMENT", 62, 87]]], ["Following overnight attachment, cells were treated with 100 \u00b5M, 500 \u00b5M, 1 mM, or 2 mM DFMO.", [["cells", "ANATOMY", 32, 37], ["DFMO", "CHEMICAL", 86, 90], ["DFMO", "CHEMICAL", 86, 90], ["cells", "CELL", 32, 37], ["DFMO", "SIMPLE_CHEMICAL", 86, 90], ["2 mM DFMO", "TREATMENT", 81, 90]]], ["Cells were incubated with DFMO for 96 h to allow for depletion of polyamines in Vero cells.", [["Cells", "ANATOMY", 0, 5], ["Vero cells", "ANATOMY", 80, 90], ["DFMO", "CHEMICAL", 26, 30], ["polyamines", "CHEMICAL", 66, 76], ["DFMO", "CHEMICAL", 26, 30], ["polyamines", "CHEMICAL", 66, 76], ["Cells", "CELL", 0, 5], ["DFMO", "SIMPLE_CHEMICAL", 26, 30], ["polyamines", "SIMPLE_CHEMICAL", 66, 76], ["Vero cells", "CELL", 80, 90], ["Vero cells", "CELL_LINE", 80, 90], ["DFMO", "TREATMENT", 26, 30], ["polyamines in Vero cells", "PROBLEM", 66, 90], ["Vero cells", "OBSERVATION", 80, 90]]], ["For DENSpm treatment, cells were treated with 100 nM, 1 \u00b5M, 10 \u00b5M, 100 \u00b5M, and 1 mM 16 h prior to infection.", [["cells", "ANATOMY", 22, 27], ["DENSpm", "CHEMICAL", 4, 10], ["infection", "DISEASE", 98, 107], ["DENSpm", "CHEMICAL", 4, 10], ["DENSpm", "SIMPLE_CHEMICAL", 4, 10], ["cells", "CELL", 22, 27], ["DENSpm treatment", "TREATMENT", 4, 20], ["infection", "PROBLEM", 98, 107], ["infection", "OBSERVATION", 98, 107]]], ["During infection, media was cleared and saved from the cells.", [["cells", "ANATOMY", 55, 60], ["infection", "DISEASE", 7, 16], ["cells", "CELL", 55, 60], ["infection", "PROBLEM", 7, 16], ["media", "PROBLEM", 18, 23], ["infection", "OBSERVATION", 7, 16], ["cells", "ANATOMY", 55, 60]]], ["The same medium containing DFMO and DENSpm was then used to replenish the cells following infection.", [["cells", "ANATOMY", 74, 79], ["DFMO", "CHEMICAL", 27, 31], ["DENSpm", "CHEMICAL", 36, 42], ["infection", "DISEASE", 90, 99], ["DFMO", "CHEMICAL", 27, 31], ["DENSpm", "CHEMICAL", 36, 42], ["DFMO", "SIMPLE_CHEMICAL", 27, 31], ["DENSpm", "SIMPLE_CHEMICAL", 36, 42], ["cells", "CELL", 74, 79], ["The same medium containing DFMO", "TREATMENT", 0, 31], ["DENSpm", "TREATMENT", 36, 42], ["infection", "PROBLEM", 90, 99], ["DFMO", "OBSERVATION", 27, 31], ["infection", "OBSERVATION", 90, 99]]], ["Cells were incubated at the appropriate temperature for the duration of the infection.RNA Purification and cDNA SynthesisMedia was cleared from cells and Trizol reagent (Zymo Research, Irvine, CA, USA) directly added.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 144, 149], ["infection", "DISEASE", 76, 85], ["Cells", "CELL", 0, 5], ["cells", "CELL", 144, 149], ["cDNA SynthesisMedia", "DNA", 107, 126], ["the infection", "PROBLEM", 72, 85], ["RNA Purification", "TEST", 86, 102], ["cDNA SynthesisMedia", "TEST", 107, 126], ["Trizol reagent", "TREATMENT", 154, 168], ["CA, USA)", "TREATMENT", 193, 201], ["infection", "OBSERVATION", 76, 85]]], ["The lysate was then collected, and RNA was purified according to the manufacturer's protocol utilizing the Direct-zol RNA Miniprep Plus Kit (Zymo Research).", [["lysate", "ANATOMY", 4, 10], ["lysate", "ORGANISM_SUBSTANCE", 4, 10], ["The lysate", "TREATMENT", 0, 10], ["the manufacturer's protocol", "TREATMENT", 65, 92], ["the Direct-zol RNA", "TREATMENT", 103, 121], ["Kit (Zymo Research", "TREATMENT", 136, 154]]], ["Purified RNA was subsequently used for cDNA synthesis using High Capacity cDNA Reverse Transcription Kits (Thermo-Fischer), according to the manufacturer's protocol, with 10-100 ng of RNA and random hexamer primers.DFMO and DENSpm Sensitivity AssaysVero cells were treated with either 100 \u00b5M to 2000 \u00b5M DFMO for 4 days or 1 \u00b5m to 100 \u00b5M DENSpm for 16 h prior to infection with CVB3 at an MOI of 0.1.", [["Vero cells", "ANATOMY", 249, 259], ["DFMO", "CHEMICAL", 215, 219], ["DENSpm", "CHEMICAL", 224, 230], ["DFMO", "CHEMICAL", 303, 307], ["DENSpm", "CHEMICAL", 337, 343], ["infection", "DISEASE", 362, 371], ["DFMO", "CHEMICAL", 215, 219], ["DENSpm", "CHEMICAL", 224, 230], ["DFMO", "CHEMICAL", 303, 307], ["DFMO", "SIMPLE_CHEMICAL", 215, 219], ["DENSpm", "SIMPLE_CHEMICAL", 224, 230], ["Vero cells", "CELL", 249, 259], ["DFMO", "SIMPLE_CHEMICAL", 303, 307], ["CVB3", "ORGANISM", 377, 381], ["Vero cells", "CELL_LINE", 249, 259], ["CVB3", "SPECIES", 377, 381], ["cDNA synthesis", "TREATMENT", 39, 53], ["High Capacity cDNA", "TREATMENT", 60, 78], ["the manufacturer's protocol", "TREATMENT", 137, 164], ["RNA", "TREATMENT", 184, 187], ["random hexamer primers", "TREATMENT", 192, 214], ["DFMO", "TREATMENT", 215, 219], ["DENSpm Sensitivity", "TEST", 224, 242], ["Vero cells", "PROBLEM", 249, 259], ["DFMO", "TREATMENT", 303, 307], ["infection", "PROBLEM", 362, 371], ["CVB3", "TREATMENT", 377, 381]]], ["At 24 hpi, supernatants were collected and titers were determined.Stability and Fitness AssaysTo measure the stability of the mutations, Vero cells were infected at an MOI of 0.1 with all of the viral mutants for 24 h.", [["supernatants", "ANATOMY", 11, 23], ["Vero cells", "ANATOMY", 137, 147], ["Vero cells", "CELL", 137, 147], ["Vero cells", "CELL_LINE", 137, 147], ["Fitness Assays", "TEST", 80, 94], ["the mutations", "PROBLEM", 122, 135], ["Vero cells", "PROBLEM", 137, 147], ["the viral mutants", "TREATMENT", 191, 208], ["stability", "OBSERVATION_MODIFIER", 109, 118]]], ["The virus was then passed to new cells by transferring 50 \u00b5L supernatant.", [["cells", "ANATOMY", 33, 38], ["supernatant", "ANATOMY", 61, 72], ["cells", "CELL", 33, 38], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["After five passages, RNA was extracted and purified from supernatants and reverse transcribed.", [["supernatants", "ANATOMY", 57, 69]]], ["Sanger sequencing was used to determine whether mutations were stable over the passages by looking at the chromatograms and determining the presence or absence of the mutant nucleotide.", [["nucleotide", "CHEMICAL", 174, 184], ["nucleotide", "CHEMICAL", 174, 184], ["Sanger sequencing", "TEST", 0, 17], ["mutations", "PROBLEM", 48, 57], ["the chromatograms", "TEST", 102, 119], ["the mutant nucleotide", "PROBLEM", 163, 184], ["stable", "OBSERVATION_MODIFIER", 63, 69]]], ["Fitness assays were similarly performed, but Vero cells were infected at an MOI of 0.1 with an equal combination of wild-type and mutant CVB3 and passaged five times.", [["Vero cells", "ANATOMY", 45, 55], ["Vero cells", "CELL", 45, 55], ["mutant CVB3", "ORGANISM", 130, 141], ["Vero cells", "CELL_LINE", 45, 55], ["CVB3", "SPECIES", 137, 141], ["Fitness assays", "TEST", 0, 14], ["Vero cells", "PROBLEM", 45, 55], ["mutant CVB3", "TREATMENT", 130, 141]]], ["Fitness was determined via Sanger sequencing and analysis of the chromatogram to determine if the wild-type or mutant nucleotide was present in the sample.Protease Plasmid CloningPrimers were designed to target either the wild-type 2A or 3C protease.", [["sample", "ANATOMY", 148, 154], ["nucleotide", "CHEMICAL", 118, 128], ["nucleotide", "CHEMICAL", 118, 128], ["wild-type 2A", "GENE_OR_GENE_PRODUCT", 222, 234], ["3C protease", "GENE_OR_GENE_PRODUCT", 238, 249], ["wild-type 2A or 3C protease", "PROTEIN", 222, 249], ["Sanger sequencing", "TEST", 27, 44], ["analysis of the chromatogram", "TEST", 49, 77], ["mutant nucleotide", "PROBLEM", 111, 128], ["Protease Plasmid CloningPrimers", "TREATMENT", 155, 186], ["3C protease", "TREATMENT", 238, 249]]], ["CVB3 plasmids containing either the 2A mutant protease or 3C mutant protease were used to clone the mutant proteases.", [["CVB3", "ORGANISM", 0, 4], ["CVB3 plasmids", "DNA", 0, 13], ["2A mutant protease", "PROTEIN", 36, 54], ["3C mutant protease", "PROTEIN", 58, 76], ["mutant proteases", "PROTEIN", 100, 116], ["CVB3", "SPECIES", 0, 4], ["CVB3 plasmids", "TREATMENT", 0, 13], ["the 2A mutant protease", "TREATMENT", 32, 54], ["3C mutant protease", "TREATMENT", 58, 76]]], ["To target the 2A and 2A mutant proteases, the primers included SacI and XbaI recognition sites (Table 1) .", [["2A", "GENE_OR_GENE_PRODUCT", 21, 23], ["SacI", "GENE_OR_GENE_PRODUCT", 63, 67], ["XbaI", "GENE_OR_GENE_PRODUCT", 72, 76], ["2A and 2A mutant proteases", "PROTEIN", 14, 40], ["SacI and XbaI recognition sites", "DNA", 63, 94], ["2A mutant proteases", "TREATMENT", 21, 40], ["the primers", "TREATMENT", 42, 53], ["SacI and XbaI recognition sites", "TREATMENT", 63, 94]]], ["Primers against the 3C and 3C mutant proteases included NotI and XbaI recognition sites.", [["NotI", "GENE_OR_GENE_PRODUCT", 56, 60], ["XbaI", "GENE_OR_GENE_PRODUCT", 65, 69], ["3C and 3C mutant proteases", "PROTEIN", 20, 46], ["NotI and XbaI recognition sites", "DNA", 56, 87], ["Primers", "TEST", 0, 7], ["the 3C", "TREATMENT", 16, 22], ["3C mutant proteases", "TREATMENT", 27, 46], ["NotI and XbaI recognition sites", "PROBLEM", 56, 87]]], ["Protease sequences were amplified via PCR and cloned into the pFLAG-CMV-LAP1 vector.", [["Protease", "GENE_OR_GENE_PRODUCT", 0, 8], ["pFLAG-CMV", "GENE_OR_GENE_PRODUCT", 62, 71], ["LAP1", "GENE_OR_GENE_PRODUCT", 72, 76], ["pFLAG-CMV-LAP1 vector", "DNA", 62, 83], ["Protease sequences", "TEST", 0, 18], ["PCR", "TEST", 38, 41]]], ["Clones were verified for sequencing (GenScript, Piscataway, NJ, USA).", [["Clones", "CELL", 0, 6]]], ["Oligonucleotide sequences corresponding to the amino acid sequence for the wild-type and mutant 2A and 3C protease targets were designed and cloned into the pGlo-3F vector and verified by sequencing (GenScript).Transfections293T cells were plated at 80%-90% confluency and either treated with 100 \u00b5M, 500 \u00b5M, 1000 \u00b5M or 2000 \u00b5M DFMO for 4-days or left untreated.", [["Transfections293T cells", "ANATOMY", 211, 234], ["amino acid", "CHEMICAL", 47, 57], ["DFMO", "CHEMICAL", 328, 332], ["amino acid", "CHEMICAL", 47, 57], ["DFMO", "CHEMICAL", 328, 332], ["amino acid", "AMINO_ACID", 47, 57], ["mutant 2A", "ORGANISM", 89, 98], ["3C", "GENE_OR_GENE_PRODUCT", 103, 105], ["pGlo-3F", "GENE_OR_GENE_PRODUCT", 157, 164], ["Transfections293T cells", "CELL", 211, 234], ["DFMO", "SIMPLE_CHEMICAL", 328, 332], ["amino acid sequence", "PROTEIN", 47, 66], ["wild-type and mutant 2A and 3C protease targets", "DNA", 75, 122], ["pGlo-3F vector", "DNA", 157, 171], ["Transfections293T cells", "CELL_LINE", 211, 234], ["Oligonucleotide sequences", "TEST", 0, 25], ["the amino acid sequence", "TEST", 43, 66], ["3C protease targets", "TREATMENT", 103, 122], ["Transfections293T cells", "TEST", 211, 234], ["DFMO", "TREATMENT", 328, 332], ["left", "ANATOMY_MODIFIER", 347, 351]]], ["The plasmids were then transfected in the combinations described in the figures, according to the manufacturer's protocol, using LipoD293 (SignaGen Laboratories, Rockville, MD, USA).", [["plasmids", "ANATOMY", 4, 12], ["plasmids", "DNA", 4, 12], ["The plasmids", "TREATMENT", 0, 12], ["plasmids", "OBSERVATION", 4, 12]]], ["The transfection was incubated at 37 \u2022 C for 24 h.Western BlotSamples were collected with Bolt LDS Buffer and Bolt Reducing Agent (Invitrogen, Waltham, MA, USA) and run on polyacrylamide gels.", [["polyacrylamide", "CHEMICAL", 172, 186], ["Bolt LDS Buffer", "TREATMENT", 90, 105], ["Bolt Reducing Agent", "TREATMENT", 110, 129], ["Invitrogen", "TREATMENT", 131, 141], ["polyacrylamide gels", "TREATMENT", 172, 191]]], ["Gels were transferred using the iBlot 2 Gel Transfer Device (Invitrogen).", [["Gels", "SIMPLE_CHEMICAL", 0, 4], ["the iBlot 2 Gel Transfer Device (Invitrogen)", "TREATMENT", 28, 72]]], ["Membranes were probed with primary antibodies for eIF4G, (1:1000, Santa Cruz Biotechnology, Dallas, TX, USA), GAPDH (1:1000, Santa Cruz Biotechnology), and \u03b2-actin (1:5000, Santa Cruz Biotechnology).", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["eIF4G", "GENE_OR_GENE_PRODUCT", 50, 55], ["GAPDH", "GENE_OR_GENE_PRODUCT", 110, 115], ["primary antibodies", "PROTEIN", 27, 45], ["eIF4G", "PROTEIN", 50, 55], ["1:1000, Santa Cruz Biotechnology, Dallas, TX, USA), GAPDH (1:1000, Santa Cruz Biotechnology", "PROTEIN", 58, 149], ["\u03b2-actin", "PROTEIN", 156, 163], ["1:5000, Santa Cruz Biotechnology", "PROTEIN", 165, 197], ["eIF4G", "TEST", 50, 55]]], ["Membranes were treated with SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific) and visualized on FluorChem E imager (Protein Simple, San Jose, CA, USA).Plaque Size MeasurementTo quantify the relative plaque sizes of the different CVB3 mutants, Vero cells were seeded in 10 cm dishes and grown to confluence.", [["Membranes", "ANATOMY", 0, 9], ["Plaque", "ANATOMY", 181, 187], ["plaque", "ANATOMY", 229, 235], ["Vero cells", "ANATOMY", 273, 283], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["plaque", "PATHOLOGICAL_FORMATION", 229, 235], ["CVB3", "ORGANISM", 259, 263], ["Vero cells", "CELL", 273, 283], ["Vero cells", "CELL_LINE", 273, 283], ["CVB3", "SPECIES", 259, 263], ["SuperSignal West Pico PLUS Chemiluminescent Substrate", "TREATMENT", 28, 81], ["Plaque Size MeasurementTo", "TEST", 181, 206], ["the relative plaque sizes", "PROBLEM", 216, 241], ["Vero cells", "TREATMENT", 273, 283], ["Size", "OBSERVATION_MODIFIER", 188, 192], ["relative", "OBSERVATION_MODIFIER", 220, 228], ["plaque", "OBSERVATION", 229, 235], ["sizes", "OBSERVATION_MODIFIER", 236, 241], ["different", "OBSERVATION_MODIFIER", 249, 258], ["CVB3 mutants", "OBSERVATION", 259, 271], ["Vero cells", "OBSERVATION", 273, 283], ["10 cm", "OBSERVATION_MODIFIER", 299, 304], ["confluence", "OBSERVATION_MODIFIER", 325, 335]]], ["Approximately 30 plaque-forming units (PFU) of each mutant was diluted in a 2.5 mL inoculum of serum-free DMEM.", [["plaque", "ANATOMY", 17, 23], ["serum", "ANATOMY", 95, 100], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["serum-free DMEM", "TREATMENT", 95, 110], ["plaque", "OBSERVATION", 17, 23], ["free DMEM", "OBSERVATION", 101, 110]]], ["The media on the Vero cells was aspirated and replaced with the 2.5 mL inoculum containing the virus.", [["Vero cells", "ANATOMY", 17, 27], ["Vero cells", "CELL", 17, 27], ["Vero cells", "CELL_LINE", 17, 27], ["the Vero cells", "TREATMENT", 13, 27], ["the 2.5 mL inoculum", "TREATMENT", 60, 79], ["the virus", "TREATMENT", 91, 100], ["media", "ANATOMY", 4, 9], ["Vero cells", "ANATOMY", 17, 27], ["virus", "OBSERVATION", 95, 100]]], ["The inoculum was incubated on the cells for approximately 30 min at 37 \u2022 C. After 30 min, an overlay of 8 mL 0.8% agarose was added to each dish.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["agarose", "SIMPLE_CHEMICAL", 114, 121], ["The inoculum", "TREATMENT", 0, 12], ["an overlay of 8 mL 0.8% agarose", "TREATMENT", 90, 121], ["inoculum", "OBSERVATION", 4, 12]]], ["The dishes were incubated at 37 \u2022 C for 2 days to allow plaque formation.", [["plaque", "ANATOMY", 56, 62], ["plaque", "DISEASE", 56, 62], ["plaque", "PATHOLOGICAL_FORMATION", 56, 62], ["plaque formation", "PROBLEM", 56, 72], ["plaque", "OBSERVATION", 56, 62]]], ["The cells were fixed with 4% formalin and the agarose plugs removed.", [["cells", "ANATOMY", 4, 9], ["formalin", "CHEMICAL", 29, 37], ["formalin", "CHEMICAL", 29, 37], ["cells", "CELL", 4, 9], ["formalin", "SIMPLE_CHEMICAL", 29, 37], ["agarose", "SIMPLE_CHEMICAL", 46, 53], ["The cells", "TREATMENT", 0, 9], ["4% formalin", "TREATMENT", 26, 37], ["the agarose plugs", "TREATMENT", 42, 59], ["agarose plugs", "OBSERVATION", 46, 59]]], ["The fixed cells were stained with crystal violet.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["The fixed cells", "PROBLEM", 0, 15], ["crystal violet", "PROBLEM", 34, 48], ["fixed cells", "OBSERVATION", 4, 15], ["crystal violet", "OBSERVATION", 34, 48]]], ["Plaque size was determined using ImageJ software (Version 1.51k) [29] .Thin Layer Chromatography Determination of PolyaminesPolyamines were separated by thin-layer chromatography as previously described [30] .", [["Plaque", "ANATOMY", 0, 6], ["Polyamines", "CHEMICAL", 114, 124], ["PolyaminesPolyamines", "SIMPLE_CHEMICAL", 114, 134], ["Plaque size", "TEST", 0, 11], ["ImageJ software", "TEST", 33, 48], ["Version", "TEST", 50, 57], ["Thin Layer Chromatography", "TEST", 71, 96], ["PolyaminesPolyamines", "TREATMENT", 114, 134], ["thin-layer chromatography", "TEST", 153, 178], ["size", "OBSERVATION_MODIFIER", 7, 11], ["PolyaminesPolyamines", "OBSERVATION", 114, 134]]], ["For all samples, cells were treated as described prior to being trypsinized and centrifuged.", [["samples", "ANATOMY", 8, 15], ["cells", "ANATOMY", 17, 22], ["cells", "CELL", 17, 22]]], ["Pellets were washed with PBS and then resuspended in 200 \u00b5L 2% perchloric acid.", [["Pellets", "ANATOMY", 0, 7], ["perchloric acid", "CHEMICAL", 63, 78], ["perchloric acid", "CHEMICAL", 63, 78], ["perchloric acid", "SIMPLE_CHEMICAL", 63, 78], ["Pellets", "TREATMENT", 0, 7], ["PBS", "TREATMENT", 25, 28]]], ["Samples were then incubated overnight at 4 \u2022 C. 200 \u00b5L of supernatant was combined with 200 \u00b5L 5 mg/mL dansyl chloride (Sigma Aldrich) in acetone and 100 \u00b5L saturated sodium bicarbonate.", [["Samples", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 58, 69], ["dansyl chloride", "CHEMICAL", 103, 118], ["acetone", "CHEMICAL", 138, 145], ["sodium bicarbonate", "CHEMICAL", 167, 185], ["dansyl chloride", "CHEMICAL", 103, 118], ["acetone", "CHEMICAL", 138, 145], ["sodium bicarbonate", "CHEMICAL", 167, 185], ["dansyl chloride", "SIMPLE_CHEMICAL", 103, 118], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 120, 133], ["acetone", "SIMPLE_CHEMICAL", 138, 145], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 167, 185], ["Samples", "TEST", 0, 7], ["supernatant", "TREATMENT", 58, 69], ["dansyl chloride (Sigma Aldrich)", "TREATMENT", 103, 134], ["acetone", "TREATMENT", 138, 145], ["100 \u00b5L saturated sodium bicarbonate", "TREATMENT", 150, 185]]], ["Samples were incubated in the dark overnight at room temperature.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Excess dansyl chloride was cleared by incubating the reaction with 100 \u00b5L 150 mg/mL proline (Sigma Aldrich).", [["dansyl chloride", "CHEMICAL", 7, 22], ["proline", "CHEMICAL", 84, 91], ["dansyl chloride", "CHEMICAL", 7, 22], ["proline", "CHEMICAL", 84, 91], ["dansyl chloride", "SIMPLE_CHEMICAL", 7, 22], ["Excess dansyl chloride", "TREATMENT", 0, 22]]], ["Dansylated polyamines were extracted with 50 \u00b5L toluene (Sigma Aldrich) and centrifuged.", [["toluene", "CHEMICAL", 48, 55], ["polyamines", "CHEMICAL", 11, 21], ["toluene", "CHEMICAL", 48, 55], ["polyamines", "SIMPLE_CHEMICAL", 11, 21], ["toluene", "SIMPLE_CHEMICAL", 48, 55], ["Dansylated polyamines", "TREATMENT", 0, 21]]], ["Five microliter of sample was added in small spots to the TLC plate (silica gel matrix; Sigma Aldrich) and exposed to ascending chromatography with 1:1 cyclohexane: ethyl acetate.", [["sample", "ANATOMY", 19, 25], ["silica gel", "CHEMICAL", 69, 79], ["1:1 cyclohexane: ethyl acetate", "CHEMICAL", 148, 178], ["silica", "CHEMICAL", 69, 75], ["cyclohexane", "CHEMICAL", 152, 163], ["ethyl acetate", "CHEMICAL", 165, 178], ["cyclohexane", "SIMPLE_CHEMICAL", 152, 163], ["ethyl acetate", "SIMPLE_CHEMICAL", 165, 178], ["Five microliter of sample", "TREATMENT", 0, 25], ["small spots", "PROBLEM", 39, 50], ["the TLC plate (silica gel matrix", "TREATMENT", 54, 86], ["Sigma Aldrich)", "TREATMENT", 88, 102], ["ascending chromatography", "TEST", 118, 142], ["ethyl acetate", "TREATMENT", 165, 178], ["small spots", "OBSERVATION", 39, 50], ["TLC", "ANATOMY", 58, 61], ["plate", "ANATOMY_MODIFIER", 62, 67], ["ascending", "ANATOMY", 118, 127]]], ["The plate was dried and visualized via exposure to UV.Statistical AnalysisPrism 6 (GraphPad) was used to generate graphs and perform statistical analysis.", [["The plate", "TREATMENT", 0, 9], ["UV", "TREATMENT", 51, 53], ["Statistical AnalysisPrism", "TEST", 54, 79], ["statistical analysis", "TEST", 133, 153], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["For all analyses, two-tailed Student's t-test was used to compare groups, unless otherwise noted, with a = 0.05.", [["all analyses", "TEST", 4, 16], ["Student's t-test", "TEST", 29, 45]]], ["For tests of sample proportions, p values were derived from calculated Z scores with two tails and a = 0.05.", [["tests of sample proportions", "TEST", 4, 31], ["p values", "TEST", 33, 41], ["calculated Z scores", "TEST", 60, 79]]], ["Half-maximal inhibitory concentration (IC50) values were calculated using Prism 6 using the built-in analysis tool.CVB3 Gains Resistance to Polyamine Depletion over Passages with DFMOOur previous work demonstrating that CVB3 was sensitive to polyamine depletion via DFMO suggested a role for polyamines in virus replication [25] .", [["Polyamine", "CHEMICAL", 140, 149], ["polyamine", "CHEMICAL", 242, 251], ["DFMO", "CHEMICAL", 266, 270], ["polyamines", "CHEMICAL", 292, 302], ["Polyamine", "CHEMICAL", 140, 149], ["polyamine", "CHEMICAL", 242, 251], ["DFMO", "CHEMICAL", 266, 270], ["polyamines", "CHEMICAL", 292, 302], ["CVB3", "ORGANISM", 115, 119], ["Polyamine", "SIMPLE_CHEMICAL", 140, 149], ["CVB3", "ORGANISM", 220, 224], ["polyamine", "SIMPLE_CHEMICAL", 242, 251], ["DFMO", "SIMPLE_CHEMICAL", 266, 270], ["polyamines", "SIMPLE_CHEMICAL", 292, 302], ["CVB3", "SPECIES", 115, 119], ["CVB3", "SPECIES", 220, 224], ["CVB3", "PROBLEM", 115, 119], ["Polyamine Depletion", "TREATMENT", 140, 159], ["CVB3", "PROBLEM", 220, 224], ["polyamine depletion", "TREATMENT", 242, 261], ["DFMO", "TREATMENT", 266, 270], ["polyamines in virus replication", "TREATMENT", 292, 323], ["Polyamine Depletion", "OBSERVATION", 140, 159]]], ["To ascertain how CVB3 evolves in response to repeated replication cycles in the absence of polyamine depletion, we passaged the virus in the presence of DFMO.", [["polyamine", "CHEMICAL", 91, 100], ["DFMO", "CHEMICAL", 153, 157], ["polyamine", "CHEMICAL", 91, 100], ["DFMO", "CHEMICAL", 153, 157], ["CVB3", "ORGANISM", 17, 21], ["polyamine", "SIMPLE_CHEMICAL", 91, 100], ["DFMO", "SIMPLE_CHEMICAL", 153, 157], ["CVB3", "SPECIES", 17, 21], ["CVB3", "PROBLEM", 17, 21], ["repeated replication cycles", "TREATMENT", 45, 72], ["polyamine depletion", "PROBLEM", 91, 110], ["the virus", "PROBLEM", 124, 133], ["DFMO", "TREATMENT", 153, 157], ["polyamine depletion", "OBSERVATION", 91, 110], ["DFMO", "OBSERVATION", 153, 157]]], ["We treated Vero-E6 cells with 500 \u00b5M DFMO or left controls untreated (NT), for four days prior to infection with CVB3 at MOI 0.1 plaque forming units (pfu)/mL.", [["Vero-E6 cells", "ANATOMY", 11, 24], ["left controls", "ANATOMY", 45, 58], ["DFMO", "CHEMICAL", 37, 41], ["infection", "DISEASE", 98, 107], ["DFMO", "CHEMICAL", 37, 41], ["Vero-E6 cells", "CELL", 11, 24], ["DFMO", "SIMPLE_CHEMICAL", 37, 41], ["CVB3", "ORGANISM", 113, 117], ["Vero-E6 cells", "CELL_LINE", 11, 24], ["Vero-E6", "SPECIES", 11, 18], ["CVB3", "SPECIES", 113, 117], ["Vero-E6 cells", "TREATMENT", 11, 24], ["500 \u00b5M DFMO", "TREATMENT", 30, 41], ["infection", "PROBLEM", 98, 107], ["CVB3 at MOI", "TREATMENT", 113, 124], ["left", "ANATOMY_MODIFIER", 45, 49], ["infection", "OBSERVATION", 98, 107]]], ["After 24 h, we collected cellular supernatant and passaged 1/10th of the volume onto na\u00efve cells.", [["cellular supernatant", "ANATOMY", 25, 45], ["cells", "ANATOMY", 91, 96], ["cellular", "CELL", 25, 33], ["cells", "CELL", 91, 96], ["na\u00efve cells", "CELL_TYPE", 85, 96], ["cellular supernatant", "TREATMENT", 25, 45], ["the volume onto na\u00efve cells", "TREATMENT", 69, 96], ["na\u00efve cells", "OBSERVATION", 85, 96]]], ["Viral titers were determined intermittently ( Figure 1A ) and at passage five, the passaged virus was exposed to increasing doses of DFMO, from 10 \u00b5M to 5 mM, and titers measured by plaque assay after 24 h of infection.", [["plaque", "ANATOMY", 182, 188], ["DFMO", "CHEMICAL", 133, 137], ["infection", "DISEASE", 209, 218], ["DFMO", "CHEMICAL", 133, 137], ["Viral", "ORGANISM", 0, 5], ["DFMO", "SIMPLE_CHEMICAL", 133, 137], ["Viral titers", "TEST", 0, 12], ["the passaged virus", "PROBLEM", 79, 97], ["DFMO", "TREATMENT", 133, 137], ["infection", "PROBLEM", 209, 218], ["plaque", "OBSERVATION", 182, 188], ["infection", "OBSERVATION", 209, 218]]], ["We observed that virus that had been passaged but not exposed to DFMO remained susceptible, with significant decreases in viral titer observed at DFMO concentrations above 100 \u00b5M and an IC50 value of 70.9 \u00b5M.", [["DFMO", "CHEMICAL", 65, 69], ["DFMO", "CHEMICAL", 146, 150], ["DFMO", "CHEMICAL", 65, 69], ["DFMO", "CHEMICAL", 146, 150], ["DFMO", "SIMPLE_CHEMICAL", 65, 69], ["DFMO", "SIMPLE_CHEMICAL", 146, 150], ["virus", "PROBLEM", 17, 22], ["DFMO", "TREATMENT", 65, 69], ["significant decreases in viral titer", "PROBLEM", 97, 133], ["DFMO concentrations", "TEST", 146, 165], ["an IC50 value", "TEST", 183, 196], ["virus", "OBSERVATION", 17, 22], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["decreases", "OBSERVATION_MODIFIER", 109, 118], ["viral titer", "OBSERVATION", 122, 133]]], ["In contrast, virus passaged in DFMO exhibited significant resistance to DFMO treatment, with an IC50 value of 293 \u00b5M, suggesting developing resistance to DFMO.CVB3 Gains Resistance to Polyamine Depletion over Passages with DFMOViruses 2019, 11, x FOR PEER REVIEW 6 of 15 determined intermittently ( Figure 1A ) and at passage five, the passaged virus was exposed to increasing doses of DFMO, from 10 \u00b5M to 5 mM, and titers measured by plaque assay after 24 h of infection.", [["plaque", "ANATOMY", 435, 441], ["DFMO", "CHEMICAL", 31, 35], ["DFMO", "CHEMICAL", 72, 76], ["DFMO", "CHEMICAL", 154, 158], ["Polyamine", "CHEMICAL", 184, 193], ["DFMO", "CHEMICAL", 386, 390], ["infection", "DISEASE", 462, 471], ["DFMO", "CHEMICAL", 31, 35], ["DFMO", "CHEMICAL", 72, 76], ["DFMO", "CHEMICAL", 154, 158], ["Polyamine", "CHEMICAL", 184, 193], ["DFMO", "CHEMICAL", 386, 390], ["DFMO", "SIMPLE_CHEMICAL", 31, 35], ["DFMO", "SIMPLE_CHEMICAL", 72, 76], ["DFMO", "SIMPLE_CHEMICAL", 154, 158], ["CVB3", "ORGANISM", 159, 163], ["Polyamine", "SIMPLE_CHEMICAL", 184, 193], ["DFMO", "SIMPLE_CHEMICAL", 386, 390], ["CVB3", "SPECIES", 159, 163], ["virus", "PROBLEM", 13, 18], ["DFMO", "TREATMENT", 31, 35], ["DFMO treatment", "TREATMENT", 72, 86], ["an IC50 value", "TEST", 93, 106], ["DFMO", "TREATMENT", 154, 158], ["CVB3", "PROBLEM", 159, 163], ["Polyamine Depletion over Passages with DFMOViruses", "TREATMENT", 184, 234], ["the passaged virus", "PROBLEM", 332, 350], ["DFMO", "TREATMENT", 386, 390], ["infection", "PROBLEM", 462, 471], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["resistance", "OBSERVATION", 58, 68], ["DFMO treatment", "OBSERVATION", 72, 86], ["resistance", "OBSERVATION", 140, 150], ["Polyamine Depletion", "OBSERVATION", 184, 203], ["plaque", "OBSERVATION", 435, 441], ["infection", "OBSERVATION", 462, 471]]], ["We observed that virus that had been passaged but not exposed to DFMO remained susceptible, with significant decreases in viral titer observed at DFMO concentrations above 100 \u00b5M and an IC50 value of 70.9 \u00b5M.", [["DFMO", "CHEMICAL", 65, 69], ["DFMO", "CHEMICAL", 146, 150], ["DFMO", "CHEMICAL", 65, 69], ["DFMO", "CHEMICAL", 146, 150], ["DFMO", "SIMPLE_CHEMICAL", 65, 69], ["DFMO", "SIMPLE_CHEMICAL", 146, 150], ["virus", "PROBLEM", 17, 22], ["DFMO", "TREATMENT", 65, 69], ["significant decreases in viral titer", "PROBLEM", 97, 133], ["DFMO concentrations", "TEST", 146, 165], ["an IC50 value", "TEST", 183, 196], ["virus", "OBSERVATION", 17, 22], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["decreases", "OBSERVATION_MODIFIER", 109, 118], ["viral titer", "OBSERVATION", 122, 133]]], ["In contrast, virus passaged in DFMO exhibited significant resistance to DFMO treatment, with an IC50 value of 293 \u00b5M, suggesting developing resistance to DFMO.", [["DFMO", "CHEMICAL", 31, 35], ["DFMO", "CHEMICAL", 72, 76], ["DFMO", "CHEMICAL", 154, 158], ["DFMO", "CHEMICAL", 31, 35], ["DFMO", "CHEMICAL", 72, 76], ["DFMO", "CHEMICAL", 154, 158], ["DFMO", "SIMPLE_CHEMICAL", 31, 35], ["DFMO", "SIMPLE_CHEMICAL", 72, 76], ["DFMO", "SIMPLE_CHEMICAL", 154, 158], ["virus", "PROBLEM", 13, 18], ["DFMO", "TREATMENT", 31, 35], ["DFMO treatment", "TREATMENT", 72, 86], ["an IC50 value", "TEST", 93, 106], ["DFMO", "TREATMENT", 154, 158], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["resistance", "OBSERVATION", 58, 68], ["DFMO treatment", "OBSERVATION", 72, 86], ["resistance", "OBSERVATION", 140, 150]]], ["Following passage of virus, RNA was extracted, purified, reverse transcribed and Sanger sequenced.", [["passage of virus", "PROBLEM", 10, 26], ["virus", "OBSERVATION", 21, 26]]], ["When the sequenced virus was aligned with the parental CVB3 genome, mutations in the two viral proteases, 2A (Q29K) and 3C (Q52R), were observed.", [["CVB3", "ORGANISM", 55, 59], ["2A (Q29K)", "GENE_OR_GENE_PRODUCT", 106, 115], ["3C", "GENE_OR_GENE_PRODUCT", 120, 122], ["CVB3 genome", "DNA", 55, 66], ["viral proteases", "PROTEIN", 89, 104], ["2A", "PROTEIN", 106, 108], ["Q29K", "PROTEIN", 110, 114], ["3C", "PROTEIN", 120, 122], ["Q52R", "PROTEIN", 124, 128], ["CVB3", "SPECIES", 55, 59], ["the sequenced virus", "PROBLEM", 5, 24]]], ["Interestingly, these mutations were observed independently in three distinct viral lineages.", [["these mutations", "PROBLEM", 15, 30], ["viral lineages", "OBSERVATION", 77, 91]]], ["Further, the 2A 29K and 3C 52R mutations were not observed in the same lineage.", [["29K", "GENE_OR_GENE_PRODUCT", 16, 19], ["3C", "GENE_OR_GENE_PRODUCT", 24, 26], ["52R", "GENE_OR_GENE_PRODUCT", 27, 30], ["2A 29K and 3C 52R mutations", "DNA", 13, 40], ["3C 52R mutations", "TREATMENT", 24, 40]]], ["Importantly, no mutations were observed in viruses passaged without treatment.CVB3 Mutations in 2A and 3C Proteases Confer Resistance to Polyamine DepletionObserving the development of resistance to DFMO and the emergence of mutants in the passaged virus, we cloned these mutations in the CVB3 parental strain using mutagenic PCR on the CVB3 infectious clone.", [["Polyamine", "CHEMICAL", 137, 146], ["DFMO", "CHEMICAL", 199, 203], ["Polyamine", "CHEMICAL", 137, 146], ["DFMO", "CHEMICAL", 199, 203], ["CVB3", "ORGANISM", 78, 82], ["Polyamine", "SIMPLE_CHEMICAL", 137, 146], ["DFMO", "SIMPLE_CHEMICAL", 199, 203], ["CVB3", "ORGANISM", 289, 293], ["CVB3", "ORGANISM", 337, 341], ["clone", "CELL", 353, 358], ["2A and 3C Proteases", "PROTEIN", 96, 115], ["CVB3", "SPECIES", 78, 82], ["CVB3", "SPECIES", 289, 293], ["CVB3", "SPECIES", 337, 341], ["mutations", "PROBLEM", 16, 25], ["treatment", "TREATMENT", 68, 77], ["CVB3 Mutations", "TREATMENT", 78, 92], ["3C Proteases", "TREATMENT", 103, 115], ["Polyamine DepletionObserving", "TREATMENT", 137, 165], ["DFMO", "TREATMENT", 199, 203], ["mutants in the passaged virus", "PROBLEM", 225, 254], ["these mutations", "PROBLEM", 266, 281], ["mutagenic PCR", "TEST", 316, 329], ["no", "UNCERTAINTY", 13, 15]]], ["In addition to 2A 29K and 3C 52R mutants, we generated a 2A 29K /3C 52R double mutant.", [["29K", "GENE_OR_GENE_PRODUCT", 18, 21], ["3C", "GENE_OR_GENE_PRODUCT", 26, 28], ["52R", "GENE_OR_GENE_PRODUCT", 29, 32], ["29K", "GENE_OR_GENE_PRODUCT", 60, 63], ["52R", "GENE_OR_GENE_PRODUCT", 68, 71], ["2A 29K and 3C 52R mutants", "PROTEIN", 15, 40], ["2A 29K /3C 52R double mutant", "PROTEIN", 57, 85]]], ["After confirming the presence of the mutations, we generated an infectious virus and measured the virus titer over several rounds of replication.", [["the mutations", "PROBLEM", 33, 46], ["an infectious virus", "PROBLEM", 61, 80], ["the virus titer", "TREATMENT", 94, 109], ["replication", "TREATMENT", 133, 144], ["infectious", "OBSERVATION", 64, 74]]], ["Vero cells were treated with 500 \u00b5M DFMO or left untreated for four days prior to infection at MOI 0.01.", [["Vero cells", "ANATOMY", 0, 10], ["DFMO", "CHEMICAL", 36, 40], ["infection", "DISEASE", 82, 91], ["DFMO", "CHEMICAL", 36, 40], ["Vero cells", "CELL", 0, 10], ["DFMO", "SIMPLE_CHEMICAL", 36, 40], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["500 \u00b5M DFMO", "TREATMENT", 29, 40], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 82, 91]]], ["Cellular supernatant samples were collected and titered via plaque assay.", [["supernatant samples", "ANATOMY", 9, 28], ["plaque", "ANATOMY", 60, 66], ["Cellular supernatant samples", "TEST", 0, 28], ["plaque", "OBSERVATION", 60, 66]]], ["As shown in Figure 2A , all viruses in untreated conditions replicated with similar kinetics and to similar levels regardless of protease mutation.", [["protease", "PROTEIN", 129, 137], ["all viruses in untreated conditions", "PROBLEM", 24, 59], ["protease mutation", "PROBLEM", 129, 146], ["viruses", "OBSERVATION", 28, 35]]], ["However, in DFMO-treated cells, the wildtype CVB3 exhibited significant reductions in titer, which persisted to 72 hpi.", [["cells", "ANATOMY", 25, 30], ["DFMO", "CHEMICAL", 12, 16], ["DFMO", "CHEMICAL", 12, 16], ["DFMO", "SIMPLE_CHEMICAL", 12, 16], ["cells", "CELL", 25, 30], ["wildtype CVB3", "ORGANISM", 36, 49], ["DFMO-treated cells", "CELL_LINE", 12, 30], ["CVB3", "SPECIES", 45, 49], ["DFMO-treated cells", "TREATMENT", 12, 30], ["the wildtype CVB3", "PROBLEM", 32, 49], ["significant reductions in titer", "PROBLEM", 60, 91], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["reductions", "OBSERVATION_MODIFIER", 72, 82]]], ["Interestingly, the protease mutants, either alone or in combination, exhibited a Following passage of virus, RNA was extracted, purified, reverse transcribed and Sanger sequenced.", [["protease mutants", "PROTEIN", 19, 35], ["the protease mutants", "TREATMENT", 15, 35]]], ["When the sequenced virus was aligned with the parental CVB3 genome, mutations in the two viral proteases, 2A (Q29K) and 3C (Q52R), were observed.", [["CVB3", "ORGANISM", 55, 59], ["2A (Q29K)", "GENE_OR_GENE_PRODUCT", 106, 115], ["3C", "GENE_OR_GENE_PRODUCT", 120, 122], ["CVB3 genome", "DNA", 55, 66], ["viral proteases", "PROTEIN", 89, 104], ["2A", "PROTEIN", 106, 108], ["Q29K", "PROTEIN", 110, 114], ["3C", "PROTEIN", 120, 122], ["Q52R", "PROTEIN", 124, 128], ["CVB3", "SPECIES", 55, 59], ["the sequenced virus", "PROBLEM", 5, 24]]], ["Interestingly, these mutations were observed independently in three distinct viral lineages.", [["these mutations", "PROBLEM", 15, 30], ["viral lineages", "OBSERVATION", 77, 91]]], ["Further, the 2A 29K and 3C 52R mutations were not observed in the same lineage.", [["29K", "GENE_OR_GENE_PRODUCT", 16, 19], ["3C", "GENE_OR_GENE_PRODUCT", 24, 26], ["52R", "GENE_OR_GENE_PRODUCT", 27, 30], ["2A 29K and 3C 52R mutations", "DNA", 13, 40], ["3C 52R mutations", "TREATMENT", 24, 40]]], ["Importantly, no mutations were observed in viruses passaged without treatment.CVB3 Mutations in 2A and 3C Proteases Confer Resistance to Polyamine DepletionObserving the development of resistance to DFMO and the emergence of mutants in the passaged virus, we cloned these mutations in the CVB3 parental strain using mutagenic PCR on the CVB3 infectious clone.", [["Polyamine", "CHEMICAL", 137, 146], ["DFMO", "CHEMICAL", 199, 203], ["Polyamine", "CHEMICAL", 137, 146], ["DFMO", "CHEMICAL", 199, 203], ["CVB3", "ORGANISM", 78, 82], ["Polyamine", "SIMPLE_CHEMICAL", 137, 146], ["DFMO", "SIMPLE_CHEMICAL", 199, 203], ["CVB3", "ORGANISM", 289, 293], ["CVB3", "ORGANISM", 337, 341], ["clone", "CELL", 353, 358], ["2A and 3C Proteases", "PROTEIN", 96, 115], ["CVB3", "SPECIES", 78, 82], ["CVB3", "SPECIES", 289, 293], ["CVB3", "SPECIES", 337, 341], ["mutations", "PROBLEM", 16, 25], ["treatment", "TREATMENT", 68, 77], ["CVB3 Mutations", "TREATMENT", 78, 92], ["3C Proteases", "TREATMENT", 103, 115], ["Polyamine DepletionObserving", "TREATMENT", 137, 165], ["DFMO", "TREATMENT", 199, 203], ["mutants in the passaged virus", "PROBLEM", 225, 254], ["these mutations", "PROBLEM", 266, 281], ["mutagenic PCR", "TEST", 316, 329], ["no", "UNCERTAINTY", 13, 15]]], ["In addition to 2A 29K and 3C 52R mutants, we generated a 2A 29K /3C 52R double mutant.", [["29K", "GENE_OR_GENE_PRODUCT", 18, 21], ["3C", "GENE_OR_GENE_PRODUCT", 26, 28], ["52R", "GENE_OR_GENE_PRODUCT", 29, 32], ["29K", "GENE_OR_GENE_PRODUCT", 60, 63], ["52R", "GENE_OR_GENE_PRODUCT", 68, 71], ["2A 29K and 3C 52R mutants", "PROTEIN", 15, 40], ["2A 29K /3C 52R double mutant", "PROTEIN", 57, 85]]], ["After confirming the presence of the mutations, we generated an infectious virus and measured the virus titer over several rounds of replication.", [["the mutations", "PROBLEM", 33, 46], ["an infectious virus", "PROBLEM", 61, 80], ["the virus titer", "TREATMENT", 94, 109], ["replication", "TREATMENT", 133, 144], ["infectious", "OBSERVATION", 64, 74]]], ["Vero cells were treated with 500 \u00b5M DFMO or left untreated for four days prior to infection at MOI 0.01.", [["Vero cells", "ANATOMY", 0, 10], ["DFMO", "CHEMICAL", 36, 40], ["infection", "DISEASE", 82, 91], ["DFMO", "CHEMICAL", 36, 40], ["Vero cells", "CELL", 0, 10], ["DFMO", "SIMPLE_CHEMICAL", 36, 40], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["500 \u00b5M DFMO", "TREATMENT", 29, 40], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 82, 91]]], ["Cellular supernatant samples were collected and titered via plaque assay.", [["supernatant samples", "ANATOMY", 9, 28], ["plaque", "ANATOMY", 60, 66], ["Cellular supernatant samples", "TEST", 0, 28], ["plaque", "OBSERVATION", 60, 66]]], ["As shown in Figure 2A , all viruses in untreated conditions replicated with similar kinetics and to similar levels regardless of protease mutation.", [["protease", "PROTEIN", 129, 137], ["all viruses in untreated conditions", "PROBLEM", 24, 59], ["protease mutation", "PROBLEM", 129, 146], ["viruses", "OBSERVATION", 28, 35]]], ["However, in DFMO-treated cells, the wildtype CVB3 exhibited significant reductions in titer, which persisted to 72 hpi.", [["cells", "ANATOMY", 25, 30], ["DFMO", "CHEMICAL", 12, 16], ["DFMO", "CHEMICAL", 12, 16], ["DFMO", "SIMPLE_CHEMICAL", 12, 16], ["cells", "CELL", 25, 30], ["wildtype CVB3", "ORGANISM", 36, 49], ["DFMO-treated cells", "CELL_LINE", 12, 30], ["CVB3", "SPECIES", 45, 49], ["DFMO-treated cells", "TREATMENT", 12, 30], ["the wildtype CVB3", "PROBLEM", 32, 49], ["significant reductions in titer", "PROBLEM", 60, 91], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["reductions", "OBSERVATION_MODIFIER", 72, 82]]], ["Interestingly, the protease mutants, either alone or in combination, exhibited a significant rescue in viral titer compared to the wildtype virus, suggesting partial resistance to polyamine depletion.CVB3 Mutations in 2A and 3C Proteases Confer Resistance to Polyamine DepletionTo quantify resistance, we measured viral titers of wildtype and protease-mutant virus in untreated and DFMO-treated Vero cells over a concentration range ( Figure 2B ).", [["Vero cells", "ANATOMY", 395, 405], ["polyamine", "CHEMICAL", 180, 189], ["Polyamine", "CHEMICAL", 259, 268], ["DFMO", "CHEMICAL", 382, 386], ["polyamine", "CHEMICAL", 180, 189], ["Polyamine", "CHEMICAL", 259, 268], ["DFMO", "CHEMICAL", 382, 386], ["wildtype virus", "ORGANISM", 131, 145], ["polyamine", "SIMPLE_CHEMICAL", 180, 189], ["CVB3", "ORGANISM", 200, 204], ["Polyamine", "SIMPLE_CHEMICAL", 259, 268], ["protease-mutant virus", "ORGANISM", 343, 364], ["DFMO", "SIMPLE_CHEMICAL", 382, 386], ["Vero cells", "CELL", 395, 405], ["protease mutants", "PROTEIN", 19, 35], ["2A and 3C Proteases", "PROTEIN", 218, 237], ["protease", "PROTEIN", 343, 351], ["DFMO-treated Vero cells", "CELL_LINE", 382, 405], ["CVB3", "SPECIES", 200, 204], ["the protease mutants", "PROBLEM", 15, 35], ["a significant rescue in viral titer", "PROBLEM", 79, 114], ["the wildtype virus", "PROBLEM", 127, 145], ["partial resistance to polyamine depletion", "PROBLEM", 158, 199], ["CVB3 Mutations", "TREATMENT", 200, 214], ["3C Proteases", "TREATMENT", 225, 237], ["Polyamine DepletionTo quantify resistance", "TREATMENT", 259, 300], ["viral titers", "TEST", 314, 326], ["wildtype and protease", "TREATMENT", 330, 351], ["mutant virus", "PROBLEM", 352, 364], ["DFMO", "TREATMENT", 382, 386], ["Vero cells", "TREATMENT", 395, 405], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["rescue", "OBSERVATION", 93, 99], ["viral titer", "OBSERVATION", 103, 114], ["partial resistance", "OBSERVATION", 158, 176], ["polyamine depletion", "OBSERVATION", 180, 199]]], ["We infected these cells at MOI 0.1 and measured viral titers at 48 hpi.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["MOI", "TEST", 27, 30], ["viral titers", "TEST", 48, 60]]], ["We again observed significant sensitivity by the wildtype virus with any concentration of DFMO; in contrast, both protease mutants exhibited significant resistance, again suggesting that these mutations confer resistance to polyamine depletion.", [["DFMO", "CHEMICAL", 90, 94], ["polyamine", "CHEMICAL", 224, 233], ["DFMO", "CHEMICAL", 90, 94], ["polyamine", "CHEMICAL", 224, 233], ["DFMO", "SIMPLE_CHEMICAL", 90, 94], ["polyamine", "SIMPLE_CHEMICAL", 224, 233], ["protease mutants", "PROTEIN", 114, 130], ["significant sensitivity", "PROBLEM", 18, 41], ["the wildtype virus", "PROBLEM", 45, 63], ["DFMO", "TREATMENT", 90, 94], ["significant resistance", "PROBLEM", 141, 163], ["these mutations", "PROBLEM", 187, 202], ["polyamine depletion", "PROBLEM", 224, 243], ["significant resistance", "OBSERVATION", 141, 163], ["polyamine depletion", "OBSERVATION", 224, 243]]], ["We then measured percent replication by dividing the titer in DFMO treatment conditions (500 \u00b5M) by the titer in untreated conditions from 48 hpi ( Figure 2C ).", [["DFMO", "CHEMICAL", 62, 66], ["DFMO", "CHEMICAL", 62, 66], ["DFMO", "SIMPLE_CHEMICAL", 62, 66], ["percent replication", "TREATMENT", 17, 36], ["DFMO treatment conditions", "TREATMENT", 62, 87]]], ["We observed that compared to wildtype virus, all mutants exhibited higher replication, and the protease mutations conferred similar levels of resistance.", [["wildtype virus", "ORGANISM", 29, 43], ["protease", "PROTEIN", 95, 103], ["wildtype virus", "PROBLEM", 29, 43], ["the protease mutations", "TREATMENT", 91, 113], ["higher replication", "OBSERVATION", 67, 85]]], ["Combination of the mutations appeared to additively enhance replication; however, this difference was not statistically significant.CVB3 Mutations in 2A and 3C Proteases Confer Resistance to Polyamine Depletionby the titer in untreated conditions from 48 hpi ( Figure 2C ).", [["Polyamine", "CHEMICAL", 191, 200], ["Polyamine", "CHEMICAL", 191, 200], ["CVB3", "ORGANISM", 132, 136], ["Polyamine", "SIMPLE_CHEMICAL", 191, 200], ["2A and 3C Proteases", "PROTEIN", 150, 169], ["CVB3", "SPECIES", 132, 136], ["the mutations", "PROBLEM", 15, 28], ["CVB3 Mutations", "TREATMENT", 132, 146], ["3C Proteases", "TREATMENT", 157, 169], ["Resistance", "PROBLEM", 177, 187], ["Polyamine Depletionby", "TREATMENT", 191, 212], ["untreated conditions", "PROBLEM", 226, 246]]], ["We observed that compared to wildtype virus, all mutants exhibited higher replication, and the protease mutations conferred similar levels of resistance.", [["wildtype virus", "ORGANISM", 29, 43], ["protease", "PROTEIN", 95, 103], ["wildtype virus", "PROBLEM", 29, 43], ["the protease mutations", "TREATMENT", 91, 113], ["higher replication", "OBSERVATION", 67, 85]]], ["Combination of the mutations appeared to additively enhance replication; however, this difference was not statistically significant.CVB3 Mutations in 2A and 3C Proteases Confer Resistance to Polyamine DepletionWhile these mutations were obtained from a serial passage in DFMO-treated cells, we wished to determine whether these mutations conferred resistance to polyamine depletion and were not a consequence of a pleiotropic effect from DFMO.", [["cells", "ANATOMY", 284, 289], ["Polyamine", "CHEMICAL", 191, 200], ["DFMO", "CHEMICAL", 271, 275], ["polyamine", "CHEMICAL", 362, 371], ["DFMO", "CHEMICAL", 438, 442], ["Polyamine", "CHEMICAL", 191, 200], ["DFMO", "CHEMICAL", 271, 275], ["polyamine", "CHEMICAL", 362, 371], ["DFMO", "CHEMICAL", 438, 442], ["CVB3", "ORGANISM", 132, 136], ["Polyamine", "SIMPLE_CHEMICAL", 191, 200], ["DFMO", "SIMPLE_CHEMICAL", 271, 275], ["cells", "CELL", 284, 289], ["polyamine", "SIMPLE_CHEMICAL", 362, 371], ["DFMO", "SIMPLE_CHEMICAL", 438, 442], ["2A and 3C Proteases", "PROTEIN", 150, 169], ["DFMO-treated cells", "CELL_LINE", 271, 289], ["CVB3", "SPECIES", 132, 136], ["the mutations", "PROBLEM", 15, 28], ["CVB3 Mutations", "TREATMENT", 132, 146], ["3C Proteases", "TREATMENT", 157, 169], ["Polyamine DepletionWhile", "TREATMENT", 191, 215], ["these mutations", "PROBLEM", 216, 231], ["a serial passage in DFMO-treated cells", "TREATMENT", 251, 289], ["these mutations", "PROBLEM", 322, 337], ["polyamine depletion", "PROBLEM", 362, 381], ["a pleiotropic effect", "PROBLEM", 412, 432], ["DFMO", "TREATMENT", 438, 442], ["polyamine depletion", "OBSERVATION", 362, 381]]], ["Toward this end, we treated cells with a different polyamine-depleting agent, diethylnorspermidine (DENSpm), which acts to accelerate polyamine catabolism by acetylating spermidine and spermine.", [["cells", "ANATOMY", 28, 33], ["polyamine", "CHEMICAL", 51, 60], ["diethylnorspermidine", "CHEMICAL", 78, 98], ["DENSpm", "CHEMICAL", 100, 106], ["polyamine", "CHEMICAL", 134, 143], ["spermidine", "CHEMICAL", 170, 180], ["spermine", "CHEMICAL", 185, 193], ["polyamine", "CHEMICAL", 51, 60], ["diethylnorspermidine", "CHEMICAL", 78, 98], ["DENSpm", "CHEMICAL", 100, 106], ["polyamine", "CHEMICAL", 134, 143], ["spermidine", "CHEMICAL", 170, 180], ["spermine", "CHEMICAL", 185, 193], ["cells", "CELL", 28, 33], ["polyamine", "SIMPLE_CHEMICAL", 51, 60], ["diethylnorspermidine", "SIMPLE_CHEMICAL", 78, 98], ["DENSpm", "SIMPLE_CHEMICAL", 100, 106], ["polyamine", "SIMPLE_CHEMICAL", 134, 143], ["spermidine", "SIMPLE_CHEMICAL", 170, 180], ["spermine", "SIMPLE_CHEMICAL", 185, 193], ["a different polyamine-depleting agent", "TREATMENT", 39, 76], ["diethylnorspermidine (DENSpm)", "TREATMENT", 78, 107], ["polyamine catabolism", "TREATMENT", 134, 154], ["acetylating spermidine", "TREATMENT", 158, 180], ["polyamine catabolism", "OBSERVATION", 134, 154]]], ["Vero cells were treated with 100 \u00b5M DENSpm for 16 h prior to infection at MOI 0.1 with wildtype and mutant CVB3.", [["Vero cells", "ANATOMY", 0, 10], ["DENSpm", "CHEMICAL", 36, 42], ["infection", "DISEASE", 61, 70], ["DENSpm", "CHEMICAL", 36, 42], ["Vero cells", "CELL", 0, 10], ["CVB3", "ORGANISM", 107, 111], ["Vero cells", "CELL_LINE", 0, 10], ["CVB3", "SPECIES", 107, 111], ["Vero cells", "PROBLEM", 0, 10], ["100 \u00b5M DENSpm", "TREATMENT", 29, 42], ["infection at MOI", "PROBLEM", 61, 77], ["wildtype and mutant CVB3", "PROBLEM", 87, 111]]], ["At 48 hpi, we measured viral titers, and again we observed significant sensitivity with the wildtype virus ( Figure 2D ).", [["viral titers", "TEST", 23, 35], ["significant sensitivity", "PROBLEM", 59, 82], ["the wildtype virus", "PROBLEM", 88, 106]]], ["However, we observed partial resistance in our protease mutant viruses.", [["protease", "PROTEIN", 47, 55], ["partial resistance in our protease mutant viruses", "PROBLEM", 21, 70], ["partial resistance", "OBSERVATION", 21, 39], ["mutant viruses", "OBSERVATION", 56, 70]]], ["As with DFMO, when we calculated the percent replication in DENSpm-treated cells compared to untreated cells, the protease mutants exhibited resistance that was additive ( Figure 2E ).", [["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 103, 108], ["DFMO", "CHEMICAL", 8, 12], ["DENSpm", "CHEMICAL", 60, 66], ["DFMO", "CHEMICAL", 8, 12], ["DFMO", "SIMPLE_CHEMICAL", 8, 12], ["DENSpm", "SIMPLE_CHEMICAL", 60, 66], ["cells", "CELL", 75, 80], ["cells", "CELL", 103, 108], ["DENSpm-treated cells", "CELL_LINE", 60, 80], ["untreated cells", "CELL_TYPE", 93, 108], ["protease mutants", "PROTEIN", 114, 130], ["DFMO", "TREATMENT", 8, 12], ["the percent replication", "TREATMENT", 33, 56], ["DENSpm-treated cells", "TREATMENT", 60, 80], ["untreated cells", "PROBLEM", 93, 108], ["the protease mutants", "TREATMENT", 110, 130]]], ["We verified that both of these molecules were depleting polyamines in our treated cells by directly visualizing polyamines via thin-layer chromatography ( Figure 2F ).", [["cells", "ANATOMY", 82, 87], ["polyamines", "CHEMICAL", 56, 66], ["polyamines", "CHEMICAL", 112, 122], ["polyamines", "CHEMICAL", 56, 66], ["polyamines", "CHEMICAL", 112, 122], ["polyamines", "SIMPLE_CHEMICAL", 56, 66], ["cells", "CELL", 82, 87], ["polyamines", "SIMPLE_CHEMICAL", 112, 122], ["treated cells", "CELL_LINE", 74, 87], ["polyamines", "TREATMENT", 56, 66], ["our treated cells", "TREATMENT", 70, 87], ["thin-layer chromatography", "TEST", 127, 152]]], ["While these mutations were obtained from a serial passage in DFMO-treated cells, we wished to determine whether these mutations conferred resistance to polyamine depletion and were not a consequence of a pleiotropic effect from DFMO.", [["cells", "ANATOMY", 74, 79], ["DFMO", "CHEMICAL", 61, 65], ["polyamine", "CHEMICAL", 152, 161], ["DFMO", "CHEMICAL", 228, 232], ["DFMO", "CHEMICAL", 61, 65], ["polyamine", "CHEMICAL", 152, 161], ["DFMO", "CHEMICAL", 228, 232], ["DFMO", "SIMPLE_CHEMICAL", 61, 65], ["cells", "CELL", 74, 79], ["polyamine", "SIMPLE_CHEMICAL", 152, 161], ["DFMO", "SIMPLE_CHEMICAL", 228, 232], ["DFMO-treated cells", "CELL_LINE", 61, 79], ["these mutations", "PROBLEM", 6, 21], ["a serial passage in DFMO-treated cells", "TREATMENT", 41, 79], ["these mutations", "PROBLEM", 112, 127], ["polyamine depletion", "PROBLEM", 152, 171], ["a pleiotropic effect", "PROBLEM", 202, 222], ["DFMO", "TREATMENT", 228, 232], ["polyamine depletion", "OBSERVATION", 152, 171]]], ["Toward this end, we treated cells with a different polyamine-depleting agent, diethylnorspermidine (DENSpm), which acts to accelerate polyamine catabolism by acetylating spermidine and spermine.", [["cells", "ANATOMY", 28, 33], ["polyamine", "CHEMICAL", 51, 60], ["diethylnorspermidine", "CHEMICAL", 78, 98], ["DENSpm", "CHEMICAL", 100, 106], ["polyamine", "CHEMICAL", 134, 143], ["spermidine", "CHEMICAL", 170, 180], ["spermine", "CHEMICAL", 185, 193], ["polyamine", "CHEMICAL", 51, 60], ["diethylnorspermidine", "CHEMICAL", 78, 98], ["DENSpm", "CHEMICAL", 100, 106], ["polyamine", "CHEMICAL", 134, 143], ["spermidine", "CHEMICAL", 170, 180], ["spermine", "CHEMICAL", 185, 193], ["cells", "CELL", 28, 33], ["polyamine", "SIMPLE_CHEMICAL", 51, 60], ["diethylnorspermidine", "SIMPLE_CHEMICAL", 78, 98], ["DENSpm", "SIMPLE_CHEMICAL", 100, 106], ["polyamine", "SIMPLE_CHEMICAL", 134, 143], ["spermidine", "SIMPLE_CHEMICAL", 170, 180], ["spermine", "SIMPLE_CHEMICAL", 185, 193], ["a different polyamine-depleting agent", "TREATMENT", 39, 76], ["diethylnorspermidine (DENSpm)", "TREATMENT", 78, 107], ["polyamine catabolism", "TREATMENT", 134, 154], ["acetylating spermidine", "TREATMENT", 158, 180], ["polyamine catabolism", "OBSERVATION", 134, 154]]], ["Vero cells were treated with 100 \u00b5M DENSpm for 16 h prior to infection at MOI 0.1 with wildtype and mutant CVB3.", [["Vero cells", "ANATOMY", 0, 10], ["DENSpm", "CHEMICAL", 36, 42], ["infection", "DISEASE", 61, 70], ["DENSpm", "CHEMICAL", 36, 42], ["Vero cells", "CELL", 0, 10], ["CVB3", "ORGANISM", 107, 111], ["Vero cells", "CELL_LINE", 0, 10], ["CVB3", "SPECIES", 107, 111], ["Vero cells", "PROBLEM", 0, 10], ["100 \u00b5M DENSpm", "TREATMENT", 29, 42], ["infection at MOI", "PROBLEM", 61, 77], ["wildtype and mutant CVB3", "PROBLEM", 87, 111]]], ["At 48 hpi, we measured viral titers, and again we observed significant sensitivity with the wildtype virus ( Figure 2D ).", [["viral titers", "TEST", 23, 35], ["significant sensitivity", "PROBLEM", 59, 82], ["the wildtype virus", "PROBLEM", 88, 106]]], ["However, we observed partial resistance in our protease mutant viruses.", [["protease", "PROTEIN", 47, 55], ["partial resistance in our protease mutant viruses", "PROBLEM", 21, 70], ["partial resistance", "OBSERVATION", 21, 39], ["mutant viruses", "OBSERVATION", 56, 70]]], ["As with DFMO, when we calculated the percent replication in DENSpm-treated cells compared to untreated cells, the protease mutants exhibited resistance that was additive ( Figure 2E ).", [["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 103, 108], ["DFMO", "CHEMICAL", 8, 12], ["DENSpm", "CHEMICAL", 60, 66], ["DFMO", "CHEMICAL", 8, 12], ["DFMO", "SIMPLE_CHEMICAL", 8, 12], ["DENSpm", "SIMPLE_CHEMICAL", 60, 66], ["cells", "CELL", 75, 80], ["cells", "CELL", 103, 108], ["DENSpm-treated cells", "CELL_LINE", 60, 80], ["untreated cells", "CELL_TYPE", 93, 108], ["protease mutants", "PROTEIN", 114, 130], ["DFMO", "TREATMENT", 8, 12], ["the percent replication", "TREATMENT", 33, 56], ["DENSpm-treated cells", "TREATMENT", 60, 80], ["untreated cells", "PROBLEM", 93, 108], ["the protease mutants", "TREATMENT", 110, 130]]], ["We verified that both of these molecules were depleting polyamines in our treated cells by directly visualizing polyamines via thin-layer chromatography ( Figure 2F ).CVB3 Stability, Fitness, and Specific Infectivity Are Not Altered with Protease MutationTo determine whether our protease-mutant viruses differed significantly from our wildtype virus, we characterized fitness and replication characteristics.", [["cells", "ANATOMY", 82, 87], ["polyamines", "CHEMICAL", 56, 66], ["polyamines", "CHEMICAL", 112, 122], ["polyamines", "CHEMICAL", 56, 66], ["polyamines", "CHEMICAL", 112, 122], ["polyamines", "SIMPLE_CHEMICAL", 56, 66], ["cells", "CELL", 82, 87], ["polyamines", "SIMPLE_CHEMICAL", 112, 122], ["CVB3", "ORGANISM", 167, 171], ["Protease", "GENE_OR_GENE_PRODUCT", 238, 246], ["protease", "GENE_OR_GENE_PRODUCT", 280, 288], ["wildtype virus", "ORGANISM", 336, 350], ["treated cells", "CELL_LINE", 74, 87], ["Protease MutationTo", "PROTEIN", 238, 257], ["protease", "PROTEIN", 280, 288], ["CVB3", "SPECIES", 167, 171], ["polyamines", "TREATMENT", 56, 66], ["our treated cells", "TREATMENT", 70, 87], ["thin-layer chromatography", "TEST", 127, 152], ["Protease MutationTo", "TREATMENT", 238, 257], ["our protease", "TEST", 276, 288], ["mutant viruses", "PROBLEM", 289, 303], ["our wildtype virus", "PROBLEM", 332, 350], ["Stability", "OBSERVATION_MODIFIER", 172, 181]]], ["As shown in Figure 2A , the wildtype and mutant viruses replicate with similar kinetics.", [["mutant viruses", "ORGANISM", 41, 55], ["the wildtype and mutant viruses", "PROBLEM", 24, 55]]], ["To ascertain whether these viruses produced similar levels of infectious particles, we measured the ratio of viral genomes to infectious virus.", [["infectious virus", "ORGANISM", 126, 142], ["viral genomes", "DNA", 109, 122], ["these viruses", "PROBLEM", 21, 34], ["infectious particles", "PROBLEM", 62, 82], ["viral genomes to infectious virus", "PROBLEM", 109, 142], ["viruses", "OBSERVATION", 27, 34], ["infectious", "OBSERVATION", 62, 72], ["viral genomes", "OBSERVATION", 109, 122], ["infectious virus", "OBSERVATION", 126, 142]]], ["Vero cells were infected with the wildtype or protease mutant viruses for 48 h, and subsequently, viral titers ( Figure 3A ) were determined by plaque assay and RNA was processed from infected cellular supernatant.", [["Vero cells", "ANATOMY", 0, 10], ["plaque", "ANATOMY", 144, 150], ["cellular supernatant", "ANATOMY", 193, 213], ["Vero cells", "CELL", 0, 10], ["cellular", "CELL", 193, 201], ["Vero cells", "CELL_LINE", 0, 10], ["protease", "PROTEIN", 46, 54], ["Vero cells", "PROBLEM", 0, 10], ["protease mutant viruses", "TREATMENT", 46, 69], ["viral titers", "TEST", 98, 110], ["plaque assay", "TEST", 144, 156], ["RNA", "TEST", 161, 164], ["infected cellular supernatant", "PROBLEM", 184, 213], ["plaque", "OBSERVATION", 144, 150], ["infected", "OBSERVATION_MODIFIER", 184, 192], ["cellular supernatant", "OBSERVATION", 193, 213]]], ["The number of viral genomes was quantified by qRT-PCR ( Figure 3B) , and the ratio of genomes to infectious virus (pfu) calculated ( Figure 3C ).", [["infectious virus", "ORGANISM", 97, 113], ["viral genomes", "DNA", 14, 27], ["viral genomes", "PROBLEM", 14, 27], ["qRT", "TEST", 46, 49], ["PCR", "TEST", 50, 53], ["infectious virus", "PROBLEM", 97, 113], ["viral genomes", "OBSERVATION", 14, 27], ["infectious", "OBSERVATION_MODIFIER", 97, 107]]], ["We observed no changes in viral titers in polyamine-sufficient conditions, and viral genomes were slightly elevated, though not statistically significant, in 2A 29K and 3C 52R mutant viruses ( Figure 3B) .", [["polyamine", "CHEMICAL", 42, 51], ["polyamine", "CHEMICAL", 42, 51], ["polyamine", "SIMPLE_CHEMICAL", 42, 51], ["3C 52R mutant viruses", "ORGANISM", 169, 190], ["viral genomes", "DNA", 79, 92], ["changes in viral titers", "PROBLEM", 15, 38], ["polyamine", "TEST", 42, 51], ["viral genomes", "TEST", 79, 92], ["slightly elevated", "PROBLEM", 98, 115], ["no", "UNCERTAINTY", 12, 14], ["viral titers", "OBSERVATION", 26, 38]]], ["Overall, the genome-to-pfu ratio was not statistically significantly different among our protease mutant viruses.CVB3 Stability, Fitness, and Specific Infectivity Are Not Altered with Protease MutationPassaging CVB3 in Vero cells can result in the emergence of a virus with fitness changes that provide a replicative advantage, as we had observed with our CHIKV mutant viruses [31] .", [["Vero cells", "ANATOMY", 219, 229], ["genome", "CELLULAR_COMPONENT", 13, 19], ["CVB3", "ORGANISM", 113, 117], ["Protease", "GENE_OR_GENE_PRODUCT", 184, 192], ["CVB3", "ORGANISM", 211, 215], ["Vero cells", "CELL", 219, 229], ["CHIKV mutant viruses", "ORGANISM", 356, 376], ["protease", "PROTEIN", 89, 97], ["Vero cells", "CELL_LINE", 219, 229], ["CVB3", "SPECIES", 113, 117], ["CVB3", "SPECIES", 211, 215], ["CHIKV", "SPECIES", 356, 361], ["our protease mutant viruses", "PROBLEM", 85, 112], ["Protease MutationPassaging CVB3", "TREATMENT", 184, 215], ["Vero cells", "PROBLEM", 219, 229], ["a virus", "PROBLEM", 261, 268], ["a replicative advantage", "TREATMENT", 303, 326], ["our CHIKV mutant viruses", "PROBLEM", 352, 376], ["mutant viruses", "OBSERVATION", 98, 112], ["Stability", "OBSERVATION_MODIFIER", 118, 127]]], ["To determine whether our CVB3 mutants had fitness enhancement manifesting as a more rapidly replicating virus, we measured virus plaque sizes of wildtype and protease mutant virus.", [["plaque", "ANATOMY", 129, 135], ["CVB3", "ORGANISM", 25, 29], ["protease mutant virus", "ORGANISM", 158, 179], ["protease", "PROTEIN", 158, 166], ["CVB3", "SPECIES", 25, 29], ["fitness enhancement", "PROBLEM", 42, 61], ["a more rapidly replicating virus", "PROBLEM", 77, 109], ["virus plaque sizes", "PROBLEM", 123, 141], ["wildtype and protease mutant virus", "PROBLEM", 145, 179], ["plaque", "OBSERVATION_MODIFIER", 129, 135], ["sizes", "OBSERVATION_MODIFIER", 136, 141]]], ["We observed no significant difference between wildtype and mutant CVB3 plaque size ( Figure 3D ).", [["plaque", "ANATOMY", 71, 77], ["CVB3", "ORGANISM", 66, 70], ["CVB3", "SPECIES", 66, 70], ["significant difference between wildtype and mutant CVB3 plaque size", "PROBLEM", 15, 82], ["no", "UNCERTAINTY", 12, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["CVB3", "OBSERVATION_MODIFIER", 66, 70], ["plaque", "OBSERVATION_MODIFIER", 71, 77], ["size", "OBSERVATION_MODIFIER", 78, 82]]], ["To better measure viral fitness via competition assay, we infected Vero cells with equal quantities of infectious virus of wildtype and 2A 29K or 3C 52R , and after five passages, we extracted RNA, reverse transcribed, amplified viral genomes by PCR, and Sanger sequenced the appropriate genomic locus corresponding to each protease (Table 1) .", [["Vero cells", "ANATOMY", 67, 77], ["Vero cells", "CELL", 67, 77], ["Vero cells", "CELL_LINE", 67, 77], ["amplified viral genomes", "DNA", 219, 242], ["genomic locus", "DNA", 288, 301], ["protease", "PROTEIN", 324, 332], ["competition assay", "TEST", 36, 53], ["infected Vero cells", "PROBLEM", 58, 77], ["infectious virus of wildtype", "PROBLEM", 103, 131], ["K", "TEST", 141, 142], ["amplified viral genomes", "PROBLEM", 219, 242], ["PCR", "TEST", 246, 249], ["Vero cells", "OBSERVATION", 67, 77], ["infectious", "OBSERVATION", 103, 113]]], ["After the fifth passage, we observed that the wildtype and either protease mutant virus existed as a mixed population, with peaks corresponding to the wildtype and mutant nucleotide present in the samples ( Figure 3E , representative of three independent passages).", [["samples", "ANATOMY", 197, 204], ["nucleotide", "CHEMICAL", 171, 181], ["nucleotide", "CHEMICAL", 171, 181], ["protease mutant virus", "ORGANISM", 66, 87], ["protease", "PROTEIN", 66, 74], ["the wildtype and either protease mutant virus", "PROBLEM", 42, 87], ["a mixed population", "PROBLEM", 99, 117], ["the wildtype and mutant nucleotide", "PROBLEM", 147, 181]]], ["Additionally, we passaged mutant virus without competition to determine the stability of the mutant.", [["mutant virus", "ORGANISM", 26, 38], ["mutant virus", "PROBLEM", 26, 38]]], ["We observed that the mutation was maintained after five passages, suggesting that there is no fitness cost to this mutation in our cell culture conditions.", [["cell", "ANATOMY", 131, 135], ["cell", "CELL", 131, 135], ["the mutation", "PROBLEM", 17, 29], ["this mutation", "PROBLEM", 110, 123], ["our cell culture conditions", "TEST", 127, 154], ["no", "UNCERTAINTY", 91, 93]]], ["Altogether, our data suggest that protease-mutant CVB3 exhibits no significant replicative advantage compared to wildtype CVB3.CVB3 Protease Activity Is Modulated by Cellular Polyamine LevelsGiven that we had observed resistance mutations in both 2A and 3C proteases after passaging virus in polyamine-depleted cells, we hypothesized that viral protease activity may be modulated by cellular polyamines.", [["cells", "ANATOMY", 311, 316], ["cellular", "ANATOMY", 383, 391], ["Polyamine", "CHEMICAL", 175, 184], ["polyamine", "CHEMICAL", 292, 301], ["Polyamine", "CHEMICAL", 175, 184], ["polyamine", "CHEMICAL", 292, 301], ["polyamines", "CHEMICAL", 392, 402], ["CVB3", "ORGANISM", 50, 54], ["CVB3", "ORGANISM", 122, 126], ["CVB3", "ORGANISM", 127, 131], ["3C", "GENE_OR_GENE_PRODUCT", 254, 256], ["polyamine", "SIMPLE_CHEMICAL", 292, 301], ["cells", "CELL", 311, 316], ["cellular", "CELL", 383, 391], ["protease", "PROTEIN", 34, 42], ["2A and 3C proteases", "PROTEIN", 247, 266], ["polyamine-depleted cells", "CELL_LINE", 292, 316], ["viral protease", "PROTEIN", 339, 353], ["CVB3", "SPECIES", 50, 54], ["CVB3", "SPECIES", 122, 126], ["CVB3", "SPECIES", 127, 131], ["our data", "TEST", 12, 20], ["mutant CVB3", "PROBLEM", 43, 54], ["CVB3 Protease", "TREATMENT", 127, 140], ["Cellular Polyamine LevelsGiven", "TEST", 166, 196], ["resistance mutations", "PROBLEM", 218, 238], ["3C proteases", "TREATMENT", 254, 266], ["passaging virus", "PROBLEM", 273, 288], ["polyamine-depleted cells", "TREATMENT", 292, 316], ["viral protease activity", "PROBLEM", 339, 362], ["cellular polyamines", "TREATMENT", 383, 402], ["depleted cells", "OBSERVATION", 302, 316], ["cellular polyamines", "OBSERVATION", 383, 402]]], ["While previous reports have suggested that polyamines enhance chymotrypsin activity [32, 33] , a role for polyamines in viral protease activity has never been reported.", [["polyamines", "CHEMICAL", 43, 53], ["polyamines", "CHEMICAL", 106, 116], ["polyamines", "CHEMICAL", 43, 53], ["polyamines", "CHEMICAL", 106, 116], ["polyamines", "SIMPLE_CHEMICAL", 43, 53], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 62, 74], ["polyamines", "SIMPLE_CHEMICAL", 106, 116], ["chymotrypsin", "PROTEIN", 62, 74], ["viral protease", "PROTEIN", 120, 134], ["polyamines enhance chymotrypsin activity", "PROBLEM", 43, 83], ["polyamines in viral protease activity", "TREATMENT", 106, 143]]], ["Toward this end, we treated cells with increasing doses of DFMO or DENSpm to deplete cellular polyamines.", [["cells", "ANATOMY", 28, 33], ["cellular", "ANATOMY", 85, 93], ["DFMO", "CHEMICAL", 59, 63], ["DENSpm", "CHEMICAL", 67, 73], ["DFMO", "CHEMICAL", 59, 63], ["DENSpm", "CHEMICAL", 67, 73], ["polyamines", "CHEMICAL", 94, 104], ["cells", "CELL", 28, 33], ["DFMO", "SIMPLE_CHEMICAL", 59, 63], ["DENSpm", "SIMPLE_CHEMICAL", 67, 73], ["cellular", "CELL", 85, 93], ["DFMO", "TREATMENT", 59, 63], ["DENSpm", "TREATMENT", 67, 73], ["cellular polyamines", "TREATMENT", 85, 104], ["cellular polyamines", "OBSERVATION", 85, 104]]], ["Following incubation with a drug, cells were infected at MOI 10 for 24 h, at which time cellular lysates were collected for western analysis.", [["cells", "ANATOMY", 34, 39], ["cellular lysates", "ANATOMY", 88, 104], ["cells", "CELL", 34, 39], ["cellular lysates", "ORGANISM_SUBSTANCE", 88, 104], ["a drug, cells", "TREATMENT", 26, 39], ["cellular lysates", "TEST", 88, 104], ["western analysis", "TEST", 124, 140]]], ["Lysates were analyzed for the presence of cleaved eIF4G, a cellular target of the viral proteases.", [["Lysates", "ANATOMY", 0, 7], ["cellular", "ANATOMY", 59, 67], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["eIF4G", "GENE_OR_GENE_PRODUCT", 50, 55], ["cellular", "CELL", 59, 67], ["eIF4G", "PROTEIN", 50, 55], ["viral proteases", "PROTEIN", 82, 97], ["Lysates", "TEST", 0, 7], ["cleaved eIF4G", "PROBLEM", 42, 55], ["the viral proteases", "PROBLEM", 78, 97], ["eIF4G", "OBSERVATION", 50, 55], ["viral proteases", "OBSERVATION", 82, 97]]], ["We observed that in infected cells, a distinct eIF4G band was present; however, in cells treated either with DFMO or DENSpm, eIF4G cleavage was significantly restricted ( Figure 4A ).", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 83, 88], ["DFMO", "CHEMICAL", 109, 113], ["DFMO", "CHEMICAL", 109, 113], ["DENSpm", "CHEMICAL", 117, 123], ["cells", "CELL", 29, 34], ["eIF4G", "GENE_OR_GENE_PRODUCT", 47, 52], ["cells", "CELL", 83, 88], ["DFMO", "SIMPLE_CHEMICAL", 109, 113], ["DENSpm", "SIMPLE_CHEMICAL", 117, 123], ["eIF4G", "GENE_OR_GENE_PRODUCT", 125, 130], ["infected cells", "CELL_TYPE", 20, 34], ["eIF4G band", "PROTEIN", 47, 57], ["eIF4G", "PROTEIN", 125, 130], ["infected cells", "PROBLEM", 20, 34], ["a distinct eIF4G band", "PROBLEM", 36, 57], ["DFMO", "TREATMENT", 109, 113], ["DENSpm", "TREATMENT", 117, 123], ["eIF4G cleavage", "TREATMENT", 125, 139], ["infected cells", "OBSERVATION", 20, 34], ["distinct", "OBSERVATION_MODIFIER", 38, 46], ["eIF4G band", "OBSERVATION", 47, 57]]], ["We were unable to visualize full-length eIF4G, likely due to its large size.CVB3 Protease Activity Is Modulated by Cellular Polyamine LevelsThe reduction in eIF4G cleavage by viral protease in the presence of polyamine depleting molecules could be the result of polyamines modulating viral protease activity, or the phenotype could be due to restriction of virus replication, protease translation, and subsequent reduction in proteolytic activity.", [["Polyamine", "CHEMICAL", 124, 133], ["polyamine", "CHEMICAL", 209, 218], ["polyamines", "CHEMICAL", 262, 272], ["Polyamine", "CHEMICAL", 124, 133], ["polyamine", "CHEMICAL", 209, 218], ["polyamines", "CHEMICAL", 262, 272], ["eIF4G", "GENE_OR_GENE_PRODUCT", 40, 45], ["CVB3", "ORGANISM", 76, 80], ["eIF4G", "GENE_OR_GENE_PRODUCT", 157, 162], ["polyamine", "SIMPLE_CHEMICAL", 209, 218], ["polyamines", "SIMPLE_CHEMICAL", 262, 272], ["eIF4G", "PROTEIN", 40, 45], ["eIF4G", "PROTEIN", 157, 162], ["viral protease", "PROTEIN", 175, 189], ["viral protease", "PROTEIN", 284, 298], ["protease", "PROTEIN", 376, 384], ["CVB3", "SPECIES", 76, 80], ["full-length eIF4G", "TREATMENT", 28, 45], ["CVB3 Protease", "TREATMENT", 76, 89], ["Cellular Polyamine Levels", "TEST", 115, 140], ["The reduction", "TREATMENT", 140, 153], ["eIF4G cleavage", "TREATMENT", 157, 171], ["viral protease", "PROBLEM", 175, 189], ["polyamine depleting molecules", "PROBLEM", 209, 238], ["polyamines modulating viral protease activity", "PROBLEM", 262, 307], ["the phenotype", "PROBLEM", 312, 325], ["virus replication", "TREATMENT", 357, 374], ["protease translation", "TREATMENT", 376, 396], ["proteolytic activity", "PROBLEM", 426, 446], ["likely due to", "UNCERTAINTY", 47, 60], ["large", "OBSERVATION_MODIFIER", 65, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["reduction", "OBSERVATION_MODIFIER", 144, 153], ["eIF4G cleavage", "OBSERVATION", 157, 171], ["viral protease", "OBSERVATION", 175, 189], ["polyamine depleting molecules", "OBSERVATION", 209, 238], ["viral protease activity", "OBSERVATION", 284, 307], ["reduction", "OBSERVATION_MODIFIER", 413, 422], ["proteolytic activity", "OBSERVATION", 426, 446]]], ["To directly measure viral protease activity in cells, we generated a proteasesensitive dual luciferase reporter system.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 92, 102], ["viral protease", "PROTEIN", 20, 34], ["viral protease activity in cells", "TREATMENT", 20, 52]]], ["In this split luciferase system, cleavage of a target sequence allows for robust firefly luciferase activity, which can be normalized to a renilla luciferase transfection control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 14, 24], ["luciferase", "GENE_OR_GENE_PRODUCT", 89, 99], ["luciferase", "GENE_OR_GENE_PRODUCT", 147, 157], ["luciferase", "PROTEIN", 14, 24], ["target sequence", "DNA", 47, 62], ["luciferase", "PROTEIN", 89, 99], ["luciferase", "PROTEIN", 147, 157], ["a target sequence", "TEST", 45, 62], ["robust firefly luciferase activity", "PROBLEM", 74, 108], ["a renilla luciferase transfection control", "TREATMENT", 137, 178]]], ["This system has previously been used to explore the activity of viral polymerases [34] [35] [36] , though it has not been considered in the context of polyamine depletion.", [["polyamine", "CHEMICAL", 151, 160], ["polyamine", "CHEMICAL", 151, 160], ["polyamine", "SIMPLE_CHEMICAL", 151, 160], ["viral polymerases", "TEST", 64, 81], ["polyamine depletion", "PROBLEM", 151, 170], ["polyamine depletion", "OBSERVATION", 151, 170]]], ["To generate this system, weCVB3 Protease Activity Is Modulated by Cellular Polyamine LevelsGiven that we had observed resistance mutations in both 2A and 3C proteases after passaging virus in polyamine-depleted cells, we hypothesized that viral protease activity may be modulated by cellular polyamines.", [["cells", "ANATOMY", 211, 216], ["cellular", "ANATOMY", 283, 291], ["Polyamine", "CHEMICAL", 75, 84], ["polyamine", "CHEMICAL", 192, 201], ["Polyamine", "CHEMICAL", 75, 84], ["polyamine", "CHEMICAL", 192, 201], ["polyamines", "CHEMICAL", 292, 302], ["3C", "GENE_OR_GENE_PRODUCT", 154, 156], ["polyamine", "SIMPLE_CHEMICAL", 192, 201], ["cells", "CELL", 211, 216], ["cellular", "CELL", 283, 291], ["2A and 3C proteases", "PROTEIN", 147, 166], ["polyamine-depleted cells", "CELL_LINE", 192, 216], ["viral protease", "PROTEIN", 239, 253], ["this system", "TREATMENT", 12, 23], ["Cellular Polyamine LevelsGiven", "TEST", 66, 96], ["resistance mutations", "PROBLEM", 118, 138], ["3C proteases", "TREATMENT", 154, 166], ["passaging virus", "PROBLEM", 173, 188], ["polyamine-depleted cells", "TREATMENT", 192, 216], ["viral protease activity", "PROBLEM", 239, 262], ["cellular polyamines", "TREATMENT", 283, 302], ["depleted cells", "OBSERVATION", 202, 216], ["viral protease activity", "OBSERVATION", 239, 262], ["cellular polyamines", "OBSERVATION", 283, 302]]], ["While previous reports have suggested that polyamines enhance chymotrypsin activity [32, 33] , a role for polyamines in viral protease activity has never been reported.", [["polyamines", "CHEMICAL", 43, 53], ["polyamines", "CHEMICAL", 106, 116], ["polyamines", "CHEMICAL", 43, 53], ["polyamines", "CHEMICAL", 106, 116], ["polyamines", "SIMPLE_CHEMICAL", 43, 53], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 62, 74], ["polyamines", "SIMPLE_CHEMICAL", 106, 116], ["chymotrypsin", "PROTEIN", 62, 74], ["viral protease", "PROTEIN", 120, 134], ["polyamines enhance chymotrypsin activity", "PROBLEM", 43, 83], ["polyamines in viral protease activity", "TREATMENT", 106, 143]]], ["Toward this end, we treated cells with increasing doses of DFMO or DENSpm to deplete cellular polyamines.", [["cells", "ANATOMY", 28, 33], ["cellular", "ANATOMY", 85, 93], ["DFMO", "CHEMICAL", 59, 63], ["DENSpm", "CHEMICAL", 67, 73], ["DFMO", "CHEMICAL", 59, 63], ["DENSpm", "CHEMICAL", 67, 73], ["polyamines", "CHEMICAL", 94, 104], ["cells", "CELL", 28, 33], ["DFMO", "SIMPLE_CHEMICAL", 59, 63], ["DENSpm", "SIMPLE_CHEMICAL", 67, 73], ["cellular", "CELL", 85, 93], ["DFMO", "TREATMENT", 59, 63], ["DENSpm", "TREATMENT", 67, 73], ["cellular polyamines", "TREATMENT", 85, 104], ["cellular polyamines", "OBSERVATION", 85, 104]]], ["Following incubation with a drug, cells were infected at MOI 10 for 24 h, at which time cellular lysates were collected for western analysis.", [["cells", "ANATOMY", 34, 39], ["cellular lysates", "ANATOMY", 88, 104], ["cells", "CELL", 34, 39], ["cellular lysates", "ORGANISM_SUBSTANCE", 88, 104], ["a drug, cells", "TREATMENT", 26, 39], ["cellular lysates", "TEST", 88, 104], ["western analysis", "TEST", 124, 140]]], ["Lysates were analyzed for the presence of cleaved eIF4G, a cellular target of the viral proteases.", [["Lysates", "ANATOMY", 0, 7], ["cellular", "ANATOMY", 59, 67], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["eIF4G", "GENE_OR_GENE_PRODUCT", 50, 55], ["cellular", "CELL", 59, 67], ["eIF4G", "PROTEIN", 50, 55], ["viral proteases", "PROTEIN", 82, 97], ["Lysates", "TEST", 0, 7], ["cleaved eIF4G", "PROBLEM", 42, 55], ["the viral proteases", "PROBLEM", 78, 97], ["eIF4G", "OBSERVATION", 50, 55], ["viral proteases", "OBSERVATION", 82, 97]]], ["We observed that in infected cells, a distinct eIF4G band was present; however, in cells treated either with DFMO or DENSpm, eIF4G cleavage was significantly restricted ( Figure 4A ).", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 83, 88], ["DFMO", "CHEMICAL", 109, 113], ["DFMO", "CHEMICAL", 109, 113], ["DENSpm", "CHEMICAL", 117, 123], ["cells", "CELL", 29, 34], ["eIF4G", "GENE_OR_GENE_PRODUCT", 47, 52], ["cells", "CELL", 83, 88], ["DFMO", "SIMPLE_CHEMICAL", 109, 113], ["DENSpm", "SIMPLE_CHEMICAL", 117, 123], ["eIF4G", "GENE_OR_GENE_PRODUCT", 125, 130], ["infected cells", "CELL_TYPE", 20, 34], ["eIF4G band", "PROTEIN", 47, 57], ["eIF4G", "PROTEIN", 125, 130], ["infected cells", "PROBLEM", 20, 34], ["a distinct eIF4G band", "PROBLEM", 36, 57], ["DFMO", "TREATMENT", 109, 113], ["DENSpm", "TREATMENT", 117, 123], ["eIF4G cleavage", "TREATMENT", 125, 139], ["infected cells", "OBSERVATION", 20, 34], ["distinct", "OBSERVATION_MODIFIER", 38, 46], ["eIF4G band", "OBSERVATION", 47, 57]]], ["We were unable to visualize full-length eIF4G, likely due to its large size.CVB3 Protease Activity Is Modulated by Cellular Polyamine LevelsThe reduction in eIF4G cleavage by viral protease in the presence of polyamine depleting molecules could be the result of polyamines modulating viral protease activity, or the phenotype could be due to restriction of virus replication, protease translation, and subsequent reduction in proteolytic activity.", [["Polyamine", "CHEMICAL", 124, 133], ["polyamine", "CHEMICAL", 209, 218], ["polyamines", "CHEMICAL", 262, 272], ["Polyamine", "CHEMICAL", 124, 133], ["polyamine", "CHEMICAL", 209, 218], ["polyamines", "CHEMICAL", 262, 272], ["eIF4G", "GENE_OR_GENE_PRODUCT", 40, 45], ["CVB3", "ORGANISM", 76, 80], ["eIF4G", "GENE_OR_GENE_PRODUCT", 157, 162], ["polyamine", "SIMPLE_CHEMICAL", 209, 218], ["polyamines", "SIMPLE_CHEMICAL", 262, 272], ["eIF4G", "PROTEIN", 40, 45], ["eIF4G", "PROTEIN", 157, 162], ["viral protease", "PROTEIN", 175, 189], ["viral protease", "PROTEIN", 284, 298], ["protease", "PROTEIN", 376, 384], ["CVB3", "SPECIES", 76, 80], ["full-length eIF4G", "TREATMENT", 28, 45], ["CVB3 Protease", "TREATMENT", 76, 89], ["Cellular Polyamine Levels", "TEST", 115, 140], ["The reduction", "TREATMENT", 140, 153], ["eIF4G cleavage", "TREATMENT", 157, 171], ["viral protease", "PROBLEM", 175, 189], ["polyamine depleting molecules", "PROBLEM", 209, 238], ["polyamines modulating viral protease activity", "PROBLEM", 262, 307], ["the phenotype", "PROBLEM", 312, 325], ["virus replication", "TREATMENT", 357, 374], ["protease translation", "TREATMENT", 376, 396], ["proteolytic activity", "PROBLEM", 426, 446], ["likely due to", "UNCERTAINTY", 47, 60], ["large", "OBSERVATION_MODIFIER", 65, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["reduction", "OBSERVATION_MODIFIER", 144, 153], ["eIF4G cleavage", "OBSERVATION", 157, 171], ["viral protease", "OBSERVATION", 175, 189], ["polyamine depleting molecules", "OBSERVATION", 209, 238], ["viral protease activity", "OBSERVATION", 284, 307], ["reduction", "OBSERVATION_MODIFIER", 413, 422], ["proteolytic activity", "OBSERVATION", 426, 446]]], ["To directly measure viral protease activity in cells, we generated a protease-sensitive dual luciferase reporter system.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 93, 103], ["viral protease", "PROTEIN", 20, 34], ["protease", "PROTEIN", 69, 77], ["viral protease activity in cells", "TREATMENT", 20, 52], ["a protease", "TREATMENT", 67, 77]]], ["In this split luciferase system, cleavage of a target sequence allows for robust firefly luciferase activity, which can be normalized to a renilla luciferase transfection control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 14, 24], ["luciferase", "GENE_OR_GENE_PRODUCT", 89, 99], ["luciferase", "GENE_OR_GENE_PRODUCT", 147, 157], ["luciferase", "PROTEIN", 14, 24], ["target sequence", "DNA", 47, 62], ["luciferase", "PROTEIN", 89, 99], ["luciferase", "PROTEIN", 147, 157], ["a target sequence", "TEST", 45, 62], ["robust firefly luciferase activity", "PROBLEM", 74, 108], ["a renilla luciferase transfection control", "TREATMENT", 137, 178]]], ["This system has previously been used to explore the activity of viral polymerases [34] [35] [36] , though it has not been considered in the context of polyamine depletion.", [["polyamine", "CHEMICAL", 151, 160], ["polyamine", "CHEMICAL", 151, 160], ["polyamine", "SIMPLE_CHEMICAL", 151, 160], ["viral polymerases", "TEST", 64, 81], ["polyamine depletion", "PROBLEM", 151, 170], ["polyamine depletion", "OBSERVATION", 151, 170]]], ["To generate this system, we cloned a 2A target sequence-MTNTGAFG-and a 3C target sequence-AMEQG-into the firefly luciferase reporter [37] .", [["MTNTGAFG", "GENE_OR_GENE_PRODUCT", 56, 64], ["luciferase", "GENE_OR_GENE_PRODUCT", 113, 123], ["2A target sequence", "DNA", 37, 55], ["MTNTGAFG-and a 3C target sequence", "DNA", 56, 89], ["AMEQG", "DNA", 90, 95], ["firefly luciferase reporter", "DNA", 105, 132]]], ["We also cloned 2A and 3C into the pCMV plasmid to drive robust protease expression.", [["plasmid", "ANATOMY", 39, 46], ["3C", "GENE_OR_GENE_PRODUCT", 22, 24], ["pCMV", "GENE_OR_GENE_PRODUCT", 34, 38], ["pCMV plasmid", "DNA", 34, 46], ["protease", "PROTEIN", 63, 71], ["the pCMV plasmid", "TREATMENT", 30, 46], ["robust protease expression", "TREATMENT", 56, 82]]], ["These constructs were cotransfected into 293T cells either left untreated or treated with increasing doses of DFMO.", [["293T cells", "ANATOMY", 41, 51], ["DFMO", "CHEMICAL", 110, 114], ["DFMO", "CHEMICAL", 110, 114], ["293T cells", "CELL", 41, 51], ["DFMO", "SIMPLE_CHEMICAL", 110, 114], ["293T cells", "CELL_LINE", 41, 51], ["DFMO", "TREATMENT", 110, 114], ["293T cells", "OBSERVATION", 41, 51], ["left", "ANATOMY_MODIFIER", 59, 63]]], ["Firefly activity was measured 24 h later and normalized to renilla activity.", [["Firefly", "GENE_OR_GENE_PRODUCT", 0, 7], ["renilla", "GENE_OR_GENE_PRODUCT", 59, 66], ["renilla activity", "OBSERVATION", 59, 75]]], ["We observed that for both 2A ( Figure 4C ) and 3C ( Figure 4D ), protease activity was significantly reduced with DFMO treatment, to levels that were nearly undetectable with DFMO concentrations at or above 500 \u00b5M.", [["DFMO", "CHEMICAL", 114, 118], ["DFMO", "CHEMICAL", 175, 179], ["DFMO", "CHEMICAL", 114, 118], ["DFMO", "CHEMICAL", 175, 179], ["DFMO", "SIMPLE_CHEMICAL", 114, 118], ["DFMO", "SIMPLE_CHEMICAL", 175, 179], ["protease", "PROTEIN", 65, 73], ["3C ( Figure 4D )", "TREATMENT", 47, 63], ["protease activity", "TREATMENT", 65, 82], ["DFMO treatment", "TREATMENT", 114, 128], ["DFMO concentrations", "TREATMENT", 175, 194]]], ["These data support our hypothesis that polyamines modulate viral protease activity, and polyamine depletion restricts virus replication by quelling viral protease activity.CVB3 Protease Activity Is Modulated by Cellular Polyamine LevelsViruses 2019, 11, x FOR PEER REVIEW 10 of 15 cloned a 2A target sequence-MTNTGAFG-and a 3C target sequence-AMEQG-into the firefly luciferase reporter [37] .", [["polyamines", "CHEMICAL", 39, 49], ["polyamine", "CHEMICAL", 88, 97], ["polyamines", "CHEMICAL", 39, 49], ["polyamine", "CHEMICAL", 88, 97], ["Polyamine", "CHEMICAL", 220, 229], ["polyamines", "SIMPLE_CHEMICAL", 39, 49], ["polyamine", "SIMPLE_CHEMICAL", 88, 97], ["CVB3", "ORGANISM", 172, 176], ["luciferase", "GENE_OR_GENE_PRODUCT", 366, 376], ["viral protease", "PROTEIN", 59, 73], ["viral protease", "PROTEIN", 148, 162], ["2A target sequence", "DNA", 290, 308], ["MTNTGAFG-and a 3C target sequence", "DNA", 309, 342], ["AMEQG", "DNA", 343, 348], ["firefly luciferase reporter", "DNA", 358, 385], ["CVB3", "SPECIES", 172, 176], ["our hypothesis", "PROBLEM", 19, 33], ["polyamines", "TREATMENT", 39, 49], ["viral protease activity", "TREATMENT", 59, 82], ["polyamine depletion restricts virus replication", "TREATMENT", 88, 135], ["viral protease activity", "TREATMENT", 148, 171], ["Cellular Polyamine LevelsViruses", "TEST", 211, 243], ["MTNTGAFG", "TEST", 309, 317], ["AMEQG", "TEST", 343, 348], ["polyamine depletion", "OBSERVATION", 88, 107]]], ["We also cloned 2A and 3C into the pCMV plasmid to drive robust protease expression.", [["plasmid", "ANATOMY", 39, 46], ["3C", "GENE_OR_GENE_PRODUCT", 22, 24], ["pCMV", "GENE_OR_GENE_PRODUCT", 34, 38], ["pCMV plasmid", "DNA", 34, 46], ["protease", "PROTEIN", 63, 71], ["the pCMV plasmid", "TREATMENT", 30, 46], ["robust protease expression", "TREATMENT", 56, 82]]], ["These constructs were cotransfected into 293T cells either left untreated or treated with increasing doses of DFMO.", [["293T cells", "ANATOMY", 41, 51], ["DFMO", "CHEMICAL", 110, 114], ["DFMO", "CHEMICAL", 110, 114], ["293T cells", "CELL", 41, 51], ["DFMO", "SIMPLE_CHEMICAL", 110, 114], ["293T cells", "CELL_LINE", 41, 51], ["DFMO", "TREATMENT", 110, 114], ["293T cells", "OBSERVATION", 41, 51], ["left", "ANATOMY_MODIFIER", 59, 63]]], ["Firefly activity was measured 24 h later and normalized to renilla activity.", [["Firefly", "GENE_OR_GENE_PRODUCT", 0, 7], ["renilla", "GENE_OR_GENE_PRODUCT", 59, 66], ["renilla activity", "OBSERVATION", 59, 75]]], ["We observed that for both 2A ( Figure 4C ) and 3C ( Figure 4D ), protease activity was significantly reduced with DFMO treatment, to levels that were nearly undetectable with DFMO concentrations at or above 500 \u00b5M.", [["DFMO", "CHEMICAL", 114, 118], ["DFMO", "CHEMICAL", 175, 179], ["DFMO", "CHEMICAL", 114, 118], ["DFMO", "CHEMICAL", 175, 179], ["DFMO", "SIMPLE_CHEMICAL", 114, 118], ["DFMO", "SIMPLE_CHEMICAL", 175, 179], ["protease", "PROTEIN", 65, 73], ["3C ( Figure 4D )", "TREATMENT", 47, 63], ["protease activity", "TREATMENT", 65, 82], ["DFMO treatment", "TREATMENT", 114, 128], ["DFMO concentrations", "TREATMENT", 175, 194]]], ["These data support our hypothesis that polyamines modulate viral protease activity, and polyamine depletion restricts virus replication by quelling viral protease activity.CVB3 Protease Mutations Enhance Proteolytic Activity in Polyamine-Depleted CellsWith resistance mutations emerging in CVB3 2A and 3C proteases, we next hypothesized that these mutations may enhance viral replication in polyamine-depleted cells by maintaining proteolytic activity.", [["cells", "ANATOMY", 410, 415], ["polyamines", "CHEMICAL", 39, 49], ["polyamine", "CHEMICAL", 88, 97], ["Polyamine", "CHEMICAL", 228, 237], ["polyamine", "CHEMICAL", 391, 400], ["polyamines", "CHEMICAL", 39, 49], ["polyamine", "CHEMICAL", 88, 97], ["Polyamine", "CHEMICAL", 228, 237], ["polyamine", "CHEMICAL", 391, 400], ["polyamines", "SIMPLE_CHEMICAL", 39, 49], ["polyamine", "SIMPLE_CHEMICAL", 88, 97], ["CVB3", "ORGANISM", 172, 176], ["Polyamine", "SIMPLE_CHEMICAL", 228, 237], ["CVB3 2A", "ORGANISM", 290, 297], ["3C", "GENE_OR_GENE_PRODUCT", 302, 304], ["polyamine", "SIMPLE_CHEMICAL", 391, 400], ["cells", "CELL", 410, 415], ["viral protease", "PROTEIN", 59, 73], ["viral protease", "PROTEIN", 148, 162], ["CVB3 2A and 3C proteases", "PROTEIN", 290, 314], ["polyamine-depleted cells", "CELL_LINE", 391, 415], ["CVB3", "SPECIES", 172, 176], ["CVB3", "SPECIES", 290, 294], ["our hypothesis", "PROBLEM", 19, 33], ["polyamines", "TREATMENT", 39, 49], ["viral protease activity", "TREATMENT", 59, 82], ["polyamine depletion restricts virus replication", "TREATMENT", 88, 135], ["viral protease activity", "TREATMENT", 148, 171], ["CVB3 Protease Mutations", "TREATMENT", 172, 195], ["Polyamine-Depleted CellsWith resistance mutations", "TREATMENT", 228, 277], ["3C proteases", "TREATMENT", 302, 314], ["these mutations", "PROBLEM", 342, 357], ["viral replication", "PROBLEM", 370, 387], ["polyamine-depleted cells", "TREATMENT", 391, 415], ["polyamine depletion", "OBSERVATION", 88, 107], ["depleted cells", "OBSERVATION", 401, 415], ["proteolytic activity", "OBSERVATION", 431, 451]]], ["To test this, we generated mutant 2A 29K and 3C 52R proteases through site-directed mutagenesis of our overexpression vectors.", [["29K", "GENE_OR_GENE_PRODUCT", 37, 40], ["52R", "GENE_OR_GENE_PRODUCT", 48, 51], ["mutant 2A 29K and 3C 52R proteases", "PROTEIN", 27, 61], ["overexpression vectors", "DNA", 103, 125], ["3C 52R proteases", "TREATMENT", 45, 61], ["our overexpression vectors", "TREATMENT", 99, 125], ["overexpression vectors", "OBSERVATION", 103, 125]]], ["We then cotransfected these proteases and the wildtypeCVB3 Protease Mutations Enhance Proteolytic Activity in Polyamine-Depleted CellsWith resistance mutations emerging in CVB3 2A and 3C proteases, we next hypothesized that these mutations may enhance viral replication in polyamine-depleted cells by maintaining proteolytic activity.", [["cells", "ANATOMY", 292, 297], ["Polyamine", "CHEMICAL", 110, 119], ["polyamine", "CHEMICAL", 273, 282], ["Polyamine", "CHEMICAL", 110, 119], ["polyamine", "CHEMICAL", 273, 282], ["wildtypeCVB3 Protease", "GENE_OR_GENE_PRODUCT", 46, 67], ["Polyamine", "SIMPLE_CHEMICAL", 110, 119], ["CVB3 2A", "ORGANISM", 172, 179], ["polyamine", "SIMPLE_CHEMICAL", 273, 282], ["cells", "CELL", 292, 297], ["proteases", "PROTEIN", 28, 37], ["CVB3 2A and 3C proteases", "PROTEIN", 172, 196], ["polyamine-depleted cells", "CELL_LINE", 273, 297], ["CVB3", "SPECIES", 172, 176], ["these proteases", "TREATMENT", 22, 37], ["the wildtypeCVB3 Protease Mutations", "TREATMENT", 42, 77], ["Polyamine-Depleted CellsWith resistance mutations", "TREATMENT", 110, 159], ["3C proteases", "TREATMENT", 184, 196], ["these mutations", "PROBLEM", 224, 239], ["viral replication", "PROBLEM", 252, 269], ["polyamine-depleted cells", "TREATMENT", 273, 297], ["Depleted CellsWith resistance", "OBSERVATION", 120, 149], ["depleted cells", "OBSERVATION", 283, 297], ["proteolytic activity", "OBSERVATION", 313, 333]]], ["To test this, we generated mutant 2A 29K and 3C 52R proteases through site-directed mutagenesis of our overexpression vectors.", [["29K", "GENE_OR_GENE_PRODUCT", 37, 40], ["52R", "GENE_OR_GENE_PRODUCT", 48, 51], ["mutant 2A 29K and 3C 52R proteases", "PROTEIN", 27, 61], ["overexpression vectors", "DNA", 103, 125], ["3C 52R proteases", "TREATMENT", 45, 61], ["our overexpression vectors", "TREATMENT", 99, 125], ["overexpression vectors", "OBSERVATION", 103, 125]]], ["We then cotransfected these proteases and the wildtype controls with our luciferase reporter system into untreated and 500 \u00b5M DFMO-treated Veros.", [["Veros", "ANATOMY", 139, 144], ["DFMO", "CHEMICAL", 126, 130], ["DFMO", "CHEMICAL", 126, 130], ["luciferase", "GENE_OR_GENE_PRODUCT", 73, 83], ["DFMO", "SIMPLE_CHEMICAL", 126, 130], ["Veros", "CELL", 139, 144], ["proteases", "PROTEIN", 28, 37], ["luciferase", "PROTEIN", 73, 83], ["500 \u00b5M DFMO-treated Veros", "CELL_LINE", 119, 144], ["the wildtype controls", "TREATMENT", 42, 63], ["DFMO", "TREATMENT", 126, 130], ["Veros", "TREATMENT", 139, 144]]], ["At 24 h, we measured luciferase activity and normalized to renilla luciferase activity and to control cells transfected with luciferase reporter alone (no protease).", [["cells", "ANATOMY", 102, 107], ["luciferase", "GENE_OR_GENE_PRODUCT", 21, 31], ["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["cells", "CELL", 102, 107], ["luciferase", "GENE_OR_GENE_PRODUCT", 125, 135], ["luciferase", "PROTEIN", 21, 31], ["luciferase", "PROTEIN", 67, 77], ["luciferase reporter", "DNA", 125, 144], ["protease", "PROTEIN", 155, 163], ["luciferase activity", "TEST", 21, 40], ["renilla luciferase activity", "TEST", 59, 86], ["luciferase reporter", "TREATMENT", 125, 144]]], ["We observed that both 2A WT and 3C WT exhibited protease activity that was DFMO-sensitive ( Figure 5A,B) .", [["DFMO", "CHEMICAL", 75, 79], ["DFMO", "CHEMICAL", 75, 79], ["2A WT", "ORGANISM", 22, 27], ["3C WT", "ORGANISM", 32, 37], ["DFMO", "SIMPLE_CHEMICAL", 75, 79], ["protease", "PROTEIN", 48, 56], ["both 2A WT", "TEST", 17, 27], ["3C WT", "TEST", 32, 37], ["protease activity", "TEST", 48, 65], ["DFMO", "TEST", 75, 79]]], ["Interestingly, we also observed that both 2A 29K and 3C 52R exhibited robust protease activity, even in DFMO-treated cells.", [["cells", "ANATOMY", 117, 122], ["DFMO", "CHEMICAL", 104, 108], ["DFMO", "CHEMICAL", 104, 108], ["29K", "GENE_OR_GENE_PRODUCT", 45, 48], ["52R", "GENE_OR_GENE_PRODUCT", 56, 59], ["DFMO", "SIMPLE_CHEMICAL", 104, 108], ["cells", "CELL", 117, 122], ["2A 29K and 3C 52R", "PROTEIN", 42, 59], ["protease", "PROTEIN", 77, 85], ["DFMO-treated cells", "CELL_LINE", 104, 122], ["3C", "TEST", 53, 55], ["robust protease activity", "TREATMENT", 70, 94], ["DFMO-treated cells", "TREATMENT", 104, 122]]], ["We also observed that 3C 52R exhibited higher protease activity than 3C WT , though this was not observed for 2A.CVB3 Protease Mutations Enhance Proteolytic Activity in Polyamine-Depleted CellsWe further hypothesized that mutant proteases may enhance proteolytic cleavage of a cellular target during viral infection to enhance virus replication.", [["cellular", "ANATOMY", 277, 285], ["Polyamine", "CHEMICAL", 169, 178], ["viral infection", "DISEASE", 300, 315], ["Polyamine", "CHEMICAL", 169, 178], ["52R", "GENE_OR_GENE_PRODUCT", 25, 28], ["2A.CVB3 Protease", "GENE_OR_GENE_PRODUCT", 110, 126], ["Polyamine", "SIMPLE_CHEMICAL", 169, 178], ["cellular", "CELL", 277, 285], ["3C 52R", "PROTEIN", 22, 28], ["protease", "PROTEIN", 46, 54], ["mutant proteases", "PROTEIN", 222, 238], ["higher protease activity", "PROBLEM", 39, 63], ["2A.CVB3 Protease Mutations", "TREATMENT", 110, 136], ["Polyamine-Depleted CellsWe", "TREATMENT", 169, 195], ["mutant proteases", "PROBLEM", 222, 238], ["proteolytic cleavage", "PROBLEM", 251, 271], ["a cellular target", "PROBLEM", 275, 292], ["viral infection", "PROBLEM", 300, 315], ["virus replication", "TREATMENT", 327, 344]]], ["To this end, we treated Veros with 500 \u00b5M DFMO or left cells untreated and then infected at MOI 10 for 24 h.", [["left cells", "ANATOMY", 50, 60], ["DFMO", "CHEMICAL", 42, 46], ["DFMO", "CHEMICAL", 42, 46], ["DFMO", "SIMPLE_CHEMICAL", 42, 46], ["cells", "CELL", 55, 60], ["left cells", "CELL_TYPE", 50, 60], ["500 \u00b5M DFMO", "TREATMENT", 35, 46], ["left cells", "TREATMENT", 50, 60]]], ["Cellular lysates were collected and analyzed for cleavage of eIF4G ( Figure 4C ).", [["Cellular lysates", "ANATOMY", 0, 16], ["Cellular lysates", "ORGANISM_SUBSTANCE", 0, 16], ["eIF4G", "GENE_OR_GENE_PRODUCT", 61, 66], ["eIF4G", "PROTEIN", 61, 66], ["Figure 4C", "PROTEIN", 69, 78], ["Cellular lysates", "TEST", 0, 16], ["eIF4G ( Figure 4C", "TREATMENT", 61, 78]]], ["In untreated cells, we observed significant cleavage of eIF4G with wildtype infection that was not enhanced with infection of CVB3-2A 29K , -3C 52R , or double protease mutant.", [["cells", "ANATOMY", 13, 18], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 113, 122], ["cells", "CELL", 13, 18], ["eIF4G", "GENE_OR_GENE_PRODUCT", 56, 61], ["CVB3-2A", "ORGANISM", 126, 133], ["-3C 52R", "GENE_OR_GENE_PRODUCT", 140, 147], ["eIF4G", "PROTEIN", 56, 61], ["double protease mutant", "PROTEIN", 153, 175], ["CVB3-2A", "SPECIES", 126, 133], ["significant cleavage of eIF4G", "PROBLEM", 32, 61], ["wildtype infection", "PROBLEM", 67, 85], ["infection", "PROBLEM", 113, 122], ["CVB3", "TEST", 126, 130], ["K", "TEST", 136, 137], ["double protease mutant", "TREATMENT", 153, 175], ["untreated cells", "OBSERVATION", 3, 18], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 113, 122]]], ["However, with DFMO treatment, eIF4G cleavage was significantly reduced in wildtype CVB3 infection, as previously observed ( Figure 4A ).", [["DFMO", "CHEMICAL", 14, 18], ["CVB3 infection", "DISEASE", 83, 97], ["DFMO", "CHEMICAL", 14, 18], ["DFMO", "SIMPLE_CHEMICAL", 14, 18], ["eIF4G", "GENE_OR_GENE_PRODUCT", 30, 35], ["wildtype CVB3", "ORGANISM", 74, 87], ["eIF4G", "PROTEIN", 30, 35], ["CVB3", "SPECIES", 83, 87], ["DFMO treatment", "TREATMENT", 14, 28], ["eIF4G cleavage", "TREATMENT", 30, 44], ["wildtype CVB3 infection", "PROBLEM", 74, 97], ["CVB3 infection", "OBSERVATION", 83, 97]]], ["When we analyzed DFMO-treated cells that were infected with protease mutant CVB3, we observed proteolytic cleavage of eIF4G, significantly higher than wildtype CVB3.", [["cells", "ANATOMY", 30, 35], ["DFMO", "CHEMICAL", 17, 21], ["DFMO", "CHEMICAL", 17, 21], ["DFMO", "SIMPLE_CHEMICAL", 17, 21], ["cells", "CELL", 30, 35], ["protease mutant CVB3", "ORGANISM", 60, 80], ["eIF4G", "GENE_OR_GENE_PRODUCT", 118, 123], ["CVB3", "ORGANISM", 160, 164], ["DFMO-treated cells", "CELL_LINE", 17, 35], ["protease", "PROTEIN", 60, 68], ["eIF4G", "PROTEIN", 118, 123], ["CVB3", "SPECIES", 76, 80], ["CVB3", "SPECIES", 160, 164], ["DFMO-treated cells", "TREATMENT", 17, 35], ["protease mutant CVB3", "TREATMENT", 60, 80], ["proteolytic cleavage of eIF4G", "PROBLEM", 94, 123]]], ["In total, our data suggest that polyamine depletion significantly reduces CVB3 protease activity and that the mutant proteases derived from our passages exhibit a rescue in this sensitivity. controls with our luciferase reporter system into untreated and 500 \u00b5M DFMO-treated Veros.", [["Veros", "ANATOMY", 275, 280], ["polyamine", "CHEMICAL", 32, 41], ["DFMO", "CHEMICAL", 262, 266], ["polyamine", "CHEMICAL", 32, 41], ["DFMO", "CHEMICAL", 262, 266], ["polyamine", "SIMPLE_CHEMICAL", 32, 41], ["CVB3", "ORGANISM", 74, 78], ["luciferase", "GENE_OR_GENE_PRODUCT", 209, 219], ["DFMO", "SIMPLE_CHEMICAL", 262, 266], ["Veros", "CELL", 275, 280], ["CVB3 protease", "PROTEIN", 74, 87], ["mutant proteases", "PROTEIN", 110, 126], ["luciferase", "PROTEIN", 209, 219], ["Veros", "CELL_LINE", 275, 280], ["CVB3", "SPECIES", 74, 78], ["our data", "TEST", 10, 18], ["polyamine depletion", "PROBLEM", 32, 51], ["CVB3 protease activity", "TREATMENT", 74, 96], ["the mutant proteases", "PROBLEM", 106, 126], ["our passages", "PROBLEM", 140, 152], ["our luciferase reporter system", "TREATMENT", 205, 235], ["DFMO", "TREATMENT", 262, 266], ["Veros", "TREATMENT", 275, 280], ["polyamine depletion", "OBSERVATION", 32, 51]]], ["At 24 h, we measured luciferase activity and normalized to renilla luciferase activity and to control cells transfected with luciferase reporter alone (no protease).", [["cells", "ANATOMY", 102, 107], ["luciferase", "GENE_OR_GENE_PRODUCT", 21, 31], ["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["cells", "CELL", 102, 107], ["luciferase", "GENE_OR_GENE_PRODUCT", 125, 135], ["luciferase", "PROTEIN", 21, 31], ["luciferase", "PROTEIN", 67, 77], ["luciferase reporter", "DNA", 125, 144], ["protease", "PROTEIN", 155, 163], ["luciferase activity", "TEST", 21, 40], ["renilla luciferase activity", "TEST", 59, 86], ["luciferase reporter", "TREATMENT", 125, 144]]], ["We observed that both 2A WT and 3C WT exhibited protease activity that was DFMO-sensitive ( Figure 5A,B) .", [["DFMO", "CHEMICAL", 75, 79], ["DFMO", "CHEMICAL", 75, 79], ["2A WT", "ORGANISM", 22, 27], ["3C WT", "ORGANISM", 32, 37], ["DFMO", "SIMPLE_CHEMICAL", 75, 79], ["protease", "PROTEIN", 48, 56], ["both 2A WT", "TEST", 17, 27], ["3C WT", "TEST", 32, 37], ["protease activity", "TEST", 48, 65], ["DFMO", "TEST", 75, 79]]], ["Interestingly, we also observed that both 2A 29K and 3C 52R exhibited robust protease activity, even in DFMO-treated cells.", [["cells", "ANATOMY", 117, 122], ["DFMO", "CHEMICAL", 104, 108], ["DFMO", "CHEMICAL", 104, 108], ["29K", "GENE_OR_GENE_PRODUCT", 45, 48], ["52R", "GENE_OR_GENE_PRODUCT", 56, 59], ["DFMO", "SIMPLE_CHEMICAL", 104, 108], ["cells", "CELL", 117, 122], ["2A 29K and 3C 52R", "PROTEIN", 42, 59], ["protease", "PROTEIN", 77, 85], ["DFMO-treated cells", "CELL_LINE", 104, 122], ["3C", "TEST", 53, 55], ["robust protease activity", "TREATMENT", 70, 94], ["DFMO-treated cells", "TREATMENT", 104, 122]]], ["We also observed that 3C 52R exhibited higher protease activity than 3C WT , though this was not observed for 2A.CVB3 Protease Mutations Enhance Proteolytic Activity in Polyamine-Depleted CellsWe further hypothesized that mutant proteases may enhance proteolytic cleavage of a cellular target during viral infection to enhance virus replication.", [["cellular", "ANATOMY", 277, 285], ["Polyamine", "CHEMICAL", 169, 178], ["viral infection", "DISEASE", 300, 315], ["Polyamine", "CHEMICAL", 169, 178], ["52R", "GENE_OR_GENE_PRODUCT", 25, 28], ["2A.CVB3 Protease", "GENE_OR_GENE_PRODUCT", 110, 126], ["Polyamine", "SIMPLE_CHEMICAL", 169, 178], ["cellular", "CELL", 277, 285], ["3C 52R", "PROTEIN", 22, 28], ["protease", "PROTEIN", 46, 54], ["mutant proteases", "PROTEIN", 222, 238], ["higher protease activity", "PROBLEM", 39, 63], ["2A.CVB3 Protease Mutations", "TREATMENT", 110, 136], ["Polyamine-Depleted CellsWe", "TREATMENT", 169, 195], ["mutant proteases", "PROBLEM", 222, 238], ["proteolytic cleavage", "PROBLEM", 251, 271], ["a cellular target", "PROBLEM", 275, 292], ["viral infection", "PROBLEM", 300, 315], ["virus replication", "TREATMENT", 327, 344]]], ["To this end, we treated Veros with 500 \u00b5M DFMO or left cells untreated and then infected at MOI 10 for 24 h.", [["left cells", "ANATOMY", 50, 60], ["DFMO", "CHEMICAL", 42, 46], ["DFMO", "CHEMICAL", 42, 46], ["DFMO", "SIMPLE_CHEMICAL", 42, 46], ["cells", "CELL", 55, 60], ["left cells", "CELL_TYPE", 50, 60], ["500 \u00b5M DFMO", "TREATMENT", 35, 46], ["left cells", "TREATMENT", 50, 60]]], ["Cellular lysates were collected and analyzed for cleavage of eIF4G ( Figure 4C ).", [["Cellular lysates", "ANATOMY", 0, 16], ["Cellular lysates", "ORGANISM_SUBSTANCE", 0, 16], ["eIF4G", "GENE_OR_GENE_PRODUCT", 61, 66], ["eIF4G", "PROTEIN", 61, 66], ["Figure 4C", "PROTEIN", 69, 78], ["Cellular lysates", "TEST", 0, 16], ["eIF4G ( Figure 4C", "TREATMENT", 61, 78]]], ["In untreated cells, we observed significant cleavage of eIF4G with wildtype infection that was not enhanced with infection of CVB3-2A 29K , -3C 52R , or double protease mutant.", [["cells", "ANATOMY", 13, 18], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 113, 122], ["cells", "CELL", 13, 18], ["eIF4G", "GENE_OR_GENE_PRODUCT", 56, 61], ["CVB3-2A", "ORGANISM", 126, 133], ["-3C 52R", "GENE_OR_GENE_PRODUCT", 140, 147], ["eIF4G", "PROTEIN", 56, 61], ["double protease mutant", "PROTEIN", 153, 175], ["CVB3-2A", "SPECIES", 126, 133], ["significant cleavage of eIF4G", "PROBLEM", 32, 61], ["wildtype infection", "PROBLEM", 67, 85], ["infection", "PROBLEM", 113, 122], ["CVB3", "TEST", 126, 130], ["K", "TEST", 136, 137], ["double protease mutant", "TREATMENT", 153, 175], ["untreated cells", "OBSERVATION", 3, 18], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 113, 122]]], ["However, with DFMO treatment, eIF4G cleavage was significantly reduced in wildtype CVB3 infection, as previously observed ( Figure 4A ).", [["DFMO", "CHEMICAL", 14, 18], ["CVB3 infection", "DISEASE", 83, 97], ["DFMO", "CHEMICAL", 14, 18], ["DFMO", "SIMPLE_CHEMICAL", 14, 18], ["eIF4G", "GENE_OR_GENE_PRODUCT", 30, 35], ["wildtype CVB3", "ORGANISM", 74, 87], ["eIF4G", "PROTEIN", 30, 35], ["CVB3", "SPECIES", 83, 87], ["DFMO treatment", "TREATMENT", 14, 28], ["eIF4G cleavage", "TREATMENT", 30, 44], ["wildtype CVB3 infection", "PROBLEM", 74, 97], ["CVB3 infection", "OBSERVATION", 83, 97]]], ["When we analyzed DFMO-treated cells that were infected with protease mutant CVB3, we observed proteolytic cleavage of eIF4G, significantly higher than wildtype CVB3.", [["cells", "ANATOMY", 30, 35], ["DFMO", "CHEMICAL", 17, 21], ["DFMO", "CHEMICAL", 17, 21], ["DFMO", "SIMPLE_CHEMICAL", 17, 21], ["cells", "CELL", 30, 35], ["protease mutant CVB3", "ORGANISM", 60, 80], ["eIF4G", "GENE_OR_GENE_PRODUCT", 118, 123], ["CVB3", "ORGANISM", 160, 164], ["DFMO-treated cells", "CELL_LINE", 17, 35], ["protease", "PROTEIN", 60, 68], ["eIF4G", "PROTEIN", 118, 123], ["CVB3", "SPECIES", 76, 80], ["CVB3", "SPECIES", 160, 164], ["DFMO-treated cells", "TREATMENT", 17, 35], ["protease mutant CVB3", "TREATMENT", 60, 80], ["proteolytic cleavage of eIF4G", "PROBLEM", 94, 123]]], ["In total, our data suggest that polyamine depletion significantly reduces CVB3 protease activity and that the mutant proteases derived from our passages exhibit a rescue in this sensitivity.DiscussionPolyamines play several roles in the eukaryotic cell and likely affect virus replication at several stages.", [["cell", "ANATOMY", 248, 252], ["polyamine", "CHEMICAL", 32, 41], ["polyamine", "CHEMICAL", 32, 41], ["polyamine", "SIMPLE_CHEMICAL", 32, 41], ["CVB3", "ORGANISM", 74, 78], ["cell", "CELL", 248, 252], ["CVB3 protease", "PROTEIN", 74, 87], ["mutant proteases", "PROTEIN", 110, 126], ["CVB3", "SPECIES", 74, 78], ["our data", "TEST", 10, 18], ["polyamine depletion", "PROBLEM", 32, 51], ["CVB3 protease activity", "TREATMENT", 74, 96], ["the mutant proteases", "PROBLEM", 106, 126], ["our passages", "PROBLEM", 140, 152], ["DiscussionPolyamines", "TREATMENT", 190, 210], ["affect virus replication", "PROBLEM", 264, 288], ["polyamine depletion", "OBSERVATION", 32, 51], ["eukaryotic cell", "OBSERVATION", 237, 252]]], ["By isolating DFMO escape mutants, we can glean insight into the mechanisms by whichDiscussionPolyamines play several roles in the eukaryotic cell and likely affect virus replication at several stages.", [["cell", "ANATOMY", 141, 145], ["DFMO", "CHEMICAL", 13, 17], ["DFMO", "CHEMICAL", 13, 17], ["DFMO", "SIMPLE_CHEMICAL", 13, 17], ["cell", "CELL", 141, 145], ["whichDiscussionPolyamines", "TREATMENT", 78, 103], ["virus replication", "TREATMENT", 164, 181], ["DFMO escape", "OBSERVATION", 13, 24], ["eukaryotic cell", "OBSERVATION", 130, 145]]], ["By isolating DFMO escape mutants, we can glean insight into the mechanisms by which polyamines function in virus infection.", [["DFMO", "CHEMICAL", 13, 17], ["infection", "DISEASE", 113, 122], ["DFMO", "CHEMICAL", 13, 17], ["polyamines", "CHEMICAL", 84, 94], ["DFMO", "SIMPLE_CHEMICAL", 13, 17], ["polyamines", "SIMPLE_CHEMICAL", 84, 94], ["isolating DFMO escape mutants", "PROBLEM", 3, 32], ["polyamines function in virus infection", "PROBLEM", 84, 122], ["DFMO escape", "OBSERVATION", 13, 24], ["virus infection", "OBSERVATION", 107, 122]]], ["Here, we have isolated two protease mutants following passage of CVB3 in DFMO.", [["DFMO", "CHEMICAL", 73, 77], ["DFMO", "CHEMICAL", 73, 77], ["CVB3", "ORGANISM", 65, 69], ["DFMO", "SIMPLE_CHEMICAL", 73, 77], ["protease mutants", "PROTEIN", 27, 43], ["CVB3", "SPECIES", 65, 69], ["two protease mutants", "TREATMENT", 23, 43], ["CVB3 in DFMO", "TREATMENT", 65, 77]]], ["We previously characterized escape mutants for chikungunya virus and found three mutations that conferred resistance when simultaneously present in the virus [31] .", [["chikungunya", "DISEASE", 47, 58], ["chikungunya virus", "ORGANISM", 47, 64], ["chikungunya virus", "SPECIES", 47, 64], ["escape mutants", "PROBLEM", 28, 42], ["chikungunya virus", "PROBLEM", 47, 64], ["three mutations", "PROBLEM", 75, 90], ["escape mutants", "OBSERVATION", 28, 42]]], ["In contrast, we find that CVB3 gains resistance to DFMO with a single mutation in either protease.", [["DFMO", "CHEMICAL", 51, 55], ["DFMO", "CHEMICAL", 51, 55], ["CVB3", "ORGANISM", 26, 30], ["DFMO", "SIMPLE_CHEMICAL", 51, 55], ["protease", "PROTEIN", 89, 97], ["CVB3", "SPECIES", 26, 30], ["CVB3", "PROBLEM", 26, 30], ["DFMO", "TREATMENT", 51, 55], ["a single mutation in either protease", "TREATMENT", 61, 97]]], ["From our data, we cannot determine whether polyamines facilitate protease activity against a specific target; however, we observe that both viral proteases maintain activity in polyamine-depleted cells with either of these mutations and that these mutations facilitate virus infection in an otherwise antiviral environment.", [["cells", "ANATOMY", 196, 201], ["polyamines", "CHEMICAL", 43, 53], ["polyamine", "CHEMICAL", 177, 186], ["infection", "DISEASE", 275, 284], ["polyamines", "CHEMICAL", 43, 53], ["polyamine", "CHEMICAL", 177, 186], ["polyamines", "SIMPLE_CHEMICAL", 43, 53], ["polyamine", "SIMPLE_CHEMICAL", 177, 186], ["cells", "CELL", 196, 201], ["protease", "PROTEIN", 65, 73], ["viral proteases", "PROTEIN", 140, 155], ["polyamine-depleted cells", "CELL_TYPE", 177, 201], ["polyamines facilitate protease activity", "PROBLEM", 43, 82], ["both viral proteases", "PROBLEM", 135, 155], ["polyamine-depleted cells", "TREATMENT", 177, 201], ["these mutations", "PROBLEM", 217, 232], ["these mutations", "PROBLEM", 242, 257], ["virus infection", "PROBLEM", 269, 284], ["depleted cells", "OBSERVATION", 187, 201]]], ["Determining the specificity of this activity is an area of important future investigation.DiscussionIn the course of passaging CVB3 in the presence of DFMO, we observed two mutations changing from glutamine to positively charged lysine or arginine.", [["CVB3", "DISEASE", 127, 131], ["DFMO", "CHEMICAL", 151, 155], ["glutamine", "CHEMICAL", 197, 206], ["lysine", "CHEMICAL", 229, 235], ["arginine", "CHEMICAL", 239, 247], ["DFMO", "CHEMICAL", 151, 155], ["glutamine", "CHEMICAL", 197, 206], ["lysine", "CHEMICAL", 229, 235], ["arginine", "CHEMICAL", 239, 247], ["CVB3", "ORGANISM", 127, 131], ["DFMO", "SIMPLE_CHEMICAL", 151, 155], ["glutamine", "AMINO_ACID", 197, 206], ["lysine", "AMINO_ACID", 229, 235], ["arginine", "AMINO_ACID", 239, 247], ["CVB3", "SPECIES", 127, 131], ["passaging CVB3", "TREATMENT", 117, 131], ["DFMO", "TREATMENT", 151, 155], ["two mutations", "PROBLEM", 169, 182], ["glutamine", "TREATMENT", 197, 206], ["arginine", "TREATMENT", 239, 247]]], ["Interestingly, we have observed such amino acid changes in our CHIKV passages [31] , in which we observed a glycine-to-arginine mutation in nsP1.", [["amino acid", "CHEMICAL", 37, 47], ["glycine", "CHEMICAL", 108, 115], ["arginine", "CHEMICAL", 119, 127], ["amino acid", "CHEMICAL", 37, 47], ["glycine", "CHEMICAL", 108, 115], ["arginine", "CHEMICAL", 119, 127], ["amino acid", "AMINO_ACID", 37, 47], ["glycine", "SIMPLE_CHEMICAL", 108, 115], ["arginine", "AMINO_ACID", 119, 127], ["nsP1", "GENE_OR_GENE_PRODUCT", 140, 144], ["nsP1", "PROTEIN", 140, 144], ["CHIKV", "SPECIES", 63, 68], ["such amino acid changes", "PROBLEM", 32, 55], ["a glycine", "TEST", 106, 115], ["arginine mutation", "PROBLEM", 119, 136], ["nsP1", "PROBLEM", 140, 144]]], ["Given that polyamines are positively-charged at physiological pH, the emergence of positively-charged amino acids in polyamine-depleted conditions suggests potential amino acid compensation for a loss of charge.", [["polyamines", "CHEMICAL", 11, 21], ["amino acids", "CHEMICAL", 102, 113], ["polyamine", "CHEMICAL", 117, 126], ["amino acid", "CHEMICAL", 166, 176], ["polyamines", "CHEMICAL", 11, 21], ["amino acids", "CHEMICAL", 102, 113], ["polyamine", "CHEMICAL", 117, 126], ["amino acid", "CHEMICAL", 166, 176], ["polyamines", "SIMPLE_CHEMICAL", 11, 21], ["amino acids", "AMINO_ACID", 102, 113], ["polyamine", "SIMPLE_CHEMICAL", 117, 126], ["amino acid", "AMINO_ACID", 166, 176], ["charged amino acids", "TREATMENT", 94, 113], ["polyamine-depleted conditions", "TREATMENT", 117, 146], ["potential amino acid compensation", "PROBLEM", 156, 189], ["a loss of charge", "PROBLEM", 194, 210], ["amino acid compensation", "OBSERVATION", 166, 189]]], ["The amino acids in which we observe mutations for CVB3 2A and 3C are not located in the active sites of either enzyme [27, 38] , suggesting that these amino acids and their associated charge may alter enzymatic activity allosterically.", [["amino acids", "CHEMICAL", 4, 15], ["amino acids", "CHEMICAL", 151, 162], ["amino acids", "CHEMICAL", 4, 15], ["amino acids", "CHEMICAL", 151, 162], ["amino acids", "AMINO_ACID", 4, 15], ["CVB3 2A", "GENE_OR_GENE_PRODUCT", 50, 57], ["3C", "GENE_OR_GENE_PRODUCT", 62, 64], ["amino acids", "AMINO_ACID", 151, 162], ["CVB3 2A and 3C", "PROTEIN", 50, 64], ["The amino acids", "TEST", 0, 15], ["mutations", "PROBLEM", 36, 45], ["CVB3 2A", "TREATMENT", 50, 57], ["either enzyme", "TEST", 104, 117], ["these amino acids", "TREATMENT", 145, 162], ["active", "OBSERVATION_MODIFIER", 88, 94]]], ["Precisely how positively-charged amino acids or polyamines contribute to protease activity remains unknown.DiscussionOthers have observed that polyamines contribute to protease activity [39, 40] .", [["amino acids", "CHEMICAL", 33, 44], ["polyamines", "CHEMICAL", 48, 58], ["polyamines", "CHEMICAL", 143, 153], ["amino acids", "CHEMICAL", 33, 44], ["polyamines", "CHEMICAL", 48, 58], ["polyamines", "CHEMICAL", 143, 153], ["amino acids", "AMINO_ACID", 33, 44], ["polyamines", "SIMPLE_CHEMICAL", 48, 58], ["polyamines", "SIMPLE_CHEMICAL", 143, 153], ["protease", "PROTEIN", 73, 81], ["protease", "PROTEIN", 168, 176], ["charged amino acids", "TREATMENT", 25, 44], ["polyamines", "TREATMENT", 48, 58], ["protease activity", "PROBLEM", 73, 90], ["polyamines", "TREATMENT", 143, 153], ["protease activity", "PROBLEM", 168, 185]]], ["Prior research in oat leaves identified polyamines as factors that reduce cellular protease activity and, as a result, leaf senescence [41] .", [["cellular", "ANATOMY", 74, 82], ["leaf", "ANATOMY", 119, 123], ["polyamines", "CHEMICAL", 40, 50], ["polyamines", "CHEMICAL", 40, 50], ["oat leaves", "ORGANISM", 18, 28], ["polyamines", "SIMPLE_CHEMICAL", 40, 50], ["cellular", "CELL", 74, 82], ["protease", "PROTEIN", 83, 91], ["oat", "SPECIES", 18, 21], ["oat", "SPECIES", 18, 21], ["cellular protease activity", "TREATMENT", 74, 100]]], ["The function of polyamines in plant tissues appears distinct from the functions in mammalian eukaryotic cells, though.", [["tissues", "ANATOMY", 36, 43], ["cells", "ANATOMY", 104, 109], ["polyamines", "CHEMICAL", 16, 26], ["polyamines", "CHEMICAL", 16, 26], ["polyamines", "SIMPLE_CHEMICAL", 16, 26], ["plant tissues", "TISSUE", 30, 43], ["mammalian eukaryotic cells", "CELL", 83, 109], ["mammalian eukaryotic cells", "CELL_TYPE", 83, 109], ["polyamines in plant tissues", "PROBLEM", 16, 43], ["polyamines", "OBSERVATION", 16, 26], ["plant tissues", "OBSERVATION", 30, 43], ["distinct", "OBSERVATION_MODIFIER", 52, 60], ["mammalian eukaryotic cells", "OBSERVATION", 83, 109]]], ["For instance, spermidine interacts with and activates the activity of mammalian chymotrypsin [32, 33] .", [["spermidine", "CHEMICAL", 14, 24], ["spermidine", "CHEMICAL", 14, 24], ["spermidine", "SIMPLE_CHEMICAL", 14, 24], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 80, 92], ["mammalian chymotrypsin", "PROTEIN", 70, 92], ["mammalian chymotrypsin", "TREATMENT", 70, 92]]], ["Whether polyamines function broadly in the function of proteases, especially viral proteases, has not been fully explored; however, our work suggests that viral proteases may be modulated by polyamines.DiscussionTargeting polyamines as an antiviral strategy shows significant promise, and the availability of FDA-approved molecules like DFMO underscores the potential of inhibiting this pathway for limiting viral infection.", [["polyamines", "CHEMICAL", 8, 18], ["polyamines", "CHEMICAL", 222, 232], ["DFMO", "CHEMICAL", 337, 341], ["viral infection", "DISEASE", 408, 423], ["polyamines", "CHEMICAL", 8, 18], ["polyamines", "CHEMICAL", 191, 201], ["polyamines", "CHEMICAL", 222, 232], ["DFMO", "CHEMICAL", 337, 341], ["polyamines", "SIMPLE_CHEMICAL", 8, 18], ["polyamines", "SIMPLE_CHEMICAL", 191, 201], ["polyamines", "SIMPLE_CHEMICAL", 222, 232], ["DFMO", "SIMPLE_CHEMICAL", 337, 341], ["proteases", "PROTEIN", 55, 64], ["viral proteases", "PROTEIN", 77, 92], ["viral proteases", "PROTEIN", 155, 170], ["polyamines function", "PROBLEM", 8, 27], ["proteases", "PROBLEM", 55, 64], ["viral proteases", "PROBLEM", 77, 92], ["viral proteases", "PROBLEM", 155, 170], ["polyamines", "TREATMENT", 222, 232], ["an antiviral strategy", "TREATMENT", 236, 257], ["DFMO", "TREATMENT", 337, 341], ["this pathway", "TREATMENT", 382, 394], ["limiting viral infection", "PROBLEM", 399, 423], ["polyamines function", "OBSERVATION", 8, 27], ["broadly", "OBSERVATION_MODIFIER", 28, 35], ["infection", "OBSERVATION", 414, 423]]], ["We previously described how DFMO reduces CVB3 replication in vitro and in vivo [25] .", [["DFMO", "CHEMICAL", 28, 32], ["DFMO", "CHEMICAL", 28, 32], ["DFMO", "SIMPLE_CHEMICAL", 28, 32], ["CVB3", "ORGANISM", 41, 45], ["CVB3", "SPECIES", 41, 45], ["CVB3 replication", "TREATMENT", 41, 57]]], ["Here, we show that CVB3 gains resistance to DFMO-mediated polyamine depletion via two distinct and independent mutations.", [["DFMO", "CHEMICAL", 44, 48], ["polyamine", "CHEMICAL", 58, 67], ["DFMO", "CHEMICAL", 44, 48], ["polyamine", "CHEMICAL", 58, 67], ["CVB3", "ORGANISM", 19, 23], ["DFMO", "SIMPLE_CHEMICAL", 44, 48], ["polyamine", "SIMPLE_CHEMICAL", 58, 67], ["CVB3", "SPECIES", 19, 23], ["CVB3", "PROBLEM", 19, 23], ["DFMO-mediated polyamine depletion", "TREATMENT", 44, 77], ["polyamine depletion", "OBSERVATION", 58, 77], ["two distinct", "OBSERVATION_MODIFIER", 82, 94]]], ["Such emergence of resistance highlights that polyamine depletion as a monotherapy may not be sufficient to quell virus replication.", [["polyamine", "CHEMICAL", 45, 54], ["polyamine", "CHEMICAL", 45, 54], ["polyamine", "SIMPLE_CHEMICAL", 45, 54], ["polyamine depletion", "TREATMENT", 45, 64], ["a monotherapy", "TREATMENT", 68, 81], ["polyamine depletion", "OBSERVATION", 45, 64]]], ["As viruses rapidly mutate and gain resistance to antivirals, potential therapy that includes polyamine depletion would necessitate combination therapy to prevent resistance.", [["polyamine", "CHEMICAL", 93, 102], ["polyamine", "CHEMICAL", 93, 102], ["polyamine", "SIMPLE_CHEMICAL", 93, 102], ["antivirals", "TREATMENT", 49, 59], ["potential therapy", "TREATMENT", 61, 78], ["polyamine depletion", "TREATMENT", 93, 112], ["combination therapy", "TREATMENT", 131, 150], ["resistance", "PROBLEM", 162, 172], ["polyamine depletion", "OBSERVATION", 93, 112]]], ["Neither protease mutant exhibited an enhanced fitness phenotype, as we had observed with CHIKV mutants [31] , suggesting that even if this virus were to emerge, the mutation may not fix in a viral population not exposed to DFMO.DiscussionBeyond underscoring combination therapy, viral escape mutants are powerful tools for understanding how antivirals function during viral infection.", [["DFMO", "CHEMICAL", 223, 227], ["viral infection", "DISEASE", 368, 383], ["DFMO", "CHEMICAL", 223, 227], ["DFMO", "SIMPLE_CHEMICAL", 223, 227], ["protease mutant", "PROTEIN", 8, 23], ["CHIKV", "SPECIES", 89, 94], ["an enhanced fitness phenotype", "PROBLEM", 34, 63], ["CHIKV mutants", "PROBLEM", 89, 102], ["this virus", "PROBLEM", 134, 144], ["the mutation", "PROBLEM", 161, 173], ["a viral population", "PROBLEM", 189, 207], ["DFMO", "TREATMENT", 223, 227], ["combination therapy", "TREATMENT", 258, 277], ["viral escape mutants", "PROBLEM", 279, 299], ["viral infection", "PROBLEM", 368, 383], ["infection", "OBSERVATION", 374, 383]]], ["By investigating how CVB3 escaped DFMO-mediated polyamine depletion, we observed novel mutations in viral proteases that led us to investigate how polyamines contribute to viral protease activity.", [["DFMO", "CHEMICAL", 34, 38], ["polyamine", "CHEMICAL", 48, 57], ["polyamines", "CHEMICAL", 147, 157], ["DFMO", "CHEMICAL", 34, 38], ["polyamine", "CHEMICAL", 48, 57], ["polyamines", "CHEMICAL", 147, 157], ["CVB3", "ORGANISM", 21, 25], ["DFMO", "SIMPLE_CHEMICAL", 34, 38], ["polyamine", "SIMPLE_CHEMICAL", 48, 57], ["polyamines", "SIMPLE_CHEMICAL", 147, 157], ["viral proteases", "PROTEIN", 100, 115], ["viral protease", "PROTEIN", 172, 186], ["CVB3", "SPECIES", 21, 25], ["DFMO-mediated polyamine depletion", "TREATMENT", 34, 67], ["novel mutations", "PROBLEM", 81, 96], ["viral proteases", "TREATMENT", 100, 115], ["viral protease activity", "PROBLEM", 172, 195], ["polyamine depletion", "OBSERVATION", 48, 67], ["viral protease activity", "OBSERVATION", 172, 195]]], ["Thus, these escape mutants have highlighted a novel function of polyamines during viral infection.", [["polyamines", "CHEMICAL", 64, 74], ["viral infection", "DISEASE", 82, 97], ["polyamines", "CHEMICAL", 64, 74], ["polyamines", "SIMPLE_CHEMICAL", 64, 74], ["these escape mutants", "PROBLEM", 6, 26], ["viral infection", "PROBLEM", 82, 97], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["As described above, these results have implications for antiviral therapy, but they also inform our understanding of basic mechanisms in virology.", [["antiviral therapy", "TREATMENT", 56, 73]]], ["Additional mechanisms whereby polyamines function in virus infection may be observed using similar means to highlight how these relatively simple molecules contribute to infection in diverse ways.", [["polyamines", "CHEMICAL", 30, 40], ["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 170, 179], ["polyamines", "CHEMICAL", 30, 40], ["polyamines", "SIMPLE_CHEMICAL", 30, 40], ["polyamines function", "PROBLEM", 30, 49], ["virus infection", "PROBLEM", 53, 68], ["infection in diverse ways", "PROBLEM", 170, 195], ["polyamines function", "OBSERVATION", 30, 49], ["infection", "OBSERVATION", 170, 179]]]], "f119a21660a2ff9ebecb3ed3f9dca668ce601496": [["IntroductionPresentation 96 The majority of patients who present for medical care will have flu like symptoms (fever 42-97 91%, cough 50-86%, fatigue 51-70%, myalgias 35.4%, and shortness of breath 30%).", [["fever", "DISEASE", 111, 116], ["cough", "DISEASE", 128, 133], ["fatigue", "DISEASE", 142, 149], ["myalgias", "DISEASE", 158, 166], ["shortness of breath", "DISEASE", 178, 197], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["medical care", "TREATMENT", 69, 81], ["flu like symptoms", "PROBLEM", 92, 109], ["fever", "PROBLEM", 111, 116], ["cough", "TEST", 128, 133], ["fatigue", "PROBLEM", 142, 149], ["myalgias", "PROBLEM", 158, 166], ["shortness of breath", "PROBLEM", 178, 197]]], ["18,36-3898Other flu like symptoms of sore throat, headache, and stuffy nose are also known but less 99 common.", [["18,36-3898", "CHEMICAL", 0, 10], ["flu", "DISEASE", 16, 19], ["sore throat", "DISEASE", 37, 48], ["headache", "DISEASE", 50, 58], ["nose", "ORGAN", 71, 75], ["Other flu like symptoms", "PROBLEM", 10, 33], ["sore throat", "PROBLEM", 37, 48], ["headache", "PROBLEM", 50, 58], ["stuffy nose", "PROBLEM", 64, 75], ["sore throat", "ANATOMY", 37, 48], ["headache", "OBSERVATION", 50, 58]]], ["37 Cough seems to be the most common first symptom.", [["Cough", "DISEASE", 3, 8], ["Cough", "PROBLEM", 3, 8]]], ["36 As little as 44% of patients 100 will have a documented fever on arrival, with 80-90% developing a fever during 101 hospitalization.", [["fever", "DISEASE", 59, 64], ["fever", "DISEASE", 102, 107], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a documented fever", "PROBLEM", 46, 64], ["a fever", "PROBLEM", 100, 107], ["fever", "OBSERVATION", 102, 107]]], ["39 Subjective fevers appear to be a more common presentation.", [["fevers", "DISEASE", 14, 20], ["Subjective fevers", "PROBLEM", 3, 20]]], ["102 Some more rare presentations of COVID-19 have been observed.", [["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "DNA", 36, 44], ["COVID", "TEST", 36, 41]]], ["Diarrhea seems to be a rare but 103 known presenting symptom, 7,40 but up to 70% of patients will develop some gastrointestinal 104 symptoms (nausea, vomiting, diarrhea, anorexia, abdominal pain, gastrointestinal bleeding).", [["gastrointestinal", "ANATOMY", 111, 127], ["abdominal", "ANATOMY", 180, 189], ["gastrointestinal", "ANATOMY", 196, 212], ["Diarrhea", "DISEASE", 0, 8], ["gastrointestinal 104 symptoms", "DISEASE", 111, 140], ["nausea", "DISEASE", 142, 148], ["vomiting", "DISEASE", 150, 158], ["diarrhea", "DISEASE", 160, 168], ["anorexia", "DISEASE", 170, 178], ["abdominal pain", "DISEASE", 180, 194], ["gastrointestinal bleeding", "DISEASE", 196, 221], ["patients", "ORGANISM", 84, 92], ["abdominal", "ORGANISM_SUBDIVISION", 180, 189], ["gastrointestinal", "ORGANISM_SUBDIVISION", 196, 212], ["patients", "SPECIES", 84, 92], ["Diarrhea", "PROBLEM", 0, 8], ["some gastrointestinal 104 symptoms", "PROBLEM", 106, 140], ["nausea", "PROBLEM", 142, 148], ["vomiting", "PROBLEM", 150, 158], ["diarrhea", "PROBLEM", 160, 168], ["anorexia", "PROBLEM", 170, 178], ["abdominal pain", "PROBLEM", 180, 194], ["gastrointestinal bleeding", "PROBLEM", 196, 221], ["gastrointestinal", "ANATOMY", 111, 127], ["abdominal", "ANATOMY", 180, 189], ["gastrointestinal", "ANATOMY", 196, 212], ["bleeding", "OBSERVATION", 213, 221]]], ["41105Loss of smell (anosmia) and loss of taste (ageusia) are also known presentations of COVID- 19.", [["Loss of smell", "DISEASE", 5, 18], ["anosmia", "DISEASE", 20, 27], ["loss of taste", "DISEASE", 33, 46], ["Loss of smell (anosmia", "PROBLEM", 5, 27], ["loss of taste", "PROBLEM", 33, 46], ["COVID", "TEST", 89, 94]]], ["42 106105The viral incubation (time from exposure to symptoms) is typically 2-14 days.", [["42 106105", "CHEMICAL", 0, 9], ["The viral incubation", "PROBLEM", 9, 29], ["symptoms", "PROBLEM", 53, 61], ["viral incubation", "OBSERVATION", 13, 29]]], ["36, 43 Most patients 107 will have contact with a person who is known or potentially positive for COVID-19, but as 108 disease incidence grows in certain areas, community spread can be presumed.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["person", "SPECIES", 50, 56], ["COVID", "TEST", 98, 103], ["community spread", "PROBLEM", 161, 177], ["community spread", "OBSERVATION", 161, 177]]], ["That is, in areas 109 with very high incidence (e.g. New York City), all patients can be presumed to have had contact 110 with a person with COVID- 19.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["person", "SPECIES", 129, 135], ["COVID", "TEST", 141, 146]]], ["111 For patients who develop severe illness, the need for hospitalization typically peaks around day 112 2-7 of symptoms, about day 10 after exposure.", [["illness", "DISEASE", 36, 43], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["severe illness", "PROBLEM", 29, 43], ["symptoms", "PROBLEM", 112, 120], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["illness", "OBSERVATION", 36, 43]]], ["38, 44 After admission, the small percentage of 113 patient who develop critical illness will do so remarkably rapidly.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["critical illness", "PROBLEM", 72, 88], ["small", "OBSERVATION_MODIFIER", 28, 33], ["illness", "OBSERVATION", 81, 88]]], ["39 Most commonly patients go 114 from minimal oxygen support to intubation within 24 hours.", [["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["patients", "ORGANISM", 17, 25], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["patients", "SPECIES", 17, 25], ["minimal oxygen support", "TREATMENT", 38, 60], ["intubation", "TREATMENT", 64, 74]]], ["In the Emergency Department, nurses often encounter critically ill patients.", [["critically ill", "DISEASE", 52, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["The instinct of many 153 emergency nurses, in particular, is to run towards a critically ill patient and initiate assessment 154 and care.", [["critically ill", "DISEASE", 78, 92], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["assessment", "TEST", 114, 124]]], ["It is important that nurses and other healthcare workers take a couple extra seconds to 155 apply appropriate PPE prior to any resuscitation.", [["any resuscitation", "TREATMENT", 123, 140]]], ["47 Nurses must care for themselves in order to be healthy and 157 available to care for future patients.158Proper donning/doffing takes additional time and often requires additional staff member to assist 159 with doffing or acting as a runner to grab additional supplies, medications, and send lab tests.160Our hospital encourages a \"spotter\", particularly during doffing, so any violations of sterility can 161 immediately be identified and remedied.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["medications", "TREATMENT", 273, 284], ["lab tests", "TEST", 295, 304]]], ["We also use erasable markers to write messages to team 162 members outside the room on glass doors.163Transport of patients will also need to be protocolized.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["For in hospital transport, careful consideration should be given to staff 165 needed, patient and staff PPE, and routes and elevators.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93]]], ["Multiple staff will likely be needed for 166 transport.168The primary initial evaluation of patients includes an adequate screening program.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["The primary initial evaluation", "TEST", 58, 88]]], ["What this 169 includes will vary depending on burden of disease in a specific area.", [["disease", "PROBLEM", 56, 63], ["disease", "OBSERVATION", 56, 63]]], ["Many triage screening tools 170 for COVID-19 initially started with travel or known contact screening.", [["Many triage screening tools", "TEST", 0, 27], ["COVID", "TEST", 36, 41], ["contact screening", "TEST", 84, 101]]], ["More recently, areas with 171 a larger number of patients have switched to symptom-based screening system.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["larger", "OBSERVATION_MODIFIER", 32, 38]]], ["Screening should include questions regarding known contacts but also places of residence, bearing in mind that 173 many congregate settings have been causes of rapid community spread.", [["rapid community spread", "PROBLEM", 160, 182], ["rapid", "OBSERVATION_MODIFIER", 160, 165], ["community spread", "OBSERVATION", 166, 182]]], ["Any patient with fever or 174 respiratory symptoms should be wearing a mask or face cover of some sort.", [["respiratory", "ANATOMY", 30, 41], ["fever", "DISEASE", 17, 22], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["fever", "PROBLEM", 17, 22], ["174 respiratory symptoms", "PROBLEM", 26, 50], ["a mask", "TREATMENT", 69, 75]]], ["Ideally, a surgical 175 mask, but even cloth masks are acceptable in areas short on PPE for healthcare workers.176Ambulance arrivals will need to be screened for COVID-19, as well.", [["a surgical 175 mask", "TREATMENT", 9, 28], ["cloth masks", "TREATMENT", 39, 50], ["COVID", "TEST", 162, 167]]], ["Clear communication with 177 pre-hospital staff prior to arrival and a standardized plan for transport for high and low risk 178 patients is needed.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137]]], ["For example, we ask that high risk patients on CPAP or BiPAP be taken off of 179 this temporarily while they are being transported through the hallway from an ambulance to a 180 room.", [["CPAP", "CHEMICAL", 47, 51], ["patients", "ORGANISM", 35, 43], ["BiPAP", "SIMPLE_CHEMICAL", 55, 60], ["patients", "SPECIES", 35, 43], ["CPAP", "TREATMENT", 47, 51], ["BiPAP", "TREATMENT", 55, 60]]], ["Our high-risk respiratory distress patients are then brought to directly to a negative 181 pressure room, ideally with necessary supplies and staff in appropriate PPE at bedside.", [["respiratory distress", "DISEASE", 14, 34], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Our high-risk respiratory distress", "PROBLEM", 0, 34], ["high", "OBSERVATION_MODIFIER", 4, 8], ["respiratory distress", "OBSERVATION", 14, 34]]], ["These Regardless, a process to obtain and transport blood samples to the clinical laboratory is needed.245Each laboratory or hospital may have different requirements.", [["blood samples", "ANATOMY", 52, 65], ["blood samples", "ORGANISM_SUBSTANCE", 52, 65], ["transport blood samples", "TEST", 42, 65]]], ["We initially did not use our 246 pneumatic tube system and had samples walked to the laboratory, but we have since started using 247 the tube system again.", [["samples", "ANATOMY", 63, 70], ["tube", "TISSUE", 137, 141], ["our 246 pneumatic tube system", "TREATMENT", 25, 54], ["the tube system", "TREATMENT", 133, 148], ["tube", "OBSERVATION", 43, 47]]], ["The nurse obtains the sample in the room and then deposits the labeled 248 samples in a specimen collection bag outside the room, held by a gloved, \"clean\" assistant.", [["a specimen collection bag", "TREATMENT", 86, 111]]], ["The Many of these patients progress to severe ARDS and need intubation.", [["ARDS", "DISEASE", 46, 50], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["severe ARDS", "PROBLEM", 39, 50], ["intubation", "TREATMENT", 60, 70], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["ARDS", "OBSERVATION", 46, 50]]], ["The presentation of ARDS 291 in these patients has been described as very atypical.", [["ARDS", "DISEASE", 20, 24], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["ARDS", "PROBLEM", 20, 24], ["ARDS", "OBSERVATION", 20, 24], ["very", "OBSERVATION_MODIFIER", 69, 73], ["atypical", "OBSERVATION_MODIFIER", 74, 82]]], ["68 Ventilator settings should be low tidal 292 volume to avoid lung injury.", [["lung", "ANATOMY", 63, 67], ["lung injury", "DISEASE", 63, 74], ["lung", "ORGAN", 63, 67], ["Ventilator settings", "TREATMENT", 3, 22], ["lung injury", "PROBLEM", 63, 74], ["lung", "ANATOMY", 63, 67], ["injury", "OBSERVATION", 68, 74]]], ["69 The ideal level of PEEP, though, continues to be debated, even among experts.", [["PEEP", "TREATMENT", 22, 26]]], ["69 Patients with ARDS are frequently given steroids.", [["ARDS", "DISEASE", 17, 21], ["steroids", "CHEMICAL", 43, 51], ["steroids", "CHEMICAL", 43, 51], ["Patients", "ORGANISM", 3, 11], ["Patients", "SPECIES", 3, 11], ["ARDS", "PROBLEM", 17, 21], ["steroids", "TREATMENT", 43, 51], ["ARDS", "OBSERVATION", 17, 21]]], ["Steroid treatment was 294 initially associated with increased mortality in some observational studies with COVID-19 and 295 was avoided; however, recent prospective data has shown steroids to be beneficial to patients 296 requiring supplemental oxygen or intubation.", [["steroids", "CHEMICAL", 180, 188], ["oxygen", "CHEMICAL", 245, 251], ["Steroid", "CHEMICAL", 0, 7], ["steroids", "CHEMICAL", 180, 188], ["oxygen", "CHEMICAL", 245, 251], ["Steroid", "SIMPLE_CHEMICAL", 0, 7], ["steroids", "SIMPLE_CHEMICAL", 180, 188], ["patients", "ORGANISM", 209, 217], ["oxygen", "SIMPLE_CHEMICAL", 245, 251], ["patients", "SPECIES", 209, 217], ["Steroid treatment", "TREATMENT", 0, 17], ["increased mortality", "PROBLEM", 52, 71], ["COVID", "TEST", 107, 112], ["steroids", "TREATMENT", 180, 188], ["supplemental oxygen", "TREATMENT", 232, 251], ["intubation", "TREATMENT", 255, 265]]], ["70 In addition to elective proning of non-intubated 297 patient, proning is used in many intubated patients based on arterial blood gas findings.", [["arterial blood", "ANATOMY", 117, 131], ["patient", "ORGANISM", 56, 63], ["patients", "ORGANISM", 99, 107], ["arterial", "MULTI-TISSUE_STRUCTURE", 117, 125], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["patient", "SPECIES", 56, 63], ["patients", "SPECIES", 99, 107], ["arterial blood gas findings", "TEST", 117, 144], ["arterial", "ANATOMY", 117, 125]]], ["Proning Chloroquine is generally less tolerated than hydroxychloroquine due to worse side effects.309Hydroxychloroquine is also used to treat autoimmune diseases like lupus and rheumatoid 310 arthritis.", [["Chloroquine", "CHEMICAL", 8, 19], ["hydroxychloroquine", "CHEMICAL", 53, 71], ["Hydroxychloroquine", "CHEMICAL", 101, 119], ["autoimmune diseases", "DISEASE", 142, 161], ["lupus", "DISEASE", 167, 172], ["rheumatoid 310 arthritis", "DISEASE", 177, 201], ["Chloroquine", "CHEMICAL", 8, 19], ["hydroxychloroquine", "CHEMICAL", 53, 71], ["Hydroxychloroquine", "CHEMICAL", 101, 119], ["Chloroquine", "SIMPLE_CHEMICAL", 8, 19], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 53, 71], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 101, 119], ["Proning", "TREATMENT", 0, 7], ["Chloroquine", "TREATMENT", 8, 19], ["hydroxychloroquine", "TREATMENT", 53, 71], ["worse side effects", "PROBLEM", 79, 97], ["Hydroxychloroquine", "TREATMENT", 101, 119], ["autoimmune diseases", "PROBLEM", 142, 161], ["lupus", "PROBLEM", 167, 172], ["rheumatoid 310 arthritis", "PROBLEM", 177, 201], ["lupus", "OBSERVATION", 167, 172], ["rheumatoid", "OBSERVATION_MODIFIER", 177, 187], ["310 arthritis", "OBSERVATION", 188, 201]]], ["There is no overwhelming evidence that this drug works for COVID-19 in human trials.311The most common side effect with this drug is QT prolongation, which can rarely lead to fatal", [["COVID-19", "CHEMICAL", 59, 67], ["QT prolongation", "DISEASE", 133, 148], ["COVID-19", "CHEMICAL", 59, 67], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["COVID", "TEST", 59, 64], ["QT prolongation", "PROBLEM", 133, 148], ["no overwhelming", "UNCERTAINTY", 9, 24], ["most common", "OBSERVATION_MODIFIER", 91, 102]]]], "365b863ed4e9eeab4027cd17c9dcbd19b967d622": [["IntroductionThere are predictable peaks in asthma exacerbations in the spring and fall in temperate climates.", [["asthma", "DISEASE", 43, 49], ["predictable peaks", "PROBLEM", 22, 39], ["asthma exacerbations", "PROBLEM", 43, 63], ["predictable", "OBSERVATION_MODIFIER", 22, 33], ["peaks", "OBSERVATION_MODIFIER", 34, 39], ["asthma", "OBSERVATION_MODIFIER", 43, 49], ["exacerbations", "OBSERVATION", 50, 63]]], ["1 ,2 For example, regular seasonal cycles of asthma hospitalizations in school-age children in Canada have been demonstrated over a 15-year period of time (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) .", [["asthma", "DISEASE", 45, 51], ["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91], ["asthma hospitalizations", "PROBLEM", 45, 68], ["seasonal cycles", "OBSERVATION_MODIFIER", 26, 41], ["asthma", "OBSERVATION", 45, 51]]], ["3, 4 Factors that contribute to the \"September epidemic\" of asthma morbidity in children are likely to include return to school and concordant exposure to viruses and allergic sensitization together with exposure to relevant airborne allergens.IntroductionDespite the close relationships between HRV infections and asthma exacerbations, the relationships between infection and the severity of clinical illness are not completely understood.", [["asthma", "DISEASE", 60, 66], ["allergic sensitization", "DISEASE", 167, 189], ["HRV infections", "DISEASE", 296, 310], ["asthma", "DISEASE", 315, 321], ["infection", "DISEASE", 363, 372], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["asthma morbidity", "PROBLEM", 60, 76], ["viruses", "PROBLEM", 155, 162], ["allergic sensitization", "PROBLEM", 167, 189], ["relevant airborne allergens", "PROBLEM", 216, 243], ["HRV infections", "PROBLEM", 296, 310], ["asthma exacerbations", "PROBLEM", 315, 335], ["infection", "PROBLEM", 363, 372], ["clinical illness", "PROBLEM", 393, 409], ["asthma", "OBSERVATION", 60, 66], ["airborne allergens", "OBSERVATION", 225, 243], ["infections", "OBSERVATION", 300, 310], ["asthma", "OBSERVATION", 315, 321], ["infection", "OBSERVATION", 363, 372]]], ["For example, HRV can cause asymptomatic infections, common colds, or exacerbations of asthma.", [["infections", "DISEASE", 40, 50], ["colds", "DISEASE", 59, 64], ["asthma", "DISEASE", 86, 92], ["HRV", "PROBLEM", 13, 16], ["asymptomatic infections", "PROBLEM", 27, 50], ["common colds", "PROBLEM", 52, 64], ["exacerbations", "PROBLEM", 69, 82], ["asthma", "PROBLEM", 86, 92], ["asymptomatic", "OBSERVATION_MODIFIER", 27, 39], ["infections", "OBSERVATION", 40, 50], ["asthma", "OBSERVATION", 86, 92]]], ["This gap in knowledge is partly related to difficulties in detecting HRV.", [["partly related to", "UNCERTAINTY", 25, 42]]], ["Early studies of HRV epidemiology used diagnostics based on tissue culture, which is insensitive.", [["tissue culture", "ANATOMY", 60, 74], ["tissue", "TISSUE", 60, 66], ["Early studies", "TEST", 0, 13], ["HRV epidemiology", "TEST", 17, 33], ["tissue culture", "TEST", 60, 74]]], ["Recent studies employing polymerase chain reaction (PCR) and other molecular techniques indicate that there are new branches on the HRV family tree, 5-8 and one characteristic of the recently detected HRV-C species is that they cannot be detected by standard tissue culture.", [["tissue culture", "ANATOMY", 259, 273], ["HRV-C species", "ORGANISM", 201, 214], ["tissue", "TISSUE", 259, 265], ["Recent studies", "TEST", 0, 14], ["polymerase chain reaction", "PROBLEM", 25, 50], ["PCR", "TEST", 52, 55], ["other molecular techniques", "TEST", 61, 87], ["C species", "PROBLEM", 205, 214], ["standard tissue culture", "TEST", 250, 273], ["new", "OBSERVATION_MODIFIER", 112, 115], ["branches", "OBSERVATION_MODIFIER", 116, 124]]], ["New molecular assays make it possible to conduct epidemiologic studies to identify and evaluate the role of specific strains, including HRV-C, in the activity of chronic asthma.", [["chronic asthma", "DISEASE", 162, 176], ["HRV-C", "GENE_OR_GENE_PRODUCT", 136, 141], ["New molecular assays", "TEST", 0, 20], ["epidemiologic studies", "TEST", 49, 70], ["specific strains", "PROBLEM", 108, 124], ["HRV", "TEST", 136, 139], ["chronic asthma", "PROBLEM", 162, 176], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["asthma", "OBSERVATION", 170, 176]]], ["For example, a recent study detected HRV-C in almost half of all children who were hospitalized with rhinovirus-associated respiratory illnesses.9IntroductionIn addition to limitations related to viral diagnostics, most previous studies have focused on detection of HRV during periods of illness: there is little information about the true rates of infection, which can be asymptomatic.", [["respiratory", "ANATOMY", 123, 134], ["respiratory illnesses", "DISEASE", 123, 144], ["infection", "DISEASE", 349, 358], ["HRV-C", "SIMPLE_CHEMICAL", 37, 42], ["children", "ORGANISM", 65, 73], ["rhinovirus", "ORGANISM", 101, 111], ["children", "SPECIES", 65, 73], ["a recent study", "TEST", 13, 27], ["HRV", "TEST", 37, 40], ["rhinovirus", "PROBLEM", 101, 111], ["respiratory illnesses", "PROBLEM", 123, 144], ["viral diagnostics", "TEST", 196, 213], ["previous studies", "TEST", 220, 236], ["HRV", "PROBLEM", 266, 269], ["illness", "PROBLEM", 288, 295], ["infection", "PROBLEM", 349, 358], ["respiratory illnesses", "OBSERVATION", 123, 144], ["infection", "OBSERVATION", 349, 358]]], ["This lack of data related to mild or asymptomatic illnesses has hampered efforts to identify host and viral factors that contribute to the illness severity.IntroductionBased on previous findings in children who were hospitalized or seen in acute care facilities, [9] [10] [11] we hypothesized that both viral infections and allergic sensitization contribute to loss of asthma control during peak HRV seasons, and that allergic children who developed HRV infections would be at greatest risk.", [["illness", "DISEASE", 139, 146], ["viral infections", "DISEASE", 303, 319], ["allergic sensitization", "DISEASE", 324, 346], ["loss of asthma", "DISEASE", 361, 375], ["allergic", "DISEASE", 418, 426], ["HRV infections", "DISEASE", 450, 464], ["children", "ORGANISM", 198, 206], ["children", "ORGANISM", 427, 435], ["children", "SPECIES", 198, 206], ["children", "SPECIES", 427, 435], ["HRV", "SPECIES", 450, 453], ["mild or asymptomatic illnesses", "PROBLEM", 29, 59], ["viral factors", "PROBLEM", 102, 115], ["the illness severity", "PROBLEM", 135, 155], ["both viral infections", "PROBLEM", 298, 319], ["allergic sensitization", "PROBLEM", 324, 346], ["asthma control", "PROBLEM", 369, 383], ["HRV infections", "PROBLEM", 450, 464], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["viral", "OBSERVATION_MODIFIER", 303, 308], ["infections", "OBSERVATION", 309, 319], ["asthma", "OBSERVATION", 369, 375], ["infections", "OBSERVATION", 454, 464]]], ["Our goals for this study were to prospectively evaluate the contribution of HRV to seasonal asthma disease activity, and to compare the clinical characteristics of viral and non viral illnesses.", [["asthma disease", "DISEASE", 92, 106], ["viral and non viral illnesses", "DISEASE", 164, 193], ["this study", "TEST", 14, 24], ["HRV", "PROBLEM", 76, 79], ["seasonal asthma disease activity", "PROBLEM", 83, 115], ["viral and non viral illnesses", "PROBLEM", 164, 193], ["asthma", "OBSERVATION", 92, 98], ["viral", "OBSERVATION", 164, 169]]], ["To accomplish these goals, we monitored viral infections in children with asthma during peak common cold seasons, and the virologic information was compared to patterns of upper and lower respiratory illnesses, allergic sensitization, and cold and asthma disease activity.Study subjects and study designThe study was approved by Human Subjects Committee of the School of Medicine and Public Health, University of Wisconsin-Madison.", [["respiratory", "ANATOMY", 188, 199], ["viral infections", "DISEASE", 40, 56], ["asthma", "DISEASE", 74, 80], ["respiratory illnesses", "DISEASE", 188, 209], ["allergic sensitization", "DISEASE", 211, 233], ["asthma disease", "DISEASE", 248, 262], ["children", "ORGANISM", 60, 68], ["upper", "ORGANISM_SUBDIVISION", 172, 177], ["Human", "ORGANISM", 329, 334], ["children", "SPECIES", 60, 68], ["Human", "SPECIES", 329, 334], ["asthma", "PROBLEM", 74, 80], ["upper and lower respiratory illnesses", "PROBLEM", 172, 209], ["allergic sensitization", "PROBLEM", 211, 233], ["cold and asthma disease activity", "PROBLEM", 239, 271], ["Study subjects", "TEST", 272, 286], ["The study", "TEST", 303, 312], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infections", "OBSERVATION", 46, 56], ["upper", "ANATOMY_MODIFIER", 172, 177], ["lower", "ANATOMY_MODIFIER", 182, 187], ["respiratory", "ANATOMY", 188, 199], ["illnesses", "OBSERVATION", 200, 209]]], ["A total of 58 children with asthma ages 6-8 years were enrolled in this study.", [["asthma", "DISEASE", 28, 34], ["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22], ["asthma ages", "PROBLEM", 28, 39], ["this study", "TEST", 67, 77]]], ["Skin prick testing (SPT) was performed on each subject at the time of enrollment, as well as fluoroenzyme immunoassays (FEIAs) using an automated instrument (Unicap\u00ae 100, Phadia) to determine total and allergen-specific IgE levels in plasma.", [["Skin", "ANATOMY", 0, 4], ["plasma", "ANATOMY", 234, 240], ["Skin", "ORGAN", 0, 4], ["IgE", "GENE_OR_GENE_PRODUCT", 220, 223], ["plasma", "ORGANISM_SUBSTANCE", 234, 240], ["IgE", "PROTEIN", 220, 223], ["Skin prick testing", "TEST", 0, 18], ["fluoroenzyme immunoassays", "TEST", 93, 118], ["an automated instrument (Unicap\u00ae", "TEST", 133, 165], ["allergen", "TEST", 202, 210], ["specific IgE levels", "TEST", 211, 230]]], ["The allergens evaluated by SPT were: alternaria, tree fluid, cladosporium, grass mix, aspergillus, ragweed, Dermatophagoides farinae, Dermatophagoides pteronyssinus, weed mix, dog dander, cat dander, cockroach (Greer Laboratories, Lenoir, NC).", [["Dermatophagoides farinae", "ORGANISM", 108, 132], ["Dermatophagoides pteronyssinus", "ORGANISM", 134, 164], ["dog", "ORGANISM", 176, 179], ["dander", "ORGANISM_SUBDIVISION", 180, 186], ["cat", "ORGANISM", 188, 191], ["dander", "ORGANISM_SUBDIVISION", 192, 198], ["cockroach", "ORGANISM_SUBDIVISION", 200, 209], ["Dermatophagoides farinae", "SPECIES", 108, 132], ["Dermatophagoides pteronyssinus", "SPECIES", 134, 164], ["dog dander", "SPECIES", 176, 186], ["cat dander", "SPECIES", 188, 198], ["Dermatophagoides farinae", "SPECIES", 108, 132], ["Dermatophagoides pteronyssinus", "SPECIES", 134, 164], ["dog dander", "SPECIES", 176, 186], ["cat dander", "SPECIES", 188, 198], ["alternaria", "PROBLEM", 37, 47], ["cladosporium", "PROBLEM", 61, 73], ["grass mix", "TREATMENT", 75, 84], ["aspergillus", "PROBLEM", 86, 97], ["ragweed", "PROBLEM", 99, 106]]], ["In addition, allergen-specific IgE to Dermatophagoides farinae, Dermatophagoides pteronyssinus, cat, dog, alternaria, ragweed, silver birch, timothy grass, cockroach, egg and peanut was measured (ImmunoCAP FEIA, Phadia).Study subjects and study designIn April 2006, nasal samples were collected every other week for a total of 6 weeks.", [["egg", "ANATOMY", 167, 170], ["nasal samples", "ANATOMY", 266, 279], ["silver", "CHEMICAL", 127, 133], ["IgE", "GENE_OR_GENE_PRODUCT", 31, 34], ["Dermatophagoides", "ORGANISM", 38, 54], ["farinae", "GENE_OR_GENE_PRODUCT", 55, 62], ["Dermatophagoides pteronyssinus", "ORGANISM", 64, 94], ["cat", "ORGANISM", 96, 99], ["dog", "ORGANISM", 101, 104], ["ragweed", "ORGANISM_SUBDIVISION", 118, 125], ["silver birch", "ORGANISM", 127, 139], ["timothy", "ORGANISM", 141, 148], ["grass", "ORGANISM_SUBDIVISION", 149, 154], ["cockroach", "ORGANISM_SUBDIVISION", 156, 165], ["egg", "ORGANISM_SUBSTANCE", 167, 170], ["peanut", "ORGANISM_SUBDIVISION", 175, 181], ["nasal samples", "CANCER", 266, 279], ["IgE", "PROTEIN", 31, 34], ["Dermatophagoides farinae", "PROTEIN", 38, 62], ["Dermatophagoides farinae", "SPECIES", 38, 62], ["Dermatophagoides pteronyssinus", "SPECIES", 64, 94], ["cat", "SPECIES", 96, 99], ["dog", "SPECIES", 101, 104], ["peanut", "SPECIES", 175, 181], ["Dermatophagoides farinae", "SPECIES", 38, 62], ["Dermatophagoides pteronyssinus", "SPECIES", 64, 94], ["dog", "SPECIES", 101, 104], ["peanut", "SPECIES", 175, 181], ["allergen", "TREATMENT", 13, 21], ["alternaria", "PROBLEM", 106, 116], ["ragweed", "PROBLEM", 118, 125], ["peanut", "TEST", 175, 181], ["Study subjects", "TEST", 220, 234], ["nasal samples", "TREATMENT", 266, 279], ["egg", "ANATOMY", 167, 170]]], ["Due to the high frequency of distinct infections, specimen collection was increased to weekly during September 2006, 2007, and April 2007, 2008 over 5-week periods.", [["specimen", "ANATOMY", 50, 58], ["infections", "DISEASE", 38, 48], ["distinct infections", "PROBLEM", 29, 48], ["specimen collection", "TEST", 50, 69], ["high", "OBSERVATION_MODIFIER", 11, 15], ["distinct", "OBSERVATION_MODIFIER", 29, 37], ["infections", "OBSERVATION", 38, 48]]], ["Children along with their parents recorded information on daily diary cards.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["The diary cards consisted of a calendar, and each day had spaces to place a sticker for cold and asthma symptoms, as well as a blank for recording AM peak expiratory flow and albuterol use.Study subjects and study designAll samples were included for the viral analysis.", [["samples", "ANATOMY", 224, 231], ["asthma symptoms", "DISEASE", 97, 112], ["albuterol", "CHEMICAL", 175, 184], ["albuterol", "CHEMICAL", 175, 184], ["albuterol", "SIMPLE_CHEMICAL", 175, 184], ["cold and asthma symptoms", "PROBLEM", 88, 112], ["albuterol use", "TREATMENT", 175, 188], ["Study subjects", "TEST", 189, 203], ["All samples", "TEST", 220, 231], ["the viral analysis", "TEST", 250, 268]]], ["For the comparison of rates of infection to respiratory symptoms we included only children who collected 5 sequential weekly nasal specimens and were missing <1 week of diary card data in any given season.", [["respiratory", "ANATOMY", 44, 55], ["nasal specimens", "ANATOMY", 125, 140], ["infection", "DISEASE", 31, 40], ["respiratory symptoms", "DISEASE", 44, 64], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["infection", "PROBLEM", 31, 40], ["respiratory symptoms", "PROBLEM", 44, 64], ["infection", "OBSERVATION", 31, 40]]], ["Of the 58 children enrolled, there were two children who did not complete any series information.", [["children", "ORGANISM", 10, 18], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 10, 18], ["children", "SPECIES", 44, 52]]], ["Included in the final analyses were 42 of the 56 children (75%) who completed at least one season, of which 19 children (34%) completed two seasons.Collection of nasal samplesAt the first study visit subjects were taught to collect samples of their own nasal mucus using a \"nose-blowing\" technique.12 ,13 Briefly, participants spray saline into each nostril, alternately occlude each nare and blow into a \"baggie\".", [["nasal samples", "ANATOMY", 162, 175], ["samples", "ANATOMY", 232, 239], ["nasal mucus", "ANATOMY", 253, 264], ["nose", "ANATOMY", 274, 278], ["nostril", "ANATOMY", 350, 357], ["children", "ORGANISM", 49, 57], ["children", "ORGANISM", 111, 119], ["nasal samples", "CANCER", 162, 175], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 253, 264], ["nose", "ORGANISM_SUBDIVISION", 274, 278], ["children", "SPECIES", 49, 57], ["children", "SPECIES", 111, 119], ["participants", "SPECIES", 314, 326], ["nasal samples", "TEST", 162, 175], ["a \"nose-blowing\" technique", "TREATMENT", 271, 297], ["participants spray saline into each nostril", "TREATMENT", 314, 357], ["nasal", "ANATOMY", 162, 167], ["samples", "OBSERVATION", 168, 175], ["nostril", "ANATOMY", 350, 357]]], ["Two mL of a solution containing buffered saline (pH 7.4) along with 0.5% gelatin is then added to the baggie, which is then sealed and placed into a container in the freezer.", [["gelatin", "CHEMICAL", 73, 80], ["saline", "SIMPLE_CHEMICAL", 41, 47], ["gelatin", "SIMPLE_CHEMICAL", 73, 80], ["a solution containing buffered saline (pH", "TREATMENT", 10, 51], ["0.5% gelatin", "TREATMENT", 68, 80], ["the baggie", "TREATMENT", 98, 108]]], ["Study materials and diaries were distributed to the homes for biweekly collection.", [["Study materials", "TEST", 0, 15], ["biweekly collection", "TEST", 62, 81]]], ["The stability of HRV collected and stored under these conditions was confirmed in preliminary experiments: HRV was detectable even at low concentrations (100 PFU of HRV16/ml)-as might be in asymptomatic children-and left at room temperature, 4\u00b0CCollection of nasal samples(refrigerated), and -20\u00b0C (home freezer) for up to 5 weeks.Identification of respiratory virusesDiagnostic virology was performed for all nasal samples whether a child had symptoms or not.", [["nasal samples", "ANATOMY", 259, 272], ["nasal samples", "ANATOMY", 410, 423], ["respiratory viruses", "DISEASE", 349, 368], ["children", "ORGANISM", 203, 211], ["nasal samples", "MULTI-TISSUE_STRUCTURE", 259, 272], ["nasal samples", "CANCER", 410, 423], ["children", "SPECIES", 203, 211], ["HRV", "TEST", 17, 20], ["HRV", "PROBLEM", 107, 110], ["nasal samples", "TEST", 259, 272], ["respiratory viruses", "PROBLEM", 349, 368], ["symptoms", "PROBLEM", 444, 452], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["left", "ANATOMY_MODIFIER", 216, 220], ["nasal", "ANATOMY", 259, 264], ["respiratory", "ANATOMY", 349, 360], ["viruses", "OBSERVATION", 361, 368]]], ["A highly sensitive multiplex PCR-based assay (Respiratory Multicode Assay [RMA]) was used to test for the following viruses; respiratory syncytial virus (RSV, groups A and B), HRV, parainfluenza (1, 2, 3, 4a, 4b), influenza (A, B), adenovirus (B, C, and E), coronavirus (229E, NL63, OC43, and SARS), enterovirus, and human metapneumovirus.", [["respiratory syncytial virus", "DISEASE", 125, 152], ["parainfluenza", "DISEASE", 181, 194], ["influenza", "DISEASE", 214, 223], ["SARS), enterovirus, and human metapneumovirus", "DISEASE", 293, 338], ["respiratory syncytial virus", "ORGANISM", 125, 152], ["RSV", "ORGANISM", 154, 157], ["parainfluenza", "ORGANISM", 181, 194], ["influenza (A, B", "ORGANISM", 214, 229], ["adenovirus", "ORGANISM", 232, 242], ["B, C, and E)", "ORGANISM", 244, 256], ["coronavirus", "ORGANISM", 258, 269], ["NL63", "GENE_OR_GENE_PRODUCT", 277, 281], ["OC43", "GENE_OR_GENE_PRODUCT", 283, 287], ["enterovirus", "ORGANISM", 300, 311], ["human", "ORGANISM", 317, 322], ["metapneumovirus", "ORGANISM", 323, 338], ["respiratory syncytial virus", "SPECIES", 125, 152], ["parainfluenza", "SPECIES", 181, 194], ["coronavirus", "SPECIES", 258, 269], ["human", "SPECIES", 317, 322], ["metapneumovirus", "SPECIES", 323, 338], ["respiratory syncytial virus", "SPECIES", 125, 152], ["RSV", "SPECIES", 154, 157], ["adenovirus", "SPECIES", 232, 242], ["human metapneumovirus", "SPECIES", 317, 338], ["multiplex PCR", "TEST", 19, 32], ["the following viruses", "PROBLEM", 102, 123], ["respiratory syncytial virus", "PROBLEM", 125, 152], ["RSV", "TEST", 154, 157], ["HRV", "TEST", 176, 179], ["parainfluenza", "TEST", 181, 194], ["4a", "TEST", 205, 207], ["influenza", "PROBLEM", 214, 223], ["adenovirus (B, C", "TEST", 232, 248], ["coronavirus", "TEST", 258, 269], ["NL63", "TEST", 277, 281], ["OC43", "TEST", 283, 287], ["SARS", "PROBLEM", 293, 297], ["enterovirus", "PROBLEM", 300, 311], ["human metapneumovirus", "PROBLEM", 317, 338], ["respiratory syncytial", "ANATOMY", 125, 146], ["metapneumovirus", "OBSERVATION", 323, 338]]], ["14 Bocavirus detection primers were also added to the RMA mixture for the purposes of this study.Molecular typing assayMolecular typing of HRV was performed as previously described (3).", [["Bocavirus detection primers", "TREATMENT", 3, 30], ["this study", "TEST", 86, 96], ["Molecular typing assayMolecular typing of HRV", "PROBLEM", 97, 142]]], ["Briefly, a 260-bp variable region at the 5\u2032 noncoding region of HRV was amplified from the cDNA from nasal specimens by semi-nested PCR.", [["nasal specimens", "ANATOMY", 101, 116], ["nasal specimens", "CANCER", 101, 116], ["260-bp variable region", "DNA", 11, 33], ["5\u2032 noncoding region", "DNA", 41, 60], ["HRV", "DNA", 64, 67], ["cDNA", "DNA", 91, 95], ["bp variable region", "PROBLEM", 15, 33], ["HRV", "PROBLEM", 64, 67], ["the cDNA", "TEST", 87, 95], ["nasal specimens", "TEST", 101, 116], ["semi-nested PCR", "TEST", 120, 135], ["nasal", "ANATOMY", 101, 106]]], ["The 260-bp fragment was cloned and sequenced.", [["260-bp fragment", "DNA", 4, 19], ["The 260-bp fragment", "TREATMENT", 0, 19]]], ["The identity of each sequence was verified by comparing to the 5\u2032 sequences of the 101 reference HRV serotypes, as well as a number of sequences from newly identified strains.", [["5\u2032 sequences", "DNA", 63, 75], ["HRV serotypes", "TEST", 97, 110], ["newly identified strains", "PROBLEM", 150, 174]]], ["5Respiratory symptoms and peak expiratory flowParents and children scored cold and asthma symptom severity based on 4-point scoring system (none, mild, moderate, and severe).", [["asthma", "DISEASE", 83, 89], ["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66], ["5Respiratory symptoms", "PROBLEM", 0, 21], ["peak expiratory flowParents", "PROBLEM", 26, 53], ["children scored cold", "PROBLEM", 58, 78], ["asthma symptom severity", "PROBLEM", 83, 106], ["mild, moderate, and severe)", "PROBLEM", 146, 173], ["peak", "OBSERVATION_MODIFIER", 26, 30], ["expiratory flowParents", "OBSERVATION", 31, 53], ["mild", "OBSERVATION_MODIFIER", 146, 150], ["moderate", "OBSERVATION_MODIFIER", 152, 160], ["severe", "OBSERVATION_MODIFIER", 166, 172]]], ["Cold symptoms were defined by the following: mild, mild stuffy or runny nose, doesn'st affect daily activities; moderate, moderate stuffy or runny nose and reduced activity but does not affect sleep; and severe, cannot breathe through nose, not able to sleep well because of symptoms.", [["nose", "ORGANISM_SUBDIVISION", 235, 239], ["Cold symptoms", "PROBLEM", 0, 13], ["mild, mild stuffy or runny nose", "PROBLEM", 45, 76], ["moderate, moderate stuffy or runny nose", "PROBLEM", 112, 151], ["reduced activity", "PROBLEM", 156, 172], ["symptoms", "PROBLEM", 275, 283], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["stuffy", "OBSERVATION", 56, 62], ["moderate", "OBSERVATION_MODIFIER", 112, 120], ["moderate", "OBSERVATION_MODIFIER", 122, 130], ["stuffy", "OBSERVATION", 131, 137]]], ["Asthma symptoms were defined by the following: mild, occasional cough or wheeze, does not affect daily activity; moderate, frequent cough or wheeze, some shortness or breath, reduced activity but not affecting sleep; and severe, not able to sleep well because of symptoms.", [["Asthma", "DISEASE", 0, 6], ["cough", "DISEASE", 64, 69], ["wheeze", "DISEASE", 73, 79], ["cough", "DISEASE", 132, 137], ["wheeze", "DISEASE", 141, 147], ["shortness or breath", "DISEASE", 154, 173], ["Asthma symptoms", "PROBLEM", 0, 15], ["mild, occasional cough", "PROBLEM", 47, 69], ["wheeze", "PROBLEM", 73, 79], ["moderate, frequent cough", "PROBLEM", 113, 137], ["wheeze", "PROBLEM", 141, 147], ["some shortness or breath", "PROBLEM", 149, 173], ["reduced activity", "PROBLEM", 175, 191], ["symptoms", "PROBLEM", 263, 271], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["occasional", "OBSERVATION_MODIFIER", 53, 63], ["cough", "OBSERVATION", 64, 69], ["moderate", "OBSERVATION_MODIFIER", 113, 121]]], ["The personal best peak expiration flow (PEF) for each subject was defined as the average of the 7 highest daily PEF during the study period.", [["the study", "TEST", 123, 132]]], ["Asthma control was defined using the current national guidelines, 15 based on symptoms, PEF and albuterol usage.", [["Asthma", "DISEASE", 0, 6], ["albuterol", "CHEMICAL", 96, 105], ["albuterol", "CHEMICAL", 96, 105], ["albuterol", "SIMPLE_CHEMICAL", 96, 105], ["Asthma control", "PROBLEM", 0, 14], ["symptoms", "PROBLEM", 78, 86], ["PEF", "TREATMENT", 88, 91], ["albuterol usage", "TREATMENT", 96, 111]]], ["The criteria for loss of asthma control consisted of at least moderate asthma symptoms and either a drop in PEF \u226520%, or use of albuterol more than 2 days per week.Infection and illness definitionsTwo methods were used to analyze the association between infection and illness.", [["asthma", "DISEASE", 25, 31], ["asthma", "DISEASE", 71, 77], ["albuterol", "CHEMICAL", 128, 137], ["Infection and illness", "DISEASE", 164, 185], ["infection", "DISEASE", 254, 263], ["illness", "DISEASE", 268, 275], ["albuterol", "CHEMICAL", 128, 137], ["albuterol", "SIMPLE_CHEMICAL", 128, 137], ["loss of asthma control", "PROBLEM", 17, 39], ["moderate asthma symptoms", "PROBLEM", 62, 86], ["a drop in PEF", "PROBLEM", 98, 111], ["albuterol", "TREATMENT", 128, 137], ["Infection", "PROBLEM", 164, 173], ["illness definitions", "PROBLEM", 178, 197], ["Two methods", "TREATMENT", 197, 208], ["infection", "PROBLEM", 254, 263], ["illness", "PROBLEM", 268, 275], ["asthma", "OBSERVATION", 25, 31], ["moderate", "OBSERVATION_MODIFIER", 62, 70], ["asthma", "OBSERVATION", 71, 77], ["infection", "OBSERVATION", 254, 263]]], ["First, weeks (Wednesday to the following Tuesday) were designated as virus positive or negative on the basis of viral detection results from nasal mucus samples that were obtained each Saturday.", [["nasal mucus samples", "ANATOMY", 141, 160], ["nasal mucus samples", "ORGANISM_SUBSTANCE", 141, 160], ["virus positive", "PROBLEM", 69, 83], ["viral detection", "TEST", 112, 127], ["nasal mucus samples", "TEST", 141, 160], ["nasal mucus", "ANATOMY", 141, 152]]], ["The presence of cold symptoms during each weekly interval was compared to viral detection data.Infection and illness definitionsSecond, we identified episodes of infection and illness based on virologic findings and clinical symptoms respectively, and either could last longer then a single week.", [["Infection and illness", "DISEASE", 95, 116], ["infection", "DISEASE", 162, 171], ["illness", "DISEASE", 176, 183], ["cold symptoms", "PROBLEM", 16, 29], ["viral detection data", "TEST", 74, 94], ["Infection", "PROBLEM", 95, 104], ["illness definitions", "PROBLEM", 109, 128], ["infection", "PROBLEM", 162, 171], ["illness", "PROBLEM", 176, 183], ["virologic findings", "TEST", 193, 211], ["clinical symptoms", "PROBLEM", 216, 233], ["cold", "OBSERVATION_MODIFIER", 16, 20], ["symptoms", "OBSERVATION", 21, 29], ["infection", "OBSERVATION", 162, 171]]], ["Infections were identified by evaluating results of molecular typing; if the same virus was detected in multiple weeks, it was considered as a single infection.", [["Infections", "DISEASE", 0, 10], ["infection", "DISEASE", 150, 159], ["Infections", "PROBLEM", 0, 10], ["molecular typing", "PROBLEM", 52, 68], ["the same virus", "PROBLEM", 73, 87], ["a single infection", "PROBLEM", 141, 159], ["infection", "OBSERVATION", 150, 159]]], ["An episode of respiratory illness, which could be viral or non viral, was defined as at least two consecutive days of cold or asthma symptoms rated at least mild in severity by the patient.Infection and illness definitionsNasal mucus samples were collected once every 7 days; therefore, we bisected the weeks and assumed an illness to be associated with a virus if signs of illness were present within 3 days of a specimen testing positive for virus.", [["respiratory", "ANATOMY", 14, 25], ["Nasal mucus samples", "ANATOMY", 222, 241], ["specimen", "ANATOMY", 414, 422], ["respiratory illness", "DISEASE", 14, 33], ["asthma", "DISEASE", 126, 132], ["Infection and illness", "DISEASE", 189, 210], ["illness", "DISEASE", 374, 381], ["patient", "ORGANISM", 181, 188], ["Nasal mucus samples", "ORGANISM_SUBSTANCE", 222, 241], ["patient", "SPECIES", 181, 188], ["respiratory illness", "PROBLEM", 14, 33], ["viral", "PROBLEM", 50, 55], ["non viral", "PROBLEM", 59, 68], ["cold or asthma symptoms", "PROBLEM", 118, 141], ["Infection", "PROBLEM", 189, 198], ["illness definitions", "PROBLEM", 203, 222], ["Nasal mucus samples", "TEST", 222, 241], ["an illness", "PROBLEM", 321, 331], ["a virus", "PROBLEM", 354, 361], ["illness", "PROBLEM", 374, 381], ["a specimen testing", "TEST", 412, 430], ["virus", "PROBLEM", 444, 449], ["respiratory illness", "OBSERVATION", 14, 33], ["mild", "OBSERVATION_MODIFIER", 157, 161], ["mucus", "OBSERVATION", 228, 233]]], ["Associations between viral detection and symptoms were complex in some instances, and the following data processing rules were established a priori to define a viral illness: 1) symptomatic periods were classified as 2 separate illnesses if there was more than a 3-day interval without symptoms, and 2) if there were different virologic findings within a period of continuous symptoms, this was classified as two illnesses.Statistical analysesPeak cold and asthma symptom scores were compared by virus recovery using the chi-square test for trend.", [["viral illness", "DISEASE", 160, 173], ["asthma", "DISEASE", 457, 463], ["viral detection", "TEST", 21, 36], ["symptoms", "PROBLEM", 41, 49], ["a viral illness", "PROBLEM", 158, 173], ["symptomatic periods", "PROBLEM", 178, 197], ["symptoms", "PROBLEM", 286, 294], ["different virologic findings", "PROBLEM", 317, 345], ["continuous symptoms", "PROBLEM", 365, 384], ["Statistical analyses", "TEST", 423, 443], ["Peak cold and asthma symptom scores", "PROBLEM", 443, 478], ["the chi-square test", "TEST", 517, 536], ["asthma", "OBSERVATION", 457, 463]]], ["All other categorical outcomes were analyzed with Fisher's exact test.", [["Fisher's exact test", "TEST", 50, 69]]], ["Differences in continuous outcomes were assessed using the Wilcoxon rank-sum test.", [["the Wilcoxon rank-sum test", "TEST", 55, 81]]], ["A two-sided 5%level test result was regarded as statistically significant.Subject characteristicsOf the 58 children with asthma enrolled in the study, 42 provided at least one complete season of nasal specimens and diary card data and are included in the final illness analyses.", [["nasal specimens", "ANATOMY", 195, 210], ["asthma", "DISEASE", 121, 127], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["A two-sided 5%level test", "TEST", 0, 24], ["asthma", "PROBLEM", 121, 127], ["the study", "TEST", 140, 149], ["nasal specimens", "TEST", 195, 210]]], ["The majority (88%) of the subjects had persistent asthma that required a daily controller therapy, and 57% had used an oral corticosteroid to relieve acute asthma symptoms in the year leading up to the study.", [["oral", "ANATOMY", 119, 123], ["asthma", "DISEASE", 50, 56], ["asthma", "DISEASE", 156, 162], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["persistent asthma", "PROBLEM", 39, 56], ["a daily controller therapy", "TREATMENT", 71, 97], ["an oral corticosteroid", "TREATMENT", 116, 138], ["acute asthma symptoms", "PROBLEM", 150, 171], ["the study", "TEST", 198, 207], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["persistent", "OBSERVATION_MODIFIER", 39, 49], ["asthma", "OBSERVATION", 50, 56], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["asthma", "OBSERVATION", 156, 162]]], ["This was an observational trial, and treatment of asthma was continued as per the child's regular physician.", [["asthma", "DISEASE", 50, 56], ["asthma", "PROBLEM", 50, 56], ["asthma", "OBSERVATION", 50, 56]]], ["Most of the children were sensitized to at least one aeroallergen, as indicated by skin tests (50%) and/or serum allergen-specific IgE (69%).", [["skin", "ANATOMY", 83, 87], ["serum", "ANATOMY", 107, 112], ["children", "ORGANISM", 12, 20], ["skin", "ORGAN", 83, 87], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["IgE", "GENE_OR_GENE_PRODUCT", 131, 134], ["serum allergen", "PROTEIN", 107, 121], ["IgE", "PROTEIN", 131, 134], ["children", "SPECIES", 12, 20], ["skin tests", "TEST", 83, 93], ["serum allergen", "TEST", 107, 121], ["skin", "ANATOMY", 83, 87]]], ["Demographics as well as baseline FEV1 were similar in those completing and not completing study procedures ( Table I) .Identification of respiratory virusesOf the 501 samples collected, 36-50% of specimens tested positive for viruses each season (Figure 1) , and all but 2 children had a virus detected at some point in time.", [["samples", "ANATOMY", 167, 174], ["specimens", "ANATOMY", 196, 205], ["samples", "CANCER", 167, 174], ["specimens", "CANCER", 196, 205], ["children", "ORGANISM", 273, 281], ["children", "SPECIES", 273, 281], ["baseline FEV1", "TEST", 24, 37], ["study procedures", "TEST", 90, 106], ["specimens", "TEST", 196, 205], ["viruses", "PROBLEM", 226, 233], ["a virus", "PROBLEM", 286, 293], ["respiratory virusesOf", "OBSERVATION", 137, 158], ["virus", "OBSERVATION", 288, 293]]], ["The 169 samples that tested positive for HRV were found to have 52 different strains (up to 18 strains per season).Identification of respiratory virusesOf the HRV specimens, 33% were Group A, 35% were Group B, and 24% were Group C and the remaining could not be typed.", [["samples", "ANATOMY", 8, 15], ["specimens", "ANATOMY", 163, 172], ["samples", "CANCER", 8, 15], ["HRV", "SPECIES", 41, 44], ["The 169 samples", "TEST", 0, 15], ["HRV", "TEST", 41, 44], ["52 different strains", "PROBLEM", 64, 84], ["respiratory virusesOf the HRV specimens", "TEST", 133, 172], ["Group B", "TEST", 201, 208], ["Group C", "TEST", 223, 230], ["respiratory virusesOf", "OBSERVATION", 133, 154]]], ["There appeared to be seasonal differences in the prevalence of HRV species (Figure 2) .", [["seasonal differences", "PROBLEM", 21, 41], ["HRV species", "PROBLEM", 63, 74], ["appeared to be", "UNCERTAINTY", 6, 20], ["seasonal", "OBSERVATION_MODIFIER", 21, 29]]], ["Overall, 48% of the April viruses were HRV-A, 51% of the September viruses were HRV-B, while similar numbers of HRV-C were detected in April (16%) and September (22%).", [["HRV-A", "CANCER", 39, 44], ["HRV-B", "CELL", 80, 85], ["HRV-C", "GENE_OR_GENE_PRODUCT", 112, 117], ["HRV-A", "SPECIES", 39, 44], ["the April viruses", "TEST", 16, 33], ["HRV", "TEST", 39, 42], ["the September viruses", "PROBLEM", 53, 74], ["HRV", "TEST", 80, 83], ["HRV", "TEST", 112, 115]]], ["Other viruses detected included 7 enteroviruses, 6 adenoviruses (4 Adv-C, 2 Adv-B), 5 coronoviruses, 5 influenza viruses, 5 metapneumoviruses, 6 bocaviruses, and 3 parainfluenza viruses.Identification of respiratory virusesWe next compared the list of HRV strains from one monitoring period to the next.", [["enteroviruses", "DISEASE", 34, 47], ["influenza viruses", "DISEASE", 103, 120], ["parainfluenza viruses", "DISEASE", 164, 185], ["adenoviruses", "ORGANISM", 51, 63], ["Adv-C", "GENE_OR_GENE_PRODUCT", 67, 72], ["Adv-B", "GENE_OR_GENE_PRODUCT", 76, 81], ["coronoviruses", "GENE_OR_GENE_PRODUCT", 86, 99], ["5", "ORGANISM", 101, 102], ["influenza viruses", "ORGANISM", 103, 120], ["parainfluenza viruses", "ORGANISM", 164, 185], ["influenza viruses", "SPECIES", 103, 120], ["parainfluenza", "SPECIES", 164, 177], ["Other viruses", "PROBLEM", 0, 13], ["7 enteroviruses", "PROBLEM", 32, 47], ["6 adenoviruses", "TREATMENT", 49, 63], ["5 influenza viruses", "PROBLEM", 101, 120], ["5 metapneumoviruses", "TREATMENT", 122, 141], ["3 parainfluenza viruses", "PROBLEM", 162, 185], ["respiratory virusesWe", "PROBLEM", 204, 225], ["HRV strains", "PROBLEM", 252, 263], ["viruses", "OBSERVATION", 6, 13], ["parainfluenza viruses", "OBSERVATION", 164, 185], ["respiratory", "ANATOMY", 204, 215]]], ["The percentage of HRV isolates that were carry-over strains, either from the previous season or the previous year, ranged from 0-28%.", [["HRV isolates", "PROBLEM", 18, 30]]], ["There were no strains found in more than two collection periods (Table II) .Weekly virus detection and respiratory symptomsWe next compared weekly viral detection rates to reported respiratory symptoms.", [["respiratory", "ANATOMY", 103, 114], ["respiratory", "ANATOMY", 181, 192], ["respiratory symptoms", "DISEASE", 103, 123], ["respiratory symptoms", "DISEASE", 181, 201], ["strains", "PROBLEM", 14, 21], ["Weekly virus detection", "TEST", 76, 98], ["respiratory symptoms", "PROBLEM", 103, 123], ["weekly viral detection", "TEST", 140, 162], ["respiratory symptoms", "PROBLEM", 181, 201], ["no", "UNCERTAINTY", 11, 13], ["strains", "OBSERVATION", 14, 21]]], ["Overall, viruses were detected in 151 of 404 (37%) evaluable weeks.", [["viruses", "PROBLEM", 9, 16], ["viruses", "OBSERVATION", 9, 16]]], ["Both cold symptoms (67% vs. 31%, p<0.001) and asthma symptoms (53% vs. 30%, p<0.001) were more likely to occur in virus-positive compared to virus-negative weeks (Supplemental Table) .", [["asthma", "DISEASE", 46, 52], ["Both cold symptoms", "PROBLEM", 0, 18], ["asthma symptoms", "PROBLEM", 46, 61], ["virus", "PROBLEM", 114, 119], ["virus", "TEST", 141, 146]]], ["In addition, viruspositive weeks were associated with greater peak cold severity (p<0.0001) and asthma symptom severity (p=0.0002, Table III ).Weekly virus detection and respiratory symptomsIllnesses were then classified into four separate patterns: no symptoms, solitary cold symptoms, solitary asthma symptoms and combined cold and asthma symptoms.", [["respiratory", "ANATOMY", 170, 181], ["asthma", "DISEASE", 96, 102], ["respiratory symptoms", "DISEASE", 170, 190], ["asthma", "DISEASE", 296, 302], ["asthma", "DISEASE", 334, 340], ["greater peak cold severity", "PROBLEM", 54, 80], ["asthma symptom severity", "PROBLEM", 96, 119], ["Weekly virus detection", "TEST", 143, 165], ["respiratory symptoms", "PROBLEM", 170, 190], ["Illnesses", "PROBLEM", 190, 199], ["symptoms", "PROBLEM", 253, 261], ["solitary cold symptoms", "PROBLEM", 263, 285], ["solitary asthma symptoms", "PROBLEM", 287, 311], ["combined cold and asthma symptoms", "PROBLEM", 316, 349], ["no", "UNCERTAINTY", 250, 252], ["solitary", "OBSERVATION_MODIFIER", 287, 295], ["asthma", "OBSERVATION", 296, 302]]], ["Virus detection rates were increased during weeks with either cold symptoms alone (43%) or the combination of cold and asthma symptoms (58%).", [["asthma symptoms", "DISEASE", 119, 134], ["Virus", "ORGANISM", 0, 5], ["Virus detection rates", "TEST", 0, 21], ["cold symptoms", "PROBLEM", 62, 75], ["cold and asthma symptoms", "PROBLEM", 110, 134], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["asthma", "OBSERVATION", 119, 125]]], ["When solitary asthma symptoms were reported, virus detection rates were the same (24%) as those in asymptomatic children.Viral vs. Non viral illnessesThe 42 children who completed at least one season of data collection had 111 defined illnesses: 66 illnesses were virus-positive and 45 were virus-negative.", [["asthma", "DISEASE", 14, 20], ["viral illnesses", "DISEASE", 135, 150], ["children", "ORGANISM", 112, 120], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 112, 120], ["children", "SPECIES", 157, 165], ["solitary asthma symptoms", "PROBLEM", 5, 29], ["virus detection rates", "TEST", 45, 66], ["data collection", "TEST", 203, 218], ["virus", "TEST", 264, 269], ["virus", "TEST", 291, 296]]], ["Of the virus-positive illnesses, 27% were associated with isolated cold symptoms, 20% were associated with isolated asthma symptoms, and 53% were associated with both.", [["cold symptoms", "DISEASE", 67, 80], ["asthma symptoms", "DISEASE", 116, 131], ["the virus-positive illnesses", "PROBLEM", 3, 31], ["isolated cold symptoms", "PROBLEM", 58, 80], ["isolated asthma symptoms", "PROBLEM", 107, 131], ["virus", "OBSERVATION", 7, 12], ["positive", "OBSERVATION_MODIFIER", 13, 21], ["illnesses", "OBSERVATION", 22, 31], ["asthma", "OBSERVATION", 116, 122]]], ["Overall, there was evidence that illnesses were more severe in the presence of viral infection (Table IV) .", [["viral infection", "DISEASE", 79, 94], ["illnesses", "PROBLEM", 33, 42], ["viral infection", "PROBLEM", 79, 94], ["illnesses", "OBSERVATION", 33, 42], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94]]], ["For example, in virus-positive illnesses the duration of cold and asthma symptoms was more than twice as long, and loss of control occurred much more frequently (47% vs. 22%).Allergic sensitization, frequency of infection, and severity of illnessFinally, we compared rates of infection (virus-positive, with or without symptoms) and illness (defined by the presence of clinical symptoms) in children who were sensitized to least one allergen vs. those who were not.", [["asthma", "DISEASE", 66, 72], ["Allergic sensitization", "DISEASE", 175, 197], ["infection", "DISEASE", 212, 221], ["illness", "DISEASE", 239, 246], ["infection", "DISEASE", 276, 285], ["illness", "DISEASE", 333, 340], ["children", "ORGANISM", 391, 399], ["children", "SPECIES", 391, 399], ["virus", "PROBLEM", 16, 21], ["cold", "PROBLEM", 57, 61], ["asthma symptoms", "PROBLEM", 66, 81], ["loss of control", "PROBLEM", 115, 130], ["Allergic sensitization", "PROBLEM", 175, 197], ["infection", "PROBLEM", 212, 221], ["illness", "PROBLEM", 239, 246], ["infection (virus-positive", "PROBLEM", 276, 301], ["symptoms", "PROBLEM", 319, 327], ["illness", "PROBLEM", 333, 340], ["clinical symptoms", "PROBLEM", 369, 386], ["virus", "OBSERVATION", 16, 21], ["positive", "OBSERVATION_MODIFIER", 22, 30], ["illnesses", "OBSERVATION", 31, 40], ["infection", "OBSERVATION", 212, 221], ["infection", "OBSERVATION", 276, 285]]], ["Of the 42 children who completed at least one season, 29 (69%) were sensitized and 13 (31%) were non-sensitized.", [["children", "ORGANISM", 10, 18], ["children", "SPECIES", 10, 18]]], ["Rates of infections, total illnesses and number of non viral illnesses per month (April, September) were similar between the two groups.", [["infections", "DISEASE", 9, 19], ["viral illnesses", "DISEASE", 55, 70], ["infections", "PROBLEM", 9, 19], ["total illnesses", "PROBLEM", 21, 36], ["non viral illnesses", "PROBLEM", 51, 70], ["infections", "OBSERVATION", 9, 19]]], ["In contrast, the sensitized group had 47% more viral associated illnesses per season (1.19 vs. 0.81, p=0.03, Table V) .Allergic sensitization, frequency of infection, and severity of illnessWe next tested for association between sensitization and the severity of symptoms associated with documented viral infections.", [["Allergic sensitization", "DISEASE", 119, 141], ["infection", "DISEASE", 156, 165], ["illness", "DISEASE", 183, 190], ["viral infections", "DISEASE", 299, 315], ["p", "TEST", 101, 102], ["Allergic sensitization", "PROBLEM", 119, 141], ["infection", "PROBLEM", 156, 165], ["illness", "PROBLEM", 183, 190], ["sensitization", "PROBLEM", 229, 242], ["symptoms", "PROBLEM", 263, 271], ["documented viral infections", "PROBLEM", 288, 315], ["infection", "OBSERVATION", 156, 165], ["viral", "OBSERVATION_MODIFIER", 299, 304], ["infections", "OBSERVATION", 305, 315]]], ["The non-sensitized children most commonly reported none or mild cold symptoms with their viral infections, whereas almost half of the viral infections in the sensitized children resulted in moderate or severe cold symptoms (p=0.01 for trend).", [["viral infections", "DISEASE", 89, 105], ["viral infections", "DISEASE", 134, 150], ["children", "ORGANISM", 19, 27], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 19, 27], ["children", "SPECIES", 169, 177], ["mild cold symptoms", "PROBLEM", 59, 77], ["their viral infections", "PROBLEM", 83, 105], ["the viral infections", "PROBLEM", 130, 150], ["moderate or severe cold symptoms", "PROBLEM", 190, 222], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["infections", "OBSERVATION", 95, 105], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["infections", "OBSERVATION", 140, 150], ["moderate", "OBSERVATION_MODIFIER", 190, 198], ["severe", "OBSERVATION_MODIFIER", 202, 208]]], ["Similarly, almost half of the viral infections in the sensitized children resulted in moderated or severe asthma symptoms and more than half of the viral infections in the non-sensitized children were reported as asymptomatic (p=0.02 for trend) (figure 3).DiscussionDuring peak HRV seasons, respiratory viruses were detected in up to half of weekly samples obtained from school age children with asthma, and viral infection was nearly universal each April and each September.", [["samples", "ANATOMY", 349, 356], ["viral infections", "DISEASE", 30, 46], ["asthma", "DISEASE", 106, 112], ["viral infections", "DISEASE", 148, 164], ["asthma", "DISEASE", 396, 402], ["viral infection", "DISEASE", 408, 423], ["children", "ORGANISM", 65, 73], ["children", "ORGANISM", 187, 195], ["children", "ORGANISM", 382, 390], ["children", "SPECIES", 65, 73], ["children", "SPECIES", 187, 195], ["children", "SPECIES", 382, 390], ["the viral infections", "PROBLEM", 26, 46], ["moderated or severe asthma symptoms", "PROBLEM", 86, 121], ["the viral infections", "PROBLEM", 144, 164], ["peak HRV seasons", "PROBLEM", 273, 289], ["respiratory viruses", "PROBLEM", 291, 310], ["asthma", "PROBLEM", 396, 402], ["viral infection", "PROBLEM", 408, 423], ["almost", "OBSERVATION_MODIFIER", 11, 17], ["half", "OBSERVATION_MODIFIER", 18, 22], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infections", "OBSERVATION", 36, 46], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["asthma", "OBSERVATION", 106, 112], ["viral", "OBSERVATION_MODIFIER", 148, 153], ["infections", "OBSERVATION", 154, 164], ["respiratory viruses", "OBSERVATION", 291, 310], ["asthma", "OBSERVATION", 396, 402], ["viral", "OBSERVATION_MODIFIER", 408, 413], ["infection", "OBSERVATION", 414, 423]]], ["While other viruses were detected, HRV made up the vast majority of viruses detected during April and September, and up to 18 viral strains were detected in a single month in the Madison area.", [["HRV", "SPECIES", 35, 38], ["other viruses", "PROBLEM", 6, 19], ["HRV", "TEST", 35, 38], ["viruses", "PROBLEM", 68, 75], ["viral strains", "PROBLEM", 126, 139], ["viruses", "OBSERVATION", 12, 19], ["viruses", "OBSERVATION", 68, 75]]], ["The specific strains of HRV differed dramatically from season-to-season and year-to-year, with relatively few strains carried over.", [["HRV", "PROBLEM", 24, 27]]], ["This study adds new information about patterns of the different species of rhinovirus, including the newly defined HRV-C.", [["rhinovirus", "DISEASE", 75, 85], ["rhinovirus", "ORGANISM", 75, 85], ["This study", "TEST", 0, 10], ["the different species", "PROBLEM", 50, 71], ["rhinovirus", "PROBLEM", 75, 85], ["rhinovirus", "OBSERVATION", 75, 85]]], ["One of the unique features of this study is that we evaluated children with asthma during peak cold seasons irrespective of whether they were having asthma and/or cold symptoms.", [["asthma", "DISEASE", 76, 82], ["asthma", "DISEASE", 149, 155], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["this study", "TEST", 30, 40], ["asthma", "PROBLEM", 76, 82], ["asthma", "PROBLEM", 149, 155], ["cold symptoms", "PROBLEM", 163, 176], ["asthma", "OBSERVATION", 149, 155]]], ["As expected, HRV infections were major contributors to cold and asthma symptoms; however, correlations between viral infections and illness were not absolute.", [["HRV infections", "DISEASE", 13, 27], ["asthma", "DISEASE", 64, 70], ["viral infections", "DISEASE", 111, 127], ["illness", "DISEASE", 132, 139], ["HRV", "SPECIES", 13, 16], ["HRV infections", "PROBLEM", 13, 27], ["cold and asthma symptoms", "PROBLEM", 55, 79], ["viral infections", "PROBLEM", 111, 127], ["illness", "PROBLEM", 132, 139], ["infections", "OBSERVATION", 17, 27]]], ["Clearly, non viral factors also contributed to upper and lower airway symptoms in these children, and many infections (24%) were asymptomatic.", [["lower airway", "ANATOMY", 57, 69], ["infections", "DISEASE", 107, 117], ["upper", "ORGANISM_SUBDIVISION", 47, 52], ["lower airway", "ORGANISM_SUBDIVISION", 57, 69], ["children", "ORGANISM", 88, 96], ["viral factors", "PROTEIN", 13, 26], ["children", "SPECIES", 88, 96], ["non viral factors", "PROBLEM", 9, 26], ["upper and lower airway symptoms", "PROBLEM", 47, 78], ["many infections", "PROBLEM", 102, 117], ["asymptomatic", "PROBLEM", 129, 141], ["upper", "ANATOMY_MODIFIER", 47, 52], ["lower", "ANATOMY_MODIFIER", 57, 62], ["airway", "ANATOMY", 63, 69], ["symptoms", "OBSERVATION", 70, 78], ["many", "OBSERVATION_MODIFIER", 102, 106], ["infections", "OBSERVATION", 107, 117]]], ["Comparison of viral to non viral illnesses demonstrated that viral illnesses lasted longer, were more severe, and were more likely to be associated with loss of asthma control.", [["viral illnesses", "DISEASE", 27, 42], ["viral illnesses", "DISEASE", 61, 76], ["loss of asthma", "DISEASE", 153, 167], ["viral to non viral illnesses", "PROBLEM", 14, 42], ["viral illnesses", "PROBLEM", 61, 76], ["loss of asthma control", "PROBLEM", 153, 175], ["viral illnesses", "OBSERVATION", 61, 76], ["more severe", "OBSERVATION_MODIFIER", 97, 108], ["asthma", "OBSERVATION", 161, 167]]], ["Finally, children with allergic sensitization had similar rates of viral infections, but significantly increased rates and severity of viral illnesses, compared to children who were not sensitized.DiscussionRates of viral infections differ based on age, season, and the presence of respiratory symptoms.DiscussionIn previous studies of patients with asthma and respiratory symptoms, viral detection were as high as 62-88% 1,3, 10 , 11 and during asymptomatic periods detection ranges from 12-44%.1 , 10 The relatively high viral detection rate (36-50%) in our study is likely a result of our sampling both symptomatic and asymptomatic patients during periods of peak HRV prevalence.", [["respiratory", "ANATOMY", 282, 293], ["respiratory", "ANATOMY", 361, 372], ["allergic sensitization", "DISEASE", 23, 45], ["viral infections", "DISEASE", 67, 83], ["viral illnesses", "DISEASE", 135, 150], ["viral infections", "DISEASE", 216, 232], ["respiratory symptoms", "DISEASE", 282, 302], ["asthma", "DISEASE", 350, 356], ["respiratory symptoms", "DISEASE", 361, 381], ["children", "ORGANISM", 9, 17], ["children", "ORGANISM", 164, 172], ["patients", "ORGANISM", 336, 344], ["patients", "ORGANISM", 635, 643], ["children", "SPECIES", 9, 17], ["children", "SPECIES", 164, 172], ["patients", "SPECIES", 336, 344], ["patients", "SPECIES", 635, 643], ["allergic sensitization", "PROBLEM", 23, 45], ["viral infections", "PROBLEM", 67, 83], ["significantly increased rates", "PROBLEM", 89, 118], ["viral illnesses", "PROBLEM", 135, 150], ["viral infections", "PROBLEM", 216, 232], ["respiratory symptoms", "PROBLEM", 282, 302], ["previous studies", "TEST", 316, 332], ["asthma", "PROBLEM", 350, 356], ["respiratory symptoms", "PROBLEM", 361, 381], ["viral detection", "TEST", 383, 398], ["asymptomatic periods detection", "TEST", 446, 476], ["our study", "TEST", 556, 565], ["our sampling both symptomatic and asymptomatic", "PROBLEM", 588, 634], ["peak HRV prevalence", "PROBLEM", 662, 681], ["viral infections", "OBSERVATION", 67, 83], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["viral illnesses", "OBSERVATION", 135, 150], ["viral", "OBSERVATION_MODIFIER", 216, 221], ["infections", "OBSERVATION", 222, 232], ["respiratory symptoms", "OBSERVATION", 282, 302], ["likely a result", "UNCERTAINTY", 569, 584], ["symptomatic", "OBSERVATION_MODIFIER", 606, 617]]], ["It is of particular interest that there was an extensive diversity of HRV strains detected in one community over the three-year study period.", [["HRV strains", "PROBLEM", 70, 81], ["extensive", "OBSERVATION_MODIFIER", 47, 56], ["diversity", "OBSERVATION_MODIFIER", 57, 66]]], ["Almost all of the strains detected each season were new (72-100%) and no one strain was detected in more than two collection periods.", [["the strains", "PROBLEM", 14, 25], ["one strain", "PROBLEM", 73, 83], ["new", "OBSERVATION_MODIFIER", 52, 55]]], ["These findings are in substantial agreement with early studies of HRV epidemiology that used culture alone to detect HRV strains, 16, 17 and add new information about patterns of newly defined HRV species.", [["early studies", "TEST", 49, 62], ["HRV epidemiology", "TEST", 66, 82], ["culture", "TEST", 93, 100], ["HRV strains", "PROBLEM", 117, 128], ["newly defined HRV species", "PROBLEM", 179, 204], ["HRV species", "OBSERVATION", 193, 204]]], ["Although the strains varied from season-to-season and year-to-year, the species clustered into a pattern: HRV-A in the spring, HRV-B in the fall, and HRV-C in both seasons.", [["the strains", "PROBLEM", 9, 20], ["HRV", "PROBLEM", 106, 109], ["HRV", "PROBLEM", 127, 130], ["the fall", "PROBLEM", 136, 144], ["HRV", "PROBLEM", 150, 153]]], ["This pattern is different than what has been reported in a previous study of hospitalized children with asthma where HRV-C appeared to predominate in the fall.9 Given the high rate of change, a longer period of evaluation will be needed before any firm conclusions can be reached regarding seasonality of HRV species.DiscussionThe high rate of viral detection during peak HRV seasons suggests that caution is needed in assigning causality between HRV detection and patterns of respiratory illness.", [["respiratory", "ANATOMY", 477, 488], ["asthma", "DISEASE", 104, 110], ["respiratory illness", "DISEASE", 477, 496], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["asthma", "PROBLEM", 104, 110], ["HRV", "TEST", 117, 120], ["evaluation", "TEST", 211, 221], ["HRV species", "PROBLEM", 305, 316], ["viral detection", "TEST", 344, 359], ["HRV detection", "TEST", 447, 460], ["respiratory illness", "PROBLEM", 477, 496], ["different", "OBSERVATION_MODIFIER", 16, 25], ["respiratory illness", "OBSERVATION", 477, 496]]], ["In fact, viral detection was not always associated with cold and/or asthma symptoms; both symptoms were also found during virus negative weeks.", [["asthma", "DISEASE", 68, 74], ["viral detection", "TEST", 9, 24], ["cold", "PROBLEM", 56, 60], ["asthma symptoms", "PROBLEM", 68, 83], ["both symptoms", "PROBLEM", 85, 98], ["viral", "OBSERVATION", 9, 14]]], ["On the other hand, there was a positive correlation between viral infection and asthma symptom severity.", [["viral infection", "DISEASE", 60, 75], ["asthma", "DISEASE", 80, 86], ["viral infection", "PROBLEM", 60, 75], ["asthma symptom severity", "PROBLEM", 80, 103], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infection", "OBSERVATION", 66, 75]]], ["In addition, we found that viral illnesses were more severe with longer duration of cold and asthma symptoms and more loss of asthma control compared to non viral illness.", [["viral illnesses", "DISEASE", 27, 42], ["asthma", "DISEASE", 93, 99], ["asthma", "DISEASE", 126, 132], ["viral illness", "DISEASE", 157, 170], ["viral illnesses", "PROBLEM", 27, 42], ["cold", "PROBLEM", 84, 88], ["asthma symptoms", "PROBLEM", 93, 108], ["asthma control", "PROBLEM", 126, 140], ["non viral illness", "PROBLEM", 153, 170], ["viral illnesses", "OBSERVATION", 27, 42], ["asthma", "OBSERVATION", 126, 132]]], ["These findings suggest that viral infections are closely associated with more significant cold and asthma symptoms, and that a combination of viral and non viral factors may be necessary to produce more severe symptoms.DiscussionThere is great interest in defining potential interactions between allergy and viral infection that promote acute respiratory symptoms.", [["respiratory", "ANATOMY", 343, 354], ["viral infections", "DISEASE", 28, 44], ["asthma", "DISEASE", 99, 105], ["allergy", "DISEASE", 296, 303], ["viral infection", "DISEASE", 308, 323], ["acute respiratory symptoms", "DISEASE", 337, 363], ["viral infections", "PROBLEM", 28, 44], ["significant cold and asthma symptoms", "PROBLEM", 78, 114], ["viral and non viral factors", "PROBLEM", 142, 169], ["more severe symptoms", "PROBLEM", 198, 218], ["allergy", "PROBLEM", 296, 303], ["viral infection", "PROBLEM", 308, 323], ["acute respiratory symptoms", "PROBLEM", 337, 363], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["infections", "OBSERVATION", 34, 44], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["cold", "OBSERVATION", 90, 94], ["asthma", "OBSERVATION", 99, 105], ["viral", "OBSERVATION", 142, 147], ["acute", "OBSERVATION_MODIFIER", 337, 342]]], ["Over two-thirds of our subjects were sensitized to at least one allergen tested; those who were sensitized had the same number of infections but experienced 47% more viral respiratory illnesses with increased severity of both cold and asthma symptoms compared to the non-sensitized children.", [["respiratory", "ANATOMY", 172, 183], ["infections", "DISEASE", 130, 140], ["viral respiratory illnesses", "DISEASE", 166, 193], ["asthma", "DISEASE", 235, 241], ["subjects", "ORGANISM", 23, 31], ["children", "ORGANISM", 282, 290], ["children", "SPECIES", 282, 290], ["infections", "PROBLEM", 130, 140], ["47% more viral respiratory illnesses", "PROBLEM", 157, 193], ["increased severity of both cold", "PROBLEM", 199, 230], ["asthma symptoms", "PROBLEM", 235, 250], ["infections", "OBSERVATION", 130, 140], ["respiratory illnesses", "OBSERVATION", 172, 193], ["increased", "OBSERVATION_MODIFIER", 199, 208], ["severity", "OBSERVATION_MODIFIER", 209, 217]]], ["Furthermore, the non-sensitized children were more likely to experience asymptomatic infections.", [["infections", "DISEASE", 85, 95], ["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40], ["asymptomatic infections", "PROBLEM", 72, 95], ["infections", "OBSERVATION", 85, 95]]], ["This would not have been apparent without routine sampling of nasal secretions.", [["nasal secretions", "ANATOMY", 62, 78], ["nasal secretions", "ORGANISM_SUBSTANCE", 62, 78], ["nasal secretions", "PROBLEM", 62, 78], ["nasal", "ANATOMY", 62, 67], ["secretions", "OBSERVATION", 68, 78]]], ["The results are consistent with observations in previous studies that have suggested that sensitization to aeroallergens is a significant risk factor, and may be critical, for severe viral illnesses.", [["viral illnesses", "DISEASE", 183, 198], ["previous studies", "TEST", 48, 64], ["aeroallergens", "PROBLEM", 107, 120], ["severe viral illnesses", "PROBLEM", 176, 198], ["consistent with", "UNCERTAINTY", 16, 31]]], ["10, 11, 18, 19 Furthermore, it has also been suggested that sensitization and allergen exposure or viral infection alone do not act as independent risk factors for an asthma hospitalization, rather only increase the risk in combination.", [["viral infection", "DISEASE", 99, 114], ["asthma", "DISEASE", 167, 173], ["sensitization", "PROBLEM", 60, 73], ["allergen exposure", "PROBLEM", 78, 95], ["viral infection", "PROBLEM", 99, 114], ["an asthma hospitalization", "PROBLEM", 164, 189], ["asthma", "OBSERVATION", 167, 173]]], ["18 Since there are currently no effective antiviral treatments for common cold viruses, there is a need for clinical studies to determine whether controlling allergic inflammation is an effective strategy for reducing the risk of severe virus-induced asthma symptoms in allergic individuals.DiscussionThe strengths of current study included the prospective study design, weekly sampling of nasal mucus regardless of symptoms; use of sensitive molecular-based viral diagnostics including molecular typing, and comparison of viral vs. non viral illnesses.", [["nasal mucus", "ANATOMY", 390, 401], ["cold viruses", "DISEASE", 74, 86], ["allergic inflammation", "DISEASE", 158, 179], ["asthma", "DISEASE", 251, 257], ["allergic", "DISEASE", 270, 278], ["viral illnesses", "DISEASE", 537, 552], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 390, 401], ["effective antiviral treatments", "TREATMENT", 32, 62], ["common cold viruses", "PROBLEM", 67, 86], ["clinical studies", "TEST", 108, 124], ["allergic inflammation", "PROBLEM", 158, 179], ["an effective strategy", "TREATMENT", 183, 204], ["severe virus", "PROBLEM", 230, 242], ["asthma symptoms", "PROBLEM", 251, 266], ["allergic individuals", "PROBLEM", 270, 290], ["current study", "TEST", 318, 331], ["the prospective study", "TEST", 341, 362], ["nasal mucus", "PROBLEM", 390, 401], ["symptoms", "PROBLEM", 416, 424], ["viral diagnostics", "TEST", 459, 476], ["molecular typing", "TEST", 487, 503], ["non viral illnesses", "PROBLEM", 533, 552], ["no", "UNCERTAINTY", 29, 31], ["effective", "OBSERVATION_MODIFIER", 32, 41], ["antiviral", "OBSERVATION", 42, 51], ["viruses", "OBSERVATION", 79, 86], ["severe", "OBSERVATION_MODIFIER", 230, 236], ["virus", "OBSERVATION", 237, 242], ["asthma", "OBSERVATION", 251, 257], ["allergic individuals", "OBSERVATION", 270, 290], ["nasal mucus", "ANATOMY", 390, 401], ["viral illnesses", "OBSERVATION", 537, 552]]], ["Limitations of the study include the absence of children without asthma, and the modest sample size.", [["asthma", "DISEASE", 65, 71], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["the study", "TEST", 15, 24], ["asthma", "PROBLEM", 65, 71], ["asthma", "OBSERVATION", 65, 71], ["modest", "OBSERVATION_MODIFIER", 81, 87], ["size", "OBSERVATION_MODIFIER", 95, 99]]], ["Based on our findings in this study, we are currently conducting a larger study that will include both children with and without asthma, and will focus on identifying additional host and viral characteristics that are associated with illness severity.DiscussionIn conclusion, this study has shown that nearly all children with asthma are infected with viruses during the peak common cold seasons.", [["asthma", "DISEASE", 129, 135], ["illness", "DISEASE", 234, 241], ["asthma", "DISEASE", 327, 333], ["children", "ORGANISM", 103, 111], ["children", "ORGANISM", 313, 321], ["children", "SPECIES", 103, 111], ["children", "SPECIES", 313, 321], ["this study", "TEST", 25, 35], ["a larger study", "TEST", 65, 79], ["asthma", "PROBLEM", 129, 135], ["additional host and viral characteristics", "PROBLEM", 167, 208], ["illness severity", "PROBLEM", 234, 250], ["this study", "TEST", 276, 286], ["asthma", "PROBLEM", 327, 333], ["viruses", "PROBLEM", 352, 359], ["infected", "OBSERVATION", 338, 346]]], ["Of the many HRV strains moving through a community in any given month, many strains were associated with loss of asthma control, including the newly discovered HRV-C species viruses.", [["loss of asthma", "DISEASE", 105, 119], ["HRV-C species viruses", "ORGANISM", 160, 181], ["the many HRV strains", "PROBLEM", 3, 23], ["many strains", "PROBLEM", 71, 83], ["loss of asthma control", "PROBLEM", 105, 127], ["C species viruses", "PROBLEM", 164, 181], ["asthma", "OBSERVATION", 113, 119], ["species viruses", "OBSERVATION", 166, 181]]], ["Additional studies are needed to determine whether there are specific characteristics of these viruses that promote wheezing and acute asthma.", [["wheezing", "DISEASE", 116, 124], ["asthma", "DISEASE", 135, 141], ["Additional studies", "TEST", 0, 18], ["these viruses", "PROBLEM", 89, 102], ["wheezing", "PROBLEM", 116, 124], ["acute asthma", "PROBLEM", 129, 141], ["viruses", "OBSERVATION", 95, 102], ["wheezing", "OBSERVATION", 116, 124], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["asthma", "OBSERVATION", 135, 141]]], ["These data also show that respiratory illnesses associated with viruses are more severe and of longer duration, and provide further evidence of interactions between allergy and virus-induced respiratory morbidity.", [["respiratory", "ANATOMY", 26, 37], ["respiratory", "ANATOMY", 191, 202], ["respiratory illnesses", "DISEASE", 26, 47], ["allergy", "DISEASE", 165, 172], ["respiratory morbidity", "DISEASE", 191, 212], ["These data", "TEST", 0, 10], ["respiratory illnesses", "PROBLEM", 26, 47], ["viruses", "PROBLEM", 64, 71], ["interactions between allergy", "PROBLEM", 144, 172], ["virus", "PROBLEM", 177, 182], ["induced respiratory morbidity", "PROBLEM", 183, 212], ["respiratory illnesses", "OBSERVATION", 26, 47], ["viruses", "OBSERVATION", 64, 71], ["respiratory morbidity", "OBSERVATION", 191, 212]]], ["Understanding the mechanisms for these interactions may be the key to designing novel and more effective treatments or preventive strategies for virus-induced exacerbations of asthma.Supplementary MaterialRefer to Web version on PubMed Central for supplementary material.", [["asthma", "DISEASE", 176, 182], ["more effective treatments", "TREATMENT", 90, 115], ["preventive strategies", "TREATMENT", 119, 140], ["virus", "PROBLEM", 145, 150], ["asthma", "PROBLEM", 176, 182], ["asthma", "OBSERVATION", 176, 182]]], ["Virology of viruses detected during routine monitoring periods Seasonality of HRV species", [["Virology of viruses", "PROBLEM", 0, 19], ["routine monitoring", "TEST", 36, 54], ["HRV species", "PROBLEM", 78, 89], ["viruses", "OBSERVATION", 12, 19]]]], "PMC7538041": [["High throughput sequencing ::: Nucleic acid detection-based technology ::: IntroductionAs the cost of high throughput sequencing of genome is very high and it also depends on the availability of sequencer and hence its applicability in the clinical diagnostic methodologies is very limited and restricted.", [["Nucleic acid", "CHEMICAL", 31, 43], ["Nucleic acid", "SIMPLE_CHEMICAL", 31, 43], ["Nucleic acid detection", "TEST", 31, 53]]], ["The dependency on the RT-qPCR based methodology is very high and it is one of the best methods to detect coronavirus with huge sensitivity.PCR based methods ::: Nucleic acid detection-based technology ::: IntroductionDue to the limited application of genome sequencing-based methodologies, the significance of PCR based method is very high.", [["coronavirus", "DISEASE", 105, 116], ["Nucleic acid", "CHEMICAL", 161, 173], ["coronavirus", "ORGANISM", 105, 116], ["Nucleic acid", "SIMPLE_CHEMICAL", 161, 173], ["The dependency", "PROBLEM", 0, 14], ["the RT", "TEST", 18, 24], ["qPCR based methodology", "TEST", 25, 47], ["coronavirus", "PROBLEM", 105, 116], ["huge sensitivity", "PROBLEM", 122, 138], ["Nucleic acid detection", "TEST", 161, 183], ["genome sequencing", "TEST", 251, 268], ["PCR based method", "TEST", 310, 326], ["dependency", "OBSERVATION_MODIFIER", 4, 14], ["very", "OBSERVATION_MODIFIER", 51, 55], ["high", "OBSERVATION", 56, 60]]], ["Among PCR based methods, RT-qPCR is a commonly used method which is a very easy, effective, and straightforward method for the identification and detection of pathogenic coronavirus from the respiratory swabs and blood samples [7].", [["respiratory swabs", "ANATOMY", 191, 208], ["blood samples", "ANATOMY", 213, 226], ["coronavirus", "ORGANISM", 170, 181], ["blood samples", "ORGANISM_SUBSTANCE", 213, 226], ["Among PCR", "TEST", 0, 9], ["RT-qPCR", "TEST", 25, 32], ["the identification", "TEST", 123, 141], ["pathogenic coronavirus", "PROBLEM", 159, 181], ["the respiratory swabs", "TEST", 187, 208], ["blood samples", "TEST", 213, 226]]], ["PCR is a molecular technique for the amplification of the copies number of gene fragments through the thermostable DNA polymerase reactions.", [["DNA", "CELLULAR_COMPONENT", 115, 118], ["gene fragments", "DNA", 75, 89], ["thermostable DNA polymerase", "PROTEIN", 102, 129], ["PCR", "TEST", 0, 3], ["a molecular technique", "TREATMENT", 7, 28], ["gene fragments", "PROBLEM", 75, 89], ["the thermostable DNA polymerase reactions", "PROBLEM", 98, 139], ["gene fragments", "OBSERVATION", 75, 89]]], ["In the PCR, first the double helix DNA is separated into two single-strand DNA in the denaturing stage and then a sequence-specific primer is ligated to both the strands in annealing steps and finally both the primer is elongated by a thermostable DNA polymerase using single-stranded DNA as the template in extending stage.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["DNA", "CELLULAR_COMPONENT", 248, 251], ["DNA", "CELLULAR_COMPONENT", 285, 288], ["double helix DNA", "DNA", 22, 38], ["single-strand DNA", "DNA", 61, 78], ["thermostable DNA polymerase", "PROTEIN", 235, 262], ["single-stranded DNA", "DNA", 269, 288], ["the PCR", "TEST", 3, 10], ["the double helix DNA", "TREATMENT", 18, 38], ["the denaturing stage", "PROBLEM", 82, 102], ["a sequence", "TEST", 112, 122], ["a thermostable DNA polymerase", "PROBLEM", 233, 262], ["single-stranded DNA", "TREATMENT", 269, 288], ["ligated", "OBSERVATION", 142, 149], ["strands", "OBSERVATION_MODIFIER", 162, 169], ["annealing steps", "OBSERVATION", 173, 188], ["elongated", "OBSERVATION_MODIFIER", 220, 229]]], ["These cycles are repeated multiple times to get multiple copies of DNA from a single copy of DNA.", [["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA", "CELLULAR_COMPONENT", 93, 96]]], ["This method increases the sample DNA to get a sufficient quantity of genetic material for laboratory analysis.", [["DNA", "CELLULAR_COMPONENT", 33, 36], ["the sample DNA", "PROBLEM", 22, 36], ["laboratory analysis", "TEST", 90, 109]]], ["For COVID-19 detection this sequence-specific method is highly utilized [8, 9].", [["COVID-19", "DNA", 4, 12], ["COVID", "TEST", 4, 9], ["this sequence", "TEST", 23, 36]]], ["The genome of SARS-CoV2 is single-stranded RNA which is first converted into complementary DNA (cDNA) through the reverse transcriptase-based process, cDNA amplified through PCR followed by and quantification and detection through specific methods.", [["SARS", "DISEASE", 14, 18], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 14, 23], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["cDNA", "CELLULAR_COMPONENT", 96, 100], ["SARS-CoV2", "DNA", 14, 23], ["single-stranded RNA", "RNA", 27, 46], ["complementary DNA", "DNA", 77, 94], ["cDNA", "DNA", 96, 100], ["reverse transcriptase", "PROTEIN", 114, 135], ["cDNA", "DNA", 151, 155], ["SARS-CoV2", "SPECIES", 14, 23], ["SARS", "PROBLEM", 14, 18], ["single-stranded RNA", "PROBLEM", 27, 46], ["the reverse transcriptase", "TREATMENT", 110, 135], ["PCR", "TEST", 174, 177], ["quantification", "TEST", 194, 208], ["SARS", "OBSERVATION", 14, 18], ["stranded RNA", "OBSERVATION_MODIFIER", 34, 46]]], ["Conventional detection methods for the PCR products are visualization on an agarose gel and DNA sequencing [10, 11].", [["agarose", "SIMPLE_CHEMICAL", 76, 83], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["Conventional detection methods", "TEST", 0, 30], ["the PCR products", "TREATMENT", 35, 51], ["an agarose gel", "TREATMENT", 73, 87], ["DNA sequencing", "TEST", 92, 106]]], ["Time-consuming, sequencing cost, and instrument dependency this detection method is not preferred for the clinical samples.PCR based methods ::: Nucleic acid detection-based technology ::: IntroductionCurrently, real-time reverse transcriptase polymerase chain reaction (RT-PCR) is the most commonly used and preferred method for the coronavirus due to its sensitivity, specificity, and simple quantitative methods [12, 13].", [["samples", "ANATOMY", 115, 122], ["Nucleic acid", "CHEMICAL", 145, 157], ["coronavirus", "DISEASE", 334, 345], ["Nucleic acid", "SIMPLE_CHEMICAL", 145, 157], ["coronavirus", "ORGANISM", 334, 345], ["reverse transcriptase", "PROTEIN", 222, 243], ["the clinical samples", "TEST", 102, 122], ["Nucleic acid detection", "TEST", 145, 167], ["IntroductionCurrently", "TREATMENT", 189, 210], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 222, 269], ["RT-PCR", "TEST", 271, 277], ["the coronavirus", "PROBLEM", 330, 345], ["specificity", "TEST", 370, 381]]], ["The RT-PCR is used for the detection of almost all the coronavirus including SARS-CoV2 [7, 14, 15].", [["coronavirus", "ORGANISM", 55, 66], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 77, 86], ["SARS-CoV2", "SPECIES", 77, 86], ["The RT-PCR", "TEST", 0, 10], ["the detection", "TEST", 23, 36], ["SARS", "TEST", 77, 81], ["coronavirus", "OBSERVATION", 55, 66]]], ["Even so, the RT-PCR is continuously improving to increase its specificity and sensitivity.", [["the RT-PCR", "TEST", 9, 19], ["sensitivity", "TEST", 78, 89]]], ["Due to the enhanced time consumption in the sample preparation, sensitivity towards contaminations, issues in handling and analysis, an improved TaqMan based RT-PCR method has been introduced by van Elden et al., for the routine diagnosis of HCoV [16].", [["sample", "ANATOMY", 44, 50], ["HCoV", "SPECIES", 242, 246], ["the sample preparation", "TREATMENT", 40, 62], ["sensitivity towards contaminations", "PROBLEM", 64, 98], ["analysis", "TEST", 123, 131], ["RT-PCR method", "TREATMENT", 158, 171]]], ["Also, to increase the sensitivity, Yip and their team structured an ongoing RT-qPCR examine for SARS-CoV by using 2 TaqMan tests, instead of 1 probe [17].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["SARS-CoV", "SPECIES", 96, 104], ["SARS", "PROBLEM", 96, 100], ["2 TaqMan tests", "TEST", 114, 128]]], ["This straightforward alteration utilizing double TaqMan tests for evaluation has huge applications in regions in which ultra-sensitivity is fundamentally required, with the SARS-CoV identification limit of 1 copy RNA per cycle.PCR based methods ::: Nucleic acid detection-based technology ::: IntroductionIn clinical identification, the absence of protected and stable outer positive controls (OPC) could turn into a difficult issue in the identification of SARS-CoV-2 and a lot of consideration has been engaged to address this issue.", [["Nucleic acid", "CHEMICAL", 249, 261], ["SARS", "DISEASE", 458, 462], ["Nucleic acid", "SIMPLE_CHEMICAL", 249, 261], ["1 copy RNA", "RNA", 206, 216], ["SARS-CoV", "SPECIES", 458, 466], ["double TaqMan tests", "TEST", 42, 61], ["evaluation", "TEST", 66, 76], ["huge applications", "TREATMENT", 81, 98], ["the SARS", "TEST", 169, 177], ["Nucleic acid detection", "TEST", 249, 271], ["SARS", "PROBLEM", 458, 462], ["CoV", "TEST", 463, 466], ["stable", "OBSERVATION_MODIFIER", 362, 368]]], ["However, these issues can be very well avoided in the case of real-time RT-PCR where OPC is a significant element.", [["OPC", "PROBLEM", 85, 88], ["significant element", "OBSERVATION", 94, 113]]], ["Yu et al. have developed an RT-PCR based assay in which the defensively covered RNA was utilized as OPC to identify the SARS-CoV-2, with a discovery cut-off value of 10 duplicates/\u03bcL [18].", [["SARS-CoV", "SPECIES", 120, 128], ["an RT-PCR based assay", "TEST", 25, 46], ["the SARS", "TEST", 116, 124], ["CoV", "TEST", 125, 128], ["a discovery cut", "TEST", 137, 152]]], ["The fast mutating behavior of coronaviruses increases the requirement for a sensitive and specific method for the detection and recognition of genetic variants of coronaviruses.", [["coronaviruses", "ORGANISM", 30, 43], ["coronaviruses", "ORGANISM", 163, 176], ["coronaviruses", "PROBLEM", 30, 43], ["the detection", "TEST", 110, 123], ["coronaviruses", "PROBLEM", 163, 176]]], ["Hence, to ameliorate the ability to detect and identify coronavirus correctly with reduced risk of false-negative results (which occur due to genetic variability in the sequences), scientists have developed multiplex real-time RT-PCR protocol with high sensitivity for the multitarget detection of CoV.", [["coronavirus", "ORGANISM", 56, 67], ["CoV", "ORGANISM", 298, 301], ["coronavirus", "PROBLEM", 56, 67], ["genetic variability", "PROBLEM", 142, 161], ["PCR protocol", "TEST", 230, 242], ["CoV", "PROBLEM", 298, 301]]], ["Hadjinicolaou et al. built up a constant RT-PCR measure utilizing befuddle tolerant sub-atomic signals to recognize disease-causing and non-disease causing strains [19].", [["a constant RT-PCR measure", "TREATMENT", 30, 55], ["disease", "PROBLEM", 116, 123], ["non-disease", "PROBLEM", 136, 147], ["strains", "PROBLEM", 156, 163], ["disease", "OBSERVATION", 116, 123]]], ["The test joined four reference points, focusing on four qualities not withstanding an inside positive control.", [["The test", "TEST", 0, 8]]], ["It was approved utilizing clinical examples, which showed target recognition capacity and explicitness with the identification breaking point of 5 duplicates for each response.PCR based methods ::: Nucleic acid detection-based technology ::: IntroductionAs soon as the outbreak of COVID-19 occurs in China in December 2019, several industries launched the qRT-PCR based diagnostic kit for the CoV.", [["Nucleic acid", "CHEMICAL", 198, 210], ["COVID-19", "CHEMICAL", 281, 289], ["Nucleic acid", "SIMPLE_CHEMICAL", 198, 210], ["CoV.", "SPECIES", 393, 397], ["target recognition capacity", "PROBLEM", 58, 85], ["Nucleic acid detection", "TEST", 198, 220]]], ["The Chinese Centre for Disease Control and Prevention (China CDC) has commended to use the sequence-specific probes as well as primers in the \u201cORF1ab\u201d and \u201cN-gene region of SARS-CoV-2\u201d through the qRT-PCR process.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 143, 149], ["N-gene region", "DNA", 156, 169], ["qRT", "DNA", 197, 200], ["Disease Control", "TREATMENT", 23, 38], ["the sequence", "TEST", 87, 99], ["SARS", "PROBLEM", 173, 177], ["CoV", "TEST", 178, 181], ["the qRT", "TEST", 193, 200]]], ["Theo separate gene locus (ORF1ab and N) on the SARS-CoV-2 gene has been detected by one-step RT-qPCR reported by Bustin and Nolan [20].", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 26, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["gene locus", "DNA", 14, 24], ["ORF1ab", "DNA", 26, 32], ["N", "DNA", 37, 38], ["SARS-CoV-2 gene", "DNA", 47, 62], ["SARS-CoV", "SPECIES", 47, 55], ["the SARS", "TEST", 43, 51], ["CoV", "TEST", 52, 55], ["gene locus", "OBSERVATION", 14, 24]]], ["In this described method, the negative control was affirmed as negative and the test sample of two patients having COVID-19 was affirmed as positive.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["the test sample", "TEST", 76, 91], ["COVID", "TEST", 115, 120]]], ["These RT-qPCR based methods have shown high sensitivity and specificity for SARS and MERS group of coronavirus [21].PCR based methods ::: Nucleic acid detection-based technology ::: IntroductionFive patients showed a negative SARS-CoV2 result through RT-qPCR but showed positive results through a chest CT scan.", [["SARS", "DISEASE", 76, 80], ["Nucleic acid", "CHEMICAL", 138, 150], ["coronavirus", "ORGANISM", 99, 110], ["Nucleic acid", "SIMPLE_CHEMICAL", 138, 150], ["patients", "ORGANISM", 199, 207], ["CoV2", "DNA", 231, 235], ["patients", "SPECIES", 199, 207], ["These RT-qPCR based methods", "TEST", 0, 27], ["high sensitivity", "PROBLEM", 39, 55], ["SARS", "PROBLEM", 76, 80], ["coronavirus", "PROBLEM", 99, 110], ["Nucleic acid detection", "TEST", 138, 160], ["RT-qPCR", "TEST", 251, 258], ["a chest CT scan", "TEST", 295, 310], ["chest", "ANATOMY", 297, 302]]], ["These patients were tested again by taking a swab sample and RT-qPCR has been performed and confirmed as infected with SARS-CoV-2 [22].", [["swab sample", "ANATOMY", 45, 56], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["SARS-CoV", "SPECIES", 119, 127], ["a swab sample", "TEST", 43, 56], ["RT-qPCR", "TEST", 61, 68], ["SARS", "TEST", 119, 123], ["CoV", "TEST", 124, 127], ["infected", "OBSERVATION", 105, 113]]], ["Based on the protocol used for the RT-qPCR and the total number of samples collected, this shows a sensitivity of 50\u201379% for the detection of SARS-CoV [23].", [["samples", "ANATOMY", 67, 74], ["SARS", "DISEASE", 142, 146], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 142, 150], ["SARS-CoV", "SPECIES", 142, 150], ["the protocol", "TEST", 9, 21], ["the RT-qPCR", "TEST", 31, 42], ["a sensitivity", "TEST", 97, 110], ["SARS", "PROBLEM", 142, 146], ["CoV", "TEST", 147, 150]]], ["And hence there is the scope of improvement in the detection rate of RT-qPCR for SARS-CoV-2 disease.", [["SARS-CoV-2 disease", "DISEASE", 81, 99], ["SARS-CoV-2", "ORGANISM", 81, 91], ["SARS-CoV", "SPECIES", 81, 89], ["the detection rate", "TEST", 47, 65], ["RT", "TEST", 69, 71], ["qPCR", "TEST", 72, 76], ["SARS", "PROBLEM", 81, 85], ["CoV-2 disease", "PROBLEM", 86, 99]]], ["Furthermore, RT-qPCR has drawbacks which include the biological hazards, cumbersome nucleic detection operations, and long sitting tight time for results.Microarrays based methodologies ::: IntroductionMicroarray technology is a rapid and high throughput molecular biology detection tool which is very capable of quantifying thousands of gene transcript from the provided test cell or tissue at one moment.", [["cell", "ANATOMY", 377, 381], ["tissue", "ANATOMY", 385, 391], ["cell", "CELL", 377, 381], ["tissue", "TISSUE", 385, 391], ["RT-qPCR", "TEST", 13, 20], ["cumbersome nucleic detection operations", "TREATMENT", 73, 112], ["gene transcript", "PROBLEM", 338, 353]]], ["The microarray has a huge number of gene fragments (in picomoles) of already known sequences arrayed in a known sequence (called as probes) of rows and columns on a glass microscopic slide.", [["picomoles", "CANCER", 55, 64], ["gene fragments", "DNA", 36, 50], ["gene fragments", "PROBLEM", 36, 50], ["a known sequence", "TEST", 104, 120], ["huge", "OBSERVATION_MODIFIER", 21, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["gene fragments", "OBSERVATION", 36, 50]]], ["In this method of coronavirus detection, the coronavirus RNA genome is first converted to a specific probe labeled cDNA by the reverse transcription process.", [["coronavirus", "ORGANISM", 18, 29], ["coronavirus", "ORGANISM", 45, 56], ["coronavirus RNA genome", "DNA", 45, 67], ["cDNA", "DNA", 115, 119], ["coronavirus", "SPECIES", 45, 56], ["coronavirus", "SPECIES", 18, 29], ["coronavirus", "SPECIES", 45, 56], ["coronavirus detection", "TEST", 18, 39], ["the coronavirus RNA genome", "PROBLEM", 41, 67], ["coronavirus", "OBSERVATION", 18, 29], ["reverse transcription", "OBSERVATION", 127, 148]]], ["These labeled cDNA will be charged into each well of the microarray plate containing prefixed oligonucleotides on solid phase and allowed to hybridize.", [["labeled cDNA", "DNA", 6, 18], ["These labeled cDNA", "TREATMENT", 0, 18], ["the microarray plate", "TREATMENT", 53, 73], ["prefixed oligonucleotides", "TREATMENT", 85, 110], ["solid phase", "OBSERVATION_MODIFIER", 114, 125]]], ["Free unbound DNA is then washed out in a series of washing steps.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["Free unbound DNA", "PROBLEM", 0, 16], ["unbound DNA", "OBSERVATION", 5, 16]]], ["The hybridized sequence is detected and due to the transcendency, the microarray-based methods are highly used protocol for the detection of coronavirus [24].", [["coronavirus", "DISEASE", 141, 152], ["coronavirus", "ORGANISM", 141, 152], ["hybridized sequence", "DNA", 4, 23], ["The hybridized sequence", "TEST", 0, 23], ["coronavirus", "PROBLEM", 141, 152]]], ["A group of researched lead by Shi et al. has designed and developed a microarray of 60 mer oligonucleotides as per the sequence of phosphatidylinositol kinase-related protein kinase (TOR2) and succeeded in the detection of coronavirus of SARS family from an isolated clinical sample.", [["sample", "ANATOMY", 276, 282], ["SARS", "DISEASE", 238, 242], ["phosphatidylinositol", "CHEMICAL", 131, 151], ["phosphatidylinositol kinase-related protein kinase", "GENE_OR_GENE_PRODUCT", 131, 181], ["TOR2", "GENE_OR_GENE_PRODUCT", 183, 187], ["coronavirus", "ORGANISM", 223, 234], ["phosphatidylinositol kinase-related protein kinase", "PROTEIN", 131, 181], ["TOR2", "PROTEIN", 183, 187], ["a microarray", "TEST", 68, 80], ["phosphatidylinositol kinase", "TEST", 131, 158], ["protein kinase", "TEST", 167, 181], ["coronavirus", "PROBLEM", 223, 234], ["coronavirus", "OBSERVATION", 223, 234]]], ["They created a thirty 60mer TOR2 sequence-specific oligo which covers the whole genome of the first submitted sequence of coronavirus strain [25].", [["coronavirus", "ORGANISM", 122, 133], ["60mer TOR2 sequence", "DNA", 22, 41], ["a thirty 60mer TOR2 sequence", "TEST", 13, 41], ["specific oligo", "PROBLEM", 42, 56], ["coronavirus strain", "PROBLEM", 122, 140]]], ["But after the consideration of high and fast mutation rates in SARS-CoV, another group of scientists leads by Guo have designed a microarray for the detection of 24 single nucleotide polymorphism in the spike gene with 100% accuracy [26].", [["SARS", "DISEASE", 63, 67], ["SARS-CoV", "ORGANISM", 63, 71], ["spike gene", "DNA", 203, 213], ["SARS-CoV", "SPECIES", 63, 71], ["high and fast mutation rates", "PROBLEM", 31, 59], ["SARS", "PROBLEM", 63, 67], ["a microarray", "TEST", 128, 140], ["the detection", "TEST", 145, 158], ["single nucleotide polymorphism", "PROBLEM", 165, 195]]], ["Due to the sudden outbreak of SARS-CoV2, it will be of great significance to design a diagnostic assay tool to detect a wide range of coronavirus and it may be placed at the Point of Care (POC) center.", [["SARS", "DISEASE", 30, 34], ["coronavirus", "DISEASE", 134, 145], ["coronavirus", "ORGANISM", 134, 145], ["SARS", "PROBLEM", 30, 34], ["a diagnostic assay tool", "TEST", 84, 107], ["coronavirus", "PROBLEM", 134, 145]]], ["Accordance with this, Luna and their team have developed a cost-effective, nonfluorescent based low-density oligonucleotide assay tool for the detection of complete coronavirus genome with the same sensitivity as to real-time PCR.", [["coronavirus", "ORGANISM", 165, 176], ["coronavirus genome", "DNA", 165, 183], ["a cost-effective, nonfluorescent based low-density oligonucleotide assay tool", "PROBLEM", 57, 134], ["the detection", "TEST", 139, 152], ["complete coronavirus genome", "PROBLEM", 156, 183], ["low-density", "OBSERVATION_MODIFIER", 96, 107], ["coronavirus genome", "OBSERVATION", 165, 183]]], ["And also, Hardick et al. have also developed a microarray-based diagnostic tool, called Mobile Analysis Platform, with an acceptable detection limit and shown good performance in the detection [28].Regular loop-mediated isothermal amplification (LAMP) based methods ::: Isothermal nucleic acid-based amplification ::: Introduction\u201cLoop-mediated isothermal amplification (LAMP)\u201d is a low-cost method for the amplification of DNA in a single tube and mainly done for the detection of specific disease [30].", [["nucleic acid", "CHEMICAL", 281, 293], ["DNA", "CELLULAR_COMPONENT", 424, 427], ["tube", "TISSUE", 440, 444], ["a microarray", "TEST", 45, 57], ["an acceptable detection limit", "TEST", 119, 148], ["Isothermal nucleic acid", "TREATMENT", 270, 293], ["Loop-mediated isothermal amplification", "TREATMENT", 331, 369], ["a low-cost method", "TREATMENT", 381, 398], ["the amplification of DNA", "TREATMENT", 403, 427], ["a single tube", "TREATMENT", 431, 444], ["specific disease", "PROBLEM", 482, 498], ["loop", "OBSERVATION", 206, 210]]], ["In this case, the target DNA sequence is amplified at a specific temperature of 60\u201365 \u00b0C by using 2\u20133 sets of primers and a DNA polymerase of large DNA strand displacement activity as well as DNA replication activity.", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["target DNA sequence", "DNA", 18, 37], ["DNA polymerase", "PROTEIN", 124, 138], ["the target DNA sequence", "TEST", 14, 37], ["primers", "TREATMENT", 110, 117], ["a DNA polymerase", "TEST", 122, 138], ["large DNA strand displacement activity", "PROBLEM", 142, 180], ["DNA replication activity", "TREATMENT", 192, 216], ["large", "OBSERVATION_MODIFIER", 142, 147], ["DNA strand", "OBSERVATION", 148, 158], ["displacement activity", "OBSERVATION", 159, 180], ["replication activity", "OBSERVATION", 196, 216]]], ["Commonly four different primers are used to amplify 6-different regions of the target DNA sequences and it induces sensitivity of the process.", [["DNA", "CELLULAR_COMPONENT", 86, 89], ["target DNA sequences", "DNA", 79, 99], ["Commonly four different primers", "PROBLEM", 0, 31], ["the target DNA sequences", "TEST", 75, 99]]], ["Along with the four specific primers, a pair of loop primer is also used to increase the speed of the process [31].", [["a pair of loop primer", "TREATMENT", 38, 59], ["loop primer", "OBSERVATION", 48, 59]]], ["The amount of amplified DNA produced by LAMP is high compared to the conventional PCR process.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["amplified DNA", "DNA", 14, 27], ["amplified DNA", "PROBLEM", 14, 27], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["DNA", "OBSERVATION_MODIFIER", 24, 27], ["high", "OBSERVATION_MODIFIER", 48, 52]]], ["The amplified product can be detected and evaluated through a photometric reaction where turbidity caused due to magnesium pyrophosphate precipitate or fluorescence dye is measured [32].", [["magnesium pyrophosphate", "CHEMICAL", 113, 136], ["magnesium pyrophosphate", "CHEMICAL", 113, 136], ["magnesium pyrophosphate", "SIMPLE_CHEMICAL", 113, 136], ["a photometric reaction", "PROBLEM", 60, 82], ["turbidity", "PROBLEM", 89, 98], ["magnesium pyrophosphate precipitate", "PROBLEM", 113, 148], ["fluorescence dye", "TEST", 152, 168]]], ["LAMP is having advantages over other DNA amplifying methods due to its simplicity, cost efficiency, and toughness.", [["DNA", "CELLULAR_COMPONENT", 37, 40], ["other DNA amplifying methods", "TREATMENT", 31, 59], ["toughness", "PROBLEM", 104, 113]]], ["It can be used for both screening purposes as well as for the point of care by diagnostic technicians.", [["both screening purposes", "TEST", 19, 42]]], ["As the process is isothermal and takes place at a specific temperature which removes the requirement of costly thermocyclers.", [["costly thermocyclers", "TREATMENT", 104, 124]]], ["LAMP is already used for the diagnosis of a large number of different diseases such as malaria [33], tuberculosis [34], sleeping sickness [35] etc. This might be one of the cost-effective diagnostic tests for the coronavirus diagnosis [36].", [["malaria", "DISEASE", 87, 94], ["tuberculosis", "DISEASE", 101, 113], ["sleeping sickness", "DISEASE", 120, 137], ["coronavirus", "DISEASE", 213, 224], ["coronavirus", "ORGANISM", 213, 224], ["LAMP", "TREATMENT", 0, 4], ["different diseases", "PROBLEM", 60, 78], ["malaria", "PROBLEM", 87, 94], ["tuberculosis", "PROBLEM", 101, 113], ["sleeping sickness", "PROBLEM", 120, 137], ["diagnostic tests", "TEST", 188, 204], ["the coronavirus diagnosis", "TEST", 209, 234], ["large", "OBSERVATION_MODIFIER", 44, 49], ["number", "OBSERVATION_MODIFIER", 50, 56], ["different", "OBSERVATION_MODIFIER", 60, 69], ["diseases", "OBSERVATION", 70, 78]]], ["There are many LAMP-based detection methods that have been designed and developed for the detection of coronavirus.Regular loop-mediated isothermal amplification (LAMP) based methods ::: Isothermal nucleic acid-based amplification ::: IntroductionLAMP-based SARS assay has been developed by Poon and his team and also demonstrated its feasibility in the diagnosis of SARS-CoV [37].", [["coronavirus", "DISEASE", 103, 114], ["nucleic acid", "CHEMICAL", 198, 210], ["SARS", "DISEASE", 367, 371], ["coronavirus", "ORGANISM", 103, 114], ["SARS-CoV", "SPECIES", 367, 375], ["many LAMP", "TEST", 10, 19], ["based detection methods", "TEST", 20, 43], ["coronavirus", "PROBLEM", 103, 114], ["Isothermal nucleic acid", "TEST", 187, 210], ["IntroductionLAMP", "TEST", 235, 251], ["SARS assay", "TEST", 258, 268], ["SARS", "PROBLEM", 367, 371], ["coronavirus", "OBSERVATION", 103, 114], ["loop", "OBSERVATION", 123, 127]]], ["ORF1b region of SARS-CoV was amplified through a LAMP based amplification reaction by using 6-primer.", [["ORF1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["ORF1b region", "DNA", 0, 12], ["SARS-CoV", "DNA", 16, 24], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "PROBLEM", 21, 24], ["a LAMP based amplification reaction", "TREATMENT", 47, 82], ["SARS", "OBSERVATION", 16, 20]]], ["The amplified product was assayed through gel electrophoresis with detection rate and sensitivity of LAMP-based amplification similar to the conventional PCR based amplification.", [["gel electrophoresis", "TEST", 42, 61], ["detection rate", "TEST", 67, 81], ["LAMP-based amplification", "TREATMENT", 101, 125], ["the conventional PCR based amplification", "TREATMENT", 137, 177]]], ["Another group of scientists leads by Pyrc developed a LAMP-based amplification method for the detection of HCoV-NL63 on agarose gel electrophoresis with desirable sensitivity and specificity [38].Regular loop-mediated isothermal amplification (LAMP) based methods ::: Isothermal nucleic acid-based amplification ::: IntroductionA valuable RT-LAMP test for the conclusion and epidemiologic reconnaissance of human MERS-CoV was created by Shirato et al. [39], which is fit for identifying as not many as 3.4 duplicates of MERS-CoV RNA and is exceptionally explicit, with no cross-response with other respiratory infections.", [["respiratory", "ANATOMY", 598, 609], ["nucleic acid", "CHEMICAL", 279, 291], ["respiratory infections", "DISEASE", 598, 620], ["HCoV-NL63", "CELL", 107, 116], ["agarose", "SIMPLE_CHEMICAL", 120, 127], ["human", "ORGANISM", 407, 412], ["MERS-CoV", "ORGANISM", 413, 421], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 520, 528], ["HCoV", "PROTEIN", 107, 111], ["NL63", "DNA", 112, 116], ["human MERS-CoV", "DNA", 407, 421], ["MERS-CoV RNA", "RNA", 520, 532], ["human", "SPECIES", 407, 412], ["HCoV", "SPECIES", 107, 111], ["human MERS-CoV", "SPECIES", 407, 421], ["MERS-CoV", "SPECIES", 520, 528], ["a LAMP", "TEST", 52, 58], ["the detection", "TEST", 90, 103], ["HCoV", "TEST", 107, 111], ["agarose gel electrophoresis", "TEST", 120, 147], ["specificity", "TEST", 179, 190], ["Isothermal nucleic acid", "TEST", 268, 291], ["LAMP test", "TEST", 342, 351], ["MERS-CoV RNA", "PROBLEM", 520, 532], ["other respiratory infections", "PROBLEM", 592, 620], ["loop", "OBSERVATION", 204, 208], ["respiratory", "ANATOMY", 598, 609], ["infections", "OBSERVATION", 610, 620]]], ["Thai et al. [40] built an one-advance single-tube continuous quantitative RT-LAMP test checked by ongoing estimation of turbidity in a photometer for the early and fast analysis of SARS-CoV.", [["SARS", "DISEASE", 181, 185], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 181, 189], ["SARS-CoV", "SPECIES", 181, 189], ["single-tube", "TREATMENT", 38, 49], ["LAMP test", "TEST", 77, 86], ["a photometer", "TREATMENT", 133, 145], ["SARS", "PROBLEM", 181, 185], ["CoV", "PROBLEM", 186, 189]]], ["When compared with clinical samples the detection was reported to be 100-fold more sensitive than that of conventional polymerase chain reaction-based methods with a detection limit of 0.01 plaque-forming units (PFU).Sequence-specific loop-mediated isothermal amplification (LAMP) methods ::: Isothermal nucleic acid-based amplification ::: IntroductionTurbidity generation due to the production of pyrophosphates at the time of polymerizing reaction or intercalation of fluorescence dyes inside the dsDNA amplicons possibility that the signal may come from primer dimerization or non-primer interactions [41].", [["nucleic acid", "CHEMICAL", 304, 316], ["pyrophosphates", "CHEMICAL", 399, 413], ["pyrophosphates", "CHEMICAL", 399, 413], ["pyrophosphates", "SIMPLE_CHEMICAL", 399, 413], ["clinical samples the detection", "TEST", 19, 49], ["conventional polymerase chain reaction", "PROBLEM", 106, 144], ["Sequence", "TEST", 217, 225], ["Isothermal nucleic acid", "TEST", 293, 316], ["IntroductionTurbidity generation", "PROBLEM", 341, 373], ["the production of pyrophosphates", "PROBLEM", 381, 413], ["polymerizing reaction", "PROBLEM", 429, 450], ["intercalation of fluorescence dyes", "TREATMENT", 454, 488], ["the dsDNA amplicons", "TREATMENT", 496, 515]]], ["This issue can be resolved by the use of a sequence-specific supervising of LAMP and some other temperature specific DNA amplification methods which produce true signal that can be differentiated from nonspecific signals.", [["DNA", "CELLULAR_COMPONENT", 117, 120], ["LAMP", "TREATMENT", 76, 80], ["some other temperature specific DNA amplification methods", "PROBLEM", 85, 142], ["nonspecific", "OBSERVATION_MODIFIER", 201, 212]]], ["Shirato and his team had modified and improved the RT-LAMP detection tool by adding quenching probes (QProbe) to detect, and supervise true signal and at the same time it has a similar performance as the normal standard RT-PCR assays for the diagnosis of MERS-CoV [42].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 255, 263], ["MERS-CoV", "SPECIES", 255, 263], ["quenching probes", "TEST", 84, 100]]], ["A more developed nucleic acid visualization tool has been reported by combining RT-LAMP and a vertical flow visualization strip (RT-LAMP-VF) for the detection and diagnosis of MERS-CoV [3].", [["nucleic acid", "CHEMICAL", 17, 29], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 176, 184], ["MERS-CoV", "SPECIES", 176, 184], ["A more developed nucleic acid visualization tool", "PROBLEM", 0, 48], ["a vertical flow visualization strip", "TEST", 92, 127], ["the detection", "TEST", 145, 158], ["MERS", "PROBLEM", 176, 180], ["nucleic acid", "OBSERVATION", 17, 29]]], ["The optimum temperature for the LAMP is near to 65 \u00b0C which is a limiting factor for its applicability.", [["The optimum temperature", "TEST", 0, 23], ["the LAMP", "TEST", 28, 36]]], ["To overcome this, Cai et al., has developed a modified version of LAMP by using phosphorothioated primers (PS-LAMP), which increases the efficient hairpin creation and elongation at the terminus of concatemers and it works at much low temperature than the optimum temperature of LAMP [43].", [["LAMP", "TREATMENT", 66, 70], ["phosphorothioated primers", "TREATMENT", 80, 105], ["efficient", "OBSERVATION_MODIFIER", 137, 146], ["hairpin", "OBSERVATION", 147, 154], ["elongation", "OBSERVATION_MODIFIER", 168, 178]]], ["A better specificity and sensitivity was observed with the performance of PS-LAMP at 40 \u00b0C when comparable with the conventional LAMP at 65 \u00b0C.CRISPR based newly developed methods ::: IntroductionCRISPR (clustered regularly interspaced short palindromic repeats)-Cas is a genome-editing tool which allows scientist to add, remove or modify the genome at a desired specific site in the DNA.", [["clustered regularly interspaced short palindromic repeats)-Cas", "GENE_OR_GENE_PRODUCT", 204, 266], ["DNA", "CELLULAR_COMPONENT", 385, 388], ["CRISPR", "DNA", 143, 149], ["clustered regularly interspaced short palindromic repeats", "DNA", 204, 261], ["Cas", "DNA", 263, 266], ["PS", "TREATMENT", 74, 76], ["LAMP", "TREATMENT", 77, 81], ["IntroductionCRISPR (clustered regularly interspaced short palindromic repeats", "TREATMENT", 184, 261], ["DNA", "ANATOMY", 385, 388]]], ["Recently, RNA targeting CRISPR-Cas13 has been reported for the fast and portable nucleic acid detection process [44, 45].", [["nucleic acid", "CHEMICAL", 81, 93], ["CRISPR-Cas13", "GENE_OR_GENE_PRODUCT", 24, 36], ["CRISPR", "DNA", 24, 30], ["Cas13", "DNA", 31, 36], ["portable nucleic acid detection process", "TEST", 72, 111]]], ["A group of scientists leads by Zhang reported the use of Cas13 to detect and destroy different mammalian viruses\u2019 single-stranded RNA genome [46].", [["Cas13", "GENE_OR_GENE_PRODUCT", 57, 62], ["Cas13", "PROTEIN", 57, 62], ["mammalian viruses\u2019 single-stranded RNA genome", "DNA", 95, 140]]], ["This group has created a specific platform-specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) by combing two different tools, isothermal preamplification with Cas13 for the detection and digestion of ssRNA or ssDNA [47].", [["Cas13", "CHEMICAL", 174, 179], ["Cas13", "SIMPLE_CHEMICAL", 174, 179], ["Cas13", "PROTEIN", 174, 179], ["a specific platform", "TEST", 23, 42], ["the detection", "TEST", 184, 197], ["ssRNA", "PROBLEM", 215, 220], ["ssDNA", "PROBLEM", 224, 229]]], ["This has already been used for the detection of dengue and Zika virus ssRNA genome and also in the liquid biopsy sample of some patients.", [["dengue", "DISEASE", 48, 54], ["Zika virus", "ORGANISM", 59, 69], ["patients", "ORGANISM", 128, 136], ["Zika virus ssRNA genome", "DNA", 59, 82], ["Zika virus", "SPECIES", 59, 69], ["patients", "SPECIES", 128, 136], ["dengue", "SPECIES", 48, 54], ["Zika virus", "SPECIES", 59, 69], ["the detection", "TEST", 31, 44], ["dengue", "PROBLEM", 48, 54], ["Zika virus ssRNA genome", "PROBLEM", 59, 82], ["the liquid biopsy", "TEST", 95, 112]]], ["Their recent protocol for the detection and diagnosis of COVID-19 is published on a website (https://broad.io/sherlockprotocol) with the title, \u201cA protocol for detection of COVID-19 using CRISPR diagnostics\u201d.", [["the detection", "TEST", 26, 39], ["COVID", "TEST", 57, 62], ["COVID", "TEST", 173, 178], ["CRISPR diagnostics", "TEST", 188, 206]]], ["This online protocol may provide some reference points to the researchers for the rapid, quantitative detection of COVID-19.CT scan and other diagnostic methodology ::: IntroductionAlthough the RT-qPCR is a sensitive and specific tool for the detection of coronavirus, but its false-positive rate could not be ignored.", [["coronavirus", "DISEASE", 256, 267], ["coronavirus", "ORGANISM", 256, 267], ["coronavirus", "SPECIES", 256, 267], ["This online protocol", "TREATMENT", 0, 20], ["COVID", "TEST", 115, 120], ["the RT-qPCR", "TEST", 190, 201], ["coronavirus", "PROBLEM", 256, 267]]], ["Hence, some clinicians have suggested that CT scanning can be one of the compulsory auxiliary diagnostic tools due to its sensitivity.", [["CT scanning", "TEST", 43, 54], ["its sensitivity", "PROBLEM", 118, 133]]], ["Combination of the repetition of RT-qPCR along with the chest CT scanning should be performed in the patients with negative RT-PCR but symptoms of SARS-CoV2.", [["SARS", "DISEASE", 147, 151], ["patients", "ORGANISM", 101, 109], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 147, 156], ["patients", "SPECIES", 101, 109], ["RT-qPCR", "TEST", 33, 40], ["the chest CT scanning", "TEST", 52, 73], ["PCR", "TEST", 127, 130], ["symptoms", "PROBLEM", 135, 143], ["SARS", "PROBLEM", 147, 151], ["chest", "ANATOMY", 56, 61]]], ["The high-resolution CT scanning of the chest (HRCT) is necessary for the preliminary diagnosis of the severity of COVID-19 in the patients infected with SARS-CoV2 [48].", [["chest", "ANATOMY", 39, 44], ["SARS", "DISEASE", 153, 157], ["chest", "ORGAN", 39, 44], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["The high-resolution CT scanning of the chest", "TEST", 0, 44], ["COVID", "TEST", 114, 119], ["chest", "ANATOMY", 39, 44]]], ["There are many pieces of literature already available for the use of CT scanning in the case of COVID-19 [49, 50].", [["CT scanning", "TEST", 69, 80], ["COVID", "TEST", 96, 101]]], ["A common visualization of CT scanning shows the bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, sometimes with a rounded morphology and a peripheral lung distribution.", [["pulmonary parenchymal", "ANATOMY", 58, 79], ["pulmonary", "ANATOMY", 111, 120], ["lung", "ANATOMY", 185, 189], ["pulmonary opacities", "DISEASE", 111, 130], ["pulmonary", "ORGAN", 58, 67], ["pulmonary", "ORGAN", 111, 120], ["lung", "ORGAN", 185, 189], ["A common visualization of CT scanning", "TEST", 0, 37], ["the bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities", "PROBLEM", 44, 130], ["a rounded morphology and a peripheral lung distribution", "PROBLEM", 147, 202], ["bilateral", "ANATOMY_MODIFIER", 48, 57], ["pulmonary", "ANATOMY", 58, 67], ["parenchymal", "ANATOMY_MODIFIER", 68, 79], ["ground-glass", "OBSERVATION", 80, 92], ["consolidative", "OBSERVATION_MODIFIER", 97, 110], ["pulmonary", "ANATOMY", 111, 120], ["opacities", "OBSERVATION", 121, 130], ["rounded", "OBSERVATION_MODIFIER", 149, 156], ["morphology", "OBSERVATION_MODIFIER", 157, 167], ["peripheral", "ANATOMY_MODIFIER", 174, 184], ["lung", "ANATOMY", 185, 189], ["distribution", "ANATOMY_MODIFIER", 190, 202]]], ["Lung affected in the patients with SARS-CoV and MERS-CoV and the CT scanning of the chest reveals that the abnormalities progress along with the ground-glass opacities in the lung.", [["Lung", "ANATOMY", 0, 4], ["chest", "ANATOMY", 84, 89], ["lung", "ANATOMY", 175, 179], ["SARS", "DISEASE", 35, 39], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 21, 29], ["SARS-CoV", "ORGANISM", 35, 43], ["MERS-CoV", "ORGANISM", 48, 56], ["chest", "ORGAN", 84, 89], ["lung", "ORGAN", 175, 179], ["patients", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 35, 43], ["MERS-CoV", "SPECIES", 48, 56], ["Lung affected", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 35, 39], ["the CT scanning of the chest", "TEST", 61, 89], ["the abnormalities", "PROBLEM", 103, 120], ["the ground-glass opacities in the lung", "PROBLEM", 141, 179], ["affected", "OBSERVATION", 5, 13], ["chest", "ANATOMY", 84, 89], ["abnormalities", "OBSERVATION", 107, 120], ["ground", "OBSERVATION_MODIFIER", 145, 151], ["glass opacities", "OBSERVATION", 152, 167], ["lung", "ANATOMY", 175, 179]]], ["A similar type of results is also seen in the case of SARS-CoV2 infections [51, 52].", [["SARS-CoV2 infections", "DISEASE", 54, 74], ["SARS-CoV2", "SIMPLE_CHEMICAL", 54, 63], ["SARS", "PROBLEM", 54, 58], ["CoV2 infections", "PROBLEM", 59, 74]]], ["These findings suggest that chest CT scanning can be a great help in the diagnosis of COVID-19 in the area with high prevalence.", [["chest", "ANATOMY", 28, 33], ["chest CT scanning", "TEST", 28, 45], ["COVID", "TEST", 86, 91], ["chest", "ANATOMY", 28, 33], ["high prevalence", "OBSERVATION", 112, 127]]], ["One of the major abnormalities of CT scanning is that it cannot differentiate between pneumonia caused due to other viruses and hysteresis of abnormal CT imaging.Summary and future prospectsPresently the detection and diagnosis of SARS-CoV-2 mainly work through the viral ssRNA genome detection of coronavirus.", [["pneumonia", "DISEASE", 86, 95], ["SARS", "DISEASE", 231, 235], ["SARS-CoV-2", "ORGANISM", 231, 241], ["coronavirus", "ORGANISM", 298, 309], ["viral ssRNA genome", "DNA", 266, 284], ["SARS-CoV", "SPECIES", 231, 239], ["the major abnormalities", "PROBLEM", 7, 30], ["CT scanning", "TEST", 34, 45], ["pneumonia", "PROBLEM", 86, 95], ["other viruses", "PROBLEM", 110, 123], ["abnormal CT imaging", "TEST", 142, 161], ["the detection", "TEST", 200, 213], ["SARS", "PROBLEM", 231, 235], ["CoV", "TEST", 236, 239], ["the viral ssRNA genome", "TREATMENT", 262, 284], ["coronavirus", "PROBLEM", 298, 309], ["major", "OBSERVATION_MODIFIER", 11, 16], ["abnormalities", "OBSERVATION", 17, 30], ["pneumonia", "OBSERVATION", 86, 95], ["viruses", "OBSERVATION", 116, 123], ["viral ssRNA genome", "OBSERVATION", 266, 284]]], ["In the diagnosis of a disease, the selection of a diagnostic method plays a very significant role.", [["a disease", "PROBLEM", 20, 29], ["disease", "OBSERVATION", 22, 29]]], ["A very high specific and sensitive method for the detection of the virus is through PCR methods, but its drawback is it needs a sophisticated instrument, costly reagents, well-established laboratory, and trained analysts.", [["the virus", "PROBLEM", 63, 72], ["PCR methods", "TEST", 84, 95], ["virus", "OBSERVATION", 67, 72]]], ["LAMP is another ultrasensitive amplification method for a nucleic acid that can detect a very small amount of DNA or RNA in less than an hour time but its drawback is the requirement of high temperature.", [["nucleic acid", "CHEMICAL", 58, 70], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["a nucleic acid", "TEST", 56, 70], ["a very small amount of DNA or RNA", "PROBLEM", 87, 120], ["high temperature", "PROBLEM", 186, 202], ["very", "OBSERVATION_MODIFIER", 89, 93], ["small", "OBSERVATION_MODIFIER", 94, 99], ["amount", "OBSERVATION_MODIFIER", 100, 106], ["DNA", "OBSERVATION", 110, 113], ["high temperature", "OBSERVATION_MODIFIER", 186, 202]]], ["In the case of microarray, its cost limits its application commonly in the detection of SARS-CoV-2.", [["SARS", "DISEASE", 88, 92], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96]]], ["Hence there is still a requirement of cost-efficient COVID-19 detection method which can be used very easily in a cost-efficient and less time along with high sensitivity and specificity.", [["cost-efficient COVID-19 detection method", "TREATMENT", 38, 78]]]], "712c86986815982dc6d918b660f70f5e05616643": [["Introduction Human respiratory syncytial virus (RSV) is a negative strand RNA virus belonging to the family Pneumoviridae.", [["respiratory syncytial virus", "DISEASE", 19, 46], ["Human respiratory syncytial virus", "ORGANISM", 13, 46], ["RSV", "ORGANISM", 48, 51], ["Pneumoviridae", "GENE_OR_GENE_PRODUCT", 108, 121], ["Human", "SPECIES", 13, 18], ["respiratory syncytial virus", "SPECIES", 19, 46], ["Human respiratory syncytial virus", "SPECIES", 13, 46], ["RSV", "SPECIES", 48, 51], ["Introduction Human respiratory syncytial virus", "PROBLEM", 0, 46], ["syncytial virus", "OBSERVATION", 31, 46]]], ["RSV is a major cause of acute lower respiratory tract infections in the pediatric population and is increasingly recognized as an important cause of severe respiratory disease in the elderly [1] [2] [3] .", [["lower respiratory tract", "ANATOMY", 30, 53], ["respiratory", "ANATOMY", 156, 167], ["RSV", "DISEASE", 0, 3], ["lower respiratory tract infections", "DISEASE", 30, 64], ["respiratory disease", "DISEASE", 156, 175], ["RSV", "ORGANISM", 0, 3], ["tract", "ORGANISM_SUBDIVISION", 48, 53], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["acute lower respiratory tract infections", "PROBLEM", 24, 64], ["severe respiratory disease", "PROBLEM", 149, 175], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["lower", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53], ["infections", "OBSERVATION", 54, 64], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["respiratory disease", "OBSERVATION", 156, 175]]], ["Despite the major clinical impact of RSV on human health worldwide, no approved vaccine or effective antiviral therapy is available.", [["RSV", "DISEASE", 37, 40], ["RSV", "ORGANISM", 37, 40], ["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["RSV", "SPECIES", 37, 40], ["human", "SPECIES", 44, 49], ["RSV", "PROBLEM", 37, 40], ["approved vaccine", "TREATMENT", 71, 87], ["effective antiviral therapy", "TREATMENT", 91, 118], ["RSV", "OBSERVATION", 37, 40]]], ["Although RSV infections do evoke humoral and cellular immune responses required to clear infection, these responses do not provide strong protection against a subsequent infection with RSV.", [["cellular", "ANATOMY", 45, 53], ["RSV infections", "DISEASE", 9, 23], ["infection", "DISEASE", 89, 98], ["infection", "DISEASE", 170, 179], ["RSV", "DISEASE", 185, 188], ["RSV", "ORGANISM", 9, 12], ["cellular", "CELL", 45, 53], ["RSV", "ORGANISM", 185, 188], ["RSV", "SPECIES", 9, 12], ["RSV", "SPECIES", 185, 188], ["RSV infections", "PROBLEM", 9, 23], ["cellular immune responses", "PROBLEM", 45, 70], ["clear infection", "PROBLEM", 83, 98], ["a subsequent infection", "PROBLEM", 157, 179], ["RSV", "PROBLEM", 185, 188], ["infections", "OBSERVATION", 13, 23], ["infection", "OBSERVATION", 89, 98], ["infection", "OBSERVATION", 170, 179]]], ["Early during infection, viral replication is sensed by the host's innate immune system, which leads to the production of type I and III interferons (IFNs), which is followed by the induction of an array of genes that code for antiviral proteins.", [["immune system", "ANATOMY", 73, 86], ["infection", "DISEASE", 13, 22], ["immune system", "ANATOMICAL_SYSTEM", 73, 86], ["type I and III interferons", "GENE_OR_GENE_PRODUCT", 121, 147], ["IFNs", "GENE_OR_GENE_PRODUCT", 149, 153], ["type I and III interferons", "PROTEIN", 121, 147], ["IFNs", "PROTEIN", 149, 153], ["antiviral proteins", "PROTEIN", 226, 244], ["Early during infection", "PROBLEM", 0, 22], ["viral replication", "PROBLEM", 24, 41], ["type I and III interferons (IFNs)", "PROBLEM", 121, 154], ["antiviral proteins", "TREATMENT", 226, 244], ["infection", "OBSERVATION", 13, 22], ["viral replication", "OBSERVATION", 24, 41]]], ["In addition, IFN will recruit and activate innate leukocytes, including antiviral monocytes and natural killer (NK) cells, and stimulate the adaptive immune response [4] .", [["leukocytes", "ANATOMY", 50, 60], ["monocytes", "ANATOMY", 82, 91], ["natural killer (NK) cells", "ANATOMY", 96, 121], ["IFN", "GENE_OR_GENE_PRODUCT", 13, 16], ["leukocytes", "CELL", 50, 60], ["monocytes", "CELL", 82, 91], ["natural killer (NK) cells", "CELL", 96, 121], ["IFN", "PROTEIN", 13, 16], ["innate leukocytes", "CELL_TYPE", 43, 60], ["antiviral monocytes", "CELL_TYPE", 72, 91], ["natural killer (NK) cells", "CELL_TYPE", 96, 121], ["IFN", "TREATMENT", 13, 16], ["innate leukocytes", "TEST", 43, 60], ["antiviral monocytes", "TREATMENT", 72, 91], ["natural killer (NK) cells", "TREATMENT", 96, 121]]], ["RSV has evolved a marvelous set of mechanisms to subvert this canonical antiviral response of the mammalian host, most notably by virtue of its nonstructural (NS) 1 and NS2 proteins.Induction of type I and III IFN upon RSV infectionThe innate immune system is an important early line of defense against pathogens.", [["RSV infection", "DISEASE", 219, 232], ["RSV", "ORGANISM", 0, 3], ["nonstructural (NS) 1", "GENE_OR_GENE_PRODUCT", 144, 164], ["NS2", "GENE_OR_GENE_PRODUCT", 169, 172], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 195, 213], ["RSV", "ORGANISM", 219, 222], ["nonstructural (NS) 1 and NS2 proteins", "PROTEIN", 144, 181], ["type I and III IFN", "PROTEIN", 195, 213], ["RSV", "SPECIES", 0, 3], ["RSV", "SPECIES", 219, 222], ["RSV", "PROBLEM", 0, 3], ["its nonstructural (NS)", "TREATMENT", 140, 162], ["type I and III IFN", "PROBLEM", 195, 213], ["RSV infection", "PROBLEM", 219, 232], ["The innate immune system", "TREATMENT", 232, 256], ["pathogens", "PROBLEM", 303, 312], ["antiviral response", "OBSERVATION", 72, 90], ["mammalian host", "OBSERVATION", 98, 112], ["RSV", "ANATOMY", 219, 222], ["infection", "OBSERVATION", 223, 232]]], ["This system comprises pattern recognition receptors (PRRs) that can recognize pathogen-associated molecular patterns (PAMPs).", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 22, 51], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 78, 116], ["PAMPs", "GENE_OR_GENE_PRODUCT", 118, 123], ["pattern recognition receptors", "PROTEIN", 22, 51], ["PRRs", "PROTEIN", 53, 57], ["pathogen-associated molecular patterns", "PROTEIN", 78, 116], ["PAMPs", "PROTEIN", 118, 123]]], ["Activated PRRs can induce the expression of cytokines, e.g., type I and III IFNs, which mount an antiviral state in an autocrine and paracrine fashion.", [["PRRs", "GENE_OR_GENE_PRODUCT", 10, 14], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 61, 80], ["PRRs", "PROTEIN", 10, 14], ["cytokines", "PROTEIN", 44, 53], ["type I and III IFNs", "PROTEIN", 61, 80], ["Activated PRRs", "TREATMENT", 0, 14], ["cytokines", "PROBLEM", 44, 53], ["type I and III IFNs", "PROBLEM", 61, 80]]], ["Upon RSV infection, airway epithelial cells, macrophages, and dendritic cells (DCs) are the main inducers of innate immune responses.", [["airway epithelial cells", "ANATOMY", 20, 43], ["macrophages", "ANATOMY", 45, 56], ["dendritic cells", "ANATOMY", 62, 77], ["DCs", "ANATOMY", 79, 82], ["RSV infection", "DISEASE", 5, 18], ["RSV", "ORGANISM", 5, 8], ["airway epithelial cells", "CELL", 20, 43], ["macrophages", "CELL", 45, 56], ["dendritic cells", "CELL", 62, 77], ["DCs", "CELL", 79, 82], ["airway epithelial cells", "CELL_TYPE", 20, 43], ["macrophages", "CELL_TYPE", 45, 56], ["dendritic cells", "CELL_TYPE", 62, 77], ["DCs", "CELL_TYPE", 79, 82], ["RSV", "SPECIES", 5, 8], ["RSV infection", "PROBLEM", 5, 18], ["airway epithelial cells", "PROBLEM", 20, 43], ["macrophages", "PROBLEM", 45, 56], ["dendritic cells", "PROBLEM", 62, 77], ["RSV", "ANATOMY", 5, 8], ["infection", "OBSERVATION", 9, 18], ["airway", "ANATOMY", 20, 26], ["epithelial cells", "OBSERVATION", 27, 43], ["macrophages", "OBSERVATION_MODIFIER", 45, 56], ["dendritic cells", "OBSERVATION", 62, 77]]], ["Several Toll-like receptors (TLRs) have been identified that can act as PRRs for RSV-derived PAMPs (Fig 1) .", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 8, 27], ["TLRs", "GENE_OR_GENE_PRODUCT", 29, 33], ["PRRs", "GENE_OR_GENE_PRODUCT", 72, 76], ["RSV", "ORGANISM", 81, 84], ["PAMPs", "GENE_OR_GENE_PRODUCT", 93, 98], ["Toll-like receptors", "PROTEIN", 8, 27], ["TLRs", "PROTEIN", 29, 33], ["PRRs", "PROTEIN", 72, 76], ["RSV-derived PAMPs", "PROTEIN", 81, 98], ["RSV", "SPECIES", 81, 84], ["RSV", "PROBLEM", 81, 84]]], ["TLR2, -3, and -6, for example, have been implicated in the induction of cytokines and chemokines upon RSV infection [5, 6] .", [["RSV infection", "DISEASE", 102, 115], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["-3", "GENE_OR_GENE_PRODUCT", 6, 8], ["-6", "GENE_OR_GENE_PRODUCT", 14, 16], ["RSV", "ORGANISM", 102, 105], ["TLR2, -3, and -6", "PROTEIN", 0, 16], ["cytokines", "PROTEIN", 72, 81], ["chemokines", "PROTEIN", 86, 96], ["RSV", "SPECIES", 102, 105], ["TLR2", "TEST", 0, 4], ["cytokines and chemokines", "TREATMENT", 72, 96], ["RSV infection", "PROBLEM", 102, 115]]], ["A role for TLR4, which is well known to respond to lipopolysaccharide, as a PRR for RSV is currently debated.", [["lipopolysaccharide", "CHEMICAL", 51, 69], ["RSV", "DISEASE", 84, 87], ["TLR4", "GENE_OR_GENE_PRODUCT", 11, 15], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 51, 69], ["RSV", "ORGANISM", 84, 87], ["TLR4", "PROTEIN", 11, 15], ["PRR", "PROTEIN", 76, 79], ["RSV", "SPECIES", 84, 87], ["TLR4", "TREATMENT", 11, 15], ["lipopolysaccharide", "TREATMENT", 51, 69], ["RSV", "PROBLEM", 84, 87]]], ["Although some groups reported an impaired innate immune response in TLR4-deficient mice [7-9], Ehl and colleagues could not confirm a role for a TLR4-mediated immune response upon RSV infection [10] .", [["RSV infection", "DISEASE", 180, 193], ["TLR4", "GENE_OR_GENE_PRODUCT", 68, 72], ["TLR4", "GENE_OR_GENE_PRODUCT", 145, 149], ["RSV", "ORGANISM", 180, 183], ["TLR4", "PROTEIN", 68, 72], ["TLR4", "PROTEIN", 145, 149], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["RSV", "SPECIES", 180, 183], ["a TLR4-mediated immune response", "TREATMENT", 143, 174], ["RSV infection", "PROBLEM", 180, 193]]], ["In addition, TLR7 might even play a role in tempering immune responses upon RSV infection [11] .", [["RSV infection", "DISEASE", 76, 89], ["TLR7", "GENE_OR_GENE_PRODUCT", 13, 17], ["RSV", "ORGANISM", 76, 79], ["TLR7", "PROTEIN", 13, 17], ["RSV", "SPECIES", 76, 79], ["TLR7", "TREATMENT", 13, 17], ["RSV infection", "PROBLEM", 76, 89]]], ["Moreover, type I IFN production by macrophages and DCs from wild-type and TLR1, -2, -4, -6, and -7 knockout mice is very similar following RSV infection [5, 11] .", [["macrophages", "ANATOMY", 35, 46], ["DCs", "ANATOMY", 51, 54], ["RSV infection", "DISEASE", 139, 152], ["type I IFN", "GENE_OR_GENE_PRODUCT", 10, 20], ["macrophages", "CELL", 35, 46], ["DCs", "CELL", 51, 54], ["TLR1", "GENE_OR_GENE_PRODUCT", 74, 78], ["-2", "GENE_OR_GENE_PRODUCT", 80, 82], ["-4", "GENE_OR_GENE_PRODUCT", 84, 86], ["-6", "GENE_OR_GENE_PRODUCT", 88, 90], ["-7", "GENE_OR_GENE_PRODUCT", 96, 98], ["mice", "ORGANISM", 108, 112], ["RSV", "ORGANISM", 139, 142], ["type I IFN", "PROTEIN", 10, 20], ["macrophages", "CELL_TYPE", 35, 46], ["DCs", "CELL_TYPE", 51, 54], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["RSV", "SPECIES", 139, 142], ["type I IFN production", "PROBLEM", 10, 31], ["DCs", "TEST", 51, 54], ["wild", "TEST", 60, 64], ["TLR1", "TEST", 74, 78], ["RSV infection", "PROBLEM", 139, 152], ["TLR1", "ANATOMY", 74, 78], ["RSV infection", "OBSERVATION", 139, 152]]], ["Finally, alveolar macrophages are the primary source of type I IFN in RSV-infected mice, and TLRs do not play a crucial role in this response [4, 12] .Induction of type I and III IFN upon RSV infectionIn contrast, retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLRs) are important for the induction of type I and possibly type III IFNs upon recognition of RSV (Fig 1) .", [["alveolar macrophages", "ANATOMY", 9, 29], ["RSV-infected", "DISEASE", 70, 82], ["retinoic-acid", "CHEMICAL", 214, 227], ["retinoic-acid", "CHEMICAL", 214, 227], ["alveolar macrophages", "CELL", 9, 29], ["type I IFN", "GENE_OR_GENE_PRODUCT", 56, 66], ["RSV", "ORGANISM", 70, 73], ["mice", "ORGANISM", 83, 87], ["TLRs", "GENE_OR_GENE_PRODUCT", 93, 97], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 164, 182], ["RSV", "ORGANISM", 188, 191], ["retinoic-acid-inducible gene-I", "GENE_OR_GENE_PRODUCT", 214, 244], ["RIG-I)-like receptors", "GENE_OR_GENE_PRODUCT", 246, 267], ["RLRs", "GENE_OR_GENE_PRODUCT", 269, 273], ["type I", "GENE_OR_GENE_PRODUCT", 310, 316], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 330, 343], ["RSV", "ORGANISM", 364, 367], ["alveolar macrophages", "CELL_TYPE", 9, 29], ["type I IFN", "PROTEIN", 56, 66], ["TLRs", "PROTEIN", 93, 97], ["type I and III IFN", "PROTEIN", 164, 182], ["retinoic-acid-inducible gene-I (RIG-I)-like receptors", "PROTEIN", 214, 267], ["RLRs", "DNA", 269, 273], ["type I and possibly type III IFNs", "PROTEIN", 310, 343], ["mice", "SPECIES", 83, 87], ["RSV", "SPECIES", 70, 73], ["mice", "SPECIES", 83, 87], ["RSV", "SPECIES", 188, 191], ["RSV", "SPECIES", 364, 367], ["alveolar macrophages", "PROBLEM", 9, 29], ["type I IFN", "PROBLEM", 56, 66], ["RSV", "PROBLEM", 70, 73], ["type I and III IFN", "PROBLEM", 164, 182], ["RSV infectionIn contrast", "TEST", 188, 212], ["retinoic", "TEST", 214, 222], ["type I", "PROBLEM", 310, 316], ["type III IFNs", "PROBLEM", 330, 343], ["RSV (Fig", "TREATMENT", 364, 372], ["alveolar macrophages", "OBSERVATION", 9, 29]]], ["Type I IFN expression is strongly hampered in the absence of mitochondrial antiviral-signaling protein (MAVS), the adaptor protein for RIG-I and melanoma differentiation-associated protein 5 (MDA5) [12, 13] .", [["mitochondrial", "ANATOMY", 61, 74], ["melanoma", "ANATOMY", 145, 153], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 0, 10], ["mitochondrial", "CELLULAR_COMPONENT", 61, 74], ["antiviral-signaling protein", "GENE_OR_GENE_PRODUCT", 75, 102], ["MAVS", "GENE_OR_GENE_PRODUCT", 104, 108], ["RIG-I", "GENE_OR_GENE_PRODUCT", 135, 140], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 145, 190], ["MDA5", "GENE_OR_GENE_PRODUCT", 192, 196], ["Type I IFN", "PROTEIN", 0, 10], ["mitochondrial antiviral-signaling protein", "PROTEIN", 61, 102], ["MAVS", "PROTEIN", 104, 108], ["adaptor protein", "PROTEIN", 115, 130], ["RIG-I", "PROTEIN", 135, 140], ["melanoma differentiation-associated protein 5", "PROTEIN", 145, 190], ["MDA5", "PROTEIN", 192, 196], ["Type I IFN expression", "PROBLEM", 0, 21], ["the adaptor protein", "TEST", 111, 130], ["RIG", "TEST", 135, 138], ["melanoma differentiation", "PROBLEM", 145, 169], ["protein", "TEST", 181, 188], ["melanoma", "OBSERVATION", 145, 153]]], ["Early on, gene expression ablation studies revealed that RIG-I is the most important RLR to detect RSV, which is supported by the observation that RSV mRNA could be coimmunoprecipitated with RIG-I but not with MDA5 [14-17].", [["RIG-I", "GENE_OR_GENE_PRODUCT", 57, 62], ["RLR", "GENE_OR_GENE_PRODUCT", 85, 88], ["RSV", "ORGANISM", 99, 102], ["RSV", "ORGANISM", 147, 150], ["RIG-I", "GENE_OR_GENE_PRODUCT", 191, 196], ["MDA5", "GENE_OR_GENE_PRODUCT", 210, 214], ["RIG-I", "PROTEIN", 57, 62], ["RLR", "PROTEIN", 85, 88], ["RSV mRNA", "RNA", 147, 155], ["RIG-I", "PROTEIN", 191, 196], ["MDA5", "PROTEIN", 210, 214], ["RSV", "SPECIES", 99, 102], ["RSV", "SPECIES", 147, 150], ["gene expression ablation studies", "TEST", 10, 42], ["RSV", "PROBLEM", 99, 102], ["RSV mRNA", "PROBLEM", 147, 155], ["MDA5", "TEST", 210, 214], ["RSV", "OBSERVATION", 99, 102]]], ["Later, however, both RIG-I and MDA5 were found to colocalize with RSV genomic RNA and the N protein [18] .", [["RIG-I", "GENE_OR_GENE_PRODUCT", 21, 26], ["MDA5", "GENE_OR_GENE_PRODUCT", 31, 35], ["RSV", "ORGANISM", 66, 69], ["RIG", "PROTEIN", 21, 24], ["MDA5", "PROTEIN", 31, 35], ["RSV genomic RNA", "RNA", 66, 81], ["N protein", "PROTEIN", 90, 99], ["RSV", "SPECIES", 66, 69], ["RSV genomic RNA", "PROBLEM", 66, 81], ["the N protein", "TEST", 86, 99]]], ["Interestingly, whereas RIG-I partially localizes to RSV-induced inclusion bodies, MDA5 and MAVS were found nearly exclusively in these inclusion bodies, thereby dramatically blunting IFN-\u03b2 induction.Induction of type I and III IFN upon RSV infectionA third class of PRRs, the nucleotide-binding oligomerization domain-like receptors (NLRs), is also important for the recognition of RSV.", [["bodies", "ANATOMY", 145, 151], ["nucleotide", "CHEMICAL", 276, 286], ["nucleotide", "CHEMICAL", 276, 286], ["RIG-I", "GENE_OR_GENE_PRODUCT", 23, 28], ["RSV", "ORGANISM", 52, 55], ["MDA5", "GENE_OR_GENE_PRODUCT", 82, 86], ["MAVS", "GENE_OR_GENE_PRODUCT", 91, 95], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 183, 188], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 212, 230], ["RSV", "ORGANISM", 236, 239], ["PRRs", "GENE_OR_GENE_PRODUCT", 266, 270], ["nucleotide-binding oligomerization domain-like receptors", "GENE_OR_GENE_PRODUCT", 276, 332], ["NLRs", "GENE_OR_GENE_PRODUCT", 334, 338], ["RSV", "ORGANISM", 382, 385], ["RIG-I", "PROTEIN", 23, 28], ["MDA5", "PROTEIN", 82, 86], ["MAVS", "PROTEIN", 91, 95], ["IFN", "PROTEIN", 183, 186], ["-\u03b2", "PROTEIN", 186, 188], ["type I and III IFN", "PROTEIN", 212, 230], ["PRRs", "PROTEIN", 266, 270], ["nucleotide-binding oligomerization domain-like receptors", "PROTEIN", 276, 332], ["NLRs", "PROTEIN", 334, 338], ["RSV", "SPECIES", 52, 55], ["RSV", "SPECIES", 236, 239], ["RSV", "SPECIES", 382, 385], ["RSV", "PROBLEM", 52, 55], ["MDA5", "TREATMENT", 82, 86], ["MAVS", "TREATMENT", 91, 95], ["dramatically blunting IFN", "PROBLEM", 161, 186], ["type I and III IFN", "PROBLEM", 212, 230], ["RSV", "PROBLEM", 236, 239], ["the nucleotide-binding oligomerization domain", "PROBLEM", 272, 317], ["RSV", "PROBLEM", 382, 385], ["RSV", "OBSERVATION", 52, 55], ["inclusion bodies", "OBSERVATION", 64, 80], ["dramatically", "OBSERVATION_MODIFIER", 161, 173], ["blunting", "OBSERVATION_MODIFIER", 174, 182], ["IFN", "OBSERVATION_MODIFIER", 183, 186], ["RSV", "OBSERVATION", 382, 385]]], ["Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) can be activated by intact genomic single-stranded RNA (ssRNA) and is involved in the induction of IFN-\u03b2 in mice in a MAVS-dependent way (Fig 1) [19].Induction of type I and III IFN upon RSV infectionCytoplasmic DNA sensors (CDSs), such as Z-DNA binding protein 1 (ZBP1) and cyclic GMP-AMP synthase (cGAS), are well known to induce innate immune responses upon recognition of pathogen-derived double-stranded DNA (dsDNA) or even RNA [20] [21] [22] .", [["infection", "DISEASE", 261, 270], ["GMP", "CHEMICAL", 352, 355], ["AMP", "CHEMICAL", 356, 359], ["Nucleotide", "CHEMICAL", 0, 10], ["cyclic GMP-AMP", "CHEMICAL", 345, 359], ["Nucleotide-binding oligomerization domain-containing protein 2", "GENE_OR_GENE_PRODUCT", 0, 62], ["NOD2", "GENE_OR_GENE_PRODUCT", 64, 68], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 169, 174], ["mice", "ORGANISM", 178, 182], ["MAVS", "GENE_OR_GENE_PRODUCT", 188, 192], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 233, 251], ["RSV", "ORGANISM", 257, 260], ["DNA", "CELLULAR_COMPONENT", 282, 285], ["Z-DNA binding protein 1", "GENE_OR_GENE_PRODUCT", 310, 333], ["ZBP1", "GENE_OR_GENE_PRODUCT", 335, 339], ["cyclic GMP-AMP synthase", "GENE_OR_GENE_PRODUCT", 345, 368], ["cGAS", "GENE_OR_GENE_PRODUCT", 370, 374], ["DNA", "CELLULAR_COMPONENT", 479, 482], ["dsDNA", "CELLULAR_COMPONENT", 484, 489], ["Nucleotide-binding oligomerization domain-containing protein 2", "PROTEIN", 0, 62], ["NOD2", "PROTEIN", 64, 68], ["genomic single-stranded RNA", "RNA", 97, 124], ["IFN", "PROTEIN", 169, 172], ["\u03b2", "PROTEIN", 173, 174], ["MAVS", "PROTEIN", 188, 192], ["type I and III IFN", "PROTEIN", 233, 251], ["CDSs", "DNA", 295, 299], ["Z-DNA binding protein 1", "PROTEIN", 310, 333], ["ZBP1", "PROTEIN", 335, 339], ["cyclic GMP-AMP synthase", "PROTEIN", 345, 368], ["cGAS", "PROTEIN", 370, 374], ["double-stranded DNA", "DNA", 463, 482], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["RSV", "SPECIES", 257, 260], ["Nucleotide-binding oligomerization domain-containing protein", "TREATMENT", 0, 60], ["IFN", "TREATMENT", 169, 172], ["type I and III IFN", "PROBLEM", 233, 251], ["RSV infection", "PROBLEM", 257, 270], ["Cytoplasmic DNA sensors (CDSs)", "PROBLEM", 270, 300], ["Z-DNA binding protein", "TEST", 310, 331], ["ZBP1", "TEST", 335, 339], ["cyclic GMP-AMP synthase (cGAS", "TEST", 345, 374], ["pathogen", "TEST", 446, 454], ["double-stranded DNA (dsDNA)", "TREATMENT", 463, 490], ["stranded RNA", "OBSERVATION_MODIFIER", 112, 124]]], ["A contribution of CDSs in innate sensing of RSV replication has not yet been reported.How RSV NS protein 1 and 2 overcome innate responsesIn contrast to other respiratory viruses, i.e., influenza virus and human respirovirus 1 (formerly named human parainfluenza virus 1), nasal washes from RSV-infected infants hardly Firstly, TLR-2, -3, -4, -6, and -7 (marked in green) are involved in the production of cytokines and chemokines upon RSV infection.", [["nasal", "ANATOMY", 273, 278], ["respiratory viruses", "DISEASE", 159, 178], ["influenza virus", "DISEASE", 186, 201], ["RSV-infected", "DISEASE", 291, 303], ["RSV infection", "DISEASE", 436, 449], ["RSV", "ORGANISM", 44, 47], ["RSV NS protein 1", "GENE_OR_GENE_PRODUCT", 90, 106], ["2", "GENE_OR_GENE_PRODUCT", 111, 112], ["influenza virus", "ORGANISM", 186, 201], ["human respirovirus 1", "ORGANISM", 206, 226], ["human", "ORGANISM", 243, 248], ["parainfluenza virus 1", "ORGANISM", 249, 270], ["nasal", "ORGANISM_SUBDIVISION", 273, 278], ["RSV", "ORGANISM", 291, 294], ["infants", "ORGANISM", 304, 311], ["TLR-2", "GENE_OR_GENE_PRODUCT", 328, 333], ["-3", "GENE_OR_GENE_PRODUCT", 335, 337], ["-4", "GENE_OR_GENE_PRODUCT", 339, 341], ["-6", "GENE_OR_GENE_PRODUCT", 343, 345], ["-7", "GENE_OR_GENE_PRODUCT", 351, 353], ["RSV", "ORGANISM", 436, 439], ["CDSs", "DNA", 18, 22], ["RSV NS protein 1 and 2", "PROTEIN", 90, 112], ["TLR", "PROTEIN", 328, 331], ["cytokines", "PROTEIN", 406, 415], ["chemokines", "PROTEIN", 420, 430], ["influenza virus", "SPECIES", 186, 201], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 243, 248], ["parainfluenza virus 1", "SPECIES", 249, 270], ["RSV", "SPECIES", 291, 294], ["infants", "SPECIES", 304, 311], ["RSV", "SPECIES", 44, 47], ["RSV", "SPECIES", 90, 93], ["influenza virus", "SPECIES", 186, 201], ["human respirovirus 1", "SPECIES", 206, 226], ["human parainfluenza virus 1", "SPECIES", 243, 270], ["RSV", "SPECIES", 291, 294], ["RSV", "SPECIES", 436, 439], ["CDSs", "TREATMENT", 18, 22], ["RSV replication", "TREATMENT", 44, 59], ["RSV NS protein", "TREATMENT", 90, 104], ["other respiratory viruses", "PROBLEM", 153, 178], ["influenza virus", "PROBLEM", 186, 201], ["human respirovirus", "TREATMENT", 206, 224], ["human parainfluenza virus", "TREATMENT", 243, 268], ["nasal washes", "TREATMENT", 273, 285], ["RSV", "TEST", 291, 294], ["TLR", "TEST", 328, 331], ["cytokines", "TREATMENT", 406, 415], ["RSV infection", "PROBLEM", 436, 449], ["RSV replication", "OBSERVATION", 44, 59], ["respiratory viruses", "ANATOMY", 159, 178], ["nasal", "ANATOMY", 273, 278], ["infected", "OBSERVATION", 295, 303], ["RSV infection", "OBSERVATION", 436, 449]]], ["Secondly, RIG-I and possibly MDA5 (RLRs, marked in red), are important in the induction of type I IFNs.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["MDA5", "GENE_OR_GENE_PRODUCT", 29, 33], ["RLRs", "GENE_OR_GENE_PRODUCT", 35, 39], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 91, 102], ["RIG-I", "PROTEIN", 10, 15], ["MDA5", "PROTEIN", 29, 33], ["RLRs", "PROTEIN", 35, 39], ["type I IFNs", "PROTEIN", 91, 102], ["MDA5", "PROBLEM", 29, 33], ["possibly", "UNCERTAINTY", 20, 28], ["MDA5", "OBSERVATION", 29, 33], ["marked", "OBSERVATION_MODIFIER", 41, 47]]], ["Thirdly, NOD2 (marked in dark blue) also induces type I IFNs upon RSV infection.", [["RSV infection", "DISEASE", 66, 79], ["NOD2", "GENE_OR_GENE_PRODUCT", 9, 13], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 49, 60], ["RSV", "ORGANISM", 66, 69], ["NOD2", "PROTEIN", 9, 13], ["type I IFNs", "PROTEIN", 49, 60], ["RSV", "SPECIES", 66, 69], ["dark blue", "PROBLEM", 25, 34], ["type I IFNs", "PROBLEM", 49, 60], ["RSV infection", "PROBLEM", 66, 79], ["NOD2", "OBSERVATION", 9, 13], ["marked", "OBSERVATION_MODIFIER", 15, 21], ["dark blue", "OBSERVATION_MODIFIER", 25, 34], ["type I", "OBSERVATION_MODIFIER", 49, 55], ["IFNs", "OBSERVATION_MODIFIER", 56, 60], ["RSV infection", "OBSERVATION", 66, 79]]], ["Currently, there is no evidence for a role of the CDSs (marked in purple), which signal through the ER-associated STING protein, as PRRs during RSV infection.", [["RSV infection", "DISEASE", 144, 157], ["ER", "GENE_OR_GENE_PRODUCT", 100, 102], ["STING", "GENE_OR_GENE_PRODUCT", 114, 119], ["PRRs", "GENE_OR_GENE_PRODUCT", 132, 136], ["RSV", "ORGANISM", 144, 147], ["CDSs", "DNA", 50, 54], ["ER", "PROTEIN", 100, 102], ["STING protein", "PROTEIN", 114, 127], ["PRRs", "PROTEIN", 132, 136], ["RSV", "SPECIES", 144, 147], ["the CDSs", "PROBLEM", 46, 54], ["STING protein", "PROBLEM", 114, 127], ["RSV infection", "PROBLEM", 144, 157], ["no evidence for", "UNCERTAINTY", 20, 35], ["marked", "OBSERVATION_MODIFIER", 56, 62], ["RSV infection", "OBSERVATION", 144, 157]]], ["Activation of the RLRs or NOD2 induces their association with the mitochondrial-associated MAVS, which recruits the adaptor proteins TRAF3 or TRAF6.", [["mitochondrial", "ANATOMY", 66, 79], ["RLRs", "GENE_OR_GENE_PRODUCT", 18, 22], ["NOD2", "GENE_OR_GENE_PRODUCT", 26, 30], ["mitochondrial", "CELLULAR_COMPONENT", 66, 79], ["MAVS", "GENE_OR_GENE_PRODUCT", 91, 95], ["TRAF3", "GENE_OR_GENE_PRODUCT", 133, 138], ["TRAF6", "GENE_OR_GENE_PRODUCT", 142, 147], ["RLRs", "PROTEIN", 18, 22], ["NOD2", "PROTEIN", 26, 30], ["MAVS", "PROTEIN", 91, 95], ["adaptor proteins", "PROTEIN", 116, 132], ["TRAF3", "PROTEIN", 133, 138], ["TRAF6", "PROTEIN", 142, 147], ["the mitochondrial-associated MAVS", "PROBLEM", 62, 95], ["the adaptor proteins TRAF3", "TREATMENT", 112, 138], ["TRAF6", "TREATMENT", 142, 147]]], ["Via the TRAF3 adaptor, the kinases IKK\u03b5 and TBK1 are subsequently activated, which phosphorylate and activate the transcription factors IRF3 and IRF7.", [["TRAF3", "GENE_OR_GENE_PRODUCT", 8, 13], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 35, 39], ["TBK1", "GENE_OR_GENE_PRODUCT", 44, 48], ["IRF3", "GENE_OR_GENE_PRODUCT", 136, 140], ["IRF7", "GENE_OR_GENE_PRODUCT", 145, 149], ["TRAF3 adaptor", "PROTEIN", 8, 21], ["kinases", "PROTEIN", 27, 34], ["IKK\u03b5", "PROTEIN", 35, 39], ["TBK1", "PROTEIN", 44, 48], ["transcription factors", "PROTEIN", 114, 135], ["IRF3", "PROTEIN", 136, 140], ["IRF7", "PROTEIN", 145, 149], ["the TRAF3 adaptor", "TREATMENT", 4, 21], ["the kinases IKK", "TEST", 23, 38], ["TBK1", "PROBLEM", 44, 48], ["phosphorylate", "TREATMENT", 83, 96], ["IRF7", "TEST", 145, 149]]], ["Via the TRAF6 adaptor, 3 kinases are activated, i.e., the IKK kinase complex, JNK, and p38 MAPK, which phosphorylate and activate multiple transcription factors such as NF-\u03baB, C-Jun, and ATF2, respectively.", [["TRAF6", "GENE_OR_GENE_PRODUCT", 8, 13], ["3", "GENE_OR_GENE_PRODUCT", 23, 24], ["IKK", "GENE_OR_GENE_PRODUCT", 58, 61], ["JNK", "GENE_OR_GENE_PRODUCT", 78, 81], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 87, 95], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 169, 174], ["C-Jun", "GENE_OR_GENE_PRODUCT", 176, 181], ["ATF2", "GENE_OR_GENE_PRODUCT", 187, 191], ["TRAF6 adaptor, 3 kinases", "PROTEIN", 8, 32], ["IKK kinase complex", "PROTEIN", 58, 76], ["JNK", "PROTEIN", 78, 81], ["p38 MAPK", "PROTEIN", 87, 95], ["transcription factors", "PROTEIN", 139, 160], ["NF-\u03baB", "PROTEIN", 169, 174], ["Jun", "PROTEIN", 178, 181], ["ATF2", "PROTEIN", 187, 191], ["the TRAF6 adaptor", "TREATMENT", 4, 21], ["the IKK kinase complex", "TEST", 54, 76], ["JNK", "TEST", 78, 81], ["p38 MAPK", "TEST", 87, 95], ["phosphorylate", "TEST", 103, 116], ["activate multiple transcription factors", "PROBLEM", 121, 160], ["NF", "TEST", 169, 171], ["ATF2", "TEST", 187, 191]]], ["Activation of TLRs leads to the recruitment of adaptor proteins, e.g., MyD88, TICAM1, TIRAP, and TRAM.", [["TLRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["MyD88", "GENE_OR_GENE_PRODUCT", 71, 76], ["TICAM1", "GENE_OR_GENE_PRODUCT", 78, 84], ["TIRAP", "GENE_OR_GENE_PRODUCT", 86, 91], ["TRAM", "GENE_OR_GENE_PRODUCT", 97, 101], ["TLRs", "PROTEIN", 14, 18], ["adaptor proteins", "PROTEIN", 47, 63], ["MyD88", "PROTEIN", 71, 76], ["TICAM1", "PROTEIN", 78, 84], ["TIRAP", "PROTEIN", 86, 91], ["TRAM", "PROTEIN", 97, 101], ["adaptor proteins", "TREATMENT", 47, 63], ["TIRAP", "TREATMENT", 86, 91], ["TRAM", "TREATMENT", 97, 101]]], ["These adaptors can signal via TRAF3 or TRAF6.", [["TRAF3", "GENE_OR_GENE_PRODUCT", 30, 35], ["TRAF6", "GENE_OR_GENE_PRODUCT", 39, 44], ["TRAF3", "PROTEIN", 30, 35], ["TRAF6", "PROTEIN", 39, 44], ["TRAF6", "TREATMENT", 39, 44]]], ["The transcription factors activated by PRR signaling ultimately induce expression of cytokines, chemokines, and IFNs.", [["PRR", "GENE_OR_GENE_PRODUCT", 39, 42], ["IFNs", "GENE_OR_GENE_PRODUCT", 112, 116], ["transcription factors", "PROTEIN", 4, 25], ["PRR", "PROTEIN", 39, 42], ["cytokines", "PROTEIN", 85, 94], ["chemokines", "PROTEIN", 96, 106], ["IFNs", "PROTEIN", 112, 116], ["The transcription factors", "PROBLEM", 0, 25], ["cytokines", "PROBLEM", 85, 94], ["chemokines", "TEST", 96, 106], ["IFNs", "TREATMENT", 112, 116]]], ["Above each PRR, the confirmed or likely RSV-derived PAMP is depicted.", [["RSV", "ORGANISM", 40, 43], ["PAMP", "GENE_OR_GENE_PRODUCT", 52, 56], ["PRR", "PROTEIN", 11, 14], ["PAMP", "PROTEIN", 52, 56], ["RSV", "SPECIES", 40, 43], ["RSV", "PROBLEM", 40, 43], ["likely", "UNCERTAINTY", 33, 39], ["RSV", "OBSERVATION", 40, 43]]], ["ATF2, activating transcription factor 2; CDS, cytoplasmic DNA sensor; ER, endoplasmic reticulum; IFN, interferon; IKK, inhibitor of nuclear factor kappa-B kinase; IKK\u03b5, inhibitor of nuclear factor kappa-B kinase subunit epsilon; IRF3, interferon regulatory factor 3; IRF7, interferon regulatory factor 7; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MAVS, mitochondrial antiviral-signaling protein; MDA5, melanoma differentiation-associated protein 5; MyD88, myeloid differentiation primary response protein MyD88; NF-kB, nuclear factor-kappa B; NOD2, nucleotide-binding oligomerization domain-containing protein 2; PAMP, pathogenassociated molecular pattern; PRR, pattern recognition receptor; RIG, retinoic-acid-inducible gene-I; RLR, RIG-I-like receptor; RSV, respiratory syncytial virus; STING, stimulator of interferon protein; TBK1, tank binding kinase 1; TICAM1, toll/interleukin-1 receptor domain-containing adapter molecule 1; TIRAP, toll/ interleukin-1 receptor domain-containing adapter protein; TLR, toll-like receptor; TRAF3, tumor necrosis factor receptor-associated factor 3; TRAF6, tumor necrosis factor receptor-associated factor 6; TRAM, toll-like receptor adaptor molecule.How RSV NS protein 1 and 2 overcome innate responseshttps://doi.org/10.1371/journal.ppat.1007984.g001 contain IFN-\u03b1 and -\u03b2 [23-26].", [["cytoplasmic", "ANATOMY", 46, 57], ["endoplasmic reticulum", "ANATOMY", 74, 95], ["mitochondrial", "ANATOMY", 381, 394], ["nucleotide", "CHEMICAL", 577, 587], ["necrosis", "DISEASE", 1070, 1078], ["necrosis", "DISEASE", 1129, 1137], ["N", "CHEMICAL", 316, 317], ["nucleotide", "CHEMICAL", 577, 587], ["ATF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["activating transcription factor 2", "GENE_OR_GENE_PRODUCT", 6, 39], ["CDS", "GENE_OR_GENE_PRODUCT", 41, 44], ["cytoplasmic", "ORGANISM_SUBSTANCE", 46, 57], ["DNA", "CELLULAR_COMPONENT", 58, 61], ["ER", "GENE_OR_GENE_PRODUCT", 70, 72], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 74, 95], ["IFN", "GENE_OR_GENE_PRODUCT", 97, 100], ["interferon", "GENE_OR_GENE_PRODUCT", 102, 112], ["IKK", "GENE_OR_GENE_PRODUCT", 114, 117], ["nuclear factor kappa-B kinase", "GENE_OR_GENE_PRODUCT", 132, 161], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 163, 167], ["kappa-B kinase subunit epsilon", "GENE_OR_GENE_PRODUCT", 197, 227], ["IRF3", "GENE_OR_GENE_PRODUCT", 229, 233], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 235, 265], ["IRF7", "GENE_OR_GENE_PRODUCT", 267, 271], ["interferon regulatory factor 7", "GENE_OR_GENE_PRODUCT", 273, 303], ["JNK", "GENE_OR_GENE_PRODUCT", 305, 308], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 310, 333], ["MAPK", "GENE_OR_GENE_PRODUCT", 335, 339], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 341, 373], ["MAVS", "GENE_OR_GENE_PRODUCT", 375, 379], ["mitochondrial", "CELLULAR_COMPONENT", 381, 394], ["MDA5", "GENE_OR_GENE_PRODUCT", 424, 428], ["melanoma differentiation-associated protein 5", "GENE_OR_GENE_PRODUCT", 430, 475], ["MyD88", "GENE_OR_GENE_PRODUCT", 477, 482], ["myeloid differentiation primary response protein MyD88", "GENE_OR_GENE_PRODUCT", 484, 538], ["NF-kB", "GENE_OR_GENE_PRODUCT", 540, 545], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 547, 569], ["NOD2", "GENE_OR_GENE_PRODUCT", 571, 575], ["nucleotide-binding oligomerization domain-containing protein 2", "GENE_OR_GENE_PRODUCT", 577, 639], ["PAMP", "GENE_OR_GENE_PRODUCT", 641, 645], ["PRR", "GENE_OR_GENE_PRODUCT", 685, 688], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 690, 718], ["RIG", "GENE_OR_GENE_PRODUCT", 720, 723], ["retinoic-acid-inducible gene-I", "GENE_OR_GENE_PRODUCT", 725, 755], ["RLR", "GENE_OR_GENE_PRODUCT", 757, 760], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 762, 781], ["RSV", "ORGANISM", 783, 786], ["respiratory syncytial virus", "ORGANISM", 788, 815], ["STING", "GENE_OR_GENE_PRODUCT", 817, 822], ["TBK1, tank binding kinase 1", "GENE_OR_GENE_PRODUCT", 858, 885], ["TICAM1", "GENE_OR_GENE_PRODUCT", 887, 893], ["interleukin-1 receptor domain-containing adapter molecule 1", "GENE_OR_GENE_PRODUCT", 900, 959], ["TIRAP", "GENE_OR_GENE_PRODUCT", 961, 966], ["interleukin-1 receptor domain-containing adapter protein", "GENE_OR_GENE_PRODUCT", 974, 1030], ["TLR", "GENE_OR_GENE_PRODUCT", 1032, 1035], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 1037, 1055], ["TRAF3", "GENE_OR_GENE_PRODUCT", 1057, 1062], ["tumor necrosis factor receptor-associated factor 3", "GENE_OR_GENE_PRODUCT", 1064, 1114], ["TRAF6", "GENE_OR_GENE_PRODUCT", 1116, 1121], ["tumor necrosis factor receptor-associated factor 6", "GENE_OR_GENE_PRODUCT", 1123, 1173], ["TRAM", "GENE_OR_GENE_PRODUCT", 1175, 1179], ["toll-like receptor adaptor molecule", "GENE_OR_GENE_PRODUCT", 1181, 1216], ["RSV NS protein 1", "GENE_OR_GENE_PRODUCT", 1221, 1237], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 1327, 1332], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 1337, 1339], ["ATF2", "PROTEIN", 0, 4], ["activating transcription factor 2", "PROTEIN", 6, 39], ["CDS", "PROTEIN", 41, 44], ["cytoplasmic DNA sensor", "PROTEIN", 46, 68], ["ER", "PROTEIN", 70, 72], ["IFN", "PROTEIN", 97, 100], ["interferon", "PROTEIN", 102, 112], ["IKK", "PROTEIN", 114, 117], ["nuclear factor kappa-B kinase", "PROTEIN", 132, 161], ["IKK\u03b5", "PROTEIN", 163, 167], ["inhibitor of nuclear factor kappa-B kinase subunit epsilon", "PROTEIN", 169, 227], ["IRF3", "PROTEIN", 229, 233], ["interferon regulatory factor 3", "PROTEIN", 235, 265], ["IRF7", "PROTEIN", 267, 271], ["interferon regulatory factor 7", "PROTEIN", 273, 303], ["JNK", "PROTEIN", 305, 308], ["c-Jun N-terminal kinase", "PROTEIN", 310, 333], ["MAPK", "PROTEIN", 335, 339], ["mitogen-activated protein kinase", "PROTEIN", 341, 373], ["MAVS", "PROTEIN", 375, 379], ["mitochondrial antiviral-signaling protein", "PROTEIN", 381, 422], ["MDA5", "PROTEIN", 424, 428], ["melanoma differentiation-associated protein 5", "PROTEIN", 430, 475], ["MyD88", "PROTEIN", 477, 482], ["myeloid differentiation primary response protein", "PROTEIN", 484, 532], ["MyD88", "PROTEIN", 533, 538], ["NF-kB", "PROTEIN", 540, 545], ["nuclear factor-kappa B", "PROTEIN", 547, 569], ["NOD2", "PROTEIN", 571, 575], ["nucleotide-binding oligomerization domain-containing protein 2", "PROTEIN", 577, 639], ["PAMP", "PROTEIN", 641, 645], ["pathogenassociated molecular pattern", "PROTEIN", 647, 683], ["PRR", "PROTEIN", 685, 688], ["pattern recognition receptor", "PROTEIN", 690, 718], ["RIG", "PROTEIN", 720, 723], ["retinoic-acid-inducible gene-I; RLR, RIG-I-like receptor", "PROTEIN", 725, 781], ["STING", "PROTEIN", 817, 822], ["interferon protein", "PROTEIN", 838, 856], ["TBK1", "PROTEIN", 858, 862], ["tank binding kinase 1", "PROTEIN", 864, 885], ["TICAM1", "PROTEIN", 887, 893], ["toll/interleukin-1 receptor domain-containing adapter molecule 1", "PROTEIN", 895, 959], ["TIRAP", "PROTEIN", 961, 966], ["toll/ interleukin-1 receptor domain-containing adapter protein", "PROTEIN", 968, 1030], ["TLR", "PROTEIN", 1032, 1035], ["toll-like receptor", "PROTEIN", 1037, 1055], ["TRAF3", "PROTEIN", 1057, 1062], ["tumor necrosis factor receptor-associated factor 3", "PROTEIN", 1064, 1114], ["TRAF6", "PROTEIN", 1116, 1121], ["tumor necrosis factor receptor-associated factor 6", "PROTEIN", 1123, 1173], ["TRAM", "PROTEIN", 1175, 1179], ["toll-like receptor adaptor molecule", "PROTEIN", 1181, 1216], ["RSV NS protein 1 and 2", "PROTEIN", 1221, 1243], ["IFN", "PROTEIN", 1327, 1330], ["respiratory syncytial virus", "SPECIES", 788, 815], ["RSV", "SPECIES", 783, 786], ["respiratory syncytial virus", "SPECIES", 788, 815], ["RSV", "SPECIES", 1221, 1224], ["activating transcription factor", "TEST", 6, 37], ["cytoplasmic DNA sensor", "TEST", 46, 68], ["IFN", "TREATMENT", 97, 100], ["interferon", "TREATMENT", 102, 112], ["IKK", "TEST", 114, 117], ["nuclear factor kappa", "TEST", 132, 152], ["kinase", "TEST", 155, 161], ["IKK\u03b5", "TEST", 163, 167], ["nuclear factor kappa", "TEST", 182, 202], ["B kinase subunit epsilon", "TREATMENT", 203, 227], ["IRF3, interferon regulatory factor", "TREATMENT", 229, 263], ["IRF7", "TEST", 267, 271], ["interferon regulatory factor", "TEST", 273, 301], ["JNK", "TEST", 305, 308], ["c", "TEST", 310, 311], ["Jun N", "TEST", 312, 317], ["terminal kinase", "TEST", 318, 333], ["MAPK", "TEST", 335, 339], ["mitogen", "TEST", 341, 348], ["activated protein kinase", "TEST", 349, 373], ["MAVS", "TEST", 375, 379], ["mitochondrial antiviral", "TEST", 381, 404], ["signaling protein", "PROBLEM", 405, 422], ["MDA5", "PROBLEM", 424, 428], ["melanoma differentiation", "TEST", 430, 454], ["protein", "TEST", 466, 473], ["MyD88", "TEST", 477, 482], ["myeloid differentiation", "TEST", 484, 507], ["MyD88", "TEST", 533, 538], ["NF", "TEST", 540, 542], ["nuclear factor", "TEST", 547, 561], ["NOD2", "PROBLEM", 571, 575], ["nucleotide-binding oligomerization domain", "TEST", 577, 618], ["protein", "TEST", 630, 637], ["PAMP", "TEST", 641, 645], ["pathogenassociated molecular pattern", "PROBLEM", 647, 683], ["PRR", "PROBLEM", 685, 688], ["receptor", "TEST", 710, 718], ["RIG", "TEST", 720, 723], ["retinoic-acid", "TEST", 725, 738], ["RLR", "TEST", 757, 760], ["RIG", "TEST", 762, 765], ["receptor", "PROBLEM", 773, 781], ["RSV", "PROBLEM", 783, 786], ["respiratory syncytial virus", "PROBLEM", 788, 815], ["interferon protein", "TREATMENT", 838, 856], ["TBK1", "TEST", 858, 862], ["tank binding kinase", "TEST", 864, 883], ["TICAM1", "TEST", 887, 893], ["toll/interleukin-1 receptor domain", "TREATMENT", 895, 929], ["adapter molecule", "TREATMENT", 941, 957], ["TIRAP", "TREATMENT", 961, 966], ["toll/ interleukin-1 receptor domain", "TREATMENT", 968, 1003], ["adapter protein", "TREATMENT", 1015, 1030], ["TLR", "TREATMENT", 1032, 1035], ["TRAF3", "PROBLEM", 1057, 1062], ["tumor necrosis factor receptor", "PROBLEM", 1064, 1094], ["associated factor 3", "PROBLEM", 1095, 1114], ["TRAF6", "PROBLEM", 1116, 1121], ["tumor necrosis factor receptor", "PROBLEM", 1123, 1153], ["TRAM", "TREATMENT", 1175, 1179], ["RSV NS protein", "TREATMENT", 1221, 1235], ["IFN", "TEST", 1327, 1330], ["endoplasmic reticulum", "ANATOMY", 74, 95], ["RLR", "ANATOMY", 757, 760], ["RSV", "ANATOMY", 783, 786], ["respiratory syncytial", "ANATOMY", 788, 809]]], ["Apparently, this virus has evolved ways to outsmart the canonical mammalian antiviral response.", [["this virus", "PROBLEM", 12, 22], ["canonical mammalian", "OBSERVATION", 56, 75], ["antiviral response", "OBSERVATION", 76, 94]]], ["Two unique viral proteins, NS1 and NS2, are responsible for the suppression of IFN induction and signaling.", [["NS1", "GENE_OR_GENE_PRODUCT", 27, 30], ["NS2", "GENE_OR_GENE_PRODUCT", 35, 38], ["IFN", "GENE_OR_GENE_PRODUCT", 79, 82], ["viral proteins", "PROTEIN", 11, 25], ["NS1", "PROTEIN", 27, 30], ["NS2", "PROTEIN", 35, 38], ["IFN", "PROTEIN", 79, 82], ["Two unique viral proteins", "TEST", 0, 25], ["NS1", "TEST", 27, 30], ["NS2", "PROBLEM", 35, 38], ["IFN induction", "TREATMENT", 79, 92], ["viral proteins", "OBSERVATION", 11, 25]]], ["Human and bovine RSV strains that lack NS1 and/or NS2 have been explored as live-attenuated vaccine candidates.", [["Human", "ORGANISM", 0, 5], ["bovine", "ORGANISM", 10, 16], ["RSV strains", "ORGANISM", 17, 28], ["NS1", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS2", "GENE_OR_GENE_PRODUCT", 50, 53], ["NS1", "PROTEIN", 39, 42], ["NS2", "PROTEIN", 50, 53], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 10, 16], ["Human", "SPECIES", 0, 5], ["RSV", "SPECIES", 17, 20], ["Human and bovine RSV strains", "TREATMENT", 0, 28], ["NS1", "TEST", 39, 42], ["NS2", "PROBLEM", 50, 53], ["bovine RSV", "OBSERVATION", 10, 20]]], ["Such viruses are strongly attenuated in in vivo RSV infection models (cotton rats, calves, and chimpanzees) as well as in human but, at least in calves and chimpanzees, retain their ability to induce antibody responses [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] .", [["RSV infection", "DISEASE", 48, 61], ["RSV", "ORGANISM", 48, 51], ["cotton rats", "ORGANISM", 70, 81], ["calves", "ORGANISM_SUBDIVISION", 83, 89], ["chimpanzees", "ORGANISM", 95, 106], ["human", "ORGANISM", 122, 127], ["calves", "ORGANISM", 145, 151], ["chimpanzees", "ORGANISM", 156, 167], ["[27] [28] [29] [30] [31] [32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 219, 268], ["rats", "SPECIES", 77, 81], ["calves", "SPECIES", 83, 89], ["human", "SPECIES", 122, 127], ["calves", "SPECIES", 145, 151], ["RSV", "SPECIES", 48, 51], ["cotton", "SPECIES", 70, 76], ["human", "SPECIES", 122, 127], ["Such viruses", "PROBLEM", 0, 12], ["antibody responses", "TEST", 200, 218], ["viruses", "OBSERVATION", 5, 12], ["attenuated", "OBSERVATION_MODIFIER", 26, 36], ["RSV infection", "OBSERVATION", 48, 61]]], ["Positioned 3 0 proximal on the negativestranded RNA genome, NS1 and NS2 are the most abundantly transcribed viral genes.", [["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS2", "GENE_OR_GENE_PRODUCT", 68, 71], ["Positioned 3 0 proximal", "DNA", 0, 23], ["negativestranded RNA genome", "DNA", 31, 58], ["NS1", "DNA", 60, 63], ["NS2", "DNA", 68, 71], ["abundantly transcribed viral genes", "DNA", 85, 119], ["NS1", "PROBLEM", 60, 63], ["NS2", "PROBLEM", 68, 71], ["proximal", "OBSERVATION_MODIFIER", 15, 23], ["RNA genome", "OBSERVATION", 48, 58], ["viral genes", "OBSERVATION", 108, 119]]], ["Recently, the crystal structure of NS1 was determined, revealing that this protein is composed of a \u03b2-sandwich flanked by 3 \u03b1-helices [37] .", [["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["NS1", "PROTEIN", 35, 38], ["the crystal structure of NS1", "PROBLEM", 10, 38], ["this protein", "PROBLEM", 70, 82], ["NS1", "OBSERVATION", 35, 38]]], ["Interestingly, the 3D structure of NS1 is very similar to the N-terminal domain of RSV M despite the complete absence of any primary sequence homology.How RSV NS protein 1 and 2 overcome innate responsesBoth NS1 and NS2 strongly reduce the induction of type I and III IFNs upon RSV infection [32, [37] [38] [39] [40] [41] .", [["RSV infection", "DISEASE", 278, 291], ["N", "CHEMICAL", 62, 63], ["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["RSV", "ORGANISM", 83, 86], ["RSV NS protein 1", "GENE_OR_GENE_PRODUCT", 155, 171], ["2", "GENE_OR_GENE_PRODUCT", 176, 177], ["NS1", "GENE_OR_GENE_PRODUCT", 208, 211], ["NS2", "GENE_OR_GENE_PRODUCT", 216, 219], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 253, 272], ["RSV", "ORGANISM", 278, 281], ["[37] [38] [39] [40", "SIMPLE_CHEMICAL", 297, 315], ["NS1", "PROTEIN", 35, 38], ["N-terminal domain", "PROTEIN", 62, 79], ["RSV M", "PROTEIN", 83, 88], ["RSV NS protein 1 and 2", "PROTEIN", 155, 177], ["NS1", "PROTEIN", 208, 211], ["NS2", "PROTEIN", 216, 219], ["type I and III IFNs", "PROTEIN", 253, 272], ["RSV", "SPECIES", 83, 86], ["RSV", "SPECIES", 155, 158], ["RSV", "SPECIES", 278, 281], ["NS1", "PROBLEM", 35, 38], ["RSV NS protein", "TREATMENT", 155, 169], ["NS1", "TEST", 208, 211], ["NS2", "TREATMENT", 216, 219], ["type I and III IFNs upon RSV infection", "PROBLEM", 253, 291], ["NS1", "OBSERVATION", 35, 38], ["very", "OBSERVATION_MODIFIER", 42, 46], ["similar", "OBSERVATION_MODIFIER", 47, 54], ["RSV", "OBSERVATION", 83, 86]]], ["Infection with recombinant viruses lacking NS1 or NS2, separately or combined, suggests that these proteins function individually and cooperatively to suppress IFN induction.", [["NS1", "GENE_OR_GENE_PRODUCT", 43, 46], ["NS2", "GENE_OR_GENE_PRODUCT", 50, 53], ["IFN", "GENE_OR_GENE_PRODUCT", 160, 163], ["NS1", "PROTEIN", 43, 46], ["NS2", "PROTEIN", 50, 53], ["IFN", "PROTEIN", 160, 163], ["Infection", "PROBLEM", 0, 9], ["recombinant viruses lacking NS1", "PROBLEM", 15, 46], ["NS2", "PROBLEM", 50, 53], ["IFN induction", "TREATMENT", 160, 173]]], ["They do so by targeting multiple proteins of the signaling cascade that starts with the recognition of PAMPs by PRRs and ends with the induction of IFN gene expression by several transcription factors.NS1 and NS2 interfere with RIG-IA widespread strategy of viruses to dampen innate immune responses is to counteract one of the early signaling steps in RLR-mediated IFN induction, i.e., the interaction of RIG-I or MDA5 with MAVS [42] [43] [44] [45] .", [["PAMPs", "GENE_OR_GENE_PRODUCT", 103, 108], ["PRRs", "GENE_OR_GENE_PRODUCT", 112, 116], ["IFN", "GENE_OR_GENE_PRODUCT", 148, 151], ["NS1", "GENE_OR_GENE_PRODUCT", 201, 204], ["NS2", "GENE_OR_GENE_PRODUCT", 209, 212], ["RIG-IA", "GENE_OR_GENE_PRODUCT", 228, 234], ["RLR", "GENE_OR_GENE_PRODUCT", 353, 356], ["IFN", "GENE_OR_GENE_PRODUCT", 366, 369], ["RIG-I", "GENE_OR_GENE_PRODUCT", 406, 411], ["MDA5", "GENE_OR_GENE_PRODUCT", 415, 419], ["MAVS [42] [43] [44] [45]", "SIMPLE_CHEMICAL", 425, 449], ["PAMPs", "PROTEIN", 103, 108], ["PRRs", "PROTEIN", 112, 116], ["IFN gene", "DNA", 148, 156], ["transcription factors", "PROTEIN", 179, 200], ["NS1", "PROTEIN", 201, 204], ["NS2", "PROTEIN", 209, 212], ["RIG", "PROTEIN", 228, 231], ["RLR", "PROTEIN", 353, 356], ["IFN", "PROTEIN", 366, 369], ["RIG-I", "PROTEIN", 406, 411], ["MDA5", "PROTEIN", 415, 419], ["MAVS", "PROTEIN", 425, 429], ["the signaling cascade", "PROBLEM", 45, 66], ["IFN gene expression", "TREATMENT", 148, 167], ["NS1", "PROBLEM", 201, 204], ["RIG", "TREATMENT", 228, 231], ["viruses", "PROBLEM", 258, 265], ["IFN induction", "TREATMENT", 366, 379], ["MAVS", "TEST", 425, 429], ["NS2", "OBSERVATION", 209, 212], ["viruses", "OBSERVATION", 258, 265]]], ["Likewise, RSV prevents the interaction of RIG-I with its adaptor MAVS.", [["RSV", "ORGANISM", 10, 13], ["RIG-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["MAVS", "GENE_OR_GENE_PRODUCT", 65, 69], ["RIG-I", "PROTEIN", 42, 47], ["adaptor MAVS", "PROTEIN", 57, 69], ["RSV", "SPECIES", 10, 13], ["RSV", "PROBLEM", 10, 13], ["its adaptor MAVS", "PROBLEM", 53, 69], ["RSV", "OBSERVATION", 10, 13]]], ["In RSV-infected HEp-2 cells and A549 cells overexpressing NS1, NS1 was shown to interact with MAVS (Fig 2) [46] .", [["HEp-2 cells", "ANATOMY", 16, 27], ["A549 cells", "ANATOMY", 32, 42], ["RSV", "ORGANISM", 3, 6], ["HEp-2 cells", "CELL", 16, 27], ["A549 cells", "CELL", 32, 42], ["NS1", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS1", "GENE_OR_GENE_PRODUCT", 63, 66], ["MAVS", "GENE_OR_GENE_PRODUCT", 94, 98], ["RSV-infected HEp-2 cells", "CELL_LINE", 3, 27], ["A549 cells", "CELL_LINE", 32, 42], ["NS1", "PROTEIN", 58, 61], ["NS1", "PROTEIN", 63, 66], ["MAVS", "PROTEIN", 94, 98], ["RSV", "SPECIES", 3, 6], ["RSV", "TEST", 3, 6], ["A549 cells", "PROBLEM", 32, 42], ["NS1", "TEST", 58, 61], ["NS1", "PROBLEM", 63, 66], ["MAVS", "TEST", 94, 98], ["RSV", "ANATOMY", 3, 6], ["infected", "OBSERVATION", 7, 15], ["HEp", "ANATOMY", 16, 19], ["A549 cells", "OBSERVATION", 32, 42]]], ["By binding to MAVS, NS1 could dose-dependently prevent the interaction between RIG-I and MAVS in A549 cells.", [["A549 cells", "ANATOMY", 97, 107], ["MAVS", "GENE_OR_GENE_PRODUCT", 14, 18], ["NS1", "GENE_OR_GENE_PRODUCT", 20, 23], ["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["MAVS", "GENE_OR_GENE_PRODUCT", 89, 93], ["A549 cells", "CELL", 97, 107], ["MAVS", "PROTEIN", 14, 18], ["NS1", "PROTEIN", 20, 23], ["RIG-I", "PROTEIN", 79, 84], ["MAVS", "PROTEIN", 89, 93], ["A549 cells", "CELL_LINE", 97, 107], ["NS1", "TREATMENT", 20, 23], ["MAVS in A549 cells", "PROBLEM", 89, 107], ["A549 cells", "OBSERVATION", 97, 107]]], ["Furthermore, Ban and colleagues demonstrated that ectopically expressed NS1 in HEK293T cells interacts with the PRY-SPRY domain of E3 ubiquitin/IFN-stimulated gene 15 (ISG15) ligase tripartite motif-containing protein 25 (TRIM25).", [["HEK293T cells", "ANATOMY", 79, 92], ["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["HEK293T cells", "CELL", 79, 92], ["PRY", "GENE_OR_GENE_PRODUCT", 112, 115], ["E3 ubiquitin/IFN-stimulated gene 15", "GENE_OR_GENE_PRODUCT", 131, 166], ["ISG15", "GENE_OR_GENE_PRODUCT", 168, 173], ["tripartite motif-containing protein 25", "GENE_OR_GENE_PRODUCT", 182, 220], ["TRIM25", "GENE_OR_GENE_PRODUCT", 222, 228], ["NS1", "PROTEIN", 72, 75], ["HEK293T cells", "CELL_LINE", 79, 92], ["PRY", "PROTEIN", 112, 115], ["SPRY domain", "PROTEIN", 116, 127], ["E3 ubiquitin/IFN-stimulated gene 15 (ISG15) ligase tripartite motif-containing protein 25", "PROTEIN", 131, 220], ["TRIM25", "PROTEIN", 222, 228], ["the PRY-SPRY domain", "TREATMENT", 108, 127], ["E3 ubiquitin/IFN", "TREATMENT", 131, 147], ["ISG15) ligase tripartite motif-containing protein", "TREATMENT", 168, 217]]], ["This domain is responsible for the interaction of TRIM25 with RIG-I [47] .", [["TRIM25", "GENE_OR_GENE_PRODUCT", 50, 56], ["RIG-I", "GENE_OR_GENE_PRODUCT", 62, 67], ["TRIM25", "PROTEIN", 50, 56], ["RIG", "PROTEIN", 62, 65]]], ["NS1 binding to the PRY-SPRY domain suppresses K63-linked polyubiquitination of RIG-I by TRIM25, which is essential for its downstream interaction with MAVS (Fig 2) .", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["PRY", "GENE_OR_GENE_PRODUCT", 19, 22], ["K63", "GENE_OR_GENE_PRODUCT", 46, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["TRIM25", "GENE_OR_GENE_PRODUCT", 88, 94], ["MAVS", "GENE_OR_GENE_PRODUCT", 151, 155], ["NS1", "PROTEIN", 0, 3], ["PRY", "PROTEIN", 19, 22], ["SPRY domain", "PROTEIN", 23, 34], ["K63", "PROTEIN", 46, 49], ["RIG-I", "PROTEIN", 79, 84], ["TRIM25", "PROTEIN", 88, 94], ["MAVS", "PROTEIN", 151, 155], ["K63", "TEST", 46, 49], ["MAVS (Fig", "TREATMENT", 151, 160], ["polyubiquitination", "OBSERVATION", 57, 75]]], ["Proteins of 2 other respiratory viruses also target the PRY-SPRY domain of TRIM25, which highlights the evolutionary importance of TRIM25 in mammalian antiviral defense.", [["PRY", "GENE_OR_GENE_PRODUCT", 56, 59], ["TRIM25", "GENE_OR_GENE_PRODUCT", 75, 81], ["TRIM25", "GENE_OR_GENE_PRODUCT", 131, 137], ["PRY", "PROTEIN", 56, 59], ["SPRY domain", "PROTEIN", 60, 71], ["TRIM25", "PROTEIN", 75, 81], ["TRIM25", "PROTEIN", 131, 137], ["Proteins of 2 other respiratory viruses", "PROBLEM", 0, 39], ["the PRY-SPRY domain of TRIM25", "TREATMENT", 52, 81], ["TRIM25", "TREATMENT", 131, 137], ["respiratory viruses", "OBSERVATION", 20, 39], ["antiviral defense", "OBSERVATION", 151, 168]]], ["By binding the PRY-SPRY domain of TRIM25, the NS1 protein of influenza A virus and the nucleocapsid protein of severe acute respiratory syndrome virus also counteract TRIM25-mediated RIG-I ubiquitination [48, 49] .", [["acute respiratory syndrome", "DISEASE", 118, 144], ["PRY", "GENE_OR_GENE_PRODUCT", 15, 18], ["TRIM25", "GENE_OR_GENE_PRODUCT", 34, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 46, 49], ["influenza A virus", "ORGANISM", 61, 78], ["severe acute respiratory syndrome virus", "ORGANISM", 111, 150], ["TRIM25", "GENE_OR_GENE_PRODUCT", 167, 173], ["RIG-I", "GENE_OR_GENE_PRODUCT", 183, 188], ["PRY", "PROTEIN", 15, 18], ["SPRY domain", "PROTEIN", 19, 30], ["TRIM25", "PROTEIN", 34, 40], ["NS1 protein", "PROTEIN", 46, 57], ["nucleocapsid protein", "PROTEIN", 87, 107], ["TRIM25", "PROTEIN", 167, 173], ["RIG", "PROTEIN", 183, 186], ["influenza A virus", "SPECIES", 61, 78], ["influenza A virus", "SPECIES", 61, 78], ["severe acute respiratory syndrome virus", "SPECIES", 111, 150], ["TRIM25", "TREATMENT", 34, 40], ["the NS1 protein", "TEST", 42, 57], ["influenza A virus", "PROBLEM", 61, 78], ["the nucleocapsid protein", "TEST", 83, 107], ["severe acute respiratory syndrome virus", "PROBLEM", 111, 150], ["TRIM25", "TEST", 167, 173], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome virus", "OBSERVATION", 124, 150]]], ["NS2 can interact with the N-terminal domain of RIG-I, both upon overexpression in HEK293T cells and during RSV infection in A549 cells (Fig 2) [50] .", [["HEK293T cells", "ANATOMY", 82, 95], ["A549 cells", "ANATOMY", 124, 134], ["RSV infection", "DISEASE", 107, 120], ["NS2", "GENE_OR_GENE_PRODUCT", 0, 3], ["RIG-I", "GENE_OR_GENE_PRODUCT", 47, 52], ["HEK293T cells", "CELL", 82, 95], ["RSV", "ORGANISM", 107, 110], ["A549 cells", "CELL", 124, 134], ["NS2", "PROTEIN", 0, 3], ["N-terminal domain", "PROTEIN", 26, 43], ["RIG-I", "PROTEIN", 47, 52], ["HEK293T cells", "CELL_LINE", 82, 95], ["A549 cells", "CELL_LINE", 124, 134], ["RSV", "SPECIES", 107, 110], ["NS2", "TREATMENT", 0, 3], ["HEK293T cells", "PROBLEM", 82, 95], ["RSV infection in A549 cells", "PROBLEM", 107, 134], ["HEK293T cells", "OBSERVATION", 82, 95], ["RSV", "ANATOMY", 107, 110], ["infection", "OBSERVATION", 111, 120], ["A549 cells", "OBSERVATION", 124, 134]]], ["As such, overexpressed NS2 disrupts the binding of RIG-I with MAVS; however, this has not yet been confirmed for endogenous NS2 expressed during an RSV infection.", [["RSV infection", "DISEASE", 148, 161], ["NS2", "GENE_OR_GENE_PRODUCT", 23, 26], ["RIG-I", "GENE_OR_GENE_PRODUCT", 51, 56], ["MAVS", "GENE_OR_GENE_PRODUCT", 62, 66], ["NS2", "GENE_OR_GENE_PRODUCT", 124, 127], ["RSV", "ORGANISM", 148, 151], ["NS2", "PROTEIN", 23, 26], ["RIG-I", "PROTEIN", 51, 56], ["MAVS", "PROTEIN", 62, 66], ["endogenous NS2", "PROTEIN", 113, 127], ["RSV", "SPECIES", 148, 151], ["MAVS", "PROBLEM", 62, 66], ["endogenous NS2", "PROBLEM", 113, 127], ["an RSV infection", "PROBLEM", 145, 161], ["NS2", "OBSERVATION", 23, 26], ["RSV", "OBSERVATION_MODIFIER", 148, 151], ["infection", "OBSERVATION", 152, 161]]], ["In addition to counteracting the interaction between RIG-I and MAVS, NS1 may also influence RIG-I expression, although the reported findings seem conflicting.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 53, 58], ["MAVS", "GENE_OR_GENE_PRODUCT", 63, 67], ["NS1", "GENE_OR_GENE_PRODUCT", 69, 72], ["RIG-I", "GENE_OR_GENE_PRODUCT", 92, 97], ["RIG-I", "PROTEIN", 53, 58], ["MAVS", "PROTEIN", 63, 67], ["NS1", "PROTEIN", 69, 72], ["RIG-I", "PROTEIN", 92, 97], ["MAVS", "PROBLEM", 63, 67], ["NS1", "PROBLEM", 69, 72]]], ["RIG-I expression in A549 cells is strongly reduced in the presence of RSV NS1, either expressed separately or in the context of an RSV infection [51] .", [["A549 cells", "ANATOMY", 20, 30], ["RSV infection", "DISEASE", 131, 144], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["A549 cells", "CELL", 20, 30], ["RSV", "ORGANISM", 70, 73], ["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["RSV", "ORGANISM", 131, 134], ["RIG", "PROTEIN", 0, 3], ["A549 cells", "CELL_LINE", 20, 30], ["RSV NS1", "PROTEIN", 70, 77], ["RSV", "SPECIES", 70, 73], ["RSV", "SPECIES", 131, 134], ["A549 cells", "PROBLEM", 20, 30], ["RSV NS1", "PROBLEM", 70, 77], ["an RSV infection", "PROBLEM", 128, 144], ["A549 cells", "OBSERVATION", 20, 30], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["RSV NS1", "OBSERVATION", 70, 77], ["RSV", "OBSERVATION_MODIFIER", 131, 134], ["infection", "OBSERVATION", 135, 144]]], ["Boyapalle and colleagues, however, reported that RIG-I expression in A549 cells is reduced following infection with an NS1-deficient RSV [46] .", [["A549 cells", "ANATOMY", 69, 79], ["infection", "DISEASE", 101, 110], ["RIG-I", "GENE_OR_GENE_PRODUCT", 49, 54], ["A549 cells", "CELL", 69, 79], ["NS1", "GENE_OR_GENE_PRODUCT", 119, 122], ["RSV", "ORGANISM", 133, 136], ["RIG", "PROTEIN", 49, 52], ["A549 cells", "CELL_LINE", 69, 79], ["NS1", "PROTEIN", 119, 122], ["RSV", "SPECIES", 133, 136], ["A549 cells", "PROBLEM", 69, 79], ["infection", "PROBLEM", 101, 110], ["an NS1-deficient RSV", "TREATMENT", 116, 136], ["A549 cells", "OBSERVATION", 69, 79], ["infection", "OBSERVATION", 101, 110]]], ["This is surprising, because RIG-I is itself an ISG.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 28, 33], ["ISG", "GENE_OR_GENE_PRODUCT", 47, 50], ["RIG-I", "PROTEIN", 28, 33], ["ISG", "OBSERVATION", 47, 50]]], ["Possibly, this discrepancy is caused by the different multiplicity of infection (MOI) used by these 2 groups (MOI 3 and 1, respectively).", [["infection", "DISEASE", 70, 79], ["infection", "PROBLEM", 70, 79], ["different", "OBSERVATION_MODIFIER", 44, 53], ["multiplicity", "OBSERVATION_MODIFIER", 54, 66], ["infection", "OBSERVATION", 70, 79]]], ["In contrast to RIG-I, MAVS appears to be resistant to NS1-and/or NS2-mediated down-regulation [51] .", [["RIG-I", "GENE_OR_GENE_PRODUCT", 15, 20], ["MAVS", "GENE_OR_GENE_PRODUCT", 22, 26], ["NS1", "GENE_OR_GENE_PRODUCT", 54, 57], ["NS2", "GENE_OR_GENE_PRODUCT", 65, 68], ["RIG", "PROTEIN", 15, 18], ["MAVS", "PROTEIN", 22, 26], ["NS1", "PROTEIN", 54, 57], ["NS2", "PROTEIN", 65, 68], ["MAVS", "PROBLEM", 22, 26], ["NS1", "TEST", 54, 57], ["NS2", "TEST", 65, 68], ["appears to be", "UNCERTAINTY", 27, 40], ["resistant", "OBSERVATION", 41, 50]]], ["All together, these results highlight that the interaction of RIG-I with MAVS is suppressed by both NS1 and NS2 and that RIG-I expression itself might be reduced by NS1.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 62, 67], ["MAVS", "GENE_OR_GENE_PRODUCT", 73, 77], ["NS1", "GENE_OR_GENE_PRODUCT", 100, 103], ["NS2", "GENE_OR_GENE_PRODUCT", 108, 111], ["RIG-I", "GENE_OR_GENE_PRODUCT", 121, 126], ["NS1", "GENE_OR_GENE_PRODUCT", 165, 168], ["RIG-I", "PROTEIN", 62, 67], ["MAVS", "PROTEIN", 73, 77], ["NS1", "PROTEIN", 100, 103], ["NS2", "PROTEIN", 108, 111], ["RIG", "PROTEIN", 121, 124], ["NS1", "PROTEIN", 165, 168], ["MAVS", "PROBLEM", 73, 77], ["NS2", "TREATMENT", 108, 111], ["NS1", "PROBLEM", 165, 168]]], ["Currently, it is not clear whether NS1 and/or NS2 can disturb the interaction of MDA5 or NOD2 with MAVS and whether they impact MDA5 or NOD2 expression levels.", [["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["NS2", "GENE_OR_GENE_PRODUCT", 46, 49], ["MDA5", "GENE_OR_GENE_PRODUCT", 81, 85], ["NOD2", "GENE_OR_GENE_PRODUCT", 89, 93], ["MAVS", "GENE_OR_GENE_PRODUCT", 99, 103], ["MDA5", "GENE_OR_GENE_PRODUCT", 128, 132], ["NOD2", "GENE_OR_GENE_PRODUCT", 136, 140], ["NS1", "PROTEIN", 35, 38], ["NS2", "PROTEIN", 46, 49], ["MDA5", "PROTEIN", 81, 85], ["NOD2", "PROTEIN", 89, 93], ["MAVS", "PROTEIN", 99, 103], ["MDA5", "PROTEIN", 128, 132], ["NOD2", "PROTEIN", 136, 140], ["NS1", "PROBLEM", 35, 38], ["NS2", "PROBLEM", 46, 49], ["MAVS", "TREATMENT", 99, 103], ["NOD2 expression levels", "TEST", 136, 158], ["not", "UNCERTAINTY", 17, 20], ["clear", "OBSERVATION", 21, 26]]], ["Type I and III IFN responses are inhibited by NS1 and NS2 at multiple levels, both during the induction of type I and III IFNs (left panel) and during IFN-induced signaling (right panel).", [["left panel", "ANATOMY", 128, 138], ["Type I and III IFN", "GENE_OR_GENE_PRODUCT", 0, 18], ["NS1", "GENE_OR_GENE_PRODUCT", 46, 49], ["NS2", "GENE_OR_GENE_PRODUCT", 54, 57], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 107, 126], ["IFN", "GENE_OR_GENE_PRODUCT", 151, 154], ["IFN", "PROTEIN", 15, 18], ["NS1", "PROTEIN", 46, 49], ["NS2", "PROTEIN", 54, 57], ["type I and III IFNs", "PROTEIN", 107, 126], ["IFN", "PROTEIN", 151, 154], ["Type I and III IFN responses", "PROBLEM", 0, 28], ["NS1 and NS2 at multiple levels", "PROBLEM", 46, 76], ["left panel", "TEST", 128, 138], ["IFN", "TEST", 151, 154], ["left", "ANATOMY_MODIFIER", 128, 132], ["right", "ANATOMY_MODIFIER", 174, 179]]], ["NS1 and NS2 can form a so-called \"NS degradasome\" complex that is stabilized by mitochondria via MAVS.", [["mitochondria", "ANATOMY", 80, 92], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["mitochondria", "CELLULAR_COMPONENT", 80, 92], ["MAVS", "GENE_OR_GENE_PRODUCT", 97, 101], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["NS degradasome\" complex", "PROTEIN", 34, 57], ["MAVS", "PROTEIN", 97, 101], ["NS1", "PROBLEM", 0, 3], ["NS2", "TREATMENT", 8, 11], ["a so-called \"NS degradasome\" complex", "TREATMENT", 21, 57], ["NS2", "OBSERVATION", 8, 11]]], ["The NSD complex is thought to contain HPs, including the proteasome \u03b12 subunit and other as yet unidentified proteins.", [["NSD complex", "GENE_OR_GENE_PRODUCT", 4, 15], ["HPs", "GENE_OR_GENE_PRODUCT", 38, 41], ["\u03b12", "GENE_OR_GENE_PRODUCT", 68, 70], ["NSD complex", "PROTEIN", 4, 15], ["HPs", "PROTEIN", 38, 41], ["proteasome \u03b12 subunit", "PROTEIN", 57, 78], ["unidentified proteins", "PROTEIN", 96, 117], ["The NSD complex", "PROBLEM", 0, 15], ["HPs", "PROBLEM", 38, 41], ["the proteasome \u03b12 subunit", "TREATMENT", 53, 78], ["HPs", "OBSERVATION", 38, 41]]], ["NS1 and NS2 prevent the interaction of RIG-I with MAVS in different ways.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["MAVS", "GENE_OR_GENE_PRODUCT", 50, 54], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["RIG-I", "PROTEIN", 39, 44], ["MAVS", "PROTEIN", 50, 54], ["NS1", "TREATMENT", 0, 3], ["NS2", "TREATMENT", 8, 11], ["MAVS", "PROBLEM", 50, 54], ["NS2", "OBSERVATION", 8, 11], ["MAVS", "OBSERVATION", 50, 54]]], ["NS1 binds to the PRY-SPRY domain of TRIM25, which is responsible for the interaction of TRIM25 with RIG-I.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["TRIM25", "GENE_OR_GENE_PRODUCT", 36, 42], ["TRIM25", "GENE_OR_GENE_PRODUCT", 88, 94], ["RIG-I.", "GENE_OR_GENE_PRODUCT", 100, 106], ["NS1", "PROTEIN", 0, 3], ["PRY", "PROTEIN", 17, 20], ["SPRY domain", "PROTEIN", 21, 32], ["TRIM25", "PROTEIN", 36, 42], ["TRIM25", "PROTEIN", 88, 94], ["RIG", "PROTEIN", 100, 103], ["the PRY-SPRY domain of TRIM25", "TREATMENT", 13, 42]]], ["As such, NS1 prevents the TRIM25-mediated K63-linked polyubiquitination of RIG-I, which is necessary for the subsequent interaction of RIG-I with MAVS (1).", [["NS1", "GENE_OR_GENE_PRODUCT", 9, 12], ["TRIM25", "GENE_OR_GENE_PRODUCT", 26, 32], ["K63", "GENE_OR_GENE_PRODUCT", 42, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 75, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 135, 140], ["MAVS", "GENE_OR_GENE_PRODUCT", 146, 150], ["NS1", "PROTEIN", 9, 12], ["TRIM25", "PROTEIN", 26, 32], ["K63", "PROTEIN", 42, 45], ["RIG-I", "PROTEIN", 75, 80], ["RIG-I", "PROTEIN", 135, 140], ["MAVS", "PROTEIN", 146, 150], ["NS1", "TREATMENT", 9, 12], ["the TRIM25", "TEST", 22, 32], ["polyubiquitination", "OBSERVATION", 53, 71]]], ["Moreover, NS2 directly interacts with RIG-I (2) and NS1 interacts with MAVS (3) to suppress binding of RIG-I to MAVS.", [["NS2", "GENE_OR_GENE_PRODUCT", 10, 13], ["RIG-I (2)", "GENE_OR_GENE_PRODUCT", 38, 47], ["NS1", "GENE_OR_GENE_PRODUCT", 52, 55], ["MAVS (3)", "GENE_OR_GENE_PRODUCT", 71, 79], ["RIG-I", "GENE_OR_GENE_PRODUCT", 103, 108], ["MAVS", "GENE_OR_GENE_PRODUCT", 112, 116], ["NS2", "PROTEIN", 10, 13], ["RIG-I (2)", "PROTEIN", 38, 47], ["NS1", "PROTEIN", 52, 55], ["MAVS (3)", "PROTEIN", 71, 79], ["RIG-I", "PROTEIN", 103, 108], ["MAVS", "PROTEIN", 112, 116], ["MAVS", "TREATMENT", 71, 75]]], ["Whether the interaction of NS1 with MAVS also prevents the interaction of NOD2 with MAVS is currently unclear.", [["NS1", "GENE_OR_GENE_PRODUCT", 27, 30], ["MAVS", "GENE_OR_GENE_PRODUCT", 36, 40], ["NOD2", "GENE_OR_GENE_PRODUCT", 74, 78], ["MAVS", "GENE_OR_GENE_PRODUCT", 84, 88], ["NS1", "PROTEIN", 27, 30], ["MAVS", "PROTEIN", 36, 40], ["NOD2", "PROTEIN", 74, 78], ["MAVS", "PROTEIN", 84, 88], ["MAVS", "TREATMENT", 36, 40], ["MAVS", "PROBLEM", 84, 88]]], ["NS1 reduces protein expression of TRAF3 and IKK\u03b5 (4), whereas NS2 modestly reduces TRAF3 and induces IKK\u03b5 and TBK1 (5).", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["TRAF3", "GENE_OR_GENE_PRODUCT", 34, 39], ["IKK\u03b5 (4)", "GENE_OR_GENE_PRODUCT", 44, 52], ["NS2", "GENE_OR_GENE_PRODUCT", 62, 65], ["TRAF3", "GENE_OR_GENE_PRODUCT", 83, 88], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 101, 105], ["TBK1", "GENE_OR_GENE_PRODUCT", 110, 114], ["NS1", "PROTEIN", 0, 3], ["TRAF3", "PROTEIN", 34, 39], ["IKK\u03b5 (4)", "PROTEIN", 44, 52], ["NS2", "PROTEIN", 62, 65], ["TRAF3", "PROTEIN", 83, 88], ["IKK\u03b5", "PROTEIN", 101, 105], ["TBK1 (5)", "PROTEIN", 110, 118], ["NS1", "PROBLEM", 0, 3], ["TRAF3", "TEST", 34, 39], ["IKK", "TEST", 44, 47], ["NS2", "TEST", 62, 65], ["TRAF3", "TEST", 83, 88], ["IKK", "TEST", 101, 104], ["TBK1", "TEST", 110, 114], ["protein expression", "OBSERVATION", 12, 30]]], ["NS1 subsequently inhibits IRF3 and IRF7 by different proposed mechanisms (6).", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["IRF3", "GENE_OR_GENE_PRODUCT", 26, 30], ["IRF7", "GENE_OR_GENE_PRODUCT", 35, 39], ["NS1", "PROTEIN", 0, 3], ["IRF3", "PROTEIN", 26, 30], ["IRF7", "PROTEIN", 35, 39], ["NS1", "PROBLEM", 0, 3], ["IRF3", "PROBLEM", 26, 30], ["IRF7", "TREATMENT", 35, 39], ["inhibits", "OBSERVATION_MODIFIER", 17, 25], ["IRF3", "OBSERVATION", 26, 30]]], ["NS1 reduces IRF3 and IRF7 protein expression and prevents the interaction between IRF3 and CBP, thereby lowering the binding of the IRF3-CBP complex to the IFN-\u03b2 promoter.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["IRF3", "GENE_OR_GENE_PRODUCT", 12, 16], ["IRF7", "GENE_OR_GENE_PRODUCT", 21, 25], ["IRF3", "GENE_OR_GENE_PRODUCT", 82, 86], ["CBP", "GENE_OR_GENE_PRODUCT", 91, 94], ["IRF3", "GENE_OR_GENE_PRODUCT", 132, 136], ["CBP", "GENE_OR_GENE_PRODUCT", 137, 140], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 156, 161], ["NS1", "PROTEIN", 0, 3], ["IRF3", "PROTEIN", 12, 16], ["IRF7", "PROTEIN", 21, 25], ["IRF3", "PROTEIN", 82, 86], ["CBP", "PROTEIN", 91, 94], ["IRF3", "PROTEIN", 132, 136], ["CBP complex", "PROTEIN", 137, 148], ["IFN-\u03b2 promoter", "DNA", 156, 170], ["NS1", "PROBLEM", 0, 3], ["IRF3", "PROBLEM", 12, 16], ["IRF7 protein expression", "TREATMENT", 21, 44], ["IRF3 and CBP", "TREATMENT", 82, 94], ["reduces", "OBSERVATION_MODIFIER", 4, 11], ["IRF3", "OBSERVATION", 12, 16], ["IRF7 protein expression", "OBSERVATION", 21, 44], ["IRF3", "OBSERVATION", 132, 136]]], ["NS2, and to a lesser extent NS1, enhances the activation and nuclear translocation of NF-\u03baB (7).", [["nuclear", "ANATOMY", 61, 68], ["NS1", "GENE_OR_GENE_PRODUCT", 28, 31], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["NF-\u03baB (7)", "GENE_OR_GENE_PRODUCT", 86, 95], ["NS2", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 28, 31], ["NF-\u03baB (7)", "PROTEIN", 86, 95], ["NS2", "TREATMENT", 0, 3], ["lesser", "OBSERVATION_MODIFIER", 14, 20], ["extent", "OBSERVATION_MODIFIER", 21, 27], ["NS1", "OBSERVATION", 28, 31]]], ["These NS1/NS2 effector functions (1-7) synergistically reduce the production of type I and III IFNs.", [["NS1", "GENE_OR_GENE_PRODUCT", 6, 9], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 80, 99], ["NS1", "PROTEIN", 6, 9], ["NS2", "PROTEIN", 10, 13], ["type I and III IFNs", "PROTEIN", 80, 99], ["These NS1/NS2 effector functions", "TEST", 0, 32], ["type I and III IFNs", "PROBLEM", 80, 99], ["NS2 effector", "OBSERVATION", 10, 22]]], ["Furthermore, NS1 and NS2 also suppress type I and III IFN receptor-mediated signal transduction.", [["NS1", "GENE_OR_GENE_PRODUCT", 13, 16], ["NS2", "GENE_OR_GENE_PRODUCT", 21, 24], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 39, 66], ["NS1", "PROTEIN", 13, 16], ["NS2", "PROTEIN", 21, 24], ["type I and III IFN receptor", "PROTEIN", 39, 66], ["NS1", "PROBLEM", 13, 16], ["NS2", "TREATMENT", 21, 24]]], ["NS1 induces miR-29a expression, which targets the mRNA coding for IFNAR1, one of the 2 subunits of the type I IFN receptor (8).", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["miR-29a", "GENE_OR_GENE_PRODUCT", 12, 19], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 66, 72], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 103, 122], ["NS1", "PROTEIN", 0, 3], ["miR", "DNA", 12, 15], ["mRNA", "RNA", 50, 54], ["IFNAR1", "PROTEIN", 66, 72], ["type I IFN receptor", "PROTEIN", 103, 122], ["IFNAR1", "PROBLEM", 66, 72], ["the type I IFN receptor", "TREATMENT", 99, 122]]], ["NS1 and NS2 may induce expression of SOCS proteins (SOCS1 and 3), which negatively regulate the tyrosine kinases JAK1 and TYK2, which are important to transmit signaling from the type I and III IFN receptors (9).", [["tyrosine", "CHEMICAL", 96, 104], ["tyrosine", "CHEMICAL", 96, 104], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["SOCS", "GENE_OR_GENE_PRODUCT", 37, 41], ["SOCS1", "GENE_OR_GENE_PRODUCT", 52, 57], ["3", "GENE_OR_GENE_PRODUCT", 62, 63], ["JAK1", "GENE_OR_GENE_PRODUCT", 113, 117], ["TYK2", "GENE_OR_GENE_PRODUCT", 122, 126], ["type I and III IFN receptors", "GENE_OR_GENE_PRODUCT", 179, 207], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["SOCS proteins", "PROTEIN", 37, 50], ["SOCS1 and 3", "PROTEIN", 52, 63], ["tyrosine kinases", "PROTEIN", 96, 112], ["JAK1", "PROTEIN", 113, 117], ["TYK2", "PROTEIN", 122, 126], ["type I and III IFN receptors", "PROTEIN", 179, 207], ["NS1", "TREATMENT", 0, 3], ["NS2", "TREATMENT", 8, 11], ["SOCS proteins", "PROBLEM", 37, 50], ["SOCS1", "TEST", 52, 57], ["the tyrosine kinases JAK1", "TEST", 92, 117], ["TYK2", "PROBLEM", 122, 126], ["tyrosine kinases JAK1", "OBSERVATION", 96, 117]]], ["NS2 inhibits JAK1/ TYK2-mediated activation of STAT1/2 by reducing STAT2 protein levels (10) and by reducing STAT1 phosphorylation (11).", [["NS2", "GENE_OR_GENE_PRODUCT", 0, 3], ["JAK1", "GENE_OR_GENE_PRODUCT", 13, 17], ["TYK2", "GENE_OR_GENE_PRODUCT", 19, 23], ["STAT1/2", "GENE_OR_GENE_PRODUCT", 47, 54], ["STAT2", "GENE_OR_GENE_PRODUCT", 67, 72], ["STAT1", "GENE_OR_GENE_PRODUCT", 109, 114], ["NS2", "PROTEIN", 0, 3], ["JAK1", "PROTEIN", 13, 17], ["TYK2", "PROTEIN", 19, 23], ["STAT1/2", "PROTEIN", 47, 54], ["STAT2", "PROTEIN", 67, 72], ["STAT1", "PROTEIN", 109, 114], ["NS2", "TREATMENT", 0, 3], ["JAK1/ TYK2", "TREATMENT", 13, 23], ["STAT1/2", "TREATMENT", 47, 54], ["STAT2 protein levels", "TEST", 67, 87], ["STAT1 phosphorylation", "TEST", 109, 130], ["JAK1", "OBSERVATION_MODIFIER", 13, 17], ["TYK2", "OBSERVATION", 19, 23]]], ["Some groups, however, reported that STAT2 expression can also be reduced by NS1 (see text) (10).", [["STAT2", "GENE_OR_GENE_PRODUCT", 36, 41], ["STAT2", "PROTEIN", 36, 41], ["NS1", "PROTEIN", 76, 79]]], ["NS1 and NS2 counteract the anti-inflammatory activity of the GR, although the exact mechanism is debated.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["GR", "GENE_OR_GENE_PRODUCT", 61, 63], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["GR", "PROTEIN", 61, 63], ["NS1", "TREATMENT", 0, 3], ["NS2", "TREATMENT", 8, 11], ["the GR", "TREATMENT", 57, 63], ["NS2", "OBSERVATION", 8, 11], ["anti-inflammatory activity", "OBSERVATION", 27, 53]]], ["In one model, NS1 interacts with the nuclear translocator IPO13, which competes with GR for its nuclear translocation (12).", [["nuclear", "ANATOMY", 37, 44], ["nuclear", "ANATOMY", 96, 103], ["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["nuclear", "CELLULAR_COMPONENT", 37, 44], ["IPO13", "GENE_OR_GENE_PRODUCT", 58, 63], ["GR", "GENE_OR_GENE_PRODUCT", 85, 87], ["nuclear", "CELLULAR_COMPONENT", 96, 103], ["NS1", "PROTEIN", 14, 17], ["nuclear translocator", "PROTEIN", 37, 57], ["IPO13", "PROTEIN", 58, 63], ["GR", "PROTEIN", 85, 87], ["NS1", "OBSERVATION", 14, 17]]], ["Recent evidence suggests that the NS proteins may also counteract antiviral effector functions of ISGs, e.g., NS1 degrades the OASL, IFIT1, and IFITM3 proteins, whereas NS2 degrades MAPK8 (13).", [["ISGs", "GENE_OR_GENE_PRODUCT", 98, 102], ["NS1", "GENE_OR_GENE_PRODUCT", 110, 113], ["OASL", "GENE_OR_GENE_PRODUCT", 127, 131], ["IFIT1", "GENE_OR_GENE_PRODUCT", 133, 138], ["IFITM3", "GENE_OR_GENE_PRODUCT", 144, 150], ["NS2", "GENE_OR_GENE_PRODUCT", 169, 172], ["MAPK8 (13)", "GENE_OR_GENE_PRODUCT", 182, 192], ["NS proteins", "PROTEIN", 34, 45], ["ISGs", "PROTEIN", 98, 102], ["NS1", "PROTEIN", 110, 113], ["OASL", "PROTEIN", 127, 131], ["IFIT1", "PROTEIN", 133, 138], ["IFITM3 proteins", "PROTEIN", 144, 159], ["NS2", "PROTEIN", 169, 172], ["MAPK8 (13)", "PROTEIN", 182, 192], ["the NS proteins", "TREATMENT", 30, 45], ["antiviral effector functions of ISGs", "PROBLEM", 66, 102], ["NS1", "PROBLEM", 110, 113], ["IFITM3 proteins", "PROBLEM", 144, 159]]], ["Full and dashed lines indicate robust and moderate inhibitory or stimulatory effector functions, respectively.", [["dashed lines", "CELL", 9, 21], ["dashed lines", "CELL_LINE", 9, 21], ["Full and dashed lines", "TREATMENT", 0, 21], ["robust", "OBSERVATION_MODIFIER", 31, 37], ["moderate", "OBSERVATION_MODIFIER", 42, 50]]], ["CBP, CREB binding protein; GR, glucocorticoid receptor; HP, host protein; IFIT, interferon-induced protein with tetratricopeptide repeats; IFITM, interferon-induced transmembrane protein; IFN, interferon; IFNAR, interferon alpha/beta receptor; IKK\u03b5, inhibitor of nuclear factor-kappa B kinase subunit epsilon; IPO13, importin-13; IRF3, interferon regulatory factor 3; ISG, IFN-stimulated gene; JAK, janus kinase; MAPK8, mitogen-activated protein kinase 8; MAVS, mitochondrial antiviral-signaling protein; NS, nonstructural; OASL, 2 0 -5 0 -oligoadenylate synthase-like protein; RIG-I, retinoic-acid-inducible gene-I; RLR, RIG-I-like receptor; RSV, respiratory syncytial virus; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of transcription; TBK1, tank binding kinase 1; TRIM25, tripartite motif-containing protein; TYK, tyrosine kinase 25.NS1 and NS2 interfere with RIG-Ihttps://doi.org/10.1371/journal.ppat.1007984.g002NS1 and NS2 interfere with signaling downstream of MAVSAssociation of RLRs with MAVS leads to the recruitment of the adaptors tumor necrosis factor receptor-associated factor 3 (TRAF3) and -6 (TRAF6).", [["mitochondrial", "ANATOMY", 462, 475], ["tyrosine", "CHEMICAL", 852, 860], ["tumor", "DISEASE", 1078, 1083], ["tyrosine", "CHEMICAL", 852, 860], ["CBP", "GENE_OR_GENE_PRODUCT", 0, 3], ["CREB binding protein", "GENE_OR_GENE_PRODUCT", 5, 25], ["GR", "GENE_OR_GENE_PRODUCT", 27, 29], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 31, 54], ["HP", "GENE_OR_GENE_PRODUCT", 56, 58], ["IFIT", "GENE_OR_GENE_PRODUCT", 74, 78], ["interferon", "GENE_OR_GENE_PRODUCT", 80, 90], ["tetratricopeptide", "GENE_OR_GENE_PRODUCT", 112, 129], ["IFITM", "GENE_OR_GENE_PRODUCT", 139, 144], ["interferon", "GENE_OR_GENE_PRODUCT", 146, 156], ["IFN", "GENE_OR_GENE_PRODUCT", 188, 191], ["interferon", "GENE_OR_GENE_PRODUCT", 193, 203], ["IFNAR", "GENE_OR_GENE_PRODUCT", 205, 210], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 212, 228], ["beta receptor", "GENE_OR_GENE_PRODUCT", 229, 242], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 244, 248], ["nuclear factor-kappa B kinase subunit epsilon", "GENE_OR_GENE_PRODUCT", 263, 308], ["IPO13", "GENE_OR_GENE_PRODUCT", 310, 315], ["importin-13", "GENE_OR_GENE_PRODUCT", 317, 328], ["IRF3", "GENE_OR_GENE_PRODUCT", 330, 334], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 336, 366], ["ISG", "GENE_OR_GENE_PRODUCT", 368, 371], ["IFN-stimulated gene", "GENE_OR_GENE_PRODUCT", 373, 392], ["JAK", "GENE_OR_GENE_PRODUCT", 394, 397], ["janus kinase", "GENE_OR_GENE_PRODUCT", 399, 411], ["MAPK8", "GENE_OR_GENE_PRODUCT", 413, 418], ["mitogen-activated protein kinase 8", "GENE_OR_GENE_PRODUCT", 420, 454], ["MAVS", "GENE_OR_GENE_PRODUCT", 456, 460], ["mitochondrial", "CELLULAR_COMPONENT", 462, 475], ["2 0 -5 0", "SIMPLE_CHEMICAL", 530, 538], ["-oligoadenylate synthase", "GENE_OR_GENE_PRODUCT", 539, 563], ["RIG-I", "GENE_OR_GENE_PRODUCT", 578, 583], ["retinoic-acid-inducible gene-I", "GENE_OR_GENE_PRODUCT", 585, 615], ["RLR", "GENE_OR_GENE_PRODUCT", 617, 620], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 622, 641], ["RSV", "ORGANISM", 643, 646], ["respiratory syncytial virus", "ORGANISM", 648, 675], ["SOCS", "GENE_OR_GENE_PRODUCT", 677, 681], ["STAT", "GENE_OR_GENE_PRODUCT", 717, 721], ["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 723, 771], ["TBK1", "GENE_OR_GENE_PRODUCT", 773, 777], ["tank binding kinase 1", "GENE_OR_GENE_PRODUCT", 779, 800], ["TRIM25", "GENE_OR_GENE_PRODUCT", 802, 808], ["tripartite motif-containing protein", "GENE_OR_GENE_PRODUCT", 810, 845], ["TYK, tyrosine kinase 25", "GENE_OR_GENE_PRODUCT", 847, 870], ["NS1", "GENE_OR_GENE_PRODUCT", 871, 874], ["NS2", "GENE_OR_GENE_PRODUCT", 879, 882], ["NS2", "GENE_OR_GENE_PRODUCT", 960, 963], ["RLRs", "GENE_OR_GENE_PRODUCT", 1022, 1026], ["MAVS", "GENE_OR_GENE_PRODUCT", 1032, 1036], ["tumor necrosis factor receptor-associated factor 3", "GENE_OR_GENE_PRODUCT", 1078, 1128], ["TRAF3", "GENE_OR_GENE_PRODUCT", 1130, 1135], ["-6", "GENE_OR_GENE_PRODUCT", 1141, 1143], ["TRAF6", "GENE_OR_GENE_PRODUCT", 1145, 1150], ["CBP", "PROTEIN", 0, 3], ["CREB binding protein", "PROTEIN", 5, 25], ["GR", "PROTEIN", 27, 29], ["glucocorticoid receptor", "PROTEIN", 31, 54], ["HP", "PROTEIN", 56, 58], ["host protein", "PROTEIN", 60, 72], ["IFIT", "PROTEIN", 74, 78], ["interferon", "PROTEIN", 80, 90], ["tetratricopeptide repeats", "PROTEIN", 112, 137], ["IFITM", "PROTEIN", 139, 144], ["interferon", "PROTEIN", 146, 156], ["transmembrane protein", "PROTEIN", 165, 186], ["IFN", "PROTEIN", 188, 191], ["interferon", "PROTEIN", 193, 203], ["IFNAR", "PROTEIN", 205, 210], ["interferon alpha/beta receptor", "PROTEIN", 212, 242], ["IKK\u03b5", "PROTEIN", 244, 248], ["inhibitor of nuclear factor-kappa B kinase subunit epsilon", "PROTEIN", 250, 308], ["IPO13", "PROTEIN", 310, 315], ["importin-13", "PROTEIN", 317, 328], ["IRF3", "PROTEIN", 330, 334], ["interferon regulatory factor 3", "PROTEIN", 336, 366], ["ISG", "PROTEIN", 368, 371], ["IFN", "PROTEIN", 373, 376], ["JAK", "PROTEIN", 394, 397], ["janus kinase", "PROTEIN", 399, 411], ["MAPK8", "PROTEIN", 413, 418], ["mitogen-activated protein kinase 8", "PROTEIN", 420, 454], ["MAVS", "PROTEIN", 456, 460], ["mitochondrial antiviral-signaling protein", "PROTEIN", 462, 503], ["NS", "PROTEIN", 505, 507], ["nonstructural; OASL, 2 0 -5 0 -oligoadenylate synthase", "PROTEIN", 509, 563], ["RIG-I", "PROTEIN", 578, 583], ["retinoic-acid-inducible gene-I; RLR, RIG-I-like receptor", "PROTEIN", 585, 641], ["SOCS", "PROTEIN", 677, 681], ["cytokine", "PROTEIN", 697, 705], ["STAT", "PROTEIN", 717, 721], ["signal transducer and activator of transcription", "PROTEIN", 723, 771], ["TBK1", "PROTEIN", 773, 777], ["tank binding kinase 1", "PROTEIN", 779, 800], ["TRIM25", "PROTEIN", 802, 808], ["tripartite motif-containing protein", "PROTEIN", 810, 845], ["TYK", "PROTEIN", 847, 850], ["tyrosine kinase 25", "PROTEIN", 852, 870], ["NS1", "PROTEIN", 871, 874], ["NS2", "PROTEIN", 879, 882], ["RIG-Ihttps://doi.org/10.1371/journal.ppat.1007984.g002NS1", "PROTEIN", 898, 955], ["NS2", "PROTEIN", 960, 963], ["RLRs", "PROTEIN", 1022, 1026], ["MAVS", "PROTEIN", 1032, 1036], ["adaptors tumor necrosis factor receptor-associated factor 3 (TRAF3) and -6", "PROTEIN", 1069, 1143], ["TRAF6", "PROTEIN", 1145, 1150], ["respiratory syncytial virus", "SPECIES", 648, 675], ["RSV", "SPECIES", 643, 646], ["respiratory syncytial virus", "SPECIES", 648, 675], ["CBP", "TEST", 0, 3], ["CREB binding protein", "TEST", 5, 25], ["GR", "TEST", 27, 29], ["glucocorticoid receptor", "TEST", 31, 54], ["HP", "TEST", 56, 58], ["host protein", "TEST", 60, 72], ["IFIT", "TEST", 74, 78], ["interferon", "TREATMENT", 80, 90], ["tetratricopeptide repeats", "TEST", 112, 137], ["IFITM", "TEST", 139, 144], ["interferon", "TREATMENT", 146, 156], ["transmembrane protein", "TREATMENT", 165, 186], ["IFN", "TREATMENT", 188, 191], ["interferon", "TREATMENT", 193, 203], ["IFNAR", "TREATMENT", 205, 210], ["interferon alpha/beta receptor", "TREATMENT", 212, 242], ["IKK\u03b5", "TREATMENT", 244, 248], ["nuclear factor", "TEST", 263, 277], ["kappa B kinase subunit epsilon", "TREATMENT", 278, 308], ["IPO13", "TEST", 310, 315], ["importin", "TEST", 317, 325], ["IRF3", "PROBLEM", 330, 334], ["interferon regulatory factor", "TEST", 336, 364], ["ISG", "TEST", 368, 371], ["IFN", "TEST", 373, 376], ["JAK, janus kinase", "TEST", 394, 411], ["MAPK8", "TEST", 413, 418], ["mitogen", "TEST", 420, 427], ["activated protein kinase", "TEST", 428, 452], ["MAVS", "TEST", 456, 460], ["mitochondrial antiviral", "TEST", 462, 485], ["signaling protein", "PROBLEM", 486, 503], ["NS", "TEST", 505, 507], ["OASL", "TEST", 524, 528], ["-oligoadenylate synthase", "TEST", 539, 563], ["protein", "TEST", 569, 576], ["RIG", "TEST", 578, 581], ["retinoic", "TEST", 585, 593], ["RLR", "TEST", 617, 620], ["RIG", "TEST", 622, 625], ["RSV", "PROBLEM", 643, 646], ["respiratory syncytial virus", "PROBLEM", 648, 675], ["cytokine signaling", "PROBLEM", 697, 715], ["activator of transcription", "TREATMENT", 745, 771], ["TBK1", "TEST", 773, 777], ["tank binding kinase", "TEST", 779, 798], ["TRIM25", "TEST", 802, 808], ["tyrosine kinase", "TREATMENT", 852, 867], ["NS1", "PROBLEM", 871, 874], ["RIG-Ihttps://doi.org/10.1371/journal.ppat.1007984.g002NS1", "TREATMENT", 898, 955], ["NS2", "TREATMENT", 960, 963], ["MAVSAssociation of RLRs", "TREATMENT", 1003, 1026], ["MAVS", "TREATMENT", 1032, 1036], ["the adaptors tumor necrosis", "PROBLEM", 1065, 1092], ["TRAF3", "TEST", 1130, 1135], ["RSV", "ANATOMY", 643, 646], ["respiratory syncytial", "ANATOMY", 648, 669], ["NS2", "OBSERVATION", 879, 882], ["tumor", "OBSERVATION", 1078, 1083]]], ["Whereas TRAF3 activates the downstream serine/threonine kinases inhibitor of nuclear factor-kappa B kinase subunit epsilon (IKK\u03b5) and tank binding kinase 1 (TBK1), TRAF6 activates the downstream kinases IKK, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK) (Fig 1) .", [["serine", "CHEMICAL", 39, 45], ["threonine", "CHEMICAL", 46, 55], ["N", "CHEMICAL", 214, 215], ["TRAF3", "GENE_OR_GENE_PRODUCT", 8, 13], ["threonine", "AMINO_ACID", 46, 55], ["nuclear factor-kappa B kinase subunit epsilon", "GENE_OR_GENE_PRODUCT", 77, 122], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 124, 128], ["tank binding kinase 1", "GENE_OR_GENE_PRODUCT", 134, 155], ["TBK1", "GENE_OR_GENE_PRODUCT", 157, 161], ["TRAF6", "GENE_OR_GENE_PRODUCT", 164, 169], ["IKK", "GENE_OR_GENE_PRODUCT", 203, 206], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 208, 231], ["JNK", "GENE_OR_GENE_PRODUCT", 233, 236], ["p38 mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 243, 279], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 281, 289], ["Fig 1", "GENE_OR_GENE_PRODUCT", 292, 297], ["TRAF3", "PROTEIN", 8, 13], ["nuclear factor-kappa B kinase subunit epsilon", "PROTEIN", 77, 122], ["IKK\u03b5", "PROTEIN", 124, 128], ["tank binding kinase 1", "PROTEIN", 134, 155], ["TBK1", "PROTEIN", 157, 161], ["TRAF6", "PROTEIN", 164, 169], ["downstream kinases", "PROTEIN", 184, 202], ["IKK", "PROTEIN", 203, 206], ["c-Jun N-terminal kinase", "PROTEIN", 208, 231], ["JNK", "PROTEIN", 233, 236], ["p38 mitogen-activated protein kinase", "PROTEIN", 243, 279], ["p38 MAPK", "PROTEIN", 281, 289], ["the downstream serine/threonine kinases inhibitor", "TREATMENT", 24, 73], ["nuclear factor", "TEST", 77, 91], ["kappa B kinase subunit epsilon (IKK\u03b5", "TEST", 92, 128], ["tank binding kinase", "TEST", 134, 153], ["the downstream kinases", "TEST", 180, 202], ["IKK", "TEST", 203, 206], ["c", "TEST", 208, 209], ["Jun N", "TEST", 210, 215], ["terminal kinase (JNK)", "TEST", 216, 237], ["p38 mitogen", "TEST", 243, 254], ["activated protein kinase", "TEST", 255, 279], ["p38 MAPK", "TEST", 281, 289], ["Fig", "TEST", 292, 295]]], ["The effect of NS1 and NS2 on TRAF3, IKK\u03b5, and TBK1 is currently inconclusive.", [["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["NS2", "GENE_OR_GENE_PRODUCT", 22, 25], ["TRAF3", "GENE_OR_GENE_PRODUCT", 29, 34], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 36, 40], ["TBK1", "GENE_OR_GENE_PRODUCT", 46, 50], ["NS1", "PROTEIN", 14, 17], ["NS2", "PROTEIN", 22, 25], ["TRAF3", "PROTEIN", 29, 34], ["IKK\u03b5", "PROTEIN", 36, 40], ["TBK1", "PROTEIN", 46, 50], ["NS1", "PROBLEM", 14, 17], ["NS2", "PROBLEM", 22, 25], ["TRAF3", "TEST", 29, 34], ["IKK\u03b5", "TEST", 36, 40], ["TBK1", "TEST", 46, 50]]], ["Some groups reported that NS1, either overexpressed or expressed during an RSV infection in A549 cells, reduces the expression levels of both TRAF3 and IKK\u03b5 (Fig 2) [51, 52] .", [["A549 cells", "ANATOMY", 92, 102], ["infection", "DISEASE", 79, 88], ["NS1", "GENE_OR_GENE_PRODUCT", 26, 29], ["RSV", "ORGANISM", 75, 78], ["A549 cells", "CELL", 92, 102], ["TRAF3", "GENE_OR_GENE_PRODUCT", 142, 147], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 152, 156], ["NS1", "PROTEIN", 26, 29], ["A549 cells", "CELL_LINE", 92, 102], ["TRAF3", "PROTEIN", 142, 147], ["IKK\u03b5", "PROTEIN", 152, 156], ["RSV", "SPECIES", 75, 78], ["NS1", "PROBLEM", 26, 29], ["an RSV infection in A549 cells", "PROBLEM", 72, 102], ["RSV", "OBSERVATION_MODIFIER", 75, 78], ["infection", "OBSERVATION", 79, 88], ["A549 cells", "OBSERVATION", 92, 102]]], ["Ren and colleagues, however, observed no difference in endogenous and recombinant TRAF3 and IKK\u03b5 expression in A549 cells in the presence or absence of NS1 [39] .", [["A549 cells", "ANATOMY", 111, 121], ["TRAF3", "GENE_OR_GENE_PRODUCT", 82, 87], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 92, 96], ["A549 cells", "CELL", 111, 121], ["TRAF3", "PROTEIN", 82, 87], ["IKK\u03b5", "PROTEIN", 92, 96], ["A549 cells", "CELL_LINE", 111, 121], ["NS1", "PROTEIN", 152, 155], ["difference in endogenous and recombinant TRAF3", "PROBLEM", 41, 87], ["A549 cells", "TEST", 111, 121], ["NS1", "TEST", 152, 155], ["A549 cells", "OBSERVATION", 111, 121]]], ["Possibly, the different strains (RSV long versus A2) or experimental timing used explain these opposing observations.", [["RSV", "ORGANISM", 33, 36], ["RSV", "SPECIES", 33, 36], ["the different strains (RSV long versus A2)", "PROBLEM", 10, 52], ["experimental timing", "TREATMENT", 56, 75]]], ["Overexpression of NS2 in A549 cells modestly reduces and slightly enhances TRAF3 and IKK\u03b5 expression levels, respectively (Fig 2) [51, 52] .", [["A549 cells", "ANATOMY", 25, 35], ["NS2", "GENE_OR_GENE_PRODUCT", 18, 21], ["A549 cells", "CELL", 25, 35], ["TRAF3", "GENE_OR_GENE_PRODUCT", 75, 80], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 85, 89], ["NS2", "PROTEIN", 18, 21], ["A549 cells", "CELL_LINE", 25, 35], ["TRAF3", "PROTEIN", 75, 80], ["IKK", "PROTEIN", 85, 88], ["\u03b5", "PROTEIN", 88, 89], ["Overexpression of NS2 in A549 cells", "PROBLEM", 0, 35], ["slightly enhances TRAF3", "PROBLEM", 57, 80], ["expression levels", "TEST", 90, 107], ["NS2", "OBSERVATION", 18, 21], ["A549 cells", "OBSERVATION", 25, 35], ["modestly", "OBSERVATION_MODIFIER", 36, 44], ["reduces", "OBSERVATION_MODIFIER", 45, 52], ["slightly", "OBSERVATION_MODIFIER", 57, 65], ["enhances TRAF3", "OBSERVATION", 66, 80]]], ["These effects of NS2 were, however, not observed with an RSV strain that lacks NS1.", [["NS2", "GENE_OR_GENE_PRODUCT", 17, 20], ["RSV", "ORGANISM", 57, 60], ["NS1", "GENE_OR_GENE_PRODUCT", 79, 82], ["NS2", "PROTEIN", 17, 20], ["NS1", "PROTEIN", 79, 82], ["RSV", "SPECIES", 57, 60], ["NS2", "PROBLEM", 17, 20], ["an RSV strain", "PROBLEM", 54, 67], ["NS1", "PROBLEM", 79, 82], ["NS2", "OBSERVATION", 17, 20], ["RSV", "OBSERVATION", 57, 60]]], ["Ling and colleagues also observed that overexpressed NS2 enhances overexpression of IKK\u03b5 and TBK1 in HEK293T cells (Fig 2) [50] .", [["HEK293T cells", "ANATOMY", 101, 114], ["NS2", "GENE_OR_GENE_PRODUCT", 53, 56], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 84, 88], ["TBK1", "GENE_OR_GENE_PRODUCT", 93, 97], ["HEK293T cells", "CELL", 101, 114], ["NS2", "PROTEIN", 53, 56], ["IKK\u03b5", "PROTEIN", 84, 88], ["TBK1", "PROTEIN", 93, 97], ["HEK293T cells", "CELL_LINE", 101, 114], ["IKK", "TEST", 84, 87], ["TBK1 in HEK293T cells", "TEST", 93, 114]]], ["To our knowledge, no data have been published on the possible effect of NS1 on the expression of TBK1.", [["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["TBK1", "GENE_OR_GENE_PRODUCT", 97, 101], ["NS1", "PROTEIN", 72, 75], ["TBK1", "PROTEIN", 97, 101], ["NS1", "TREATMENT", 72, 75], ["TBK1", "PROBLEM", 97, 101], ["TBK1", "OBSERVATION", 97, 101]]], ["Coexpression of NS1 and NS2 in A549 cells reduces recombinant IKK\u03b5 expression, suggesting that the inhibitory effect of NS1 is dominant over the enhancing effect of NS2 [52] .", [["A549 cells", "ANATOMY", 31, 41], ["NS1", "GENE_OR_GENE_PRODUCT", 16, 19], ["NS2", "GENE_OR_GENE_PRODUCT", 24, 27], ["A549 cells", "CELL", 31, 41], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 62, 66], ["NS1", "GENE_OR_GENE_PRODUCT", 120, 123], ["NS1", "PROTEIN", 16, 19], ["NS2", "PROTEIN", 24, 27], ["A549 cells", "CELL_LINE", 31, 41], ["IKK\u03b5", "PROTEIN", 62, 66], ["NS1", "PROTEIN", 120, 123], ["NS2", "PROTEIN", 165, 168], ["NS1", "PROBLEM", 16, 19], ["NS2 in A549 cells", "TREATMENT", 24, 41], ["NS1", "PROBLEM", 120, 123], ["NS1", "OBSERVATION", 16, 19], ["A549 cells", "OBSERVATION", 31, 41], ["dominant", "OBSERVATION_MODIFIER", 127, 135]]], ["These results suggest that NS1 suppresses TRAF3 and IKK\u03b5 expression, although more evidence is needed to confirm this hypothesis.", [["NS1", "GENE_OR_GENE_PRODUCT", 27, 30], ["TRAF3", "GENE_OR_GENE_PRODUCT", 42, 47], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 52, 56], ["NS1", "PROTEIN", 27, 30], ["TRAF3", "PROTEIN", 42, 47], ["IKK", "PROTEIN", 52, 55], ["\u03b5", "PROTEIN", 55, 56], ["NS1 suppresses TRAF3", "TREATMENT", 27, 47], ["this hypothesis", "PROBLEM", 113, 128]]], ["Ectopic expression of NS2 slightly suppresses TRAF3 expression and enhances IKK\u03b5 and TBK1 expression, although these effects need to be confirmed during an RSV infection.NS1 and NS2 interfere with signaling downstream of MAVSWhether NS1 and/or NS2 affect the TRAF6 adaptor has not been investigated yet.", [["RSV infection", "DISEASE", 156, 169], ["NS2", "GENE_OR_GENE_PRODUCT", 22, 25], ["TRAF3", "GENE_OR_GENE_PRODUCT", 46, 51], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 76, 80], ["TBK1", "GENE_OR_GENE_PRODUCT", 85, 89], ["RSV", "ORGANISM", 156, 159], ["NS1", "GENE_OR_GENE_PRODUCT", 170, 173], ["NS2", "GENE_OR_GENE_PRODUCT", 178, 181], ["MAVSWhether NS1", "GENE_OR_GENE_PRODUCT", 221, 236], ["NS2", "GENE_OR_GENE_PRODUCT", 244, 247], ["TRAF6", "GENE_OR_GENE_PRODUCT", 259, 264], ["NS2", "PROTEIN", 22, 25], ["TRAF3", "PROTEIN", 46, 51], ["IKK\u03b5", "PROTEIN", 76, 80], ["TBK1", "PROTEIN", 85, 89], ["NS1", "PROTEIN", 170, 173], ["NS2", "PROTEIN", 178, 181], ["MAVSWhether", "PROTEIN", 221, 232], ["NS1", "PROTEIN", 233, 236], ["NS2", "PROTEIN", 244, 247], ["TRAF6", "PROTEIN", 259, 264], ["RSV", "SPECIES", 156, 159], ["Ectopic expression of NS2 slightly suppresses TRAF3 expression", "PROBLEM", 0, 62], ["IKK", "TEST", 76, 79], ["TBK1 expression", "PROBLEM", 85, 100], ["an RSV infection", "PROBLEM", 153, 169], ["NS1", "PROBLEM", 170, 173], ["NS2", "TREATMENT", 178, 181], ["MAVSWhether NS1", "TREATMENT", 221, 236], ["the TRAF6 adaptor", "TREATMENT", 255, 272], ["NS2", "OBSERVATION_MODIFIER", 22, 25], ["slightly", "OBSERVATION_MODIFIER", 26, 34], ["TBK1 expression", "OBSERVATION", 85, 100], ["RSV", "OBSERVATION_MODIFIER", 156, 159], ["infection", "OBSERVATION", 160, 169], ["NS2", "OBSERVATION", 178, 181]]], ["Some evidence indicates that RSV may indeed affect TRAF6 expression.", [["RSV", "ORGANISM", 29, 32], ["TRAF6", "GENE_OR_GENE_PRODUCT", 51, 56], ["TRAF6", "PROTEIN", 51, 56], ["RSV", "SPECIES", 29, 32], ["RSV", "PROBLEM", 29, 32], ["RSV", "OBSERVATION", 29, 32]]], ["In different models, TRAF6 expression has been shown to be down-regulated by the microRNA (miRNA) miR-146a [53, 54] .", [["TRAF6", "GENE_OR_GENE_PRODUCT", 21, 26], ["miR-146a", "GENE_OR_GENE_PRODUCT", 98, 106], ["TRAF6", "PROTEIN", 21, 26], ["microRNA (miRNA) miR-146a", "DNA", 81, 106]]], ["Interestingly, Eilam-Frenkel and colleagues found that miR-146a expression was up-regulated in RSV-infected HEp-2 cells [55] .", [["HEp-2 cells", "ANATOMY", 108, 119], ["miR-146a", "GENE_OR_GENE_PRODUCT", 55, 63], ["RSV", "ORGANISM", 95, 98], ["HEp-2 cells", "CELL", 108, 119], ["miR", "DNA", 55, 58], ["HEp-2 cells", "CELL_LINE", 108, 119], ["RSV", "SPECIES", 95, 98], ["RSV", "TEST", 95, 98], ["RSV", "ANATOMY", 95, 98]]], ["Future research may elucidate whether RSV can downregulate TRAF6 expression via up-regulating miR-146a and whether this is mediated by NS1 and/or NS2.NS1 and NS2 interfere with the interferon regulatory factor and nuclear factor-kappa B transcription factorsActivated IKK\u03b5 and TBK1 phosphorylate the transcription factors Interferon Regulatory Factor (IRF)-3 and IRF7, which induces conformational changes that allow the formation of homo-and heterodimers of IRF3 and -7 that translocate to the nucleus.", [["nucleus", "ANATOMY", 495, 502], ["RSV", "ORGANISM", 38, 41], ["TRAF6", "GENE_OR_GENE_PRODUCT", 59, 64], ["miR-146a", "GENE_OR_GENE_PRODUCT", 94, 102], ["NS1", "GENE_OR_GENE_PRODUCT", 135, 138], ["NS2", "GENE_OR_GENE_PRODUCT", 146, 149], ["NS1", "GENE_OR_GENE_PRODUCT", 150, 153], ["NS2", "GENE_OR_GENE_PRODUCT", 158, 161], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 181, 209], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 214, 236], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 268, 272], ["TBK1", "GENE_OR_GENE_PRODUCT", 277, 281], ["Interferon Regulatory Factor (IRF)-3", "GENE_OR_GENE_PRODUCT", 322, 358], ["IRF7", "GENE_OR_GENE_PRODUCT", 363, 367], ["IRF3", "GENE_OR_GENE_PRODUCT", 459, 463], ["-7", "GENE_OR_GENE_PRODUCT", 468, 470], ["nucleus", "CELLULAR_COMPONENT", 495, 502], ["TRAF6", "PROTEIN", 59, 64], ["miR-146a", "DNA", 94, 102], ["NS1", "PROTEIN", 135, 138], ["NS2", "PROTEIN", 146, 149], ["NS1", "PROTEIN", 150, 153], ["NS2", "PROTEIN", 158, 161], ["interferon regulatory factor", "PROTEIN", 181, 209], ["nuclear factor-kappa B transcription factors", "PROTEIN", 214, 258], ["IKK\u03b5", "PROTEIN", 268, 272], ["TBK1", "PROTEIN", 277, 281], ["transcription factors", "PROTEIN", 300, 321], ["Interferon Regulatory Factor (IRF)-3", "PROTEIN", 322, 358], ["IRF7", "PROTEIN", 363, 367], ["heterodimers", "PROTEIN", 443, 455], ["IRF3 and -7", "PROTEIN", 459, 470], ["RSV", "SPECIES", 38, 41], ["RSV", "PROBLEM", 38, 41], ["NS2", "PROBLEM", 146, 149], ["NS1", "PROBLEM", 150, 153], ["NS2", "TREATMENT", 158, 161], ["the interferon regulatory factor", "TREATMENT", 177, 209], ["nuclear factor", "TEST", 214, 228], ["kappa B transcription factors", "TREATMENT", 229, 258], ["Activated IKK\u03b5", "TREATMENT", 258, 272], ["TBK1 phosphorylate", "TREATMENT", 277, 295], ["Interferon Regulatory Factor (IRF)", "TREATMENT", 322, 356], ["IRF7", "TREATMENT", 363, 367], ["conformational changes", "PROBLEM", 383, 405], ["homo-and heterodimers of IRF3", "TREATMENT", 434, 463], ["NS2", "OBSERVATION", 158, 161], ["nucleus", "ANATOMY", 495, 502]]], ["Phosphorylation of inhibitor of kappa B (I\u03baB), e.g., by the canonical IKK\u03b1/\u03b2/\u03b3 complex, initiates its degradation with subsequent release and nuclear translocation of nuclear factor-kappa B (NF-\u03baB).", [["nuclear", "ANATOMY", 142, 149], ["inhibitor of kappa B", "GENE_OR_GENE_PRODUCT", 19, 39], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 41, 44], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 70, 74], ["\u03b2", "GENE_OR_GENE_PRODUCT", 75, 76], ["\u03b3", "GENE_OR_GENE_PRODUCT", 77, 78], ["nuclear", "CELLULAR_COMPONENT", 142, 149], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 167, 189], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 191, 196], ["inhibitor of kappa B", "PROTEIN", 19, 39], ["I\u03baB", "PROTEIN", 41, 44], ["IKK\u03b1", "PROTEIN", 70, 74], ["\u03b2", "PROTEIN", 75, 76], ["\u03b3 complex", "PROTEIN", 77, 86], ["nuclear factor-kappa B", "PROTEIN", 167, 189], ["NF-\u03baB", "PROTEIN", 191, 196], ["Phosphorylation of inhibitor", "TREATMENT", 0, 28], ["nuclear factor", "TEST", 167, 181]]], ["The IRF and NF-\u03baB transcription factors are essential for the induction of type I and III IFNs (Fig 1) .NS1 and NS2 interfere with the interferon regulatory factor and nuclear factor-kappa B transcription factorsSeveral observations highlight that NS1 and NS2 can impair the activation and effector functions of IRF transcription factors.", [["IRF", "GENE_OR_GENE_PRODUCT", 4, 7], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 12, 17], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 75, 94], ["Fig 1", "GENE_OR_GENE_PRODUCT", 96, 101], ["NS1", "GENE_OR_GENE_PRODUCT", 104, 107], ["NS2", "GENE_OR_GENE_PRODUCT", 112, 115], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 135, 163], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 168, 190], ["NS1", "GENE_OR_GENE_PRODUCT", 248, 251], ["NS2", "GENE_OR_GENE_PRODUCT", 256, 259], ["IRF transcription factors", "GENE_OR_GENE_PRODUCT", 312, 337], ["IRF", "PROTEIN", 4, 7], ["NF-\u03baB", "PROTEIN", 12, 17], ["transcription factors", "PROTEIN", 18, 39], ["type I and III IFNs", "PROTEIN", 75, 94], ["NS1", "PROTEIN", 104, 107], ["NS2", "PROTEIN", 112, 115], ["interferon regulatory factor", "PROTEIN", 135, 163], ["nuclear factor-kappa B transcription factors", "PROTEIN", 168, 212], ["NS1", "PROTEIN", 248, 251], ["NS2", "PROTEIN", 256, 259], ["IRF transcription factors", "PROTEIN", 312, 337], ["The IRF", "TEST", 0, 7], ["NF", "TEST", 12, 14], ["B transcription factors", "TREATMENT", 16, 39], ["NS1", "PROBLEM", 104, 107], ["NS2", "TREATMENT", 112, 115], ["the interferon regulatory factor", "TREATMENT", 131, 163], ["nuclear factor", "TEST", 168, 182], ["kappa B transcription factors", "TREATMENT", 183, 212], ["NS1", "TREATMENT", 248, 251], ["NS2", "TREATMENT", 256, 259], ["IRF transcription factors", "PROBLEM", 312, 337], ["IRF", "OBSERVATION", 4, 7], ["NS2", "OBSERVATION", 112, 115]]], ["Initial work with recombinant RSV strains lacking one or both NS proteins in A549 cells highlighted that NS1 and NS2 prevent nuclear translocation of IRF3, especially late (>9 hours post infection) in the RSV replication cycle [40, 50, 56] .", [["A549 cells", "ANATOMY", 77, 87], ["nuclear", "ANATOMY", 125, 132], ["infection", "DISEASE", 187, 196], ["RSV", "ORGANISM", 30, 33], ["A549 cells", "CELL", 77, 87], ["NS1", "GENE_OR_GENE_PRODUCT", 105, 108], ["NS2", "GENE_OR_GENE_PRODUCT", 113, 116], ["nuclear", "CELLULAR_COMPONENT", 125, 132], ["IRF3", "GENE_OR_GENE_PRODUCT", 150, 154], ["RSV", "ORGANISM", 205, 208], ["NS proteins", "PROTEIN", 62, 73], ["A549 cells", "CELL_LINE", 77, 87], ["NS1", "PROTEIN", 105, 108], ["NS2", "PROTEIN", 113, 116], ["IRF3", "PROTEIN", 150, 154], ["RSV", "SPECIES", 30, 33], ["RSV", "SPECIES", 205, 208], ["recombinant RSV strains", "TREATMENT", 18, 41], ["both NS proteins", "TREATMENT", 57, 73], ["A549 cells", "TREATMENT", 77, 87], ["NS1", "TREATMENT", 105, 108], ["NS2", "TREATMENT", 113, 116], ["nuclear translocation of IRF3", "PROBLEM", 125, 154], ["infection", "PROBLEM", 187, 196], ["IRF3", "OBSERVATION", 150, 154], ["RSV", "ANATOMY", 205, 208]]], ["This might, in part, be explained by the ability of NS1 to directly reduce the recombinant expression of IRF3 and IRF7 (Fig 2) [51] .", [["NS1", "GENE_OR_GENE_PRODUCT", 52, 55], ["IRF3", "GENE_OR_GENE_PRODUCT", 105, 109], ["IRF7", "GENE_OR_GENE_PRODUCT", 114, 118], ["NS1", "PROTEIN", 52, 55], ["IRF3", "PROTEIN", 105, 109], ["IRF7", "PROTEIN", 114, 118], ["NS1", "TREATMENT", 52, 55], ["IRF3", "PROBLEM", 105, 109]]], ["In addition, by preventing the formation of the IRF3/CREB binding protein (CBP) complex in the nucleus, NS1 may also inhibit IRF3-dependent gene expression downstream of the nuclear translocation of IRF3 (Fig 2) [37, 39] .", [["nucleus", "ANATOMY", 95, 102], ["nuclear", "ANATOMY", 174, 181], ["IRF3", "GENE_OR_GENE_PRODUCT", 48, 52], ["CREB binding protein (CBP) complex", "GENE_OR_GENE_PRODUCT", 53, 87], ["nucleus", "CELLULAR_COMPONENT", 95, 102], ["NS1", "GENE_OR_GENE_PRODUCT", 104, 107], ["IRF3", "GENE_OR_GENE_PRODUCT", 125, 129], ["nuclear", "CELLULAR_COMPONENT", 174, 181], ["IRF3", "GENE_OR_GENE_PRODUCT", 199, 203], ["IRF3", "PROTEIN", 48, 52], ["CREB binding protein (CBP) complex", "PROTEIN", 53, 87], ["NS1", "PROTEIN", 104, 107], ["IRF3", "PROTEIN", 125, 129], ["IRF3", "PROTEIN", 199, 203], ["the IRF3/CREB binding protein", "TEST", 44, 73], ["complex in the nucleus", "PROBLEM", 80, 102], ["NS1", "PROBLEM", 104, 107], ["IRF3", "PROBLEM", 125, 129], ["nucleus", "ANATOMY", 95, 102]]], ["It is important to note that this NS1 effector function has only been demonstrated upon overexpression in HEK293T cells, so additional confirmation in an RSV infection is necessary.NS1 and NS2 interfere with the interferon regulatory factor and nuclear factor-kappa B transcription factorsIn A549 and Vero cells, NF-\u03baB activation and nuclear translocation occur early after RSV infection and are clearly enhanced by NS2 and, to some extent, by NS1 (Fig 2) [56, 57] .", [["HEK293T cells", "ANATOMY", 106, 119], ["A549", "ANATOMY", 292, 296], ["Vero cells", "ANATOMY", 301, 311], ["nuclear", "ANATOMY", 334, 341], ["RSV infection", "DISEASE", 154, 167], ["RSV infection", "DISEASE", 374, 387], ["NS1", "GENE_OR_GENE_PRODUCT", 34, 37], ["HEK293T cells", "CELL", 106, 119], ["RSV", "ORGANISM", 154, 157], ["NS1", "GENE_OR_GENE_PRODUCT", 181, 184], ["NS2", "GENE_OR_GENE_PRODUCT", 189, 192], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 212, 240], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 245, 267], ["A549", "CELL", 292, 296], ["Vero cells", "CELL", 301, 311], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 313, 318], ["nuclear", "CELLULAR_COMPONENT", 334, 341], ["RSV", "ORGANISM", 374, 377], ["NS2", "GENE_OR_GENE_PRODUCT", 416, 419], ["NS1", "GENE_OR_GENE_PRODUCT", 444, 447], ["NS1", "PROTEIN", 34, 37], ["HEK293T cells", "CELL_LINE", 106, 119], ["NS1", "PROTEIN", 181, 184], ["NS2", "PROTEIN", 189, 192], ["interferon regulatory factor", "PROTEIN", 212, 240], ["nuclear factor-kappa B transcription factors", "PROTEIN", 245, 289], ["A549", "CELL_LINE", 292, 296], ["Vero cells", "CELL_LINE", 301, 311], ["NF-\u03baB", "PROTEIN", 313, 318], ["NS2", "PROTEIN", 416, 419], ["NS1", "PROTEIN", 444, 447], ["RSV", "SPECIES", 154, 157], ["RSV", "SPECIES", 374, 377], ["this NS1 effector function", "PROBLEM", 29, 55], ["overexpression in HEK293T cells", "PROBLEM", 88, 119], ["additional confirmation", "TEST", 124, 147], ["an RSV infection", "PROBLEM", 151, 167], ["NS1", "PROBLEM", 181, 184], ["NS2", "TREATMENT", 189, 192], ["the interferon regulatory factor", "TREATMENT", 208, 240], ["nuclear factor", "TEST", 245, 259], ["kappa B transcription factors", "TEST", 260, 289], ["Vero cells", "TEST", 301, 311], ["NF", "TEST", 313, 315], ["B activation", "PROBLEM", 317, 329], ["nuclear translocation", "PROBLEM", 334, 355], ["RSV infection", "PROBLEM", 374, 387], ["HEK293T cells", "OBSERVATION", 106, 119], ["infection", "OBSERVATION", 158, 167], ["NS2", "OBSERVATION", 189, 192], ["Vero cells", "OBSERVATION", 301, 311], ["infection", "OBSERVATION", 378, 387]]], ["In addition to the canonical I\u03baB phosphorylation and subsequent degradation, RSV-induced NF-\u03baB activation involves p65Ser536 phosphorylation via the RIG-I/MAVS/TRAF6/IKK\u03b2 signaling pathway [16] .", [["I\u03baB", "GENE_OR_GENE_PRODUCT", 29, 32], ["RSV", "ORGANISM", 77, 80], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 89, 94], ["p65Ser536", "GENE_OR_GENE_PRODUCT", 115, 124], ["RIG-I", "GENE_OR_GENE_PRODUCT", 149, 154], ["MAVS", "GENE_OR_GENE_PRODUCT", 155, 159], ["TRAF6", "GENE_OR_GENE_PRODUCT", 160, 165], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 166, 170], ["I\u03baB", "PROTEIN", 29, 32], ["NF-\u03baB", "PROTEIN", 89, 94], ["p65Ser536", "PROTEIN", 115, 124], ["RIG-I", "PROTEIN", 149, 154], ["MAVS", "PROTEIN", 155, 159], ["TRAF6", "PROTEIN", 160, 165], ["IKK\u03b2", "PROTEIN", 166, 170], ["RSV", "SPECIES", 77, 80], ["subsequent degradation", "PROBLEM", 53, 75], ["RSV", "TEST", 77, 80]]], ["Although NF-\u03baB contributes to the induction of type I and III IFNs, NF-\u03baB also strongly induces the expression of anti-apoptotic genes.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 9, 14], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 47, 66], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 68, 73], ["NF-\u03baB", "PROTEIN", 9, 14], ["type I and III IFNs", "PROTEIN", 47, 66], ["NF-\u03baB", "PROTEIN", 68, 73], ["anti-apoptotic genes", "DNA", 114, 134], ["type I and III IFNs", "PROBLEM", 47, 66], ["anti-apoptotic genes", "OBSERVATION", 114, 134]]], ["In the context of an RSV infection, the induction of an anti-apoptotic cellular environment by NF-\u03baB likely dominates the contribution of NF-\u03baB over the induction of IFN, which is primarily controlled by IRF3/7 activation.NS1 and NS2 interfere with the interferon regulatory factor and nuclear factor-kappa B transcription factorsTaken together, NS1 and NS2 suppress the induction of type I and III IFNs by targeting multiple proteins of the signaling cascade that leads to type I or III gene activation, i.e., RIG-I, MAVS, TRAF3, IKK\u03b5, TBK1, IRF3, and IRF7.", [["cellular", "ANATOMY", 71, 79], ["RSV infection", "DISEASE", 21, 34], ["RSV", "ORGANISM", 21, 24], ["cellular", "CELL", 71, 79], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 138, 143], ["IFN", "GENE_OR_GENE_PRODUCT", 166, 169], ["IRF3", "GENE_OR_GENE_PRODUCT", 204, 208], ["7", "GENE_OR_GENE_PRODUCT", 209, 210], ["NS1", "GENE_OR_GENE_PRODUCT", 222, 225], ["NS2", "GENE_OR_GENE_PRODUCT", 230, 233], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 253, 281], ["nuclear factor-kappa B", "GENE_OR_GENE_PRODUCT", 286, 308], ["NS1", "GENE_OR_GENE_PRODUCT", 346, 349], ["NS2", "GENE_OR_GENE_PRODUCT", 354, 357], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 384, 403], ["type I or III", "GENE_OR_GENE_PRODUCT", 474, 487], ["RIG-I", "GENE_OR_GENE_PRODUCT", 511, 516], ["MAVS", "GENE_OR_GENE_PRODUCT", 518, 522], ["TRAF3", "GENE_OR_GENE_PRODUCT", 524, 529], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 531, 535], ["TBK1", "GENE_OR_GENE_PRODUCT", 537, 541], ["IRF3", "GENE_OR_GENE_PRODUCT", 543, 547], ["IRF7", "GENE_OR_GENE_PRODUCT", 553, 557], ["NF-\u03baB", "PROTEIN", 95, 100], ["NF-\u03baB", "PROTEIN", 138, 143], ["IFN", "PROTEIN", 166, 169], ["IRF3/7", "PROTEIN", 204, 210], ["NS1", "PROTEIN", 222, 225], ["NS2", "PROTEIN", 230, 233], ["interferon regulatory factor", "PROTEIN", 253, 281], ["nuclear factor-kappa B transcription factors", "PROTEIN", 286, 330], ["NS1", "PROTEIN", 346, 349], ["NS2", "PROTEIN", 354, 357], ["type I and III IFNs", "PROTEIN", 384, 403], ["RIG", "PROTEIN", 511, 514], ["MAVS", "PROTEIN", 518, 522], ["TRAF3", "PROTEIN", 524, 529], ["IKK\u03b5", "PROTEIN", 531, 535], ["TBK1", "PROTEIN", 537, 541], ["IRF3", "PROTEIN", 543, 547], ["IRF7", "PROTEIN", 553, 557], ["RSV", "SPECIES", 21, 24], ["an RSV infection", "PROBLEM", 18, 34], ["NF", "PROBLEM", 138, 140], ["the induction of IFN", "TREATMENT", 149, 169], ["NS1", "PROBLEM", 222, 225], ["NS2", "TREATMENT", 230, 233], ["the interferon regulatory factor", "TREATMENT", 249, 281], ["nuclear factor", "TEST", 286, 300], ["NS1", "TREATMENT", 346, 349], ["NS2", "TREATMENT", 354, 357], ["type I and III IFNs", "PROBLEM", 384, 403], ["the signaling cascade", "PROBLEM", 438, 459], ["type I or III gene activation", "PROBLEM", 474, 503], ["MAVS", "PROBLEM", 518, 522], ["TRAF3", "PROBLEM", 524, 529], ["TBK1", "PROBLEM", 537, 541], ["IRF3", "PROBLEM", 543, 547], ["IRF7", "PROBLEM", 553, 557], ["RSV", "OBSERVATION", 21, 24], ["infection", "OBSERVATION", 25, 34], ["NS2", "OBSERVATION", 230, 233]]], ["Although some of these effector functions have been confirmed in RSV-infected cells, others have so far only been identified with overexpression of NS1 or NS2 alone.", [["cells", "ANATOMY", 78, 83], ["RSV-infected", "DISEASE", 65, 77], ["RSV", "ORGANISM", 65, 68], ["cells", "CELL", 78, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 148, 151], ["NS2", "GENE_OR_GENE_PRODUCT", 155, 158], ["RSV-infected cells", "CELL_TYPE", 65, 83], ["NS1", "PROTEIN", 148, 151], ["NS2", "PROTEIN", 155, 158], ["RSV", "SPECIES", 65, 68], ["RSV", "PROBLEM", 65, 68], ["infected cells", "PROBLEM", 69, 83], ["NS1", "TREATMENT", 148, 151], ["NS2", "TREATMENT", 155, 158], ["infected cells", "OBSERVATION", 69, 83]]], ["So, future research is needed to elucidate the biological relevance of these recombinant responses, particularly because NS2 can relocate NS1 to the mitochondria [58] .NS1 and NS2 suppress type I and III IFN receptor-mediated signal transductionBinding of type I and III IFNs to their heterodimeric receptor complex induces a Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling cascade that induces an antiviral state by expression of ISGs.", [["mitochondria", "ANATOMY", 149, 161], ["NS2", "GENE_OR_GENE_PRODUCT", 121, 124], ["NS1", "GENE_OR_GENE_PRODUCT", 138, 141], ["mitochondria", "CELLULAR_COMPONENT", 149, 161], ["NS1", "GENE_OR_GENE_PRODUCT", 168, 171], ["NS2", "GENE_OR_GENE_PRODUCT", 176, 179], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 189, 216], ["type I and III IFNs", "GENE_OR_GENE_PRODUCT", 256, 275], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 326, 338], ["JAK", "GENE_OR_GENE_PRODUCT", 340, 343], ["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 345, 393], ["STAT", "GENE_OR_GENE_PRODUCT", 395, 399], ["ISGs", "GENE_OR_GENE_PRODUCT", 468, 472], ["NS2", "PROTEIN", 121, 124], ["NS1", "PROTEIN", 138, 141], ["NS1", "PROTEIN", 168, 171], ["NS2", "PROTEIN", 176, 179], ["type I and III IFN receptor", "PROTEIN", 189, 216], ["type I and III IFNs", "PROTEIN", 256, 275], ["heterodimeric receptor complex", "PROTEIN", 285, 315], ["Janus kinase", "PROTEIN", 326, 338], ["JAK", "PROTEIN", 340, 343], ["STAT", "PROTEIN", 395, 399], ["ISGs", "DNA", 468, 472], ["NS2", "PROBLEM", 121, 124], ["NS1", "PROBLEM", 168, 171], ["NS2 suppress type I and III IFN receptor", "TREATMENT", 176, 216], ["signal transduction", "TREATMENT", 226, 245], ["type I and III IFNs", "PROBLEM", 256, 275], ["a Janus kinase (JAK)", "TREATMENT", 324, 344], ["signal transducer and activator of transcription", "TREATMENT", 345, 393], ["signaling cascade", "PROBLEM", 401, 418], ["ISGs", "PROBLEM", 468, 472]]], ["Compared with wild-type RSV, RSV strains that lack NS1 and/or NS2 are more sensitive to type I IFN treatment [30, 51] .", [["IFN", "CHEMICAL", 95, 98], ["wild-type RSV", "ORGANISM", 14, 27], ["RSV", "ORGANISM", 29, 32], ["NS1", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS2", "GENE_OR_GENE_PRODUCT", 62, 65], ["type I IFN", "GENE_OR_GENE_PRODUCT", 88, 98], ["NS1", "PROTEIN", 51, 54], ["NS2", "PROTEIN", 62, 65], ["type I IFN", "PROTEIN", 88, 98], ["RSV", "SPECIES", 24, 27], ["RSV", "SPECIES", 29, 32], ["type RSV", "PROBLEM", 19, 27], ["RSV strains", "PROBLEM", 29, 40], ["NS1", "TEST", 51, 54], ["NS2", "PROBLEM", 62, 65], ["type I IFN treatment", "TREATMENT", 88, 108]]], ["Thus, RSV NS proteins also have effector functions downstream of the induction of IFN synthesis to suppress IFNinduced antiviral responses.NS1 and NS2 suppress type I and III IFN receptor-mediated signal transductionIn RSV-infected A549 cells, NS1 induces the expression of the miRNA miR-29a, which targets the mRNA coding for interferon alpha/beta receptor 1 (IFNAR1) by an unknown mechanism (Fig 2) [59] .", [["A549 cells", "ANATOMY", 232, 242], ["RSV", "ORGANISM", 6, 9], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["NS1", "GENE_OR_GENE_PRODUCT", 139, 142], ["NS2", "GENE_OR_GENE_PRODUCT", 147, 150], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 160, 187], ["RSV", "ORGANISM", 219, 222], ["A549 cells", "CELL", 232, 242], ["NS1", "ORGANISM", 244, 247], ["miR-29a", "GENE_OR_GENE_PRODUCT", 284, 291], ["interferon alpha/beta receptor 1", "GENE_OR_GENE_PRODUCT", 327, 359], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 361, 367], ["RSV NS proteins", "PROTEIN", 6, 21], ["IFN", "PROTEIN", 82, 85], ["NS1", "PROTEIN", 139, 142], ["NS2", "PROTEIN", 147, 150], ["type I and III IFN receptor", "PROTEIN", 160, 187], ["A549 cells", "CELL_LINE", 232, 242], ["NS1", "PROTEIN", 244, 247], ["miRNA miR-29a", "DNA", 278, 291], ["mRNA", "RNA", 311, 315], ["interferon alpha/beta receptor 1", "PROTEIN", 327, 359], ["IFNAR1", "PROTEIN", 361, 367], ["RSV", "SPECIES", 6, 9], ["RSV", "SPECIES", 219, 222], ["RSV NS proteins", "TREATMENT", 6, 21], ["IFN synthesis", "TREATMENT", 82, 95], ["NS1", "PROBLEM", 139, 142], ["III IFN receptor", "TEST", 171, 187], ["signal transductionIn RSV", "TEST", 197, 222], ["infected A549 cells", "PROBLEM", 223, 242], ["NS1", "PROBLEM", 244, 247], ["the miRNA miR", "TEST", 274, 287], ["interferon alpha/beta receptor", "TREATMENT", 327, 357], ["NS2", "OBSERVATION", 147, 150], ["infected", "OBSERVATION_MODIFIER", 223, 231], ["A549 cells", "OBSERVATION", 232, 242]]], ["As a result, the IFNAR1 protein levels are reduced, which decreases responsiveness to type I IFNs of RSV-infected cells and thus favors RSV replication.", [["cells", "ANATOMY", 114, 119], ["RSV-infected", "DISEASE", 101, 113], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 17, 23], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 86, 97], ["RSV", "ORGANISM", 101, 104], ["cells", "CELL", 114, 119], ["RSV", "ORGANISM", 136, 139], ["IFNAR1", "PROTEIN", 17, 23], ["type I IFNs", "PROTEIN", 86, 97], ["RSV-infected cells", "CELL_TYPE", 101, 119], ["RSV", "SPECIES", 101, 104], ["RSV", "SPECIES", 136, 139], ["the IFNAR1 protein levels", "TEST", 13, 38], ["RSV", "PROBLEM", 101, 104], ["infected cells", "PROBLEM", 105, 119], ["RSV replication", "TREATMENT", 136, 151], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["infected cells", "OBSERVATION", 105, 119], ["favors", "UNCERTAINTY", 129, 135], ["RSV replication", "OBSERVATION", 136, 151]]], ["The induction of an antiviral state by type I and type III IFNs requires the phosphorylation of STAT1 and STAT2 proteins in the proximity of the type I and III receptors.NS1 and NS2 suppress type I and III IFN receptor-mediated signal transductionTwo tyrosine kinases, JAK1 and tyrosine kinase 2 (Tyk2), are responsible for the phosphorylation and activation of STAT proteins after activation of the type I and III IFN receptor ( Fig 2) .", [["tyrosine", "CHEMICAL", 251, 259], ["tyrosine", "CHEMICAL", 278, 286], ["tyrosine", "CHEMICAL", 251, 259], ["tyrosine", "CHEMICAL", 278, 286], ["type I", "GENE_OR_GENE_PRODUCT", 39, 45], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 50, 63], ["STAT1", "GENE_OR_GENE_PRODUCT", 96, 101], ["STAT2", "GENE_OR_GENE_PRODUCT", 106, 111], ["type I and III receptors", "GENE_OR_GENE_PRODUCT", 145, 169], ["NS1", "GENE_OR_GENE_PRODUCT", 170, 173], ["NS2", "GENE_OR_GENE_PRODUCT", 178, 181], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 191, 218], ["JAK1", "GENE_OR_GENE_PRODUCT", 269, 273], ["tyrosine kinase 2", "GENE_OR_GENE_PRODUCT", 278, 295], ["Tyk2", "GENE_OR_GENE_PRODUCT", 297, 301], ["STAT", "GENE_OR_GENE_PRODUCT", 362, 366], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 400, 427], ["Fig 2", "GENE_OR_GENE_PRODUCT", 430, 435], ["type I and type III IFNs", "PROTEIN", 39, 63], ["STAT1", "PROTEIN", 96, 101], ["STAT2 proteins", "PROTEIN", 106, 120], ["type I and III receptors", "PROTEIN", 145, 169], ["NS1", "PROTEIN", 170, 173], ["NS2", "PROTEIN", 178, 181], ["type I and III IFN receptor", "PROTEIN", 191, 218], ["tyrosine kinases", "PROTEIN", 251, 267], ["JAK1", "PROTEIN", 269, 273], ["tyrosine kinase 2", "PROTEIN", 278, 295], ["Tyk2", "PROTEIN", 297, 301], ["STAT proteins", "PROTEIN", 362, 375], ["type I and III IFN receptor", "PROTEIN", 400, 427], ["Fig 2", "PROTEIN", 430, 435], ["an antiviral state", "TREATMENT", 17, 35], ["type I and type III IFNs", "PROBLEM", 39, 63], ["the phosphorylation", "TREATMENT", 73, 92], ["STAT1 and STAT2 proteins", "TREATMENT", 96, 120], ["NS1", "PROBLEM", 170, 173], ["III IFN receptor", "TREATMENT", 202, 218], ["signal transduction", "TEST", 228, 247], ["Two tyrosine kinases", "TEST", 247, 267], ["JAK1", "TEST", 269, 273], ["tyrosine kinase", "TEST", 278, 293], ["the phosphorylation", "PROBLEM", 324, 343], ["STAT proteins", "TREATMENT", 362, 375], ["the type I and III IFN receptor ( Fig", "TREATMENT", 396, 433], ["NS2", "OBSERVATION", 178, 181]]], ["For now, there is no evidence that NS1 or NS2 may alter the levels and activation status of these 2 kinases.", [["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["NS2", "GENE_OR_GENE_PRODUCT", 42, 45], ["NS1", "PROTEIN", 35, 38], ["NS2", "PROTEIN", 42, 45], ["kinases", "PROTEIN", 100, 107], ["NS1", "PROBLEM", 35, 38], ["NS2", "PROBLEM", 42, 45], ["the levels", "TEST", 56, 66], ["no evidence", "UNCERTAINTY", 18, 29], ["NS1", "OBSERVATION", 35, 38]]], ["Several groups reported that the phosphorylation and total protein levels of Tyk2 are not altered by the expression of NS1 and/or NS2 [60] [61] [62] .", [["Tyk2", "GENE_OR_GENE_PRODUCT", 77, 81], ["NS1", "GENE_OR_GENE_PRODUCT", 119, 122], ["Tyk2", "PROTEIN", 77, 81], ["NS1", "PROTEIN", 119, 122], ["NS2", "PROTEIN", 130, 133], ["the phosphorylation", "TEST", 29, 48], ["total protein levels", "TEST", 53, 73], ["NS1", "TEST", 119, 122], ["NS2", "TEST", 130, 133]]], ["Whether this also accounts for JAK1 is currently not clear.", [["JAK1", "GENE_OR_GENE_PRODUCT", 31, 35], ["JAK1", "PROTEIN", 31, 35], ["JAK1", "PROBLEM", 31, 35], ["clear", "OBSERVATION", 53, 58]]], ["Infection of airway epithelial cell lines with human metapneumovirus, a respiratory virus closely related to RSV, does reduce both JAK1 and Tyk2 protein levels [63] .NS1 and NS2 suppress type I and III IFN receptor-mediated signal transductionAdditionally, JAK kinase activity is regulated by a negative feedback loop that consists of the suppressor of cytokine signaling (SOCS) family, with SOCS1 and 3 being the strongest inhibitors of JAK kinases.", [["airway epithelial cell lines", "ANATOMY", 13, 41], ["human metapneumovirus", "DISEASE", 47, 68], ["airway epithelial cell lines", "CELL", 13, 41], ["human", "ORGANISM", 47, 52], ["metapneumovirus", "ORGANISM", 53, 68], ["RSV", "ORGANISM", 109, 112], ["JAK1", "GENE_OR_GENE_PRODUCT", 131, 135], ["Tyk2", "GENE_OR_GENE_PRODUCT", 140, 144], ["NS1", "GENE_OR_GENE_PRODUCT", 166, 169], ["NS2", "GENE_OR_GENE_PRODUCT", 174, 177], ["type I and III IFN receptor", "GENE_OR_GENE_PRODUCT", 187, 214], ["JAK kinase", "GENE_OR_GENE_PRODUCT", 257, 267], ["suppressor of cytokine signaling", "GENE_OR_GENE_PRODUCT", 339, 371], ["SOCS", "GENE_OR_GENE_PRODUCT", 373, 377], ["SOCS1", "GENE_OR_GENE_PRODUCT", 392, 397], ["3", "GENE_OR_GENE_PRODUCT", 402, 403], ["JAK kinases", "GENE_OR_GENE_PRODUCT", 438, 449], ["airway epithelial cell lines", "CELL_LINE", 13, 41], ["JAK1", "PROTEIN", 131, 135], ["Tyk2", "PROTEIN", 140, 144], ["NS1", "PROTEIN", 166, 169], ["NS2", "PROTEIN", 174, 177], ["type I and III IFN receptor", "PROTEIN", 187, 214], ["JAK kinase", "PROTEIN", 257, 267], ["suppressor of cytokine signaling (SOCS) family", "PROTEIN", 339, 385], ["SOCS1", "PROTEIN", 392, 397], ["JAK kinases", "PROTEIN", 438, 449], ["human", "SPECIES", 47, 52], ["metapneumovirus", "SPECIES", 53, 68], ["human metapneumovirus", "SPECIES", 47, 68], ["RSV", "SPECIES", 109, 112], ["Infection of airway epithelial cell lines", "PROBLEM", 0, 41], ["human metapneumovirus", "PROBLEM", 47, 68], ["a respiratory virus", "PROBLEM", 70, 89], ["RSV", "PROBLEM", 109, 112], ["Tyk2 protein levels", "TEST", 140, 159], ["NS1", "PROBLEM", 166, 169], ["III IFN receptor-mediated signal transduction", "TREATMENT", 198, 243], ["JAK kinase activity", "PROBLEM", 257, 276], ["a negative feedback loop", "PROBLEM", 293, 317], ["JAK kinases", "TREATMENT", 438, 449], ["airway", "ANATOMY", 13, 19], ["epithelial cell lines", "OBSERVATION", 20, 41], ["metapneumovirus", "OBSERVATION", 53, 68], ["respiratory virus", "OBSERVATION", 72, 89], ["NS2", "OBSERVATION", 174, 177]]], ["It has been reported that NS1 and/or NS2 may regulate the expression of SOCS1 and/or SOCS3, thereby enhancing RSV replication [64] [65] [66] [67] .", [["NS1", "GENE_OR_GENE_PRODUCT", 26, 29], ["NS2", "GENE_OR_GENE_PRODUCT", 37, 40], ["SOCS1", "GENE_OR_GENE_PRODUCT", 72, 77], ["SOCS3", "GENE_OR_GENE_PRODUCT", 85, 90], ["RSV", "ORGANISM", 110, 113], ["NS1", "PROTEIN", 26, 29], ["NS2", "PROTEIN", 37, 40], ["SOCS1", "PROTEIN", 72, 77], ["SOCS3", "PROTEIN", 85, 90], ["RSV", "SPECIES", 110, 113], ["NS1", "TREATMENT", 26, 29], ["NS2", "TREATMENT", 37, 40], ["SOCS1", "PROBLEM", 72, 77], ["SOCS1", "OBSERVATION", 72, 77]]], ["Heterodimers of phosphorylated STAT1 and 2 transcription factors are important for the induction of ISGs.", [["STAT1", "GENE_OR_GENE_PRODUCT", 31, 36], ["2", "GENE_OR_GENE_PRODUCT", 41, 42], ["phosphorylated STAT1 and 2 transcription factors", "PROTEIN", 16, 64], ["ISGs", "DNA", 100, 104], ["phosphorylated STAT1", "TREATMENT", 16, 36], ["2 transcription factors", "TREATMENT", 41, 64], ["the induction of ISGs", "TREATMENT", 83, 104], ["phosphorylated STAT1", "OBSERVATION", 16, 36]]], ["Consequently, numerous viral proteins counteract STAT1 and 2 proteins by using different strategies, e.g., by preventing STAT1/2 heterodimer formation (Nipah and Hendra virus nucleoprotein), by suppressing STAT1/2 nuclear translocation (Ebolavirus VP24), or by degrading STAT1 and/or 2 (Paramyxovirus V protein) [68] [69] [70] .", [["nuclear", "ANATOMY", 214, 221], ["STAT1", "GENE_OR_GENE_PRODUCT", 49, 54], ["2", "GENE_OR_GENE_PRODUCT", 59, 60], ["STAT1", "GENE_OR_GENE_PRODUCT", 121, 126], ["2", "GENE_OR_GENE_PRODUCT", 127, 128], ["Nipah", "ORGANISM", 152, 157], ["Hendra virus nucleoprotein", "ORGANISM", 162, 188], ["STAT1", "GENE_OR_GENE_PRODUCT", 206, 211], ["2", "GENE_OR_GENE_PRODUCT", 212, 213], ["Ebolavirus VP24", "GENE_OR_GENE_PRODUCT", 237, 252], ["STAT1", "GENE_OR_GENE_PRODUCT", 271, 276], ["Paramyxovirus V", "GENE_OR_GENE_PRODUCT", 287, 302], ["viral proteins", "PROTEIN", 23, 37], ["STAT1 and 2 proteins", "PROTEIN", 49, 69], ["STAT1", "PROTEIN", 121, 126], ["STAT1", "PROTEIN", 206, 211], ["Ebolavirus VP24", "PROTEIN", 237, 252], ["STAT1", "PROTEIN", 271, 276], ["Paramyxovirus V protein", "PROTEIN", 287, 310], ["Hendra virus", "SPECIES", 162, 174], ["Hendra virus", "SPECIES", 162, 174], ["STAT1/2 heterodimer formation", "TREATMENT", 121, 150], ["Nipah and Hendra virus nucleoprotein", "TREATMENT", 152, 188], ["STAT1 and/or 2 (Paramyxovirus V protein", "TEST", 271, 310], ["viral proteins", "OBSERVATION", 23, 37]]], ["Both STAT1 and 2 are targets for RSV.", [["STAT1", "GENE_OR_GENE_PRODUCT", 5, 10], ["2", "GENE_OR_GENE_PRODUCT", 15, 16], ["RSV", "ORGANISM", 33, 36], ["STAT1", "PROTEIN", 5, 10], ["RSV", "SPECIES", 33, 36], ["RSV", "PROBLEM", 33, 36], ["RSV", "OBSERVATION", 33, 36]]], ["In human tracheobronchial epithelial cells and A549 cells, infection with RSV slightly increases total STAT1 protein levels, likely because STAT proteins are themselves ISG products [60-62, 71, 72] .", [["tracheobronchial epithelial cells", "ANATOMY", 9, 42], ["A549 cells", "ANATOMY", 47, 57], ["infection", "DISEASE", 59, 68], ["human", "ORGANISM", 3, 8], ["tracheobronchial epithelial cells", "CELL", 9, 42], ["A549 cells", "CELL", 47, 57], ["RSV", "ORGANISM", 74, 77], ["STAT1", "GENE_OR_GENE_PRODUCT", 103, 108], ["STAT", "GENE_OR_GENE_PRODUCT", 140, 144], ["ISG", "GENE_OR_GENE_PRODUCT", 169, 172], ["human tracheobronchial epithelial cells", "CELL_TYPE", 3, 42], ["A549 cells", "CELL_LINE", 47, 57], ["STAT1", "PROTEIN", 103, 108], ["STAT proteins", "PROTEIN", 140, 153], ["ISG products", "PROTEIN", 169, 181], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["RSV", "SPECIES", 74, 77], ["A549 cells", "PROBLEM", 47, 57], ["infection", "PROBLEM", 59, 68], ["RSV", "PROBLEM", 74, 77], ["total STAT1 protein levels", "TEST", 97, 123], ["STAT proteins", "TEST", 140, 153], ["tracheobronchial", "ANATOMY", 9, 25], ["epithelial cells", "OBSERVATION", 26, 42], ["A549 cells", "OBSERVATION", 47, 57], ["infection", "OBSERVATION", 59, 68], ["RSV", "OBSERVATION_MODIFIER", 74, 77], ["slightly", "OBSERVATION_MODIFIER", 78, 86], ["increases", "OBSERVATION_MODIFIER", 87, 96]]], ["STAT1 phosphorylation induced by exogenous type I IFN, however, is clearly reduced by NS2 but not by NS1 (Fig 2) [ [60] [61] [62] 73] .", [["STAT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["type I IFN", "GENE_OR_GENE_PRODUCT", 43, 53], ["STAT1", "PROTEIN", 0, 5], ["exogenous type I IFN", "PROTEIN", 33, 53], ["NS2", "PROTEIN", 86, 89], ["NS1", "PROTEIN", 101, 104], ["STAT1 phosphorylation", "TREATMENT", 0, 21], ["exogenous type I IFN", "PROBLEM", 33, 53]]], ["Whether NS2 also reduces STAT1 phosphorylation during an RSV infection has not been reported yet.", [["RSV infection", "DISEASE", 57, 70], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["STAT1", "GENE_OR_GENE_PRODUCT", 25, 30], ["RSV", "ORGANISM", 57, 60], ["NS2", "PROTEIN", 8, 11], ["STAT1", "PROTEIN", 25, 30], ["RSV", "SPECIES", 57, 60], ["NS2", "PROBLEM", 8, 11], ["STAT1 phosphorylation", "PROBLEM", 25, 46], ["an RSV infection", "PROBLEM", 54, 70], ["infection", "OBSERVATION", 61, 70]]], ["In contrast to STAT1, both phosphorylated and nonphosphorylated STAT2 protein levels are clearly reduced by RSV infection [60, 62, 73] .", [["RSV infection", "DISEASE", 108, 121], ["STAT1", "GENE_OR_GENE_PRODUCT", 15, 20], ["STAT2", "GENE_OR_GENE_PRODUCT", 64, 69], ["RSV", "ORGANISM", 108, 111], ["STAT1", "PROTEIN", 15, 20], ["STAT2", "PROTEIN", 64, 69], ["RSV", "SPECIES", 108, 111], ["both phosphorylated and nonphosphorylated STAT2 protein levels", "TEST", 22, 84], ["RSV infection", "PROBLEM", 108, 121], ["reduced", "OBSERVATION_MODIFIER", 97, 104], ["RSV infection", "OBSERVATION", 108, 121]]], ["Whether NS1, NS2, or both reduce STAT2 levels is currently debated.", [["NS1", "GENE_OR_GENE_PRODUCT", 8, 11], ["NS2", "GENE_OR_GENE_PRODUCT", 13, 16], ["STAT2", "GENE_OR_GENE_PRODUCT", 33, 38], ["NS1", "PROTEIN", 8, 11], ["NS2", "PROTEIN", 13, 16], ["STAT2", "PROTEIN", 33, 38], ["NS1", "PROBLEM", 8, 11], ["NS2", "TREATMENT", 13, 16], ["STAT2 levels", "TEST", 33, 45]]], ["Based on overexpression experiments and infections with RSV strains lacking NS1 and/or NS2, several groups reported that NS2, but not NS1, reduces STAT2 levels in vitro (Fig 2) [51, 52, 61, 62] .", [["infections", "DISEASE", 40, 50], ["RSV", "ORGANISM", 56, 59], ["NS1", "GENE_OR_GENE_PRODUCT", 76, 79], ["NS2", "GENE_OR_GENE_PRODUCT", 87, 90], ["NS2", "GENE_OR_GENE_PRODUCT", 121, 124], ["NS1", "GENE_OR_GENE_PRODUCT", 134, 137], ["STAT2", "GENE_OR_GENE_PRODUCT", 147, 152], ["NS1", "PROTEIN", 76, 79], ["NS2", "PROTEIN", 87, 90], ["NS2", "PROTEIN", 121, 124], ["NS1", "PROTEIN", 134, 137], ["STAT2", "PROTEIN", 147, 152], ["RSV", "SPECIES", 56, 59], ["overexpression experiments", "PROBLEM", 9, 35], ["infections", "PROBLEM", 40, 50], ["RSV strains", "PROBLEM", 56, 67], ["NS2", "PROBLEM", 87, 90], ["NS2", "TREATMENT", 121, 124], ["NS1", "PROBLEM", 134, 137], ["STAT2 levels", "TEST", 147, 159], ["infections", "OBSERVATION", 40, 50]]], ["Others, however, also observed reduced STAT2 levels after overexpression of NS1 (Fig 2) [66, 73] .", [["STAT2", "GENE_OR_GENE_PRODUCT", 39, 44], ["NS1", "GENE_OR_GENE_PRODUCT", 76, 79], ["STAT2", "PROTEIN", 39, 44], ["NS1", "PROTEIN", 76, 79], ["reduced STAT2 levels", "PROBLEM", 31, 51]]], ["Lo and colleagues reported that recombinant coexpression of NS1 and NS2 reduces STAT2 levels stronger than NS2 alone, although expression of NS1 alone did not affect STAT2 levels [62] .", [["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS2", "GENE_OR_GENE_PRODUCT", 68, 71], ["STAT2", "GENE_OR_GENE_PRODUCT", 80, 85], ["NS2", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS1", "GENE_OR_GENE_PRODUCT", 141, 144], ["STAT2", "GENE_OR_GENE_PRODUCT", 166, 171], ["NS1", "PROTEIN", 60, 63], ["NS2", "PROTEIN", 68, 71], ["STAT2", "PROTEIN", 80, 85], ["NS2", "PROTEIN", 107, 110], ["NS1", "PROTEIN", 141, 144], ["STAT2", "PROTEIN", 166, 171], ["NS1", "TREATMENT", 60, 63], ["NS2", "TREATMENT", 68, 71], ["STAT2 levels", "TEST", 80, 92], ["NS2", "TREATMENT", 107, 110], ["NS1", "PROBLEM", 141, 144], ["STAT2 levels", "TEST", 166, 178]]], ["In addition to reducing total STAT2 levels, RSV also seems to suppress nuclear translocation of the residual STAT2 proteins, an effect that depends on NS1 and/or NS2 [62] .", [["nuclear", "ANATOMY", 71, 78], ["STAT2", "GENE_OR_GENE_PRODUCT", 30, 35], ["RSV", "ORGANISM", 44, 47], ["nuclear", "CELLULAR_COMPONENT", 71, 78], ["STAT2", "GENE_OR_GENE_PRODUCT", 109, 114], ["NS1", "GENE_OR_GENE_PRODUCT", 151, 154], ["STAT2", "PROTEIN", 30, 35], ["STAT2 proteins", "PROTEIN", 109, 123], ["NS1", "PROTEIN", 151, 154], ["NS2", "PROTEIN", 162, 165], ["RSV", "SPECIES", 44, 47], ["total STAT2 levels", "TEST", 24, 42], ["RSV", "PROBLEM", 44, 47], ["the residual STAT2 proteins", "PROBLEM", 96, 123], ["NS1", "PROBLEM", 151, 154], ["NS2", "PROBLEM", 162, 165], ["residual STAT2", "OBSERVATION", 100, 114]]], ["So far, the possible impact of RSV NS proteins on STAT1 and 2 expression levels in vivo has not yet been demonstrated.", [["RSV", "ORGANISM", 31, 34], ["STAT1", "GENE_OR_GENE_PRODUCT", 50, 55], ["2", "GENE_OR_GENE_PRODUCT", 60, 61], ["RSV NS proteins", "PROTEIN", 31, 46], ["STAT1", "PROTEIN", 50, 55], ["RSV", "SPECIES", 31, 34], ["RSV NS proteins", "TREATMENT", 31, 46], ["STAT1 and 2 expression levels", "TREATMENT", 50, 79], ["RSV", "OBSERVATION", 31, 34]]], ["Because mouse STAT2 appears resistant to NS2, primary human airway epithelial cell cultures or experiments in nonhuman primates may be required to confirm that NS2-mediated STAT2 reduction also occurs in vivo [62] .NS1 and NS2 interfere with ISG productsEvidence is rising that the NS proteins also suppress the antiviral activity of at least some ISG products.", [["airway epithelial cell cultures", "ANATOMY", 60, 91], ["mouse", "ORGANISM", 8, 13], ["STAT2", "GENE_OR_GENE_PRODUCT", 14, 19], ["NS2", "GENE_OR_GENE_PRODUCT", 41, 44], ["human", "ORGANISM", 54, 59], ["airway epithelial cell cultures", "CELL", 60, 91], ["nonhuman", "ORGANISM", 110, 118], ["primates", "ORGANISM", 119, 127], ["NS2", "GENE_OR_GENE_PRODUCT", 160, 163], ["STAT2", "GENE_OR_GENE_PRODUCT", 173, 178], ["NS1", "GENE_OR_GENE_PRODUCT", 215, 218], ["NS2", "GENE_OR_GENE_PRODUCT", 223, 226], ["ISG", "GENE_OR_GENE_PRODUCT", 242, 245], ["mouse STAT2", "PROTEIN", 8, 19], ["NS2", "PROTEIN", 41, 44], ["primary human airway epithelial cell cultures", "CELL_LINE", 46, 91], ["NS2", "PROTEIN", 160, 163], ["STAT2", "PROTEIN", 173, 178], ["NS1", "PROTEIN", 215, 218], ["NS2", "PROTEIN", 223, 226], ["ISG products", "PROTEIN", 242, 254], ["NS proteins", "PROTEIN", 282, 293], ["ISG products", "PROTEIN", 348, 360], ["mouse", "SPECIES", 8, 13], ["human", "SPECIES", 54, 59], ["mouse", "SPECIES", 8, 13], ["human", "SPECIES", 54, 59], ["mouse STAT2", "PROBLEM", 8, 19], ["NS2", "TREATMENT", 41, 44], ["primary human airway epithelial cell cultures", "TEST", 46, 91], ["NS2-mediated STAT2 reduction", "TREATMENT", 160, 188], ["NS1", "TREATMENT", 215, 218], ["NS2", "TREATMENT", 223, 226], ["ISG products", "TREATMENT", 242, 254], ["the NS proteins", "TREATMENT", 278, 293], ["some ISG products", "TREATMENT", 343, 360], ["resistant", "OBSERVATION_MODIFIER", 28, 37], ["airway", "ANATOMY", 60, 66], ["epithelial cell", "OBSERVATION", 67, 82], ["NS2", "OBSERVATION", 223, 226], ["rising", "OBSERVATION_MODIFIER", 266, 272], ["antiviral activity", "OBSERVATION", 312, 330], ["ISG products", "OBSERVATION", 348, 360]]], ["Cells that express myxovirus resistance protein A (MxA) or cells pretreated with type I IFN only modestly limit RSV replication [74] .", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 59, 64], ["Cells", "CELL", 0, 5], ["myxovirus resistance protein A", "GENE_OR_GENE_PRODUCT", 19, 49], ["MxA", "GENE_OR_GENE_PRODUCT", 51, 54], ["cells", "CELL", 59, 64], ["type I IFN", "GENE_OR_GENE_PRODUCT", 81, 91], ["RSV", "ORGANISM", 112, 115], ["myxovirus resistance protein A", "PROTEIN", 19, 49], ["MxA", "PROTEIN", 51, 54], ["type I IFN", "PROTEIN", 81, 91], ["RSV", "SPECIES", 112, 115], ["Cells", "TEST", 0, 5], ["myxovirus resistance protein A (MxA) or cells", "PROBLEM", 19, 64], ["type I IFN", "PROBLEM", 81, 91], ["myxovirus resistance", "OBSERVATION", 19, 39]]], ["Moreover, ectopic expression of NS1 and NS2 in HEK293-derived cells has been shown to degrade certain ISG products, i.e., 2 0 -5 0 oligoadenylate synthetase-like protein (OASL), interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), interferon-induced transmembrane protein 3 (IFITM3), and MAPK8, in a selective manner (Fig 2) [75, 76] .", [["HEK293-derived cells", "ANATOMY", 47, 67], ["NS1", "GENE_OR_GENE_PRODUCT", 32, 35], ["NS2", "GENE_OR_GENE_PRODUCT", 40, 43], ["HEK293-derived cells", "CELL", 47, 67], ["ISG", "GENE_OR_GENE_PRODUCT", 102, 105], ["oligoadenylate synthetase-like protein", "GENE_OR_GENE_PRODUCT", 131, 169], ["OASL", "GENE_OR_GENE_PRODUCT", 171, 175], ["interferon", "GENE_OR_GENE_PRODUCT", 178, 188], ["tetratricopeptide repeats 1", "GENE_OR_GENE_PRODUCT", 210, 237], ["IFIT1", "GENE_OR_GENE_PRODUCT", 239, 244], ["interferon-induced transmembrane protein 3", "GENE_OR_GENE_PRODUCT", 247, 289], ["IFITM3", "GENE_OR_GENE_PRODUCT", 291, 297], ["MAPK8", "GENE_OR_GENE_PRODUCT", 304, 309], ["NS1", "PROTEIN", 32, 35], ["NS2", "PROTEIN", 40, 43], ["HEK293-derived cells", "CELL_LINE", 47, 67], ["ISG products", "PROTEIN", 102, 114], ["2 0 -5 0 oligoadenylate synthetase", "PROTEIN", 122, 156], ["like protein", "PROTEIN", 157, 169], ["OASL", "PROTEIN", 171, 175], ["interferon", "PROTEIN", 178, 188], ["tetratricopeptide repeats 1", "PROTEIN", 210, 237], ["IFIT1", "PROTEIN", 239, 244], ["interferon", "PROTEIN", 247, 257], ["transmembrane protein 3", "PROTEIN", 266, 289], ["IFITM3", "PROTEIN", 291, 297], ["MAPK8", "PROTEIN", 304, 309], ["ectopic expression", "PROBLEM", 10, 28], ["NS1", "PROBLEM", 32, 35], ["NS2 in HEK293", "TEST", 40, 53], ["oligoadenylate synthetase", "TEST", 131, 156], ["OASL", "TEST", 171, 175], ["interferon", "TREATMENT", 178, 188], ["tetratricopeptide repeats", "TEST", 210, 235], ["interferon", "TREATMENT", 247, 257], ["transmembrane protein", "TEST", 266, 287], ["MAPK8", "TEST", 304, 309]]], ["An important remark, however, is that these effector functions have not yet been validated during an RSV infection.", [["RSV infection", "DISEASE", 101, 114], ["RSV", "ORGANISM", 101, 104], ["RSV", "SPECIES", 101, 104], ["an RSV infection", "PROBLEM", 98, 114], ["RSV", "OBSERVATION_MODIFIER", 101, 104], ["infection", "OBSERVATION", 105, 114]]], ["As stated by Ribaudo and Barik, a comprehensive screen of all known ISGs will likely unravel additional substrates of NS1 and/or NS2 [76] .Other effector functions of RSV NS1 and NS2NS1 and NS2 affect the induction of apoptosis and cell shedding.", [["cell", "ANATOMY", 232, 236], ["NS1", "GENE_OR_GENE_PRODUCT", 118, 121], ["RSV", "ORGANISM", 167, 170], ["NS1", "GENE_OR_GENE_PRODUCT", 171, 174], ["NS2NS1", "GENE_OR_GENE_PRODUCT", 179, 185], ["NS2", "GENE_OR_GENE_PRODUCT", 190, 193], ["cell", "CELL", 232, 236], ["ISGs", "DNA", 68, 72], ["NS1", "PROTEIN", 118, 121], ["NS2", "PROTEIN", 129, 132], ["RSV NS1", "PROTEIN", 167, 174], ["NS2NS1", "PROTEIN", 179, 185], ["NS2", "PROTEIN", 190, 193], ["RSV", "SPECIES", 167, 170], ["a comprehensive screen", "TEST", 32, 54], ["NS1", "TREATMENT", 118, 121], ["NS2", "PROBLEM", 129, 132], ["RSV NS1", "TREATMENT", 167, 174], ["NS2NS1", "TREATMENT", 179, 185], ["NS2", "TREATMENT", 190, 193], ["apoptosis", "PROBLEM", 218, 227], ["cell shedding", "PROBLEM", 232, 245], ["apoptosis", "OBSERVATION", 218, 227]]], ["NS1 and NS2 individually and cooperatively delay apoptosis in RSV-infected cells, with NS2 being stronger than NS1 in doing so [57] .", [["cells", "ANATOMY", 75, 80], ["RSV-infected", "DISEASE", 62, 74], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["RSV", "ORGANISM", 62, 65], ["cells", "CELL", 75, 80], ["NS2", "GENE_OR_GENE_PRODUCT", 87, 90], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["RSV-infected cells", "CELL_TYPE", 62, 80], ["NS2", "PROTEIN", 87, 90], ["NS1", "PROTEIN", 111, 114], ["RSV", "SPECIES", 62, 65], ["NS1", "PROBLEM", 0, 3], ["NS2", "TREATMENT", 8, 11], ["cooperatively delay apoptosis", "PROBLEM", 29, 58], ["RSV", "PROBLEM", 62, 65], ["infected cells", "PROBLEM", 66, 80], ["NS2", "PROBLEM", 87, 90], ["NS2", "OBSERVATION", 8, 11], ["cooperatively", "OBSERVATION_MODIFIER", 29, 42], ["delay", "OBSERVATION_MODIFIER", 43, 48], ["apoptosis", "OBSERVATION_MODIFIER", 49, 58], ["RSV", "ANATOMY", 62, 65], ["infected cells", "OBSERVATION", 66, 80]]], ["The early expression of NS1 and NS2 after infection activates the antiapoptotic 3-phophoinositide-dependent protein kinase (PDK)-RAC serine/threonine-protein kinase (AKT)-glycogen synthase kinase (GSK) pathway [56, 57, 77] .", [["infection", "DISEASE", 42, 51], ["glycogen", "CHEMICAL", 171, 179], ["3-phophoinositide", "CHEMICAL", 80, 97], ["serine", "CHEMICAL", 133, 139], ["threonine", "CHEMICAL", 140, 149], ["NS1", "GENE_OR_GENE_PRODUCT", 24, 27], ["NS2", "GENE_OR_GENE_PRODUCT", 32, 35], ["phophoinositide-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 82, 122], ["PDK", "GENE_OR_GENE_PRODUCT", 124, 127], ["RAC serine/threonine-protein kinase", "GENE_OR_GENE_PRODUCT", 129, 164], ["AKT", "GENE_OR_GENE_PRODUCT", 166, 169], ["glycogen synthase kinase", "GENE_OR_GENE_PRODUCT", 171, 195], ["GSK", "GENE_OR_GENE_PRODUCT", 197, 200], ["NS1", "PROTEIN", 24, 27], ["NS2", "PROTEIN", 32, 35], ["antiapoptotic 3-phophoinositide-dependent protein kinase (PDK)-RAC serine/threonine-protein kinase", "PROTEIN", 66, 164], ["AKT", "PROTEIN", 166, 169], ["glycogen synthase kinase", "PROTEIN", 171, 195], ["GSK", "PROTEIN", 197, 200], ["NS1", "PROBLEM", 24, 27], ["NS2", "PROBLEM", 32, 35], ["infection", "PROBLEM", 42, 51], ["the antiapoptotic", "TEST", 62, 79], ["dependent protein kinase", "PROBLEM", 98, 122], ["PDK", "TEST", 124, 127], ["RAC serine/threonine-protein kinase", "TEST", 129, 164], ["AKT", "TEST", 166, 169], ["glycogen synthase kinase", "TEST", 171, 195]]], ["Later in infection (>24 hours), activation of this pathway drops, and the incidence of apoptosis increases [57] .", [["infection", "DISEASE", 9, 18], ["infection", "PROBLEM", 9, 18], ["this pathway drops", "TREATMENT", 46, 64], ["apoptosis increases", "PROBLEM", 87, 106], ["infection", "OBSERVATION", 9, 18]]], ["By delaying apoptosis, NS1 and NS2 may facilitate prolonged RSV replication with increased viral yields.Other effector functions of RSV NS1 and NS2A typical hallmark of severe disease following RSV infection is the obstruction of the smaller airways by plugs consisting of infiltrating immune cells, mucus, and shed infected epithelial cells.", [["airways", "ANATOMY", 242, 249], ["immune cells", "ANATOMY", 286, 298], ["mucus", "ANATOMY", 300, 305], ["epithelial cells", "ANATOMY", 325, 341], ["RSV infection", "DISEASE", 194, 207], ["NS1", "GENE_OR_GENE_PRODUCT", 23, 26], ["NS2", "GENE_OR_GENE_PRODUCT", 31, 34], ["RSV", "ORGANISM", 60, 63], ["RSV NS1", "ORGANISM", 132, 139], ["NS2A", "GENE_OR_GENE_PRODUCT", 144, 148], ["RSV", "ORGANISM", 194, 197], ["airways", "MULTI-TISSUE_STRUCTURE", 242, 249], ["immune cells", "CELL", 286, 298], ["mucus", "ORGANISM_SUBSTANCE", 300, 305], ["epithelial cells", "CELL", 325, 341], ["NS1", "PROTEIN", 23, 26], ["NS2", "PROTEIN", 31, 34], ["RSV NS1", "PROTEIN", 132, 139], ["NS2A", "PROTEIN", 144, 148], ["infiltrating immune cells", "CELL_TYPE", 273, 298], ["shed infected epithelial cells", "CELL_TYPE", 311, 341], ["RSV", "SPECIES", 60, 63], ["RSV", "SPECIES", 132, 135], ["RSV", "SPECIES", 194, 197], ["apoptosis", "PROBLEM", 12, 21], ["NS1", "TREATMENT", 23, 26], ["NS2", "TREATMENT", 31, 34], ["prolonged RSV replication", "TREATMENT", 50, 75], ["increased viral yields", "PROBLEM", 81, 103], ["RSV NS1", "TEST", 132, 139], ["severe disease", "PROBLEM", 169, 183], ["RSV infection", "PROBLEM", 194, 207], ["the obstruction of the smaller airways by plugs", "PROBLEM", 211, 258], ["infiltrating immune cells", "PROBLEM", 273, 298], ["mucus", "PROBLEM", 300, 305], ["shed infected epithelial cells", "PROBLEM", 311, 341], ["RSV replication", "OBSERVATION", 60, 75], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["viral yields", "OBSERVATION", 91, 103], ["RSV NS1", "OBSERVATION", 132, 139], ["hallmark", "OBSERVATION_MODIFIER", 157, 165], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["disease", "OBSERVATION", 176, 183], ["RSV infection", "OBSERVATION", 194, 207], ["obstruction", "OBSERVATION", 215, 226], ["smaller", "OBSERVATION_MODIFIER", 234, 241], ["airways", "ANATOMY", 242, 249], ["plugs", "OBSERVATION", 253, 258], ["infiltrating immune cells", "OBSERVATION", 273, 298], ["mucus", "OBSERVATION_MODIFIER", 300, 305], ["infected epithelial cells", "OBSERVATION", 316, 341]]], ["In primary human airway epithelial cells and in an in vivo hamster model, it has been shown by experiments with a set of elegant recombinant virus constructs that RSV NS2 is necessary and sufficient to induce shedding of infected epithelial cells [78] .", [["airway epithelial cells", "ANATOMY", 17, 40], ["hamster", "ANATOMY", 59, 66], ["epithelial cells", "ANATOMY", 230, 246], ["human", "ORGANISM", 11, 16], ["airway epithelial cells", "CELL", 17, 40], ["hamster", "ORGANISM", 59, 66], ["RSV", "ORGANISM", 163, 166], ["NS2", "ORGANISM", 167, 170], ["epithelial cells", "CELL", 230, 246], ["primary human airway epithelial cells", "CELL_TYPE", 3, 40], ["RSV NS2", "PROTEIN", 163, 170], ["infected epithelial cells", "CELL_TYPE", 221, 246], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["hamster", "SPECIES", 59, 66], ["RSV", "SPECIES", 163, 166], ["primary human airway epithelial cells", "PROBLEM", 3, 40], ["elegant recombinant virus constructs", "TREATMENT", 121, 157], ["RSV NS2", "TREATMENT", 163, 170], ["infected epithelial cells", "PROBLEM", 221, 246], ["airway epithelial cells", "OBSERVATION", 17, 40], ["infected epithelial cells", "OBSERVATION", 221, 246]]], ["Interestingly, cell death, associated with nuclear changes that are indicative of apoptosis, of infected epithelial cells only occurred after these cells were detached from the epithelial layer.", [["cell", "ANATOMY", 15, 19], ["nuclear", "ANATOMY", 43, 50], ["epithelial cells", "ANATOMY", 105, 121], ["cells", "ANATOMY", 148, 153], ["epithelial layer", "ANATOMY", 177, 193], ["death", "DISEASE", 20, 25], ["cell", "CELL", 15, 19], ["nuclear", "CELLULAR_COMPONENT", 43, 50], ["epithelial cells", "CELL", 105, 121], ["cells", "CELL", 148, 153], ["epithelial layer", "TISSUE", 177, 193], ["infected epithelial cells", "CELL_TYPE", 96, 121], ["cell death", "PROBLEM", 15, 25], ["nuclear changes", "PROBLEM", 43, 58], ["apoptosis", "PROBLEM", 82, 91], ["infected epithelial cells", "PROBLEM", 96, 121], ["these cells", "PROBLEM", 142, 153], ["cell death", "OBSERVATION", 15, 25], ["indicative of", "UNCERTAINTY", 68, 81], ["apoptosis", "OBSERVATION", 82, 91], ["infected", "OBSERVATION_MODIFIER", 96, 104], ["epithelial cells", "OBSERVATION", 105, 121], ["epithelial", "ANATOMY_MODIFIER", 177, 187], ["layer", "OBSERVATION_MODIFIER", 188, 193]]], ["Moreover, shedding of infected epithelial cells coincided with reducing viral titers.Other effector functions of RSV NS1 and NS2All together, these results suggest that expression of NS2 early after infection delays apoptosis and induces changes in cell morphology that ultimately result in shedding of infected cells in the airway lumen.", [["epithelial cells", "ANATOMY", 31, 47], ["cell", "ANATOMY", 249, 253], ["cells", "ANATOMY", 312, 317], ["airway lumen", "ANATOMY", 325, 337], ["infection", "DISEASE", 199, 208], ["epithelial cells", "CELL", 31, 47], ["RSV", "ORGANISM", 113, 116], ["NS1", "ORGANISM", 117, 120], ["NS2", "ORGANISM", 125, 128], ["NS2", "GENE_OR_GENE_PRODUCT", 183, 186], ["cell", "CELL", 249, 253], ["cells", "CELL", 312, 317], ["airway lumen", "MULTI-TISSUE_STRUCTURE", 325, 337], ["infected epithelial cells", "CELL_TYPE", 22, 47], ["RSV NS1", "PROTEIN", 113, 120], ["NS2", "PROTEIN", 125, 128], ["NS2", "PROTEIN", 183, 186], ["infected cells", "CELL_TYPE", 303, 317], ["RSV", "SPECIES", 113, 116], ["infected epithelial cells", "PROBLEM", 22, 47], ["reducing viral titers", "PROBLEM", 63, 84], ["RSV NS1", "TREATMENT", 113, 120], ["NS2", "PROBLEM", 183, 186], ["infection delays apoptosis", "PROBLEM", 199, 225], ["changes in cell morphology", "PROBLEM", 238, 264], ["infected cells in the airway lumen", "PROBLEM", 303, 337], ["infected epithelial cells", "OBSERVATION", 22, 47], ["reducing", "OBSERVATION_MODIFIER", 63, 71], ["viral titers", "OBSERVATION", 72, 84], ["cell morphology", "OBSERVATION", 249, 264], ["infected cells", "OBSERVATION", 303, 317], ["airway", "ANATOMY", 325, 331], ["lumen", "ANATOMY_MODIFIER", 332, 337]]], ["These shed and detached infected epithelial cells die.", [["epithelial cells", "ANATOMY", 33, 49], ["epithelial cells", "CELL", 33, 49], ["detached infected epithelial cells", "CELL_TYPE", 15, 49], ["detached infected epithelial cells die", "PROBLEM", 15, 53], ["infected", "OBSERVATION_MODIFIER", 24, 32], ["epithelial cells die", "OBSERVATION", 33, 53]]], ["As shedding (and ultimately clearance by mucociliary transport) of infected epithelial cells reduces RSV viral titers, it seems that the bulk of viral spread precedes cell shedding.", [["mucociliary", "ANATOMY", 41, 52], ["epithelial cells", "ANATOMY", 76, 92], ["cell", "ANATOMY", 167, 171], ["mucociliary", "ORGAN", 41, 52], ["epithelial cells", "CELL", 76, 92], ["RSV", "ORGANISM", 101, 104], ["cell", "CELL", 167, 171], ["infected epithelial cells", "CELL_TYPE", 67, 92], ["RSV", "SPECIES", 101, 104], ["infected epithelial cells", "PROBLEM", 67, 92], ["RSV viral titers", "PROBLEM", 101, 117], ["viral spread", "PROBLEM", 145, 157], ["infected", "OBSERVATION_MODIFIER", 67, 75], ["epithelial cells", "OBSERVATION", 76, 92], ["RSV viral titers", "OBSERVATION", 101, 117], ["viral spread", "OBSERVATION", 145, 157], ["cell shedding", "OBSERVATION", 167, 180]]], ["Possibly, (early) changes in cell morphology that ultimately lead to shedding of infected epithelial cells may facilitate RSV production and spreading.", [["cell", "ANATOMY", 29, 33], ["epithelial cells", "ANATOMY", 90, 106], ["cell", "CELL", 29, 33], ["epithelial cells", "CELL", 90, 106], ["RSV", "ORGANISM", 122, 125], ["infected epithelial cells", "CELL_TYPE", 81, 106], ["RSV", "SPECIES", 122, 125], ["changes in cell morphology", "PROBLEM", 18, 44], ["infected epithelial cells", "PROBLEM", 81, 106], ["RSV production", "PROBLEM", 122, 136], ["cell morphology", "OBSERVATION", 29, 44], ["infected epithelial cells", "OBSERVATION", 81, 106], ["RSV production", "OBSERVATION", 122, 136], ["spreading", "OBSERVATION_MODIFIER", 141, 150]]], ["As such, NS2 plays a pivotal role in the production and spreading of RSV virions.", [["NS2", "GENE_OR_GENE_PRODUCT", 9, 12], ["RSV", "ORGANISM", 69, 72], ["NS2", "PROTEIN", 9, 12], ["RSV", "SPECIES", 69, 72], ["NS2", "TREATMENT", 9, 12], ["RSV virions", "PROBLEM", 69, 80], ["RSV virions", "OBSERVATION", 69, 80]]], ["NS1 and NS2 counteract the anti-inflammatory activity of the glucocorticoid receptor.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 61, 84], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["glucocorticoid receptor", "PROTEIN", 61, 84], ["NS1", "TREATMENT", 0, 3], ["NS2", "TREATMENT", 8, 11], ["the glucocorticoid receptor", "TREATMENT", 57, 84], ["NS2", "OBSERVATION", 8, 11], ["anti-inflammatory activity", "OBSERVATION", 27, 53], ["glucocorticoid receptor", "OBSERVATION", 61, 84]]], ["Although RSV-induced bronchiolitis is characterized by a (severe) inflammatory response, the use of anti-inflammatory glucocorticoids has shown no clinical benefits against (severe) disease [79] [80] [81] .", [["bronchiolitis", "DISEASE", 21, 34], ["glucocorticoids", "CHEMICAL", 118, 133], ["RSV", "ORGANISM", 9, 12], ["RSV", "SPECIES", 9, 12], ["RSV", "PROBLEM", 9, 12], ["bronchiolitis", "PROBLEM", 21, 34], ["a (severe) inflammatory response", "PROBLEM", 55, 87], ["anti-inflammatory glucocorticoids", "TREATMENT", 100, 133], ["(severe) disease", "PROBLEM", 173, 189], ["RSV", "OBSERVATION", 9, 12], ["bronchiolitis", "OBSERVATION", 21, 34], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78], ["anti-inflammatory glucocorticoids", "OBSERVATION", 100, 133]]], ["Based on experiments with different transformed and primary cell cultures as well as mice, several groups concluded that RSV can inhibit the anti-inflammatory activity of glucocorticoids via the glucocorticoid receptor (GR) [82] [83] [84] [85] [86] [87] [88] .", [["primary cell cultures", "ANATOMY", 52, 73], ["RSV", "CHEMICAL", 121, 124], ["glucocorticoids", "CHEMICAL", 171, 186], ["cell cultures", "CELL", 60, 73], ["mice", "ORGANISM", 85, 89], ["RSV", "ORGANISM", 121, 124], ["glucocorticoids", "SIMPLE_CHEMICAL", 171, 186], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 195, 218], ["GR", "GENE_OR_GENE_PRODUCT", 220, 222], ["83] [84] [85] [86] [87] [88]", "SIMPLE_CHEMICAL", 230, 258], ["primary cell cultures", "CELL_LINE", 52, 73], ["glucocorticoid receptor", "PROTEIN", 195, 218], ["GR", "PROTEIN", 220, 222], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["RSV", "SPECIES", 121, 124], ["primary cell cultures", "TEST", 52, 73], ["RSV", "PROBLEM", 121, 124]]], ["One group demonstrated that RSV blocks glucocorticoid-mediated GR activation in A549, BEAS-2B, and primary human small airway epithelial cells but not in the monocytic THP-1 cell line, suggesting that the effect is restricted to RSV-infected epithelial cells [83, 85] .", [["A549", "ANATOMY", 80, 84], ["BEAS-2B", "ANATOMY", 86, 93], ["small airway epithelial cells", "ANATOMY", 113, 142], ["monocytic THP-1 cell line", "ANATOMY", 158, 183], ["epithelial cells", "ANATOMY", 242, 258], ["RSV", "ORGANISM", 28, 31], ["glucocorticoid", "SIMPLE_CHEMICAL", 39, 53], ["GR", "GENE_OR_GENE_PRODUCT", 63, 65], ["A549", "CELL", 80, 84], ["BEAS-2B", "CELL", 86, 93], ["human", "ORGANISM", 107, 112], ["small airway epithelial cells", "CELL", 113, 142], ["monocytic THP-1 cell line", "CELL", 158, 183], ["RSV", "ORGANISM", 229, 232], ["epithelial cells", "CELL", 242, 258], ["GR", "PROTEIN", 63, 65], ["A549", "CELL_LINE", 80, 84], ["BEAS-2B", "CELL_LINE", 86, 93], ["primary human small airway epithelial cells", "CELL_TYPE", 99, 142], ["monocytic THP-1 cell line", "CELL_LINE", 158, 183], ["RSV-infected epithelial cells", "CELL_TYPE", 229, 258], ["human", "SPECIES", 107, 112], ["RSV", "SPECIES", 28, 31], ["human", "SPECIES", 107, 112], ["RSV", "SPECIES", 229, 232], ["RSV blocks glucocorticoid", "TEST", 28, 53], ["GR activation", "TEST", 63, 76], ["A549", "TEST", 80, 84], ["BEAS", "TEST", 86, 90], ["primary human small airway epithelial cells", "PROBLEM", 99, 142], ["the monocytic THP", "TEST", 154, 171], ["RSV", "PROBLEM", 229, 232], ["infected epithelial cells", "PROBLEM", 233, 258], ["RSV", "OBSERVATION", 28, 31], ["small", "OBSERVATION_MODIFIER", 113, 118], ["airway epithelial cells", "OBSERVATION", 119, 142], ["cell line", "OBSERVATION", 174, 183], ["infected", "OBSERVATION_MODIFIER", 233, 241], ["epithelial cells", "OBSERVATION", 242, 258]]], ["Further mechanistic analysis in A549 cells suggested that NS1 and NS2 reduce the binding of the GR to GR-responsive promoters, without affecting GR total protein levels and nuclear translocation [83, 84, 86] .", [["A549 cells", "ANATOMY", 32, 42], ["nuclear", "ANATOMY", 173, 180], ["A549 cells", "CELL", 32, 42], ["NS1", "GENE_OR_GENE_PRODUCT", 58, 61], ["NS2", "GENE_OR_GENE_PRODUCT", 66, 69], ["GR", "GENE_OR_GENE_PRODUCT", 96, 98], ["GR", "GENE_OR_GENE_PRODUCT", 102, 104], ["GR", "GENE_OR_GENE_PRODUCT", 145, 147], ["nuclear", "CELLULAR_COMPONENT", 173, 180], ["A549 cells", "CELL_LINE", 32, 42], ["NS1", "PROTEIN", 58, 61], ["NS2", "PROTEIN", 66, 69], ["GR", "PROTEIN", 96, 98], ["GR", "PROTEIN", 102, 104], ["responsive promoters", "DNA", 105, 125], ["GR", "PROTEIN", 145, 147], ["Further mechanistic analysis", "TEST", 0, 28], ["A549 cells", "TEST", 32, 42], ["NS1", "TREATMENT", 58, 61], ["NS2", "TREATMENT", 66, 69], ["affecting GR total protein levels", "PROBLEM", 135, 168], ["nuclear translocation", "TEST", 173, 194], ["responsive promoters", "OBSERVATION", 105, 125]]], ["Interestingly, knockdown of MAVS in A549 cells lowered dexamethasone-induced transforming growth factor \u03b2 (TGF-\u03b2)-stimulated clone 22 (TSC22) domain family member 3 (also known as glucocorticoid-induced leucine zipper protein [GILZ]) mRNA expression to a level similar to that of an RSV infection [86] .", [["A549 cells", "ANATOMY", 36, 46], ["dexamethasone", "CHEMICAL", 55, 68], ["RSV infection", "DISEASE", 283, 296], ["dexamethasone", "CHEMICAL", 55, 68], ["leucine", "CHEMICAL", 203, 210], ["MAVS", "GENE_OR_GENE_PRODUCT", 28, 32], ["A549 cells", "CELL", 36, 46], ["dexamethasone", "SIMPLE_CHEMICAL", 55, 68], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 77, 105], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 107, 112], ["clone 22", "GENE_OR_GENE_PRODUCT", 125, 133], ["TSC22) domain family member 3", "GENE_OR_GENE_PRODUCT", 135, 164], ["glucocorticoid-induced leucine zipper protein", "GENE_OR_GENE_PRODUCT", 180, 225], ["GILZ", "GENE_OR_GENE_PRODUCT", 227, 231], ["RSV", "ORGANISM", 283, 286], ["MAVS", "PROTEIN", 28, 32], ["A549 cells", "CELL_LINE", 36, 46], ["transforming growth factor \u03b2 (TGF-\u03b2)-stimulated clone 22 (TSC22) domain family member 3", "PROTEIN", 77, 164], ["glucocorticoid-induced leucine zipper protein", "PROTEIN", 180, 225], ["GILZ", "PROTEIN", 227, 231], ["RSV", "SPECIES", 283, 286], ["MAVS", "PROBLEM", 28, 32], ["A549 cells", "PROBLEM", 36, 46], ["dexamethasone", "TREATMENT", 55, 68], ["transforming growth factor", "PROBLEM", 77, 103], ["TGF", "TEST", 107, 110], ["stimulated clone", "PROBLEM", 114, 130], ["glucocorticoid-induced leucine zipper protein [GILZ]", "TREATMENT", 180, 232], ["mRNA expression", "PROBLEM", 234, 249], ["an RSV infection", "PROBLEM", 280, 296], ["MAVS", "OBSERVATION", 28, 32], ["A549 cells", "OBSERVATION", 36, 46], ["RSV", "OBSERVATION", 283, 286]]], ["These results suggest that MAVS plays a role in glucocorticoidinduced GR activation in A549 cells and that NS1 and NS2 may indirectly suppress GR activation through inhibition of MAVS (see \"NS1 and NS2 interfere with RIG-I\").Other effector functions of RSV NS1 and NS2Xia and colleagues used BEAS-2B and primary differentiated human bronchial epithelial cells grown at an air-liquid interface to demonstrate that RSV suppresses glucocorticoidinduced GR activation by a mechanism that involves up-regulation of TGF-\u03b2 expression [87] .", [["A549 cells", "ANATOMY", 87, 97], ["bronchial epithelial cells", "ANATOMY", 333, 359], ["MAVS", "GENE_OR_GENE_PRODUCT", 27, 31], ["GR", "GENE_OR_GENE_PRODUCT", 70, 72], ["A549 cells", "CELL", 87, 97], ["NS1", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS2", "GENE_OR_GENE_PRODUCT", 115, 118], ["GR", "GENE_OR_GENE_PRODUCT", 143, 145], ["MAVS", "GENE_OR_GENE_PRODUCT", 179, 183], ["NS1", "GENE_OR_GENE_PRODUCT", 190, 193], ["NS2", "GENE_OR_GENE_PRODUCT", 198, 201], ["RIG-I", "GENE_OR_GENE_PRODUCT", 217, 222], ["RSV", "ORGANISM", 253, 256], ["NS1", "ORGANISM", 257, 260], ["BEAS-2B", "CELL", 292, 299], ["human", "ORGANISM", 327, 332], ["bronchial epithelial cells", "CELL", 333, 359], ["RSV", "ORGANISM", 413, 416], ["glucocorticoidinduced GR", "GENE_OR_GENE_PRODUCT", 428, 452], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 510, 515], ["MAVS", "PROTEIN", 27, 31], ["GR", "PROTEIN", 70, 72], ["A549 cells", "CELL_LINE", 87, 97], ["NS1", "PROTEIN", 107, 110], ["NS2", "PROTEIN", 115, 118], ["GR", "PROTEIN", 143, 145], ["MAVS", "PROTEIN", 179, 183], ["NS1", "PROTEIN", 190, 193], ["NS2", "PROTEIN", 198, 201], ["RIG", "PROTEIN", 217, 220], ["RSV NS1", "PROTEIN", 253, 260], ["NS2Xia", "PROTEIN", 265, 271], ["BEAS-2B", "PROTEIN", 292, 299], ["primary differentiated human bronchial epithelial cells", "CELL_TYPE", 304, 359], ["GR", "PROTEIN", 450, 452], ["TGF-\u03b2", "PROTEIN", 510, 515], ["human", "SPECIES", 327, 332], ["RSV", "SPECIES", 253, 256], ["human", "SPECIES", 327, 332], ["RSV", "SPECIES", 413, 416], ["glucocorticoidinduced GR activation in A549 cells", "TREATMENT", 48, 97], ["NS1", "TREATMENT", 107, 110], ["NS2", "TREATMENT", 115, 118], ["MAVS", "PROBLEM", 179, 183], ["RSV NS1", "TEST", 253, 260], ["BEAS", "TEST", 292, 296], ["primary differentiated human bronchial epithelial cells", "PROBLEM", 304, 359], ["an air-liquid interface", "PROBLEM", 369, 392], ["RSV suppresses", "PROBLEM", 413, 427], ["A549 cells", "OBSERVATION", 87, 97], ["bronchial", "ANATOMY", 333, 342], ["epithelial cells", "OBSERVATION", 343, 359], ["air-liquid", "OBSERVATION", 372, 382], ["RSV", "OBSERVATION", 413, 416]]], ["A model was proposed in which viral infection is sensed by TLR3, which induces TGF-\u03b2 that subsequently activates the type I TGF-\u03b2 receptor activin receptor-like kinase 5 (ALK5).", [["viral infection", "DISEASE", 30, 45], ["TLR3", "GENE_OR_GENE_PRODUCT", 59, 63], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 79, 84], ["type I TGF-\u03b2 receptor activin receptor-like kinase 5", "GENE_OR_GENE_PRODUCT", 117, 169], ["ALK5", "GENE_OR_GENE_PRODUCT", 171, 175], ["TLR3", "PROTEIN", 59, 63], ["TGF-\u03b2", "PROTEIN", 79, 84], ["type I TGF-\u03b2 receptor activin receptor-like kinase 5", "PROTEIN", 117, 169], ["ALK5", "PROTEIN", 171, 175], ["viral infection", "PROBLEM", 30, 45], ["TGF", "TEST", 79, 82], ["the type I TGF", "TEST", 113, 127], ["receptor activin receptor", "TEST", 130, 155], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45]]], ["ALK5 activation subsequently counteracts glucocorticoid activity through an unknown mechanism.", [["ALK5", "GENE_OR_GENE_PRODUCT", 0, 4], ["glucocorticoid", "SIMPLE_CHEMICAL", 41, 55], ["ALK5", "PROTEIN", 0, 4], ["ALK5 activation", "PROBLEM", 0, 15], ["glucocorticoid activity", "PROBLEM", 41, 64], ["counteracts glucocorticoid activity", "OBSERVATION", 29, 64]]], ["In accordance with the aforementioned study, no difference in total GR\u03b1 protein levels or nuclear translocation were observed upon RSV infection.", [["nuclear", "ANATOMY", 90, 97], ["RSV infection", "DISEASE", 131, 144], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 68, 71], ["nuclear", "CELLULAR_COMPONENT", 90, 97], ["RSV", "ORGANISM", 131, 134], ["GR\u03b1", "PROTEIN", 68, 71], ["RSV", "SPECIES", 131, 134], ["the aforementioned study", "TEST", 19, 43], ["total GR\u03b1 protein levels", "TEST", 62, 86], ["nuclear translocation", "PROBLEM", 90, 111], ["RSV infection", "PROBLEM", 131, 144], ["RSV infection", "OBSERVATION", 131, 144]]], ["Interestingly, blocking ALK5 with the selective inhibitor SB431542 and reducing TGF-\u03b2 activity by tranilast (a compound used to manage a wide variety of diseases, including inflammatory diseases) could subvert the RSVmediated suppression of glucocorticoid activity.", [["SB431542", "CHEMICAL", 58, 66], ["tranilast", "CHEMICAL", 98, 107], ["inflammatory diseases", "DISEASE", 173, 194], ["SB431542", "CHEMICAL", 58, 66], ["tranilast", "CHEMICAL", 98, 107], ["ALK5", "GENE_OR_GENE_PRODUCT", 24, 28], ["SB431542", "SIMPLE_CHEMICAL", 58, 66], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 80, 85], ["tranilast", "SIMPLE_CHEMICAL", 98, 107], ["glucocorticoid", "SIMPLE_CHEMICAL", 241, 255], ["ALK5", "PROTEIN", 24, 28], ["TGF-\u03b2", "PROTEIN", 80, 85], ["blocking ALK5", "PROBLEM", 15, 28], ["the selective inhibitor SB431542", "TREATMENT", 34, 66], ["TGF", "TEST", 80, 83], ["a wide variety of diseases", "PROBLEM", 135, 161], ["inflammatory diseases", "PROBLEM", 173, 194], ["diseases", "OBSERVATION", 153, 161], ["inflammatory", "OBSERVATION_MODIFIER", 173, 185], ["glucocorticoid activity", "OBSERVATION", 241, 264]]], ["Although Xia and colleagues did not investigate the role of NS1 or NS2, NS1 may contribute to RSV-induced TGF-\u03b2 expression by up-regulating the transcription factor Kruppel-like factor 6 (discussed in the next paragraph) [89] .Other effector functions of RSV NS1 and NS2Another study concluded that RSV NS1 prevents GR nuclear translocation [88] .", [["nuclear", "ANATOMY", 319, 326], ["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS2", "GENE_OR_GENE_PRODUCT", 67, 70], ["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["RSV", "ORGANISM", 94, 97], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 106, 111], ["Kruppel-like factor 6", "GENE_OR_GENE_PRODUCT", 165, 186], ["RSV NS1", "ORGANISM", 255, 262], ["NS2Another", "GENE_OR_GENE_PRODUCT", 267, 277], ["RSV", "ORGANISM", 299, 302], ["NS1", "ORGANISM", 303, 306], ["GR", "GENE_OR_GENE_PRODUCT", 316, 318], ["NS1", "PROTEIN", 60, 63], ["NS2", "PROTEIN", 67, 70], ["NS1", "PROTEIN", 72, 75], ["TGF", "PROTEIN", 106, 109], ["\u03b2", "PROTEIN", 110, 111], ["transcription factor", "PROTEIN", 144, 164], ["Kruppel-like factor 6", "PROTEIN", 165, 186], ["RSV NS1", "PROTEIN", 255, 262], ["NS2Another", "PROTEIN", 267, 277], ["RSV NS1", "PROTEIN", 299, 306], ["GR", "PROTEIN", 316, 318], ["RSV", "SPECIES", 94, 97], ["RSV", "SPECIES", 255, 258], ["RSV", "SPECIES", 299, 302], ["NS1", "TREATMENT", 60, 63], ["NS2", "TREATMENT", 67, 70], ["NS1", "TREATMENT", 72, 75], ["RSV", "PROBLEM", 94, 97], ["RSV NS1", "TREATMENT", 255, 262], ["NS2Another study", "TEST", 267, 283], ["RSV NS1", "TREATMENT", 299, 306], ["GR nuclear translocation", "PROBLEM", 316, 340]]], ["This finding was based on experiments with A549 cells, mouse lung tissue, but also analysis of nasopharyngeal aspirates from RSV-infected infants.", [["A549 cells", "ANATOMY", 43, 53], ["lung tissue", "ANATOMY", 61, 72], ["nasopharyngeal aspirates", "ANATOMY", 95, 119], ["RSV-infected", "DISEASE", 125, 137], ["A549 cells", "CELL", 43, 53], ["mouse", "ORGANISM", 55, 60], ["lung tissue", "TISSUE", 61, 72], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 95, 119], ["RSV", "ORGANISM", 125, 128], ["infants", "ORGANISM", 138, 145], ["A549 cells", "CELL_LINE", 43, 53], ["mouse", "SPECIES", 55, 60], ["infants", "SPECIES", 138, 145], ["mouse", "SPECIES", 55, 60], ["RSV", "SPECIES", 125, 128], ["A549 cells", "TREATMENT", 43, 53], ["mouse lung tissue", "PROBLEM", 55, 72], ["nasopharyngeal aspirates", "PROBLEM", 95, 119], ["RSV", "PROBLEM", 125, 128], ["A549 cells", "OBSERVATION", 43, 53], ["lung tissue", "ANATOMY", 61, 72], ["nasopharyngeal", "ANATOMY", 95, 109], ["aspirates", "OBSERVATION", 110, 119], ["infected", "OBSERVATION", 129, 137]]], ["Moreover, expression of GR\u03b1 and importin-13, which is important for GR nuclear entry, was reduced at the mRNA and protein level in mouse lungs, whereas GR\u03b2 and IPO13 expression at the mRNA level were reduced in the nasopharyngeal aspirates upon RSV infection.", [["nuclear", "ANATOMY", 71, 78], ["lungs", "ANATOMY", 137, 142], ["nasopharyngeal aspirates", "ANATOMY", 215, 239], ["RSV infection", "DISEASE", 245, 258], ["GR\u03b1", "GENE_OR_GENE_PRODUCT", 24, 27], ["importin-13", "GENE_OR_GENE_PRODUCT", 32, 43], ["GR", "GENE_OR_GENE_PRODUCT", 68, 70], ["nuclear", "CELLULAR_COMPONENT", 71, 78], ["mouse", "ORGANISM", 131, 136], ["lungs", "ORGAN", 137, 142], ["GR\u03b2", "GENE_OR_GENE_PRODUCT", 152, 155], ["IPO13", "GENE_OR_GENE_PRODUCT", 160, 165], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 215, 239], ["RSV", "ORGANISM", 245, 248], ["GR\u03b1", "PROTEIN", 24, 27], ["importin-13", "PROTEIN", 32, 43], ["GR", "PROTEIN", 68, 70], ["GR\u03b2", "PROTEIN", 152, 155], ["IPO13", "PROTEIN", 160, 165], ["mouse", "SPECIES", 131, 136], ["mouse", "SPECIES", 131, 136], ["RSV", "SPECIES", 245, 248], ["the mRNA level", "TEST", 180, 194], ["the nasopharyngeal aspirates", "PROBLEM", 211, 239], ["RSV infection", "PROBLEM", 245, 258], ["lungs", "ANATOMY", 137, 142], ["reduced", "OBSERVATION_MODIFIER", 200, 207], ["nasopharyngeal", "ANATOMY", 215, 229], ["aspirates", "OBSERVATION", 230, 239], ["RSV infection", "OBSERVATION", 245, 258]]], ["Mechanistically, NS1 was found to directly interact with IPO13 and can thus compete with GR for IPO13 binding.Other effector functions of RSV NS1 and NS2The capacity of RSV to suppress the anti-inflammatory effect of glucocorticoids through NS1 and NS2 are in line with the ineffectiveness of glucocorticoid treatments off severely ill RSV patients.NS1 and NS2 interfere with the induction of miRNAs.In addition to miR-29a, NS proteins also regulate the expression of the miRNAs miR-24, let-7i, and miR-30b [59, 89, 90] .", [["glucocorticoids", "CHEMICAL", 217, 232], ["RSV", "DISEASE", 336, 339], ["NS1", "GENE_OR_GENE_PRODUCT", 17, 20], ["IPO13", "GENE_OR_GENE_PRODUCT", 57, 62], ["GR", "GENE_OR_GENE_PRODUCT", 89, 91], ["IPO13", "GENE_OR_GENE_PRODUCT", 96, 101], ["RSV", "ORGANISM", 138, 141], ["NS1", "ORGANISM", 142, 145], ["NS2", "ORGANISM", 150, 153], ["RSV", "ORGANISM", 169, 172], ["glucocorticoids", "SIMPLE_CHEMICAL", 217, 232], ["NS1", "GENE_OR_GENE_PRODUCT", 241, 244], ["NS2", "GENE_OR_GENE_PRODUCT", 249, 252], ["glucocorticoid", "SIMPLE_CHEMICAL", 293, 307], ["RSV", "ORGANISM", 336, 339], ["patients", "ORGANISM", 340, 348], ["NS1", "GENE_OR_GENE_PRODUCT", 349, 352], ["NS2", "GENE_OR_GENE_PRODUCT", 357, 360], ["miR-29a", "GENE_OR_GENE_PRODUCT", 415, 422], ["NS proteins", "GENE_OR_GENE_PRODUCT", 424, 435], ["miR-24", "GENE_OR_GENE_PRODUCT", 479, 485], ["let-7i", "GENE_OR_GENE_PRODUCT", 487, 493], ["miR-30b", "GENE_OR_GENE_PRODUCT", 499, 506], ["NS1", "PROTEIN", 17, 20], ["IPO13", "PROTEIN", 57, 62], ["GR", "PROTEIN", 89, 91], ["IPO13", "PROTEIN", 96, 101], ["RSV NS1", "PROTEIN", 138, 145], ["NS2", "PROTEIN", 150, 153], ["NS1", "PROTEIN", 241, 244], ["NS2", "PROTEIN", 249, 252], ["NS1", "PROTEIN", 349, 352], ["NS2", "PROTEIN", 357, 360], ["miRNAs", "DNA", 393, 399], ["miR-29a", "DNA", 415, 422], ["NS proteins", "PROTEIN", 424, 435], ["miRNAs miR-24", "DNA", 472, 485], ["let-7i", "DNA", 487, 493], ["miR-30b", "DNA", 499, 506], ["patients", "SPECIES", 340, 348], ["RSV", "SPECIES", 138, 141], ["RSV", "SPECIES", 169, 172], ["RSV", "SPECIES", 336, 339], ["IPO13", "TREATMENT", 57, 62], ["RSV NS1", "TREATMENT", 138, 145], ["RSV", "PROBLEM", 169, 172], ["glucocorticoids", "TREATMENT", 217, 232], ["NS1", "TREATMENT", 241, 244], ["NS2", "TREATMENT", 249, 252], ["glucocorticoid treatments", "TREATMENT", 293, 318], ["severely ill RSV patients", "PROBLEM", 323, 348], ["NS1", "PROBLEM", 349, 352], ["NS2", "TREATMENT", 357, 360], ["the induction of miRNAs", "TREATMENT", 376, 399], ["NS proteins", "TREATMENT", 424, 435], ["the miRNAs miR", "TEST", 468, 482], ["miR", "TEST", 499, 502], ["RSV", "OBSERVATION", 169, 172], ["anti-inflammatory", "OBSERVATION_MODIFIER", 189, 206], ["NS2", "OBSERVATION", 357, 360]]], ["In RSV-infected A549 cells, NS1 suppresses miR-24 expression by up-regulating the transcription factor Kruppel-like factor 6, which drives the expression of TGF-\u03b2 [89] .", [["A549 cells", "ANATOMY", 16, 26], ["RSV-infected", "DISEASE", 3, 15], ["RSV", "ORGANISM", 3, 6], ["A549 cells", "CELL", 16, 26], ["NS1", "GENE_OR_GENE_PRODUCT", 28, 31], ["miR-24", "GENE_OR_GENE_PRODUCT", 43, 49], ["Kruppel-like factor 6", "GENE_OR_GENE_PRODUCT", 103, 124], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["RSV-infected A549 cells", "CELL_LINE", 3, 26], ["NS1", "PROTEIN", 28, 31], ["miR-24", "DNA", 43, 49], ["transcription factor", "PROTEIN", 82, 102], ["Kruppel-like factor 6", "PROTEIN", 103, 124], ["TGF", "PROTEIN", 157, 160], ["RSV", "SPECIES", 3, 6], ["RSV", "TEST", 3, 6], ["infected A549 cells", "PROBLEM", 7, 26], ["NS1 suppresses miR", "TEST", 28, 46], ["TGF", "TEST", 157, 160], ["RSV", "ANATOMY", 3, 6], ["infected", "OBSERVATION_MODIFIER", 7, 15], ["A549 cells", "OBSERVATION", 16, 26]]], ["Remarkably, inhibition of miR-24 was shown to actually repress RSV replication in A549 cells [91] .", [["A549 cells", "ANATOMY", 82, 92], ["miR-24", "GENE_OR_GENE_PRODUCT", 26, 32], ["RSV", "ORGANISM", 63, 66], ["A549 cells", "CELL", 82, 92], ["miR-24", "DNA", 26, 32], ["A549 cells", "CELL_LINE", 82, 92], ["RSV", "SPECIES", 63, 66], ["A549 cells", "OBSERVATION", 82, 92]]], ["This apparent discrepancy could be explained by the difference in time points after infection that were analyzed (1 day versus 3 days post infection).", [["infection", "DISEASE", 84, 93], ["infection", "DISEASE", 139, 148], ["infection", "PROBLEM", 84, 93], ["infection", "PROBLEM", 139, 148], ["could be explained", "UNCERTAINTY", 26, 44], ["infection", "OBSERVATION", 84, 93], ["infection", "OBSERVATION", 139, 148]]], ["Possibly, NS1 suppresses the RSV-induced up-regulation of miR-24 within 24 hours post infection, whereas later on, miR-24 expression may be up-regulated to enhance viral replication.", [["infection", "DISEASE", 86, 95], ["NS1", "GENE_OR_GENE_PRODUCT", 10, 13], ["RSV", "ORGANISM", 29, 32], ["miR-24", "GENE_OR_GENE_PRODUCT", 58, 64], ["miR-24", "GENE_OR_GENE_PRODUCT", 115, 121], ["NS1", "PROTEIN", 10, 13], ["miR-24", "DNA", 58, 64], ["miR-24", "DNA", 115, 121], ["RSV", "SPECIES", 29, 32], ["the RSV", "PROBLEM", 25, 32], ["infection", "PROBLEM", 86, 95], ["viral replication", "TREATMENT", 164, 181], ["infection", "OBSERVATION", 86, 95], ["viral replication", "OBSERVATION", 164, 181]]], ["Investigating miR-24 expression levels beyond 24 hours post infection and the impact of NS1 on these levels may result in a better understanding of the role of miR-24 in RSV replication.", [["infection", "DISEASE", 60, 69], ["miR-24", "GENE_OR_GENE_PRODUCT", 14, 20], ["NS1", "GENE_OR_GENE_PRODUCT", 88, 91], ["miR-24", "GENE_OR_GENE_PRODUCT", 160, 166], ["RSV", "ORGANISM", 170, 173], ["miR-24", "DNA", 14, 20], ["NS1", "PROTEIN", 88, 91], ["miR-24", "DNA", 160, 166], ["RSV", "SPECIES", 170, 173], ["infection", "PROBLEM", 60, 69], ["NS1", "TREATMENT", 88, 91], ["these levels", "TEST", 95, 107], ["RSV replication", "TREATMENT", 170, 185], ["infection", "OBSERVATION", 60, 69], ["RSV replication", "OBSERVATION", 170, 185]]], ["In normal human bronchial epithelial cells, Let-7i and miR-30b expression is up-regulated during an RSV infection by a type I IFN and NF-\u03baBdependent mechanism, respectively, and further increased in the absence of NS1 or NS2 [90] .", [["bronchial epithelial cells", "ANATOMY", 16, 42], ["infection", "DISEASE", 104, 113], ["human", "ORGANISM", 10, 15], ["bronchial epithelial cells", "CELL", 16, 42], ["Let-7i", "GENE_OR_GENE_PRODUCT", 44, 50], ["miR-30b", "GENE_OR_GENE_PRODUCT", 55, 62], ["RSV", "ORGANISM", 100, 103], ["type I IFN", "GENE_OR_GENE_PRODUCT", 119, 129], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 134, 138], ["NS1", "GENE_OR_GENE_PRODUCT", 214, 217], ["normal human bronchial epithelial cells", "CELL_TYPE", 3, 42], ["NS1", "PROTEIN", 214, 217], ["NS2", "PROTEIN", 221, 224], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["RSV", "SPECIES", 100, 103], ["Let", "TEST", 44, 47], ["miR", "TEST", 55, 58], ["an RSV infection", "PROBLEM", 97, 113], ["a type I IFN", "TREATMENT", 117, 129], ["NF", "PROBLEM", 134, 136], ["NS1", "PROBLEM", 214, 217], ["NS2", "PROBLEM", 221, 224], ["normal", "OBSERVATION", 3, 9], ["human", "ANATOMY_MODIFIER", 10, 15], ["bronchial", "ANATOMY", 16, 25], ["epithelial cells", "OBSERVATION", 26, 42], ["RSV", "OBSERVATION_MODIFIER", 100, 103], ["infection", "OBSERVATION", 104, 113]]], ["This can be expected for let-7i, as the NS proteins suppress the type I IFN response.", [["let-7i", "GENE_OR_GENE_PRODUCT", 25, 31], ["type I IFN", "GENE_OR_GENE_PRODUCT", 65, 75], ["let-7i", "PROTEIN", 25, 31], ["NS proteins", "PROTEIN", 40, 51], ["IFN", "PROTEIN", 72, 75], ["the NS proteins", "TREATMENT", 36, 51]]], ["Moreover, the miR-30b promoter can be activated by the NF-\u03baB family member p65, which is activated during an RSV infection through a RIG-I/MAVS/TRAF6/IKK\u03b2 signaling pathway [16, 92] .", [["infection", "DISEASE", 113, 122], ["miR-30b", "GENE_OR_GENE_PRODUCT", 14, 21], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 55, 60], ["p65", "GENE_OR_GENE_PRODUCT", 75, 78], ["RSV", "ORGANISM", 109, 112], ["RIG-I", "GENE_OR_GENE_PRODUCT", 133, 138], ["MAVS", "GENE_OR_GENE_PRODUCT", 139, 143], ["TRAF6", "GENE_OR_GENE_PRODUCT", 144, 149], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 150, 154], ["miR-30b promoter", "DNA", 14, 30], ["NF-\u03baB family member", "PROTEIN", 55, 74], ["p65", "PROTEIN", 75, 78], ["MAVS", "PROTEIN", 139, 143], ["TRAF6", "PROTEIN", 144, 149], ["IKK\u03b2", "PROTEIN", 150, 154], ["RSV", "SPECIES", 109, 112], ["the miR-30b promoter", "TREATMENT", 10, 30], ["an RSV infection", "PROBLEM", 106, 122], ["infection", "OBSERVATION", 113, 122]]], ["By counteracting the interaction between RIG-I and MAVS (see \"NS1 and NS2 interfere with RIG-I\"), the NS proteins may dampen this pathway, leading to reduced activation of p65 and subsequent expression of miR-30b.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 41, 46], ["MAVS", "GENE_OR_GENE_PRODUCT", 51, 55], ["NS1", "GENE_OR_GENE_PRODUCT", 62, 65], ["NS2", "GENE_OR_GENE_PRODUCT", 70, 73], ["RIG-I", "GENE_OR_GENE_PRODUCT", 89, 94], ["p65", "GENE_OR_GENE_PRODUCT", 172, 175], ["miR-30b", "GENE_OR_GENE_PRODUCT", 205, 212], ["RIG-I", "PROTEIN", 41, 46], ["MAVS", "PROTEIN", 51, 55], ["NS1", "PROTEIN", 62, 65], ["NS2", "PROTEIN", 70, 73], ["RIG-I", "PROTEIN", 89, 94], ["NS proteins", "PROTEIN", 102, 113], ["p65", "PROTEIN", 172, 175], ["miR-30b", "DNA", 205, 212], ["MAVS", "PROBLEM", 51, 55], ["the NS proteins", "TREATMENT", 98, 113], ["reduced activation of p65", "PROBLEM", 150, 175], ["miR", "TEST", 205, 208]]], ["To our knowledge, the effect of NS1 and/or NS2 on the RSV-induced activation of p65 has not been investigated yet.", [["NS1", "GENE_OR_GENE_PRODUCT", 32, 35], ["NS2", "GENE_OR_GENE_PRODUCT", 43, 46], ["RSV", "ORGANISM", 54, 57], ["p65", "GENE_OR_GENE_PRODUCT", 80, 83], ["NS1", "PROTEIN", 32, 35], ["NS2", "PROTEIN", 43, 46], ["p65", "PROTEIN", 80, 83], ["RSV", "SPECIES", 54, 57], ["NS1", "TREATMENT", 32, 35], ["NS2", "TREATMENT", 43, 46], ["the RSV", "TREATMENT", 50, 57]]], ["This could readily be tested by comparing total levels of activated p65 between cells infected with wild-type RSV and NS deletion strains.", [["cells", "ANATOMY", 80, 85], ["p65", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 80, 85], ["wild-type RSV", "ORGANISM", 100, 113], ["p65", "PROTEIN", 68, 71], ["RSV", "SPECIES", 110, 113], ["activated p65 between cells", "TREATMENT", 58, 85], ["wild-type RSV", "TREATMENT", 100, 113], ["NS deletion strains", "TREATMENT", 118, 137]]], ["Whether the NS protein-mediated suppression of let7i and miR-30b favors or counteracts RSV replication is currently unclear.NS1 and NS2 interfere with the induction of miRNAs.NS1 and NS2 interfere with the adaptive immune response.", [["miR-30b", "CHEMICAL", 57, 64], ["let7i", "GENE_OR_GENE_PRODUCT", 47, 52], ["miR-30b", "GENE_OR_GENE_PRODUCT", 57, 64], ["RSV", "ORGANISM", 87, 90], ["NS1", "GENE_OR_GENE_PRODUCT", 124, 127], ["NS2", "GENE_OR_GENE_PRODUCT", 132, 135], ["NS1", "GENE_OR_GENE_PRODUCT", 175, 178], ["NS2", "GENE_OR_GENE_PRODUCT", 183, 186], ["NS protein", "PROTEIN", 12, 22], ["let7i", "PROTEIN", 47, 52], ["miR-30b", "DNA", 57, 64], ["NS1", "PROTEIN", 124, 127], ["NS2", "PROTEIN", 132, 135], ["miRNAs", "DNA", 168, 174], ["NS1", "PROTEIN", 175, 178], ["NS2", "PROTEIN", 183, 186], ["RSV", "SPECIES", 87, 90], ["the NS protein", "TEST", 8, 22], ["let7i", "TEST", 47, 52], ["miR", "TEST", 57, 60], ["RSV replication", "PROBLEM", 87, 102], ["NS1", "PROBLEM", 124, 127], ["NS2", "TREATMENT", 132, 135], ["the induction of miRNAs", "TREATMENT", 151, 174], ["NS1", "PROBLEM", 175, 178], ["NS2", "TREATMENT", 183, 186], ["RSV replication", "OBSERVATION", 87, 102], ["NS2", "OBSERVATION", 132, 135], ["NS2", "OBSERVATION", 183, 186]]], ["The NS proteins also play a role in the development of adaptive immune responses during RSV infection, partly as a consequence of their capacity to suppress type I and III IFN levels.", [["RSV infection", "DISEASE", 88, 101], ["RSV", "ORGANISM", 88, 91], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 157, 175], ["NS proteins", "PROTEIN", 4, 15], ["IFN", "PROTEIN", 172, 175], ["RSV", "SPECIES", 88, 91], ["The NS proteins", "TREATMENT", 0, 15], ["adaptive immune responses", "TREATMENT", 55, 80], ["RSV infection", "PROBLEM", 88, 101], ["their capacity", "PROBLEM", 130, 144], ["type I and III IFN levels", "PROBLEM", 157, 182], ["infection", "OBSERVATION", 92, 101]]], ["In addition to airway epithelial cells, RSV can infect DCs and activate PRRs by PAMPs [93] .", [["airway epithelial cells", "ANATOMY", 15, 38], ["DCs", "ANATOMY", 55, 58], ["airway epithelial cells", "CELL", 15, 38], ["RSV", "ORGANISM", 40, 43], ["DCs", "CELL", 55, 58], ["PRRs", "GENE_OR_GENE_PRODUCT", 72, 76], ["airway epithelial cells", "CELL_TYPE", 15, 38], ["DCs", "CELL_TYPE", 55, 58], ["PRRs", "PROTEIN", 72, 76], ["PAMPs", "PROTEIN", 80, 85], ["RSV", "SPECIES", 40, 43], ["airway epithelial cells", "PROBLEM", 15, 38], ["RSV", "PROBLEM", 40, 43], ["airway", "ANATOMY", 15, 21], ["epithelial cells", "OBSERVATION", 22, 38]]], ["Munir and colleagues investigated the activation status of isolated human monocyte-derived myeloid DCs upon RSV infection by quantifying several maturation markers, including cluster of differentiation (CD)38, 54, 80, 83, and 86 [41] .", [["monocyte", "ANATOMY", 74, 82], ["myeloid DCs", "ANATOMY", 91, 102], ["RSV infection", "DISEASE", 108, 121], ["human", "ORGANISM", 68, 73], ["monocyte", "CELL", 74, 82], ["myeloid DCs", "CELL", 91, 102], ["RSV", "ORGANISM", 108, 111], ["cluster of differentiation (CD)38", "GENE_OR_GENE_PRODUCT", 175, 208], ["isolated human monocyte-derived myeloid DCs", "CELL_TYPE", 59, 102], ["maturation markers", "PROTEIN", 145, 163], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["RSV", "SPECIES", 108, 111], ["isolated human monocyte", "PROBLEM", 59, 82], ["myeloid DCs", "PROBLEM", 91, 102], ["RSV infection", "PROBLEM", 108, 121], ["myeloid DCs", "OBSERVATION", 91, 102], ["RSV infection", "OBSERVATION", 108, 121]]], ["Infection with wild-type and NS-deficient RSV strains highlighted that NS1, and to a lesser extent NS2, suppress the maturation of human DCs.", [["DCs", "ANATOMY", 137, 140], ["NS-deficient RSV", "ORGANISM", 29, 45], ["NS1", "GENE_OR_GENE_PRODUCT", 71, 74], ["NS2", "GENE_OR_GENE_PRODUCT", 99, 102], ["human", "ORGANISM", 131, 136], ["DCs", "CELL", 137, 140], ["NS1", "PROTEIN", 71, 74], ["NS2", "PROTEIN", 99, 102], ["human DCs", "CELL_TYPE", 131, 140], ["human", "SPECIES", 131, 136], ["RSV", "SPECIES", 42, 45], ["human", "SPECIES", 131, 136], ["Infection", "PROBLEM", 0, 9], ["NS", "TREATMENT", 29, 31], ["deficient RSV strains", "PROBLEM", 32, 53], ["NS1", "PROBLEM", 71, 74], ["a lesser extent NS2", "TREATMENT", 83, 102], ["human DCs", "TREATMENT", 131, 140], ["RSV strains", "OBSERVATION", 42, 53]]], ["By using an IFNAR2-blocking antibody, this suppression was shown to partially depend on the capacity of the NS proteins to counteract the production of type I IFNs.", [["IFNAR2", "GENE_OR_GENE_PRODUCT", 12, 18], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 152, 163], ["IFNAR2", "PROTEIN", 12, 18], ["NS proteins", "PROTEIN", 108, 119], ["type I IFNs", "PROTEIN", 152, 163], ["an IFNAR2-blocking antibody", "TREATMENT", 9, 36], ["the NS proteins", "TREATMENT", 104, 119], ["type I IFNs", "PROBLEM", 152, 163]]], ["Moreover, in vivo pulmonary conventional DC activation, as measured by the up-regulation of CD86 and CD80, was strongly hampered in RSV-infected mice that are deficient for MAVS, an essential signaling protein for RSV-induced type I IFN production [12] .", [["pulmonary", "ANATOMY", 18, 27], ["DC", "ANATOMY", 41, 43], ["RSV-infected", "DISEASE", 132, 144], ["pulmonary", "ORGAN", 18, 27], ["CD86", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD80", "GENE_OR_GENE_PRODUCT", 101, 105], ["RSV", "ORGANISM", 132, 135], ["mice", "ORGANISM", 145, 149], ["MAVS", "GENE_OR_GENE_PRODUCT", 173, 177], ["RSV", "ORGANISM", 214, 217], ["type I IFN", "GENE_OR_GENE_PRODUCT", 226, 236], ["DC", "CELL_TYPE", 41, 43], ["CD86", "PROTEIN", 92, 96], ["CD80", "PROTEIN", 101, 105], ["MAVS", "PROTEIN", 173, 177], ["signaling protein", "PROTEIN", 192, 209], ["IFN", "PROTEIN", 233, 236], ["mice", "SPECIES", 145, 149], ["RSV", "SPECIES", 132, 135], ["mice", "SPECIES", 145, 149], ["RSV", "SPECIES", 214, 217], ["RSV", "PROBLEM", 132, 135], ["MAVS", "PROBLEM", 173, 177], ["an essential signaling protein", "PROBLEM", 179, 209], ["RSV", "PROBLEM", 214, 217], ["type I IFN production", "PROBLEM", 226, 247], ["pulmonary", "ANATOMY", 18, 27]]], ["Taken together, these results highlight that type I IFNs play a role in RSV-induced DC maturation.", [["DC", "ANATOMY", 84, 86], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 45, 56], ["RSV", "ORGANISM", 72, 75], ["DC", "CELL", 84, 86], ["type I IFNs", "PROTEIN", 45, 56], ["DC", "CELL_TYPE", 84, 86], ["RSV", "SPECIES", 72, 75], ["RSV-induced DC maturation", "TREATMENT", 72, 97]]], ["As such, the pleiotropic effector functions of NS1 and NS2 to counteract the production of type I IFNs likely account for the reduced DC maturation by NS1 and NS2.NS1 and NS2 interfere with the induction of miRNAs.In a follow-up report, Munir and colleagues investigated the consequence of reduced DC maturation by NS1 and NS2 on subsequent activation of T-cell responses by co-cultivation of RSV-infected human monocyte-derived DCs and autologous T cells [94] .", [["DC", "ANATOMY", 134, 136], ["DC", "ANATOMY", 298, 300], ["T-cell", "ANATOMY", 355, 361], ["monocyte", "ANATOMY", 412, 420], ["DCs", "ANATOMY", 429, 432], ["T cells", "ANATOMY", 448, 455], ["NS1", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS2", "GENE_OR_GENE_PRODUCT", 55, 58], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 91, 102], ["DC", "CELL", 134, 136], ["NS1", "GENE_OR_GENE_PRODUCT", 151, 154], ["NS2", "GENE_OR_GENE_PRODUCT", 159, 162], ["NS1", "GENE_OR_GENE_PRODUCT", 163, 166], ["NS2", "GENE_OR_GENE_PRODUCT", 171, 174], ["DC", "CELL", 298, 300], ["NS1", "GENE_OR_GENE_PRODUCT", 315, 318], ["NS2", "GENE_OR_GENE_PRODUCT", 323, 326], ["T-cell", "CELL", 355, 361], ["RSV", "ORGANISM", 393, 396], ["human", "ORGANISM", 406, 411], ["monocyte", "CELL", 412, 420], ["DCs", "CELL", 429, 432], ["T cells", "CELL", 448, 455], ["NS1", "PROTEIN", 47, 50], ["NS2", "PROTEIN", 55, 58], ["type I IFNs", "PROTEIN", 91, 102], ["DC", "CELL_TYPE", 134, 136], ["NS1", "PROTEIN", 151, 154], ["NS2", "PROTEIN", 159, 162], ["NS1", "PROTEIN", 163, 166], ["NS2", "PROTEIN", 171, 174], ["miRNAs", "DNA", 207, 213], ["DC", "CELL_TYPE", 298, 300], ["NS1", "PROTEIN", 315, 318], ["NS2", "PROTEIN", 323, 326], ["human monocyte", "CELL_TYPE", 406, 420], ["DCs", "CELL_TYPE", 429, 432], ["autologous T cells", "CELL_TYPE", 437, 455], ["human", "SPECIES", 406, 411], ["RSV", "SPECIES", 393, 396], ["human", "SPECIES", 406, 411], ["NS1", "TREATMENT", 47, 50], ["NS2", "TREATMENT", 55, 58], ["type I IFNs", "PROBLEM", 91, 102], ["the reduced DC maturation", "TREATMENT", 122, 147], ["NS2", "TREATMENT", 159, 162], ["NS1", "PROBLEM", 163, 166], ["NS2", "TREATMENT", 171, 174], ["the induction of miRNAs", "TREATMENT", 190, 213], ["reduced DC maturation", "TREATMENT", 290, 311], ["NS1", "TREATMENT", 315, 318], ["NS2", "TREATMENT", 323, 326], ["T-cell responses", "TREATMENT", 355, 371], ["RSV", "TEST", 393, 396], ["infected human monocyte", "TREATMENT", 397, 420], ["autologous T cells", "TEST", 437, 455], ["NS2", "OBSERVATION", 171, 174]]], ["Deletion of NS1 was found to promote the proliferation and activation of CD103 + CD8 + T cells and T-helper 17 cells, 2 cell populations that can counteract RSV, and to suppress the activation of IL-4-producing CD4 + T cells.", [["CD103 + CD8 + T cells", "ANATOMY", 73, 94], ["T-helper 17 cells", "ANATOMY", 99, 116], ["cell", "ANATOMY", 120, 124], ["IL-4-producing CD4 + T cells", "ANATOMY", 196, 224], ["NS1", "GENE_OR_GENE_PRODUCT", 12, 15], ["CD103", "GENE_OR_GENE_PRODUCT", 73, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 81, 84], ["2 cell populations", "CELL", 118, 136], ["RSV", "ORGANISM", 157, 160], ["IL-4", "GENE_OR_GENE_PRODUCT", 196, 200], ["CD4", "GENE_OR_GENE_PRODUCT", 211, 214], ["NS1", "PROTEIN", 12, 15], ["CD103", "PROTEIN", 73, 78], ["CD8 + T cells", "CELL_TYPE", 81, 94], ["T-helper 17 cells", "CELL_TYPE", 99, 116], ["IL-4", "PROTEIN", 196, 200], ["CD4", "PROTEIN", 211, 214], ["T cells", "CELL_TYPE", 217, 224], ["RSV", "SPECIES", 157, 160], ["Deletion of NS1", "PROBLEM", 0, 15], ["the proliferation", "PROBLEM", 37, 54], ["CD103", "TEST", 73, 78], ["CD8", "TEST", 81, 84], ["T cells", "TEST", 87, 94], ["T", "TEST", 99, 100], ["2 cell populations", "PROBLEM", 118, 136], ["RSV", "PROBLEM", 157, 160], ["IL", "TEST", 196, 198], ["CD4 + T cells", "PROBLEM", 211, 224], ["NS1", "OBSERVATION", 12, 15]]], ["Remarkably, none of these effects on T cells appeared to depend on type I IFN.", [["T cells", "ANATOMY", 37, 44], ["T cells", "CELL", 37, 44], ["type I IFN", "GENE_OR_GENE_PRODUCT", 67, 77], ["T cells", "CELL_TYPE", 37, 44], ["type I IFN", "PROTEIN", 67, 77], ["T cells", "PROBLEM", 37, 44]]], ["Possibly, IL-12\u03b2 and IL-23\u03b1 play a role as these cytokines were suppressed in DCs by NS1 in a type I IFN-independent manner.", [["DCs", "ANATOMY", 78, 81], ["IL-12\u03b2", "GENE_OR_GENE_PRODUCT", 10, 16], ["IL-23\u03b1", "GENE_OR_GENE_PRODUCT", 21, 27], ["DCs", "CELL", 78, 81], ["NS1", "GENE_OR_GENE_PRODUCT", 85, 88], ["type I IFN", "GENE_OR_GENE_PRODUCT", 94, 104], ["IL-12\u03b2", "PROTEIN", 10, 16], ["IL-23\u03b1", "PROTEIN", 21, 27], ["cytokines", "PROTEIN", 49, 58], ["DCs", "CELL_TYPE", 78, 81], ["NS1", "PROTEIN", 85, 88], ["IFN", "PROTEIN", 101, 104]]], ["In contrast, a study by Kotelkin and colleagues in mice identified that NS2, and not NS1, suppresses CD8 + T-cell responses in a type I IFNdependent manner [95] .", [["CD8 + T-cell", "ANATOMY", 101, 113], ["mice", "ORGANISM", 51, 55], ["NS2", "GENE_OR_GENE_PRODUCT", 72, 75], ["NS1", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD8", "GENE_OR_GENE_PRODUCT", 101, 104], ["NS2", "PROTEIN", 72, 75], ["NS1", "PROTEIN", 85, 88], ["CD8", "PROTEIN", 101, 104], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["a study", "TEST", 13, 20], ["NS2", "TEST", 72, 75], ["NS1", "TEST", 85, 88], ["CD8", "TEST", 101, 104]]], ["Remarkably, although RSV-induced activation of DCs in MAVS -/-and MAVS -/myeloid differentiation primary response protein MyD88 (MyD88) -/mice was strongly impaired, these mice could still mount comparable CD8 + T-cell responses as wildtype mice [12] .", [["DCs", "ANATOMY", 47, 50], ["myeloid", "ANATOMY", 73, 80], ["CD8 + T-cell", "ANATOMY", 206, 218], ["RSV", "ORGANISM", 21, 24], ["DCs", "CELL", 47, 50], ["MAVS", "GENE_OR_GENE_PRODUCT", 54, 58], ["MAVS", "GENE_OR_GENE_PRODUCT", 66, 70], ["MyD88", "GENE_OR_GENE_PRODUCT", 122, 127], ["MyD88)", "GENE_OR_GENE_PRODUCT", 129, 135], ["mice", "ORGANISM", 172, 176], ["CD8", "GENE_OR_GENE_PRODUCT", 206, 209], ["mice", "ORGANISM", 241, 245], ["DCs", "CELL_TYPE", 47, 50], ["MAVS", "PROTEIN", 54, 58], ["MAVS", "PROTEIN", 66, 70], ["myeloid differentiation primary response protein", "PROTEIN", 73, 121], ["MyD88", "PROTEIN", 122, 127], ["D88", "PROTEIN", 131, 134], ["CD8", "PROTEIN", 206, 209], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 241, 245], ["RSV", "SPECIES", 21, 24], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 241, 245], ["RSV", "PROBLEM", 21, 24], ["DCs", "PROBLEM", 47, 50], ["MAVS", "TEST", 54, 58], ["MAVS", "TEST", 66, 70], ["RSV", "OBSERVATION", 21, 24], ["myeloid", "ANATOMY", 73, 80]]], ["This may in part be explained by the approximately 100-fold higher viral loads in MAVS -/mice compared with wild-type mice.", [["MAVS", "GENE_OR_GENE_PRODUCT", 82, 86], ["mice", "ORGANISM", 89, 93], ["mice", "ORGANISM", 118, 122], ["MAVS", "PROTEIN", 82, 86], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 118, 122], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 118, 122], ["fold higher viral loads in MAVS", "PROBLEM", 55, 86], ["viral loads", "OBSERVATION", 67, 78]]], ["In addition, a small residual population of CD86-positive pulmonary DCs was still present in these mice that could migrate to the draining mediastinal lymph node to activate naive CD8 + T cells.", [["pulmonary DCs", "ANATOMY", 58, 71], ["mediastinal lymph node", "ANATOMY", 139, 161], ["CD8 + T cells", "ANATOMY", 180, 193], ["CD86", "GENE_OR_GENE_PRODUCT", 44, 48], ["mice", "ORGANISM", 99, 103], ["mediastinal lymph node", "MULTI-TISSUE_STRUCTURE", 139, 161], ["CD8", "GENE_OR_GENE_PRODUCT", 180, 183], ["CD86", "PROTEIN", 44, 48], ["positive pulmonary DCs", "CELL_TYPE", 49, 71], ["naive CD8 + T cells", "CELL_TYPE", 174, 193], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["a small residual population of CD86", "PROBLEM", 13, 48], ["positive pulmonary DCs", "PROBLEM", 49, 71], ["small", "OBSERVATION_MODIFIER", 15, 20], ["residual", "OBSERVATION_MODIFIER", 21, 29], ["population", "OBSERVATION_MODIFIER", 30, 40], ["CD86", "OBSERVATION", 44, 48], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["pulmonary", "ANATOMY", 58, 67], ["DCs", "OBSERVATION", 68, 71], ["draining", "ANATOMY_MODIFIER", 130, 138], ["mediastinal", "ANATOMY", 139, 150], ["lymph node", "OBSERVATION", 151, 161], ["naive CD8 + T cells", "OBSERVATION", 174, 193]]], ["As MAVS -/-MyD88 -/mice are still functional for toll/interleukin-1 receptor domain-containing adapter molecule 1 (TICAM1), the adaptor of TLR3, these DCs may have matured after the activation of TLR3 by RSVderived double-stranded RNA (dsRNA) [96] .NS1 and NS2 interfere with the induction of miRNAs.Live-attenuated RSV vaccines with a targeted deletion in NS2 have been tested for use in infants [35] .", [["DCs", "ANATOMY", 151, 154], ["MAVS", "GENE_OR_GENE_PRODUCT", 3, 7], ["-/-MyD88", "GENE_OR_GENE_PRODUCT", 8, 16], ["interleukin-1 receptor domain-containing adapter molecule 1", "GENE_OR_GENE_PRODUCT", 54, 113], ["TICAM1", "GENE_OR_GENE_PRODUCT", 115, 121], ["TLR3", "GENE_OR_GENE_PRODUCT", 139, 143], ["DCs", "CELL", 151, 154], ["TLR3", "GENE_OR_GENE_PRODUCT", 196, 200], ["RSVderived double-stranded RNA", "GENE_OR_GENE_PRODUCT", 204, 234], ["NS1", "GENE_OR_GENE_PRODUCT", 249, 252], ["NS2", "GENE_OR_GENE_PRODUCT", 257, 260], ["RSV", "ORGANISM", 316, 319], ["NS2", "GENE_OR_GENE_PRODUCT", 357, 360], ["infants", "ORGANISM", 389, 396], ["MAVS", "PROTEIN", 3, 7], ["-/-MyD88", "PROTEIN", 8, 16], ["toll/interleukin-1 receptor domain-containing adapter molecule 1", "PROTEIN", 49, 113], ["TICAM1", "PROTEIN", 115, 121], ["TLR3", "PROTEIN", 139, 143], ["DCs", "CELL_TYPE", 151, 154], ["TLR3", "PROTEIN", 196, 200], ["NS1", "PROTEIN", 249, 252], ["NS2", "PROTEIN", 257, 260], ["miRNAs", "DNA", 293, 299], ["NS2", "PROTEIN", 357, 360], ["mice", "SPECIES", 19, 23], ["infants", "SPECIES", 389, 396], ["mice", "SPECIES", 19, 23], ["RSV", "SPECIES", 316, 319], ["toll/interleukin-1 receptor domain", "TREATMENT", 49, 83], ["adapter molecule", "TREATMENT", 95, 111], ["the adaptor of TLR3", "TREATMENT", 124, 143], ["these DCs", "TREATMENT", 145, 154], ["TLR3", "TREATMENT", 196, 200], ["RSVderived double-stranded RNA (dsRNA", "TREATMENT", 204, 241], ["NS1", "PROBLEM", 249, 252], ["NS2", "TREATMENT", 257, 260], ["the induction of miRNAs", "TREATMENT", 276, 299], ["RSV vaccines", "TREATMENT", 316, 328], ["a targeted deletion in NS2", "TREATMENT", 334, 360], ["NS2", "OBSERVATION", 257, 260]]], ["Whereas a strain with only NS2 deleted was insufficiently attenuated, 2 other NS2 deletion strains with additional mutations were found to be over-attenuated, highlighting the importance of a right balance between attenuation and immunogenicity.", [["NS2", "PROTEIN", 27, 30], ["NS2 deletion strains", "DNA", 78, 98], ["a strain", "PROBLEM", 8, 16], ["NS2 deleted", "PROBLEM", 27, 38], ["2 other NS2 deletion strains", "PROBLEM", 70, 98], ["additional mutations", "PROBLEM", 104, 124], ["right", "ANATOMY_MODIFIER", 192, 197], ["attenuation", "OBSERVATION_MODIFIER", 214, 225]]], ["Currently, 2 phase I clinical trials with other NS2 deletion strains (ClinicalTrials.gov Identifiers: NCT03422237 and NCT03387137) and one with an NS1 deletion (ClinicalTrials.gov Identifier: NCT03596801) are ongoing.", [["NS1", "GENE_OR_GENE_PRODUCT", 147, 150], ["NS1 deletion", "DNA", 147, 159], ["other NS2 deletion strains", "TREATMENT", 42, 68], ["an NS1 deletion", "PROBLEM", 144, 159]]], ["The primary endpoints of these ongoing phase I trials with the live-attenuated RSV strains that lack either NS1 or NS2 are measures for safety, vaccine virus infectivity, and the induction of RSV-neutralizing titers.", [["RSV", "ORGANISM", 79, 82], ["NS1", "GENE_OR_GENE_PRODUCT", 108, 111], ["NS2", "GENE_OR_GENE_PRODUCT", 115, 118], ["RSV", "ORGANISM", 192, 195], ["NS1", "PROTEIN", 108, 111], ["NS2", "PROTEIN", 115, 118], ["RSV", "SPECIES", 79, 82], ["RSV", "SPECIES", 192, 195], ["attenuated RSV strains", "PROBLEM", 68, 90], ["NS1", "TREATMENT", 108, 111], ["NS2", "TREATMENT", 115, 118], ["vaccine virus infectivity", "PROBLEM", 144, 169], ["RSV", "PROBLEM", 192, 195], ["neutralizing titers", "PROBLEM", 196, 215]]], ["To our knowledge, cellular immune responses after immunization with these live-attenuated RSV vaccines have not been investigated.Mechanism(s) of effector functionsTaking into account the small size of NS1 and NS2, it is remarkable how many host functions are affected by these RSV proteins.", [["cellular", "ANATOMY", 18, 26], ["cellular", "CELL", 18, 26], ["RSV", "ORGANISM", 90, 93], ["NS1", "GENE_OR_GENE_PRODUCT", 202, 205], ["NS2", "GENE_OR_GENE_PRODUCT", 210, 213], ["RSV", "ORGANISM", 278, 281], ["NS1", "PROTEIN", 202, 205], ["NS2", "PROTEIN", 210, 213], ["RSV proteins", "PROTEIN", 278, 290], ["RSV", "SPECIES", 90, 93], ["RSV", "SPECIES", 278, 281], ["immunization", "TREATMENT", 50, 62], ["these live-attenuated RSV vaccines", "TREATMENT", 68, 102], ["effector functions", "PROBLEM", 146, 164], ["NS1", "PROBLEM", 202, 205], ["NS2", "PROBLEM", 210, 213], ["these RSV proteins", "PROBLEM", 272, 290], ["small", "OBSERVATION_MODIFIER", 188, 193], ["size", "OBSERVATION_MODIFIER", 194, 198], ["NS1", "OBSERVATION", 202, 205], ["NS2", "OBSERVATION", 210, 213], ["RSV", "OBSERVATION", 278, 281]]], ["Goswami and colleagues hypothesized that NS1 and NS2 form a large (300 to 750 kDa) degradative complex, which they called the NS degradasome (NSD) [51] .", [["NS1", "GENE_OR_GENE_PRODUCT", 41, 44], ["NS2", "GENE_OR_GENE_PRODUCT", 49, 52], ["NS1", "PROTEIN", 41, 44], ["NS2", "PROTEIN", 49, 52], ["degradative complex", "PROTEIN", 83, 102], ["NS1", "TEST", 41, 44], ["degradative complex", "PROBLEM", 83, 102], ["large", "OBSERVATION_MODIFIER", 60, 65]]], ["In A549 cells, this complex could selectively degrade particular innate immune signaling proteins of which RIG-I was also confirmed as a substrate of NSD complexes isolated from RSV-infected cells.", [["A549 cells", "ANATOMY", 3, 13], ["cells", "ANATOMY", 191, 196], ["RSV-infected", "DISEASE", 178, 190], ["A549 cells", "CELL", 3, 13], ["RIG-I", "GENE_OR_GENE_PRODUCT", 107, 112], ["NSD complexes", "GENE_OR_GENE_PRODUCT", 150, 163], ["RSV", "ORGANISM", 178, 181], ["cells", "CELL", 191, 196], ["A549 cells", "CELL_LINE", 3, 13], ["innate immune signaling proteins", "PROTEIN", 65, 97], ["RIG-I", "PROTEIN", 107, 112], ["NSD complexes", "PROTEIN", 150, 163], ["RSV-infected cells", "CELL_TYPE", 178, 196], ["RSV", "SPECIES", 178, 181], ["NSD complexes", "PROBLEM", 150, 163], ["RSV", "PROBLEM", 178, 181], ["infected cells", "PROBLEM", 182, 196], ["A549 cells", "OBSERVATION", 3, 13], ["infected cells", "OBSERVATION", 182, 196]]], ["In this respect, it would be interesting to assess whether other reported NS target proteins are also substrates of the proposed NSD complexes in RSV-infected cells.Mechanism(s) of effector functionsThe NSD complex appears to be metastable, and its activity is enhanced by mitochondria via MAVS, possibly through stabilizing the NSD complex [51] .", [["cells", "ANATOMY", 159, 164], ["mitochondria", "ANATOMY", 273, 285], ["RSV-infected", "DISEASE", 146, 158], ["RSV", "ORGANISM", 146, 149], ["cells", "CELL", 159, 164], ["NSD complex", "GENE_OR_GENE_PRODUCT", 203, 214], ["mitochondria", "CELLULAR_COMPONENT", 273, 285], ["MAVS", "GENE_OR_GENE_PRODUCT", 290, 294], ["NS target proteins", "PROTEIN", 74, 92], ["NSD complexes", "PROTEIN", 129, 142], ["RSV-infected cells", "CELL_TYPE", 146, 164], ["NSD complex", "PROTEIN", 203, 214], ["MAVS", "PROTEIN", 290, 294], ["NSD complex", "PROTEIN", 329, 340], ["RSV", "SPECIES", 146, 149], ["NS target proteins", "TREATMENT", 74, 92], ["the proposed NSD complexes", "PROBLEM", 116, 142], ["RSV", "PROBLEM", 146, 149], ["infected cells", "PROBLEM", 150, 164], ["effector functions", "PROBLEM", 181, 199], ["The NSD complex", "PROBLEM", 199, 214], ["infected cells", "OBSERVATION", 150, 164], ["appears to be", "UNCERTAINTY", 215, 228], ["metastable", "OBSERVATION", 229, 239], ["activity", "OBSERVATION_MODIFIER", 249, 257], ["MAVS", "OBSERVATION", 290, 294]]], ["Interestingly, in MAVS-deficient cells stimulated with IFN-\u03b1, wild-type RSV is almost equally attenuated as RSV lacking NS1 and NS2, confirming the importance of MAVS for NS protein-mediated suppression of type I IFN responses.", [["cells", "ANATOMY", 33, 38], ["MAVS", "GENE_OR_GENE_PRODUCT", 18, 22], ["cells", "CELL", 33, 38], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["wild-type", "ORGANISM", 62, 71], ["RSV", "ORGANISM", 72, 75], ["RSV", "ORGANISM", 108, 111], ["NS1", "GENE_OR_GENE_PRODUCT", 120, 123], ["NS2", "GENE_OR_GENE_PRODUCT", 128, 131], ["MAVS", "GENE_OR_GENE_PRODUCT", 162, 166], ["type I IFN", "GENE_OR_GENE_PRODUCT", 206, 216], ["MAVS", "PROTEIN", 18, 22], ["IFN", "PROTEIN", 55, 58], ["\u03b1", "PROTEIN", 59, 60], ["NS1", "PROTEIN", 120, 123], ["NS2", "PROTEIN", 128, 131], ["MAVS", "PROTEIN", 162, 166], ["NS protein", "PROTEIN", 171, 181], ["type I IFN", "PROTEIN", 206, 216], ["RSV", "SPECIES", 72, 75], ["RSV", "SPECIES", 108, 111], ["deficient cells", "PROBLEM", 23, 38], ["IFN", "TEST", 55, 58], ["type RSV", "PROBLEM", 67, 75], ["NS2", "TREATMENT", 128, 131], ["NS protein", "TREATMENT", 171, 181]]], ["In line with these results, NS2 mainly localizes to mitochondria and seems to recruit NS1 towards the mitochondria [58] .", [["mitochondria", "ANATOMY", 52, 64], ["mitochondria", "ANATOMY", 102, 114], ["NS2", "GENE_OR_GENE_PRODUCT", 28, 31], ["mitochondria", "CELLULAR_COMPONENT", 52, 64], ["NS1", "GENE_OR_GENE_PRODUCT", 86, 89], ["mitochondria", "CELLULAR_COMPONENT", 102, 114], ["NS2", "PROTEIN", 28, 31], ["NS1", "PROTEIN", 86, 89], ["NS2", "TREATMENT", 28, 31]]], ["Furthermore, NS target proteins, but not other innate proteins, relocate from the cytoplasm to the mitochondria upon expression of NS1 and NS2 [51] .", [["cytoplasm", "ANATOMY", 82, 91], ["mitochondria", "ANATOMY", 99, 111], ["cytoplasm", "ORGANISM_SUBSTANCE", 82, 91], ["mitochondria", "CELLULAR_COMPONENT", 99, 111], ["NS1", "GENE_OR_GENE_PRODUCT", 131, 134], ["NS2 [51]", "GENE_OR_GENE_PRODUCT", 139, 147], ["NS target proteins", "PROTEIN", 13, 31], ["innate proteins", "PROTEIN", 47, 62], ["NS1", "PROTEIN", 131, 134], ["NS2", "PROTEIN", 139, 142], ["NS target proteins", "TREATMENT", 13, 31], ["NS1", "PROBLEM", 131, 134]]], ["All together, these results support the hypothesis of the formation of a mitochondrialassociated NSD complex to selectively degrade innate immune proteins in RSV-infected cells.Mechanism(s) of effector functionsAlthough the exact composition of the NSD complex is still unresolved, the presence of the \u03b12 subunit from the 20S core proteasome sparked the idea that the NSD complex might act in a similar way as the host 26S proteasome [51] .", [["cells", "ANATOMY", 171, 176], ["RSV-infected", "DISEASE", 158, 170], ["RSV", "ORGANISM", 158, 161], ["cells", "CELL", 171, 176], ["NSD complex", "GENE_OR_GENE_PRODUCT", 249, 260], ["\u03b12", "GENE_OR_GENE_PRODUCT", 302, 304], ["20S", "GENE_OR_GENE_PRODUCT", 322, 325], ["NSD complex", "GENE_OR_GENE_PRODUCT", 368, 379], ["26S", "GENE_OR_GENE_PRODUCT", 419, 422], ["mitochondrialassociated NSD complex", "PROTEIN", 73, 108], ["innate immune proteins", "PROTEIN", 132, 154], ["RSV-infected cells", "CELL_TYPE", 158, 176], ["NSD complex", "PROTEIN", 249, 260], ["\u03b12 subunit", "PROTEIN", 302, 312], ["20S core proteasome", "PROTEIN", 322, 341], ["NSD complex", "PROTEIN", 368, 379], ["26S proteasome", "PROTEIN", 419, 433], ["RSV", "SPECIES", 158, 161], ["a mitochondrialassociated NSD complex", "PROBLEM", 71, 108], ["RSV", "PROBLEM", 158, 161], ["infected cells", "PROBLEM", 162, 176], ["effector functions", "PROBLEM", 193, 211], ["the NSD complex", "PROBLEM", 245, 260], ["the NSD complex", "PROBLEM", 364, 379], ["infected cells", "OBSERVATION", 162, 176]]], ["In line with this hypothesis, NS protein-induced STAT2 and OASL degradation is (partially) blocked by the proteasome inhibitors MG132 and lactacystin [51, 60, 61, 73, 75] .", [["MG132", "CHEMICAL", 128, 133], ["lactacystin", "CHEMICAL", 138, 149], ["MG132", "CHEMICAL", 128, 133], ["lactacystin", "CHEMICAL", 138, 149], ["NS protein", "GENE_OR_GENE_PRODUCT", 30, 40], ["STAT2", "GENE_OR_GENE_PRODUCT", 49, 54], ["OASL", "GENE_OR_GENE_PRODUCT", 59, 63], ["MG132", "SIMPLE_CHEMICAL", 128, 133], ["lactacystin", "SIMPLE_CHEMICAL", 138, 149], ["NS protein", "PROTEIN", 30, 40], ["STAT2", "PROTEIN", 49, 54], ["OASL", "PROTEIN", 59, 63], ["this hypothesis", "PROBLEM", 13, 28], ["NS protein", "TREATMENT", 30, 40], ["OASL degradation", "PROBLEM", 59, 75], ["the proteasome inhibitors MG132", "TREATMENT", 102, 133], ["lactacystin", "TEST", 138, 149]]], ["In contrast, NS protein-induced TRAF3 and IKK\u03b5 degradation appears insensitive to MG132 [52] .", [["MG132", "CHEMICAL", 82, 87], ["MG132", "CHEMICAL", 82, 87], ["TRAF3", "GENE_OR_GENE_PRODUCT", 32, 37], ["IKK\u03b5", "GENE_OR_GENE_PRODUCT", 42, 46], ["MG132", "SIMPLE_CHEMICAL", 82, 87], ["NS protein", "PROTEIN", 13, 23], ["TRAF3", "PROTEIN", 32, 37], ["IKK\u03b5", "PROTEIN", 42, 46], ["NS protein", "TEST", 13, 23], ["TRAF3", "PROBLEM", 32, 37], ["IKK\u03b5 degradation", "PROBLEM", 42, 58], ["MG132", "TEST", 82, 87]]], ["Proteasome-like activity of the NSD complex is further supported by the identification of NS1 and NS2 as potential inducers of host protein ubiquitination [73, 97] .", [["Proteasome", "GENE_OR_GENE_PRODUCT", 0, 10], ["NSD complex", "GENE_OR_GENE_PRODUCT", 32, 43], ["NS1", "GENE_OR_GENE_PRODUCT", 90, 93], ["NS2", "GENE_OR_GENE_PRODUCT", 98, 101], ["Proteasome", "PROTEIN", 0, 10], ["NSD complex", "PROTEIN", 32, 43], ["NS1", "PROTEIN", 90, 93], ["NS2", "PROTEIN", 98, 101], ["Proteasome", "TREATMENT", 0, 10], ["the NSD complex", "PROBLEM", 28, 43], ["NS1", "TREATMENT", 90, 93], ["NS2", "TREATMENT", 98, 101], ["host protein ubiquitination", "TEST", 127, 154], ["like activity", "OBSERVATION_MODIFIER", 11, 24]]], ["Whereas NS1 is a putative Elongin B/C-Cullin 2/5-SOCS box-type E3 ubiquitin ligase, NS2 does not contain an Elongin C binding consensus sequence [73, 97, 98] .", [["NS1", "GENE_OR_GENE_PRODUCT", 8, 11], ["Elongin B", "GENE_OR_GENE_PRODUCT", 26, 35], ["C", "GENE_OR_GENE_PRODUCT", 36, 37], ["Elongin C", "GENE_OR_GENE_PRODUCT", 108, 117], ["NS1", "PROTEIN", 8, 11], ["Elongin B/C-Cullin 2/5-SOCS box-type E3 ubiquitin ligase", "PROTEIN", 26, 82], ["NS2", "PROTEIN", 84, 87], ["Elongin C binding consensus sequence", "DNA", 108, 144], ["Cullin", "TREATMENT", 38, 44], ["ubiquitin ligase", "OBSERVATION", 66, 82]]], ["Interestingly, an RSV strain with 3 mutated NS2 residues that appear essential for ubiquitination activity and NS2-mediated STAT2 degradation is nearly equally attenuated as an NS2 deletion strain [97] .", [["RSV", "ORGANISM", 18, 21], ["NS2", "GENE_OR_GENE_PRODUCT", 111, 114], ["STAT2", "GENE_OR_GENE_PRODUCT", 124, 129], ["NS2 residues", "PROTEIN", 44, 56], ["NS2", "PROTEIN", 111, 114], ["STAT2", "PROTEIN", 124, 129], ["NS2", "PROTEIN", 177, 180], ["RSV", "SPECIES", 18, 21], ["an RSV strain", "PROBLEM", 15, 28], ["3 mutated NS2 residues", "PROBLEM", 34, 56], ["ubiquitination activity", "PROBLEM", 83, 106], ["NS2-mediated STAT2 degradation", "PROBLEM", 111, 141], ["an NS2 deletion strain", "PROBLEM", 174, 196], ["RSV strain", "OBSERVATION", 18, 28], ["NS2 residues", "OBSERVATION", 44, 56], ["essential for", "UNCERTAINTY", 69, 82], ["ubiquitination activity", "OBSERVATION", 83, 106]]], ["These results suggest that NS2 and NS1 may induce ubiquitination of host proteins, which are then degraded by the NSD complex.", [["NS2", "GENE_OR_GENE_PRODUCT", 27, 30], ["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["NSD complex", "GENE_OR_GENE_PRODUCT", 114, 125], ["NS2", "PROTEIN", 27, 30], ["NS1", "PROTEIN", 35, 38], ["host proteins", "PROTEIN", 68, 81], ["NSD complex", "PROTEIN", 114, 125], ["NS2 and NS1", "TREATMENT", 27, 38], ["ubiquitination of host proteins", "PROBLEM", 50, 81], ["host proteins", "OBSERVATION", 68, 81], ["NSD complex", "OBSERVATION", 114, 125]]], ["It is currently not known, however, if NS1 and/or NS2 selectively mark innate immune proteins for degradation, which would explain the selective degradative activity of the NSD complex.", [["NS1", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS2", "GENE_OR_GENE_PRODUCT", 50, 53], ["NSD complex", "GENE_OR_GENE_PRODUCT", 173, 184], ["NS1", "PROTEIN", 39, 42], ["NS2", "PROTEIN", 50, 53], ["innate immune proteins", "PROTEIN", 71, 93], ["NSD complex", "PROTEIN", 173, 184], ["NS1", "PROBLEM", 39, 42], ["NS2", "PROBLEM", 50, 53], ["the selective degradative activity of the NSD complex", "PROBLEM", 131, 184]]], ["Recently, the crystal structure of NS1 was determined and revealed a remarkable structural homology with the N-terminal domain of the matrix protein of RSV [37].", [["N", "CHEMICAL", 109, 110], ["NS1", "GENE_OR_GENE_PRODUCT", 35, 38], ["matrix", "CELLULAR_COMPONENT", 134, 140], ["RSV", "ORGANISM", 152, 155], ["NS1", "PROTEIN", 35, 38], ["N-terminal domain", "PROTEIN", 109, 126], ["matrix protein", "PROTEIN", 134, 148], ["RSV", "SPECIES", 152, 155], ["the crystal structure of NS1", "TEST", 10, 38], ["a remarkable structural homology", "PROBLEM", 67, 99], ["NS1", "OBSERVATION", 35, 38]]], ["One clear difference between NS1 and M is the presence of an \u03b1-helix (called \u03b13) at the C-terminus of NS1.", [["NS1", "GENE_OR_GENE_PRODUCT", 29, 32], ["\u03b13", "GENE_OR_GENE_PRODUCT", 77, 79], ["NS1", "GENE_OR_GENE_PRODUCT", 102, 105], ["NS1", "PROTEIN", 29, 32], ["\u03b1-helix", "PROTEIN", 61, 68], ["\u03b13", "PROTEIN", 77, 79], ["C-terminus", "PROTEIN", 88, 98], ["NS1", "PROTEIN", 102, 105], ["clear", "OBSERVATION_MODIFIER", 4, 9], ["difference", "OBSERVATION", 10, 20]]], ["A truncated NS1 lacking this helix or mutation of 3 residues that are important for the interaction of helix \u03b13 with the rest of NS1 partially abrogates NS1-mediated suppression of IFN-\u03b2 induction and attenuates recombinant RSV strains.", [["NS1", "GENE_OR_GENE_PRODUCT", 12, 15], ["helix \u03b13", "GENE_OR_GENE_PRODUCT", 103, 111], ["NS1", "GENE_OR_GENE_PRODUCT", 129, 132], ["NS1", "GENE_OR_GENE_PRODUCT", 153, 156], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 181, 186], ["RSV", "ORGANISM", 224, 227], ["NS1", "PROTEIN", 12, 15], ["helix \u03b13", "PROTEIN", 103, 111], ["NS1", "PROTEIN", 129, 132], ["NS1", "PROTEIN", 153, 156], ["IFN", "PROTEIN", 181, 184], ["\u03b2", "PROTEIN", 185, 186], ["RSV", "SPECIES", 224, 227], ["A truncated NS1", "PROBLEM", 0, 15], ["mutation of 3 residues", "PROBLEM", 38, 60], ["NS1", "TREATMENT", 129, 132], ["NS1", "PROBLEM", 153, 156], ["IFN-\u03b2 induction", "TREATMENT", 181, 196], ["attenuates recombinant RSV strains", "PROBLEM", 201, 235], ["NS1", "OBSERVATION", 12, 15], ["RSV strains", "OBSERVATION", 224, 235]]], ["These results confirm that helix \u03b13 is important for at least some NS1-mediated effector functions.", [["helix \u03b13", "GENE_OR_GENE_PRODUCT", 27, 35], ["NS1", "GENE_OR_GENE_PRODUCT", 67, 70], ["helix \u03b13", "PROTEIN", 27, 35], ["NS1", "PROTEIN", 67, 70], ["helix \u03b13", "TREATMENT", 27, 35]]], ["Unravelling the crystal structure of NS2 and the composition of the NSD complex would greatly enhance our understanding of the remarkable diverse effector functions of NS1 and NS2.", [["NS2", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 168, 171], ["NS2", "GENE_OR_GENE_PRODUCT", 176, 179], ["NS2", "PROTEIN", 37, 40], ["NSD complex", "PROTEIN", 68, 79], ["NS1", "PROTEIN", 168, 171], ["NS2", "PROTEIN", 176, 179], ["NS2", "PROBLEM", 37, 40], ["the NSD complex", "PROBLEM", 64, 79], ["NS2", "PROBLEM", 176, 179], ["crystal structure", "OBSERVATION", 16, 33], ["NS2", "OBSERVATION", 37, 40], ["NSD", "OBSERVATION", 68, 71]]], ["Moreover, NS1 and/or NS2 may be attractive targets for antiviral therapy.", [["NS1", "GENE_OR_GENE_PRODUCT", 10, 13], ["NS2", "GENE_OR_GENE_PRODUCT", 21, 24], ["NS1", "PROTEIN", 10, 13], ["NS2", "PROTEIN", 21, 24], ["NS1", "TEST", 10, 13], ["NS2", "PROBLEM", 21, 24], ["antiviral therapy", "TREATMENT", 55, 72], ["may be", "UNCERTAINTY", 25, 31], ["antiviral therapy", "OBSERVATION", 55, 72]]], ["Intranasal administration of nanoparticles carrying a plasmid encoding an NS1-targeting small interfering RNA (siRNA) in mice can reduce lung viral titers, airway hyperresponsiveness, and pulmonary inflammation, both in a prophylactic as well as therapeutic setting [99] .", [["plasmid", "ANATOMY", 54, 61], ["lung", "ANATOMY", 137, 141], ["airway", "ANATOMY", 156, 162], ["pulmonary", "ANATOMY", 188, 197], ["pulmonary inflammation", "DISEASE", 188, 210], ["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["mice", "ORGANISM", 121, 125], ["lung", "ORGAN", 137, 141], ["airway", "MULTI-TISSUE_STRUCTURE", 156, 162], ["pulmonary", "ORGAN", 188, 197], ["plasmid", "DNA", 54, 61], ["NS1", "PROTEIN", 74, 77], ["small interfering RNA", "RNA", 88, 109], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["Intranasal administration of nanoparticles", "TREATMENT", 0, 42], ["a plasmid", "TREATMENT", 52, 61], ["an NS1-targeting small interfering RNA (siRNA)", "TREATMENT", 71, 117], ["lung viral titers", "PROBLEM", 137, 154], ["airway hyperresponsiveness", "PROBLEM", 156, 182], ["pulmonary inflammation", "PROBLEM", 188, 210], ["a prophylactic", "TREATMENT", 220, 234], ["small", "OBSERVATION_MODIFIER", 88, 93], ["interfering RNA", "OBSERVATION", 94, 109], ["lung", "ANATOMY", 137, 141], ["viral titers", "OBSERVATION", 142, 154], ["airway", "ANATOMY", 156, 162], ["hyperresponsiveness", "OBSERVATION", 163, 182], ["pulmonary", "ANATOMY", 188, 197], ["inflammation", "OBSERVATION", 198, 210]]], ["A recent small compound high-throughput screen revealed 4 candidate inhibitors of NS2, highlighting that NS2 could be targeted by a small compound drug [100] .General conclusionIn humans, RSV infections induce remarkably low levels of IFN-\u03b1 and -\u03b2 compared with other respiratory viruses.", [["RSV infections", "DISEASE", 188, 202], ["respiratory viruses", "DISEASE", 268, 287], ["NS2", "GENE_OR_GENE_PRODUCT", 82, 85], ["NS2", "GENE_OR_GENE_PRODUCT", 105, 108], ["humans", "ORGANISM", 180, 186], ["RSV", "ORGANISM", 188, 191], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 235, 240], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 245, 247], ["NS2", "PROTEIN", 82, 85], ["NS2", "PROTEIN", 105, 108], ["IFN", "PROTEIN", 235, 238], ["-\u03b1", "PROTEIN", 238, 240], ["-\u03b2", "PROTEIN", 245, 247], ["humans", "SPECIES", 180, 186], ["humans", "SPECIES", 180, 186], ["RSV", "SPECIES", 188, 191], ["A recent small compound high-throughput screen", "PROBLEM", 0, 46], ["NS2", "TREATMENT", 82, 85], ["NS2", "TREATMENT", 105, 108], ["RSV infections", "PROBLEM", 188, 202], ["remarkably low levels of IFN-\u03b1", "PROBLEM", 210, 240], ["other respiratory viruses", "PROBLEM", 262, 287], ["small", "OBSERVATION_MODIFIER", 9, 14], ["compound", "OBSERVATION_MODIFIER", 15, 23], ["high", "OBSERVATION_MODIFIER", 24, 28], ["small", "OBSERVATION_MODIFIER", 132, 137], ["RSV", "ANATOMY", 188, 191], ["infections", "OBSERVATION", 192, 202], ["low levels", "OBSERVATION_MODIFIER", 221, 231], ["respiratory", "ANATOMY", 268, 279], ["viruses", "OBSERVATION", 280, 287]]], ["This is largely the consequence of 2 unique viral proteins, NS1 and NS2, that strongly suppress the induction and signaling of IFN.", [["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS2", "GENE_OR_GENE_PRODUCT", 68, 71], ["IFN", "GENE_OR_GENE_PRODUCT", 127, 130], ["viral proteins", "PROTEIN", 44, 58], ["NS1", "PROTEIN", 60, 63], ["NS2", "PROTEIN", 68, 71], ["IFN", "PROTEIN", 127, 130], ["NS1", "TREATMENT", 60, 63], ["NS2", "TREATMENT", 68, 71], ["signaling of IFN", "PROBLEM", 114, 130]]], ["In recent years, evidence is rising that, in addition, antiviral activities of ISGs may be hampered by the NS proteins.", [["ISGs", "PROTEIN", 79, 83], ["NS proteins", "PROTEIN", 107, 118], ["antiviral activities of ISGs", "TREATMENT", 55, 83], ["the NS proteins", "TREATMENT", 103, 118], ["rising", "OBSERVATION_MODIFIER", 29, 35]]], ["NS1 and NS2 exert additional functions, such as delaying cell apoptosis, and loss of NS1 is associated with a stronger adaptive immune response and reduced in vivo viral replication.", [["cell", "ANATOMY", 57, 61], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["cell", "CELL", 57, 61], ["NS1", "GENE_OR_GENE_PRODUCT", 85, 88], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["NS1", "PROTEIN", 85, 88], ["NS1", "PROBLEM", 0, 3], ["NS2", "PROBLEM", 8, 11], ["delaying cell apoptosis", "PROBLEM", 48, 71], ["loss of NS1", "PROBLEM", 77, 88], ["vivo viral replication", "TREATMENT", 159, 181], ["NS2", "OBSERVATION", 8, 11], ["cell apoptosis", "OBSERVATION", 57, 71], ["viral replication", "OBSERVATION", 164, 181]]], ["NS1 and NS2 are thought to form a so-called \"NS degradasome\" complex, which may function as a proteasome-like complex that selectively degrades a plethora of innate immune proteins.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS2", "GENE_OR_GENE_PRODUCT", 8, 11], ["NS1", "PROTEIN", 0, 3], ["NS2", "PROTEIN", 8, 11], ["NS degradasome\" complex", "PROTEIN", 45, 68], ["proteasome-like complex", "PROTEIN", 94, 117], ["innate immune proteins", "PROTEIN", 158, 180], ["NS1", "PROBLEM", 0, 3], ["NS2", "PROBLEM", 8, 11], ["innate immune proteins", "PROBLEM", 158, 180], ["NS2", "OBSERVATION", 8, 11]]], ["Further insight in the composition of the NSD and the resolution of the structure of NS2 will likely help to explain the remarkable diverse effector functions of NS1 and NS2.", [["NS2", "GENE_OR_GENE_PRODUCT", 85, 88], ["NS1", "GENE_OR_GENE_PRODUCT", 162, 165], ["NS2", "GENE_OR_GENE_PRODUCT", 170, 173], ["NS2", "PROTEIN", 85, 88], ["NS1", "PROTEIN", 162, 165], ["NS2", "PROTEIN", 170, 173], ["the NSD", "PROBLEM", 38, 45], ["NS2", "TREATMENT", 85, 88], ["NS2", "PROBLEM", 170, 173]]], ["Some effector functions, however, have so far only been identified in artificial cell systems and should be interpreted carefully.", [["cell", "ANATOMY", 81, 85], ["cell", "CELL", 81, 85], ["artificial cell systems", "TEST", 70, 93], ["effector functions", "OBSERVATION", 5, 23]]], ["Large-scale protein-protein interaction screens, preferentially performed using multiple complementary protein-protein interaction techniques in the context of an RSV infection, will generate a more comprehensive list of host proteins that interact with NS1 and/or NS2.", [["RSV infection", "DISEASE", 163, 176], ["RSV", "ORGANISM", 163, 166], ["NS1", "GENE_OR_GENE_PRODUCT", 254, 257], ["NS2", "GENE_OR_GENE_PRODUCT", 265, 268], ["host proteins", "PROTEIN", 221, 234], ["NS1", "PROTEIN", 254, 257], ["NS2", "PROTEIN", 265, 268], ["RSV", "SPECIES", 163, 166], ["protein interaction screens", "TEST", 20, 47], ["multiple complementary protein-protein interaction techniques", "TREATMENT", 80, 141], ["an RSV infection", "PROBLEM", 160, 176], ["host proteins", "TREATMENT", 221, 234], ["NS1", "TREATMENT", 254, 257], ["NS2", "TREATMENT", 265, 268], ["RSV", "ANATOMY", 163, 166], ["infection", "OBSERVATION", 167, 176]]], ["Such new knowledge, combined with co-crystal structure analysis of RSV NS1 and NS2 in complex with host protein factors, will be instrumental to design antiviral drugs that impact on the RSV-host interface and thereby complement directly acting antivirals.", [["RSV NS1", "ORGANISM", 67, 74], ["NS2", "GENE_OR_GENE_PRODUCT", 79, 82], ["RSV", "ORGANISM", 187, 190], ["RSV NS1", "PROTEIN", 67, 74], ["NS2", "PROTEIN", 79, 82], ["host protein factors", "PROTEIN", 99, 119], ["RSV", "SPECIES", 67, 70], ["RSV", "SPECIES", 187, 190], ["co-crystal structure analysis", "TEST", 34, 63], ["RSV NS1", "PROBLEM", 67, 74], ["NS2", "PROBLEM", 79, 82], ["host protein factors", "PROBLEM", 99, 119], ["antiviral drugs", "TREATMENT", 152, 167], ["the RSV-host interface", "TREATMENT", 183, 205], ["antivirals", "TREATMENT", 245, 255], ["RSV NS1", "OBSERVATION", 67, 74]]]], "PMC7518967": [["Although match rates have increased in recent years, the average number of applications submitted per applicant has also steadily and disproportionately risen over the past 7 cycles.1,2 Among the factors motivating excess applications is a dearth of published data on successful applicants, which may provoke anxiety among applicants about having too few publications, too few interviews, and too few programs to rank.", [["anxiety", "DISEASE", 309, 316], ["anxiety", "PROBLEM", 309, 316], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["disproportionately", "OBSERVATION_MODIFIER", 134, 152], ["risen", "OBSERVATION_MODIFIER", 153, 158]]]], "PMC7334896": [["IntroductionSince the first case was reported in Wuhan, China in December, 2019, the Coronavirus Disease 2019 (COVID-19) has evolved into a pandemic within merely 3 months (World Health Organization 2020).", [["Coronavirus Disease", "DISEASE", 85, 104], ["COVID-19", "CHEMICAL", 111, 119], ["the Coronavirus Disease", "PROBLEM", 81, 104], ["COVID", "TEST", 111, 116], ["Coronavirus", "ANATOMY", 85, 96]]], ["The virus is known to transmit from person to person either directly through droplets produced by coughing, sneezing, and talking or indirectly through contaminated surfaces (Bourouiba 2020; Lai et al. 2020).", [["coughing", "DISEASE", 98, 106], ["person", "SPECIES", 36, 42], ["person", "SPECIES", 46, 52], ["The virus", "PROBLEM", 0, 9], ["coughing", "PROBLEM", 98, 106], ["sneezing", "PROBLEM", 108, 116], ["virus", "OBSERVATION", 4, 9]]], ["The combination of high reproduction and fatality rates of COVID-19, as well as the lack of vaccine and herd immunity, forces governments around the world to issue travel restriction, business closedown, and social distancing measures in the hope to \u201cflatten\u201d the outbreak curve so that new cases would not overwhelm the health care system.", [["high reproduction", "PROBLEM", 19, 36], ["COVID", "TEST", 59, 64], ["vaccine", "TREATMENT", 92, 99], ["high", "OBSERVATION_MODIFIER", 19, 23], ["reproduction", "OBSERVATION_MODIFIER", 24, 36]]], ["This partially reflects a non-uniform enforcement of social distancing among the states and different demographic features such as population density and age distribution.", [["non-uniform", "OBSERVATION_MODIFIER", 26, 37], ["enforcement", "OBSERVATION_MODIFIER", 38, 49], ["population", "OBSERVATION_MODIFIER", 131, 141], ["density", "OBSERVATION", 142, 149]]], ["Local meteorology, however, may be an unignorable factor.", [["unignorable factor", "PROTEIN", 38, 56], ["an unignorable factor", "PROBLEM", 35, 56]]], ["It was reported that temperature, relative humidity, and wind speed influences the survival and transmission of Severe Acute Respiratory Syndrome (SARS) coronavirus, a close relative to the COVID-19 (Yuan et al. 2006; Yip et al. 2007).", [["Acute Respiratory Syndrome (SARS) coronavirus", "DISEASE", 119, 164], ["Severe Acute Respiratory Syndrome (SARS) coronavirus", "SPECIES", 112, 164], ["Severe Acute Respiratory Syndrome", "PROBLEM", 112, 145], ["SARS) coronavirus", "PROBLEM", 147, 164], ["the COVID", "TEST", 186, 195], ["Severe", "OBSERVATION_MODIFIER", 112, 118], ["Acute", "OBSERVATION_MODIFIER", 119, 124], ["Respiratory Syndrome", "OBSERVATION", 125, 145]]], ["Laboratory studies also suggest that coronaviruses prefer cool and dry ambient conditions, where it may remain viable up to days (Chan et al. 2011; van Doremalen et al. 2013).", [["coronaviruses", "ORGANISM", 37, 50], ["Laboratory studies", "TEST", 0, 18], ["coronaviruses", "PROBLEM", 37, 50], ["dry ambient conditions", "PROBLEM", 67, 89], ["coronaviruses", "OBSERVATION", 37, 50]]], ["There is a hypothesis that the pandemic will slow down in the coming summer of the northern hemisphere, much like seasonal influenza, though this hypothesis has yet been tested at the population level (Araujo and Naimi 2020).IntroductionWhile the U.S. territory spans multiple climate zones, this research represents one of the first epidemiological studies that investigate relationships between COVID-19 incidence and weather conditions at the county level.", [["influenza", "DISEASE", 123, 132], ["a hypothesis", "PROBLEM", 9, 21], ["the pandemic", "PROBLEM", 27, 39], ["seasonal influenza", "PROBLEM", 114, 132], ["COVID", "TEST", 397, 402], ["northern hemisphere", "ANATOMY", 83, 102], ["seasonal", "OBSERVATION_MODIFIER", 114, 122], ["influenza", "OBSERVATION", 123, 132], ["territory", "OBSERVATION_MODIFIER", 252, 261], ["spans", "OBSERVATION_MODIFIER", 262, 267], ["multiple", "OBSERVATION_MODIFIER", 268, 276], ["climate", "OBSERVATION_MODIFIER", 277, 284], ["zones", "OBSERVATION_MODIFIER", 285, 290]]], ["Our findings should catalyze further research in this area, and inform the modelling of COVID-19 outbreak for better projections and management efforts.Study area, study period, and data sourceWe selected the top 50 most prevalent counties with COVID-19 in the U.S. for the period of March 16, 2020 to April 22, 2020 because the county level data were not available until March 16, 2020.", [["COVID", "TEST", 88, 93], ["management efforts", "TREATMENT", 133, 151], ["Study area", "TEST", 152, 162], ["COVID", "TEST", 245, 250], ["the county level data", "TEST", 325, 346]]], ["These counties are mostly located in the eastern U.S., with 20 of them in the New York and New Jersey States.", [["New", "OBSERVATION_MODIFIER", 91, 94]]], ["The confirmed cases of COVID-19 were downloaded from Johns Hopkins Coronavirus Resource Center (Dong et al. 2020).", [["COVID-19", "DNA", 23, 31], ["COVID", "TEST", 23, 28]]], ["The original data were accumulative over days, from which we calculated daily new confirmed cases in each county.", [["accumulative", "OBSERVATION_MODIFIER", 23, 35]]], ["The meteorological data were based on long-term weather stations in each county, typically at the main airports, and downloaded from the Weather Underground database (https://www.wunderground.com/).", [["The meteorological data", "TEST", 0, 23]]], ["Because some of them are highly correlated (e.g., temperature and dew point temperature) or not known to associate with respiratory diseases (e.g., wind speed and sea level pressure), we only selected seven measures: Maximum temperature, minimum temperature, average temperature, maximum relative humidity, minimum relative humidity, average relative humidity, and precipitation for further analyses.", [["respiratory", "ANATOMY", 120, 131], ["respiratory diseases", "DISEASE", 120, 140], ["dew point temperature", "PROBLEM", 66, 87], ["respiratory diseases", "PROBLEM", 120, 140], ["sea level pressure", "TEST", 163, 181], ["Maximum temperature", "TEST", 217, 236], ["minimum temperature", "TEST", 238, 257], ["average temperature", "TEST", 259, 278], ["further analyses", "TEST", 383, 399]]], ["Lastly, we adopted confounding variables about socioeconomic status from American Community Survey\u2019s 5-year (2014\u20132018) estimates, including county-specific population, age, gender, and racial compositions, and poverty level (U.S. Census Bureau 2019).Statistical analyses and findingsWe applied the generalized additive model (Hastie and Tibshirani 1990) to evaluate the association between meteorological factors and the incidence of COVID-19.", [["Statistical analyses", "TEST", 251, 271], ["the generalized additive model (Hastie and Tibshirani", "TREATMENT", 295, 348], ["COVID", "TEST", 435, 440]]], ["We proposed three models sharing the same confounding variables in terms of the day-of-the-week, county\u2019s federal information processing standard, median age, male percentage, White percentage, Black percentage, Hispanic percentage, and poverty percentage.", [["White percentage", "TEST", 176, 192], ["Black", "OBSERVATION_MODIFIER", 194, 199], ["percentage", "OBSERVATION_MODIFIER", 200, 210]]], ["The spatial function also explained unobserved risk factors in each county, such as human activities and policies (e.g., stay-at-home order).", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89]]], ["The main difference of the three models is how meteorological measures were estimated.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["In Model 2, we alternative considered a p-spline for each meteorological measure.", [["a p-spline", "TREATMENT", 38, 48]]], ["Each model was fitted seven times for seven meteorological measures separately to identify whether meteorological impacts on COVID-19 were linear or nonlinear by using the Akaike information criterion (AIC).Statistical analyses and findingsTable 1 shows that six of seven meteorological factors were significantly and linearly associated with COVID-19 according to Model 1.", [["COVID", "TEST", 125, 130], ["Statistical analyses", "TEST", 207, 227], ["COVID", "TEST", 343, 348]]], ["Temperature and precipitation measures were all negatively related to COVID-19, while relative humidity measures were positively related to COVID-19.", [["Temperature", "TEST", 0, 11], ["precipitation measures", "TEST", 16, 38], ["COVID", "TEST", 70, 75], ["relative humidity measures", "TREATMENT", 86, 112], ["COVID", "TEST", 140, 145]]], ["Comparing the AIC between Model 1 and Model 2, all AICs were smaller in Model 2, suggesting nonlinearly meteorological impacts on COVID-19.Statistical analyses and findingsFigure 1 shows that the percentage change of relative risk (RR %) of COVID-19 incidence had diverse variations among different meteorological factors.", [["meteorological factors", "PROTEIN", 299, 321], ["Model", "TEST", 26, 31], ["all AICs", "TEST", 47, 55], ["nonlinearly meteorological impacts", "PROBLEM", 92, 126], ["COVID", "TEST", 130, 135], ["Statistical analyses", "TEST", 139, 159], ["RR", "TEST", 232, 234], ["COVID", "TEST", 241, 246], ["diverse variations", "PROBLEM", 264, 282], ["smaller", "OBSERVATION_MODIFIER", 61, 68], ["suggesting", "UNCERTAINTY", 81, 91], ["nonlinearly", "OBSERVATION_MODIFIER", 92, 103], ["meteorological impacts", "OBSERVATION", 104, 126], ["meteorological factors", "OBSERVATION", 299, 321]]], ["Comparing the three temperature measures, average temperature had the smallest AIC and so best address the association with the incidence of COVID-19.", [["COVID-19", "CHEMICAL", 141, 149], ["COVID", "TEST", 141, 146]]], ["A RR % larger than 10% was more likely observed in 63.44 \u00b0F or higher, and the highest RR % was 19.33% (95% CI = 16.54, 22.20) when the average temperature increased to 67.30 \u00b0F. After that, the RR % decreased to negative when the average temperature exceeded 74.37 \u00b0F. Moreover, compared to the three relative humidity measures, minimum relative humidity had the smallest AIC and thus best address the association with the incidence of COVID-19.", [["COVID-19", "CHEMICAL", 437, 445], ["A RR", "TEST", 0, 4], ["the highest RR", "TEST", 75, 89], ["CI", "TEST", 108, 110], ["the average temperature", "TEST", 132, 155], ["the RR", "TEST", 191, 197], ["the average temperature", "TEST", 227, 250], ["the smallest AIC", "PROBLEM", 360, 376], ["COVID", "TEST", 437, 442], ["smallest", "OBSERVATION_MODIFIER", 364, 372]]], ["A higher RR % was more likely observed with a lower level of minimum relative humidity from 0 to 10%, while it was not reliable because of very limited observations in this range.", [["A higher RR %", "TREATMENT", 0, 13]]], ["The RR % appeared another surge with a higher level of minimum relative humidity over 92.61%.", [["The RR", "TEST", 0, 6]]], ["Furthermore, precipitation had a positive impact on COVID-19 between 1.27 and 1.74 inches, resulting in the largest increase in the RR % of COVID-19 incidence up to 33.89% (95% CI = 28.63, 39.35) with 1.55 inches of precipitation.", [["COVID", "TEST", 52, 57], ["the RR", "TEST", 128, 134], ["COVID", "TEST", 140, 145], ["CI", "TEST", 177, 179], ["precipitation", "PROBLEM", 216, 229], ["largest", "OBSERVATION_MODIFIER", 108, 115], ["increase", "OBSERVATION_MODIFIER", 116, 124]]], ["Then, the RR % significantly declined to negative when precipitation increased over 1.77 inches.Statistical analyses and findingsFinally, according to the smallest AIC in temperature and relative humidity measures, the average temperature and minimum relative humidity were selected to fit with precipitation in Model 3 to investigate the compound influence on COVID-19 incidence.", [["the RR", "TEST", 6, 12], ["Statistical analyses", "TEST", 96, 116], ["relative humidity measures", "TREATMENT", 187, 213], ["the average temperature", "TEST", 215, 238]]], ["Model 3 resulted in the smallest AIC = 13537271, compared to all AICs in Model 1 and Model 2.", [["the smallest AIC", "PROBLEM", 20, 36]]], ["We evaluated the overall impact of each selected meteorological factor by summing up all smoothing functions from the main effect and three lagged effects, shown in Fig. 2.", [["main", "OBSERVATION_MODIFIER", 118, 122]]], ["In particular, the overall impact of average temperature had a clear threshold by 59.5 \u00b0F, where the overall impact turned from negative to positive.", [["average temperature", "PROBLEM", 37, 56]]], ["After reaching the greatest RR % (73.40%; 95% CI = 62.81, 84.66), the overall impact consistently decreased after 68.45 \u00b0F. The level of RR % was downward below 0% when the average temperature increased over 84.67 \u00b0F, while the overall impact was no longer significant.", [["RR", "TEST", 28, 30], ["CI", "TEST", 46, 48], ["RR", "TEST", 137, 139], ["the average temperature", "TEST", 169, 192], ["decreased", "OBSERVATION_MODIFIER", 98, 107], ["no longer", "UNCERTAINTY", 247, 256]]], ["Moreover, the overall impact was higher with lower levels of minimum relative humidity, while the trend gradually went downward to reach the smallest RR % by -36.22 (95% CI = \u2212 40.14, \u2212 32.04) when the minimum relative humidity increased to 91.42%.", [["CI", "TEST", 170, 172], ["overall", "OBSERVATION_MODIFIER", 14, 21], ["impact", "OBSERVATION_MODIFIER", 22, 28], ["higher", "OBSERVATION_MODIFIER", 33, 39]]], ["Nonetheless, its overall impact returned to positive as it increased over 97.28%.", [["increased", "OBSERVATION_MODIFIER", 59, 68]]], ["Furthermore, the overall impact on COVID-19 climbed to the highest level (RR % = 232.07%; 95% CI = 199.77, 267.85) with 1.60 inches of precipitation, and then significantly reduced to negative when precipitation increased over 1.85 inches.Discussion and conclusionAlong with the development of the COVID-19 pandemic, biomedical researchers have devoted a great effort to looking for treatments and vaccines against COVID-19 (Chen et al. 2020; Cascella et al. 2020).", [["COVID", "TEST", 35, 40], ["RR", "TEST", 74, 76], ["CI", "TEST", 94, 96], ["precipitation", "TREATMENT", 135, 148], ["the COVID", "TEST", 294, 303], ["treatments", "TREATMENT", 383, 393], ["vaccines", "TREATMENT", 398, 406], ["COVID", "TEST", 415, 420]]], ["Unfortunately, the process of clinical trials also needs time to go through several phases to confirm that a treatment or a vaccine can efficiently work without side effects (Gouglas et al. 2018).", [["a treatment", "TREATMENT", 107, 118], ["a vaccine", "TREATMENT", 122, 131], ["side effects", "PROBLEM", 161, 173]]], ["Previous experience from SARS and Zika did not have successful treatments and vaccines because both epidemics ended before treatment and vaccine developments were complete (Lurie et al. 2020).", [["SARS", "DISEASE", 25, 29], ["SARS", "PROBLEM", 25, 29], ["Zika", "PROBLEM", 34, 38], ["successful treatments", "TREATMENT", 52, 73], ["vaccines", "TREATMENT", 78, 86], ["both epidemics", "PROBLEM", 95, 109], ["treatment", "TREATMENT", 123, 132], ["vaccine", "TREATMENT", 137, 144]]], ["It is alleged that approval treatments or vaccines of COVID-19 probably cannot be developed sooner than 12\u201318 months (Lanese 2020).", [["COVID-19", "CHEMICAL", 54, 62], ["approval treatments", "TREATMENT", 19, 38], ["vaccines", "TREATMENT", 42, 50], ["COVID", "TREATMENT", 54, 59]]], ["Therefore, people turned to anticipate that the mitigation of the COVID-19 pandemic will happen in the summer because another similar disease, SARS, started the epidemic since February 2003, and quickly diminished in July 2003 (Dutton 2020).Discussion and conclusionLiterature has revealed that a higher level of temperature and humidity can reduce the transmission of COVID-19 (Wang et al. 2020), and a preliminary research hosted by the U.S. Department of Homeland Security indicates that the coronavirus died faster in hotter and more humid conditions\u2014despite the raw data and analytic report have not been released and peer-reviewed (U.S. Department of Homeland Security 2020).", [["SARS", "DISEASE", 143, 147], ["coronavirus", "DISEASE", 495, 506], ["people", "ORGANISM", 11, 17], ["COVID-19", "ORGANISM", 66, 74], ["coronavirus", "ORGANISM", 495, 506], ["people", "SPECIES", 11, 17], ["the COVID", "TREATMENT", 62, 71], ["another similar disease", "PROBLEM", 118, 141], ["SARS", "PROBLEM", 143, 147], ["COVID", "TEST", 369, 374], ["the coronavirus", "PROBLEM", 491, 506], ["disease", "OBSERVATION", 134, 141], ["diminished", "OBSERVATION_MODIFIER", 203, 213]]], ["Some multi-city studies in China found no strong evidence to support that COVID-19 epidemic could mitigate when the weather becomes warmer (Xie and Zhu 2020; Yao et al. 2020).", [["COVID-19", "CHEMICAL", 74, 82], ["city studies", "TEST", 11, 23], ["COVID", "TEST", 74, 79], ["no strong evidence to", "UNCERTAINTY", 39, 60]]], ["In our study, we first investigated the linear association between meteorological factors and COVID-19 in the U.S. We found that higher temperatures significantly reduced the risk of COVID-19, while higher relative humidities significantly increased the risk.", [["meteorological factors", "PROTEIN", 67, 89], ["our study", "TEST", 3, 12], ["COVID", "TEST", 94, 99], ["higher temperatures", "PROBLEM", 129, 148], ["COVID", "TEST", 183, 188], ["higher", "OBSERVATION_MODIFIER", 129, 135], ["temperatures", "OBSERVATION_MODIFIER", 136, 148], ["significantly", "OBSERVATION_MODIFIER", 149, 162], ["reduced", "OBSERVATION_MODIFIER", 163, 170]]], ["We further verified that the nonlinear association might be better to address the impact of meteorological factors on COVID-19.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 118, 126], ["meteorological factors", "PROTEIN", 92, 114], ["COVID-19", "DNA", 118, 126], ["COVID", "TEST", 118, 123]]], ["While increasing temperature and relative humidity may lead to a decline of risk, it only happened within certain temperature/relative humidity ranges.", [["increasing temperature", "PROBLEM", 6, 28], ["a decline of risk", "PROBLEM", 63, 80]]], ["In the final model (Model 3), our findings did not support the hypothesis and expectation that a higher level of temperature was significantly negatively associated with COVID-19, while the RR % was significantly decreased.", [["the hypothesis", "PROBLEM", 59, 73], ["a higher level of temperature", "PROBLEM", 95, 124], ["COVID", "TEST", 170, 175], ["the RR", "TEST", 186, 192], ["decreased", "OBSERVATION_MODIFIER", 213, 222]]], ["However, it is still too early to conclude that the pandemic will be mitigated in the summer.Discussion and conclusionA new finding which has not been fully discussed in literature is that precipitation can greatly reduce the risk of COVID-19.", [["COVID-19", "CHEMICAL", 234, 242], ["COVID", "TEST", 234, 239]]], ["We used to wonder whether the variation to COVID-19 incidence was more likely explained by rainfall rather than relative humidity.", [["COVID", "TEST", 43, 48]]], ["Nonetheless, the correlation between precipitation and relative humidity is quite low (\u03c1 = \u2212 0.06\u20130.20).", [["relative humidity", "TEST", 55, 72], ["low", "OBSERVATION_MODIFIER", 82, 85]]], ["We haven not seen reliable evidence of precipitation reducing the risk of COVID-19 from literature yet, while our finding in precipitation should be explained conservatively because such a short study period can hardly represent the true profile of precipitation during this year.Discussion and conclusionTo sum up, the study found that average temperature, minimum relative humidity, and precipitation can better address the impact of meteorological factors on COVID-19.", [["meteorological factors", "PROTEIN", 436, 458], ["COVID-19", "PROTEIN", 462, 470], ["COVID", "TEST", 74, 79], ["a short study", "TEST", 187, 200], ["the study", "TEST", 316, 325], ["average temperature", "PROBLEM", 337, 356], ["COVID", "TEST", 462, 467], ["precipitation", "OBSERVATION", 39, 52]]], ["However, we did not find evidence of reducing the risk of COVID-19 from the higher level of minimum relative humidity.", [["COVID-19", "CHEMICAL", 58, 66], ["COVID", "TEST", 58, 63]]], ["Despite an increasing average temperature likely can reduce the risk of COVID-19, the evidence on the highest level of average temperature was still not strong enough.", [["an increasing average temperature", "PROBLEM", 8, 41], ["COVID", "TEST", 72, 77], ["average temperature", "TEST", 119, 138], ["increasing", "OBSERVATION_MODIFIER", 11, 21]]], ["Precipitation can greatly reduce the risk of COVID-19, though observations of heavy precipitation are few in this study.", [["COVID-19", "CHEMICAL", 45, 53], ["Precipitation", "TREATMENT", 0, 13], ["COVID", "TEST", 45, 50], ["heavy precipitation", "PROBLEM", 78, 97], ["this study", "TEST", 109, 119], ["heavy", "OBSERVATION_MODIFIER", 78, 83], ["precipitation", "OBSERVATION", 84, 97]]], ["Notice that valid data points were few for the lowest and highest ranges of each meteorological measure because of a short study period, making the results more uncertain in those ranges.", [["a short study", "TEST", 115, 128]]], ["Our findings alert people that the fight on the pandemic is still on-going, and we human beings have no capital to relax from COVID-19 yet.", [["people", "ORGANISM", 19, 25], ["human", "ORGANISM", 83, 88], ["people", "SPECIES", 19, 25], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["COVID", "TEST", 126, 131]]], ["Therefore, rather than expecting that the natural environment can curb coronavirus, it is more realistic to have a better self-protection during the pandemic, and be patient to wait for treatments and vaccines.", [["coronavirus", "DISEASE", 71, 82], ["coronavirus", "ORGANISM", 71, 82], ["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 166, 173], ["coronavirus", "PROBLEM", 71, 82], ["treatments", "TREATMENT", 186, 196], ["vaccines", "TREATMENT", 201, 209]]]], "PMC7262274": [["Reported shortages of personal protective equipment (PPE) in the NHS have caused anxiety among healthcare workers 1.", [["anxiety", "DISEASE", 81, 88], ["anxiety", "PROBLEM", 81, 88]]], ["Several designs for improvised PPE have been circulated online and via social media.", [["improvised PPE", "TREATMENT", 20, 34]]], ["One particularly widely shared design involves a 3D printed adaptor to allow the mating of a standard anaesthetic heat and moisture exchange (HME) filter to a commercially available snorkelling mask.", [["3D printed adaptor", "PROTEIN", 49, 67], ["a 3D printed adaptor", "TREATMENT", 47, 67], ["a standard anaesthetic heat", "TREATMENT", 91, 118], ["moisture exchange (HME) filter", "TREATMENT", 123, 153], ["snorkelling mask", "TREATMENT", 182, 198]]]], "PMC7118539": [["In The Lancet Infectious Diseases, Francois-Xavier Lescure and colleagues1 describe the first cases of coronavirus disease 2019 (COVID-19) in Europe, which were reported in France.", [["Infectious Diseases", "DISEASE", 14, 33], ["coronavirus disease", "DISEASE", 103, 122], ["coronavirus", "ORGANISM", 103, 114], ["coronavirus disease", "PROBLEM", 103, 122], ["COVID", "TEST", 129, 134], ["Infectious", "OBSERVATION_MODIFIER", 14, 24], ["coronavirus disease", "OBSERVATION", 103, 122]]], ["The detailed clinical features of five patients with COVID-19 are aligned with the quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA load from nasopharyngeal and other selected sampling sites.", [["nasopharyngeal", "ANATOMY", 177, 191], ["acute respiratory syndrome coronavirus", "DISEASE", 103, 141], ["patients", "ORGANISM", 39, 47], ["SARS-CoV-2", "ORGANISM", 145, 155], ["nasopharyngeal", "CANCER", 177, 191], ["COVID-19", "DNA", 53, 61], ["patients", "SPECIES", 39, 47], ["severe acute respiratory syndrome coronavirus", "SPECIES", 96, 141], ["SARS-CoV-2", "SPECIES", 145, 155], ["COVID", "TEST", 53, 58], ["the quantitative severe acute respiratory syndrome coronavirus", "PROBLEM", 79, 141], ["SARS", "TEST", 145, 149], ["CoV", "TEST", 150, 153], ["viral RNA load from nasopharyngeal and other selected sampling sites", "PROBLEM", 157, 225], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome coronavirus", "OBSERVATION", 109, 141], ["nasopharyngeal", "ANATOMY", 177, 191]]], ["Previous studies in patients with SARS, Middle East respiratory syndrome (MERS), and COVID-19 generally provide insufficient detail to allow examination of the relationship between individual patient clinical course and viral RNA load.2, 3, 4 Although patient numbers are small, the authors provide the first COVID-19 time series correlating viral RNA load and detailed clinical manifestations.1 Importantly, the dataset is provided in sufficient detail so it could be readily combined with future similar studies for deeper analysis.", [["SARS", "DISEASE", 34, 38], ["Middle East respiratory syndrome", "DISEASE", 40, 72], ["patients", "ORGANISM", 20, 28], ["patient", "ORGANISM", 192, 199], ["patient", "ORGANISM", 252, 259], ["viral RNA", "RNA", 220, 229], ["patients", "SPECIES", 20, 28], ["patient", "SPECIES", 192, 199], ["patient", "SPECIES", 252, 259], ["Previous studies", "TEST", 0, 16], ["SARS", "PROBLEM", 34, 38], ["Middle East respiratory syndrome", "PROBLEM", 40, 72], ["COVID", "TEST", 85, 90], ["examination", "TEST", 141, 152], ["viral RNA load", "PROBLEM", 220, 234], ["viral RNA load", "PROBLEM", 342, 356], ["deeper analysis", "TEST", 518, 533], ["Middle", "ANATOMY_MODIFIER", 40, 46], ["respiratory syndrome", "OBSERVATION", 52, 72], ["small", "OBSERVATION_MODIFIER", 272, 277]]]], "7211b3ff42f7c7405f728697a9bd60267b06176f": [["Acute respiratory dysfunction caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially noted by alert physicians in Wuhan, China.", [["respiratory", "ANATOMY", 6, 17], ["respiratory dysfunction", "DISEASE", 6, 29], ["acute respiratory syndrome coronavirus", "DISEASE", 57, 95], ["severe acute respiratory syndrome coronavirus", "SPECIES", 50, 95], ["SARS-CoV-2", "SPECIES", 99, 109], ["Acute respiratory dysfunction", "PROBLEM", 0, 29], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 40, 95], ["SARS-CoV", "TEST", 99, 107], ["respiratory dysfunction", "OBSERVATION", 6, 29], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["It then turned out to cause serious endemic and epidemic pneumonia with rapid deterioration to acute respiratory distress syndrome (ARDS) with high mortality in complicated patients.", [["respiratory", "ANATOMY", 101, 112], ["pneumonia", "DISEASE", 57, 66], ["acute respiratory distress syndrome", "DISEASE", 95, 130], ["ARDS", "DISEASE", 132, 136], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["serious endemic", "PROBLEM", 28, 43], ["epidemic pneumonia", "PROBLEM", 48, 66], ["rapid deterioration", "PROBLEM", 72, 91], ["acute respiratory distress syndrome", "PROBLEM", 95, 130], ["ARDS", "PROBLEM", 132, 136], ["serious", "OBSERVATION_MODIFIER", 28, 35], ["endemic", "OBSERVATION_MODIFIER", 36, 43], ["epidemic", "OBSERVATION_MODIFIER", 48, 56], ["pneumonia", "OBSERVATION", 57, 66], ["rapid", "OBSERVATION_MODIFIER", 72, 77], ["deterioration", "OBSERVATION_MODIFIER", 78, 91], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory distress", "OBSERVATION", 101, 121]]], ["The first case was identified on December 8, 2019, and this disease was initially reported by China to the World Health Organization (WHO) on December 31, 2019.", [["this disease", "PROBLEM", 55, 67]]], ["1,2 On March 11, 2020, the WHO characterized this coronavirus disease 2019 (COVID-19) as a global pandemic because of the rapidly increasing numbers of infected cases throughout countries in Europe and America, and the confirmed case numbers reached more than 125 000 cases.", [["coronavirus disease", "DISEASE", 50, 69], ["coronavirus", "ORGANISM", 50, 61], ["this coronavirus disease", "PROBLEM", 45, 69], ["COVID", "TEST", 76, 81], ["a global pandemic", "PROBLEM", 89, 106], ["coronavirus disease", "OBSERVATION", 50, 69], ["rapidly", "OBSERVATION_MODIFIER", 122, 129], ["increasing", "OBSERVATION_MODIFIER", 130, 140], ["numbers", "OBSERVATION_MODIFIER", 141, 148], ["infected", "OBSERVATION", 152, 160]]], ["A total of 619 of 3700 passengers and crew (17%) tested SARS-CoV-2-positive by February 20, 2020.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 66], ["crew", "TEST", 38, 42], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64]]], ["4 Subsequently, an explosive outbreak started from a religious group in the end of February 2020, and the Republic of Korea temporarily became into the second largest confirmed COVID-19 country after China on March 2, 2020.", [["an explosive outbreak", "PROBLEM", 16, 37], ["explosive", "OBSERVATION_MODIFIER", 19, 28], ["outbreak", "OBSERVATION", 29, 37]]], ["5 Since early March 2020, the confirmed case number has increased rapidly in Italy and Iran, and subsequently in many other countries of Europe and America.", [["increased", "OBSERVATION_MODIFIER", 56, 65], ["rapidly", "OBSERVATION_MODIFIER", 66, 73]]], ["Importantly and disconcertingly, the pattern of confirmed cases and deaths has shown a terrible and exponential increase since the middle of March ( Fig. 1 ) around the world.", [["deaths", "DISEASE", 68, 74], ["a terrible", "PROBLEM", 85, 95], ["terrible", "OBSERVATION_MODIFIER", 87, 95], ["exponential", "OBSERVATION_MODIFIER", 100, 111], ["increase", "OBSERVATION_MODIFIER", 112, 120], ["middle", "ANATOMY_MODIFIER", 131, 137]]], ["3 At 16:56 (Taipei time) on April 7, 2020, the report of the confirmed COVID-19 case number in the world reached to 1 350 841 with 74 870 deaths in 184 countries/ regions.", [["deaths", "DISEASE", 138, 144]]], ["The overall case fatality rate (CFR) reached to 5.5%.", [["CFR", "TEST", 32, 35]]], ["3 The United States became the country with the highest number of confirmed COVID-19 cases (n = 368 449; deaths = 10 993; CFR = 3.0%), followed by Spain (n = 136 675; deaths = 13 341; CFR = 9.8%).", [["COVID", "DISEASE", 76, 81], ["deaths", "DISEASE", 105, 111], ["deaths", "DISEASE", 167, 173], ["COVID", "TEST", 76, 81], ["deaths", "TEST", 105, 111], ["CFR", "TEST", 122, 125], ["deaths", "TEST", 167, 173], ["CFR", "TEST", 184, 187]]], ["6 The highest CFR remained at 12.5% in Italy (n = 132 547; deaths = 16 523).", [["deaths", "DISEASE", 59, 65], ["The highest CFR", "TEST", 2, 17], ["deaths", "TEST", 59, 65]]], ["6 China remained with the highest number of confirmed cases in Asia during the past 3 months (n = 82 697; deaths = 3335; CFR = 4.0%).", [["deaths", "DISEASE", 106, 112], ["CFR", "TEST", 121, 124]]], ["Fighting COVID-19 has become a true war of saving human lives all over the world.INITIAL PRESENTATIONS OF COVID-19Fever and cough seem to be the most common initial symptoms in SARS-CoV-2-positive patients, followed by dyspnea and fatigue in cases with severe pneumonia.", [["COVID-19", "CHEMICAL", 9, 17], ["cough", "DISEASE", 124, 129], ["SARS", "DISEASE", 177, 181], ["dyspnea", "DISEASE", 219, 226], ["fatigue", "DISEASE", 231, 238], ["pneumonia", "DISEASE", 260, 269], ["human", "ORGANISM", 50, 55], ["SARS-CoV-2", "ORGANISM", 177, 187], ["patients", "ORGANISM", 197, 205], ["human", "SPECIES", 50, 55], ["patients", "SPECIES", 197, 205], ["human", "SPECIES", 50, 55], ["SARS-CoV", "SPECIES", 177, 185], ["COVID", "TEST", 106, 111], ["cough", "PROBLEM", 124, 129], ["initial symptoms", "PROBLEM", 157, 173], ["SARS", "PROBLEM", 177, 181], ["CoV", "TEST", 182, 185], ["dyspnea", "PROBLEM", 219, 226], ["fatigue", "PROBLEM", 231, 238], ["severe pneumonia", "PROBLEM", 253, 269], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["pneumonia", "OBSERVATION", 260, 269]]], ["In a recent systematic review by Rodriguez-Morales et al, 7 a total of 19 original articles and 39 separate case reports from January and February, including 656 confirmed COVID-19 patients, were analyzed.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["COVID", "TEST", 172, 177]]], ["The top three symptoms of these confirmed COVID-19 cases were fever (88.7%), cough (57.6%), and dyspnea (45.6%).", [["COVID", "DISEASE", 42, 47], ["fever", "DISEASE", 62, 67], ["cough", "DISEASE", 77, 82], ["dyspnea", "DISEASE", 96, 103], ["COVID", "TEST", 42, 47], ["fever", "PROBLEM", 62, 67], ["cough", "TEST", 77, 82], ["dyspnea", "PROBLEM", 96, 103]]], ["Among them, 20.3% required intensive care, and the CFR of these hospitalized COVID-19 patients was 13.9%.", [["COVID", "DISEASE", 77, 82], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["COVID", "TEST", 77, 82]]], ["7 In another meta-analysis by Yang et al 8 on the cases of China, they analyzed eight studies with a total of 46 248 infected patients and demonstrated that the most prevalent clinical symptoms were fever (91% \u00b1 3%, 95% CI, 86%-97%), cough (67% \u00b1 7%, 95% CI, 59%-76%), fatigue (51% \u00b1 0%, 95% CI, 34%-68%), and dyspnea (30% \u00b1 4, 95% CI, 21%-40%).", [["fever", "DISEASE", 199, 204], ["cough", "DISEASE", 234, 239], ["fatigue", "DISEASE", 269, 276], ["dyspnea", "DISEASE", 310, 317], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["clinical symptoms", "PROBLEM", 176, 193], ["fever", "PROBLEM", 199, 204], ["CI", "TEST", 220, 222], ["cough", "TEST", 234, 239], ["CI", "TEST", 255, 257], ["fatigue", "PROBLEM", 269, 276], ["CI", "TEST", 292, 294], ["dyspnea", "PROBLEM", 310, 317], ["CI", "TEST", 332, 334]]], ["8 The findings were similar in these two studies.INITIAL PRESENTATIONS OF COVID-19Other symptoms, including sore throat, rhinorrhea, stuffy nose, muscle aches, muscle soreness, headache, vomiting, and diarrhea, are also observed in the beginning of the disease.", [["nose", "ANATOMY", 140, 144], ["muscle", "ANATOMY", 146, 152], ["muscle", "ANATOMY", 160, 166], ["sore throat", "DISEASE", 108, 119], ["rhinorrhea", "DISEASE", 121, 131], ["muscle aches", "DISEASE", 146, 158], ["muscle soreness", "DISEASE", 160, 175], ["headache", "DISEASE", 177, 185], ["vomiting", "DISEASE", 187, 195], ["diarrhea", "DISEASE", 201, 209], ["nose", "ORGANISM_SUBDIVISION", 140, 144], ["muscle", "ORGAN", 146, 152], ["muscle", "ORGAN", 160, 166], ["these two studies", "TEST", 31, 48], ["COVID", "TEST", 74, 79], ["19Other symptoms", "PROBLEM", 80, 96], ["sore throat", "PROBLEM", 108, 119], ["rhinorrhea", "PROBLEM", 121, 131], ["stuffy nose", "PROBLEM", 133, 144], ["muscle aches", "PROBLEM", 146, 158], ["muscle soreness", "PROBLEM", 160, 175], ["headache", "PROBLEM", 177, 185], ["vomiting", "PROBLEM", 187, 195], ["diarrhea", "PROBLEM", 201, 209], ["the disease", "PROBLEM", 249, 260], ["similar", "OBSERVATION_MODIFIER", 20, 27], ["sore throat", "ANATOMY", 108, 119], ["rhinorrhea", "OBSERVATION", 121, 131], ["stuffy nose", "ANATOMY", 133, 144], ["muscle aches", "ANATOMY", 146, 158], ["muscle", "ANATOMY", 160, 166], ["soreness", "OBSERVATION", 167, 175], ["headache", "OBSERVATION", 177, 185], ["diarrhea", "OBSERVATION", 201, 209], ["disease", "OBSERVATION", 253, 260]]], ["2, 7, 8 Additionally, loss of smell (anosmia) and/or taste (ageusia) has been noted in younger patients since March 2020.", [["loss of smell", "DISEASE", 22, 35], ["anosmia", "DISEASE", 37, 44], ["smell", "ORGANISM_SUBDIVISION", 30, 35], ["taste", "ORGANISM_SUBDIVISION", 53, 58], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["loss of smell (anosmia)", "PROBLEM", 22, 45]]], ["9 These symptoms were rarely mentioned in the early cases in China, but they were frequently mentioned in young people living in or travelling back to their countries from Europe or America.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["These symptoms", "PROBLEM", 2, 16]]], ["10 A proportion of SARS-CoV-2-infected people are completely asymptomatic.", [["SARS", "DISEASE", 19, 23], ["SARS-CoV-2", "ORGANISM", 19, 29], ["people", "ORGANISM", 39, 45], ["CoV-2", "SPECIES", 24, 29], ["people", "SPECIES", 39, 45], ["SARS-CoV", "SPECIES", 19, 27], ["SARS", "PROBLEM", 19, 23], ["CoV", "TEST", 24, 27], ["asymptomatic", "PROBLEM", 61, 73], ["asymptomatic", "OBSERVATION", 61, 73]]], ["11 In one report of childhood cases, 94/731 (12.9%) SARS-CoV-2-positive children had no symptoms according to nucleic acid tests, and more than 70% of them were between the ages of 6 and 15 years.", [["SARS", "DISEASE", 52, 56], ["nucleic acid", "CHEMICAL", 110, 122], ["SARS-CoV-2", "ORGANISM", 52, 62], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["symptoms", "PROBLEM", 88, 96], ["nucleic acid tests", "TEST", 110, 128]]], ["12 The proportion of asymptomatic subjects may be underestimated because many potentially infected people do not receive a SARS-CoV-2 test when they have no symptoms.", [["SARS", "DISEASE", 123, 127], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["asymptomatic subjects", "PROBLEM", 21, 42], ["a SARS", "TEST", 121, 127], ["CoV-2 test", "TEST", 128, 138], ["symptoms", "PROBLEM", 157, 165], ["asymptomatic", "OBSERVATION", 21, 33], ["may be", "UNCERTAINTY", 43, 49], ["infected", "OBSERVATION", 90, 98]]], ["However, asymptomatic carriers have the potential to transmit the coronavirus that causes COVID-19.", [["coronavirus", "DISEASE", 66, 77], ["coronavirus", "ORGANISM", 66, 77], ["asymptomatic carriers", "PROBLEM", 9, 30], ["the coronavirus", "PROBLEM", 62, 77], ["COVID", "TEST", 90, 95]]], ["13 It has been proposed that up to 80% of infected people are asymptomatic carriers.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["asymptomatic carriers", "PROBLEM", 62, 83]]], ["14 Further investigations should be carried out to clarify this issue regarding the prevalence of asymptomatic carriers.COMMON PRESENTATIONS OF COVID-19 IN CHILDRENRegarding children, they were relatively rarely diagnosed at the beginning of COVID-19's presence in the world.", [["COVID-19's", "CHEMICAL", 242, 252], ["children", "ORGANISM", 174, 182], ["children", "SPECIES", 174, 182], ["Further investigations", "TEST", 3, 25], ["asymptomatic carriers", "PROBLEM", 98, 119]]], ["It was initially thought that children may be less susceptible to In one report by Wu and McGoogan 2 enrolling cases from December 8 to February 20, 2020, only 1% of teenagers and 1% of children younger than 10 years old in China were affected.", [["children", "ORGANISM", 30, 38], ["teenagers", "ORGANISM", 166, 175], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 30, 38], ["children", "SPECIES", 186, 194]]], ["2 In a recent report from United States up to March 16, 2020 , no intensive care unit (ICU) admissions or deaths among persons aged \u226419 years were reported among a total of 4226 confirmed COVID-19 cases.", [["deaths", "DISEASE", 106, 112], ["persons", "ORGANISM", 119, 126], ["persons", "SPECIES", 119, 126], ["COVID", "TEST", 188, 193]]], ["The authors summarized that the risk for serious disease and death from COVID-19 is higher in older age groups, in close agreement with other reports.", [["death", "DISEASE", 61, 66], ["COVID-19", "CHEMICAL", 72, 80], ["serious disease", "PROBLEM", 41, 56], ["death", "PROBLEM", 61, 66], ["COVID", "TEST", 72, 77]]], ["16 However, more and more young people have been diagnosed along with the pandemic progression of the disease and the development of rapid COVID-19 testing techniques.", [["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38], ["the disease", "PROBLEM", 98, 109], ["rapid COVID", "TEST", 133, 144], ["testing techniques", "TEST", 148, 166], ["disease", "OBSERVATION", 102, 109]]], ["Currently, we know that young people also can be seriously affected by SARS-CoV-2.", [["SARS", "DISEASE", 71, 75], ["people", "ORGANISM", 30, 36], ["SARS-CoV-2", "ORGANISM", 71, 81], ["people", "SPECIES", 30, 36], ["SARS-CoV", "SPECIES", 71, 79]]], ["5, 17 Most children became infected after close contact with confirmed COVID-19 patients, either family or other members of the public.", [["5, 17", "CHEMICAL", 0, 5], ["children", "ORGANISM", 11, 19], ["patients", "ORGANISM", 80, 88], ["children", "SPECIES", 11, 19], ["patients", "SPECIES", 80, 88], ["infected", "OBSERVATION", 27, 35]]], ["The published reports in children with COVID-19 are summarized in Table 1 , and most of the publications analyzed cases from China before April 2020.", [["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33]]], ["12, [18] [19] [20] [21] [22] [23] In Vietnam, one 3-monthold infant was reported.", [["[18] [19] [20] [21] [22] [23", "SIMPLE_CHEMICAL", 4, 32], ["infant", "ORGANISM", 61, 67], ["infant", "SPECIES", 61, 67]]], ["21 As shown, fever is the most common initial symptom in children, followed by dry cough.", [["fever", "DISEASE", 13, 18], ["dry cough", "DISEASE", 79, 88], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["fever", "PROBLEM", 13, 18], ["dry cough", "PROBLEM", 79, 88], ["fever", "OBSERVATION", 13, 18], ["cough", "OBSERVATION", 83, 88]]], ["12, [18] [19] [20] [21] [22] [23] Other symptoms of the respiratory tract, gastrointestinal tract, muscle and nervous system, and fatigue were all reported, but some infected children are completely symptom free.", [["respiratory tract", "ANATOMY", 56, 73], ["gastrointestinal tract", "ANATOMY", 75, 97], ["muscle", "ANATOMY", 99, 105], ["nervous system", "ANATOMY", 110, 124], ["gastrointestinal tract, muscle and nervous system", "DISEASE", 75, 124], ["fatigue", "DISEASE", 130, 137], ["[18] [19] [20] [21] [22] [23", "SIMPLE_CHEMICAL", 4, 32], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 75, 97], ["muscle", "ORGAN", 99, 105], ["nervous system", "ANATOMICAL_SYSTEM", 110, 124], ["children", "ORGANISM", 175, 183], ["children", "SPECIES", 175, 183], ["Other symptoms of the respiratory tract", "PROBLEM", 34, 73], ["muscle and nervous system", "PROBLEM", 99, 124], ["fatigue", "PROBLEM", 130, 137], ["respiratory tract", "ANATOMY", 56, 73], ["gastrointestinal tract", "ANATOMY", 75, 97], ["muscle", "ANATOMY", 99, 105], ["nervous system", "ANATOMY", 110, 124]]], ["12, 18, 20, 23 In moderate to severe cases, dyspnea and hypoxia could occur and require various types of respiratory support.", [["respiratory", "ANATOMY", 105, 116], ["dyspnea", "DISEASE", 44, 51], ["hypoxia", "DISEASE", 56, 63], ["moderate to severe cases", "PROBLEM", 18, 42], ["dyspnea", "PROBLEM", 44, 51], ["hypoxia", "PROBLEM", 56, 63], ["respiratory support", "TREATMENT", 105, 124], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["cases", "OBSERVATION", 37, 42], ["dyspnea", "OBSERVATION", 44, 51], ["hypoxia", "OBSERVATION", 56, 63], ["respiratory support", "OBSERVATION", 105, 124]]], ["ARDS and lifethreatening multiple organ failure had been reported in a few critical cases.", [["organ", "ANATOMY", 34, 39], ["ARDS", "DISEASE", 0, 4], ["organ failure", "DISEASE", 34, 47], ["organ", "ORGAN", 34, 39], ["ARDS", "PROBLEM", 0, 4], ["lifethreatening multiple organ failure", "PROBLEM", 9, 47], ["multiple", "OBSERVATION_MODIFIER", 25, 33], ["organ", "ANATOMY", 34, 39], ["failure", "OBSERVATION", 40, 47]]], ["12CRITICAL CASES AND MORTALITY IN CHILDREN AND INFANTS WITH COVID-19Even though most infected children have mild symptoms, SARS-CoV-2-infected children might sill become severely ill.", [["SARS-CoV-2-infected", "DISEASE", 123, 142], ["COVID-19Even", "ORGANISM", 60, 72], ["children", "ORGANISM", 94, 102], ["SARS-CoV-2", "ORGANISM", 123, 133], ["children", "ORGANISM", 143, 151], ["children", "SPECIES", 94, 102], ["children", "SPECIES", 143, 151], ["mild symptoms", "PROBLEM", 108, 121], ["severely ill", "PROBLEM", 170, 182], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["severely", "OBSERVATION_MODIFIER", 170, 178], ["ill", "OBSERVATION", 179, 182]]], ["25 The recent published and unpublished reports of critical children and infants are summarized in Table 2 .", [["children", "ORGANISM", 60, 68], ["infants", "ORGANISM", 73, 80], ["children", "SPECIES", 60, 68], ["infants", "SPECIES", 73, 80]]], ["As shown, most of current published cases are from China, and infants and teenagers are common subjects in all published and unpublished critical cases.", [["infants", "ORGANISM", 62, 69], ["infants", "SPECIES", 62, 69]]], ["12, 20, 22, 23, [26] [27] [28] [29] [30] In the published reports from 10 hospitals across Hubei province of China, two of 25 (8%) SARS-CoV-2-positive children were critical and required intubation.", [["SARS", "DISEASE", 131, 135], ["20, 22, 23, [26] [27] [28] [29", "SIMPLE_CHEMICAL", 4, 34], ["SARS-CoV-2", "ORGANISM", 131, 141], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["intubation", "TREATMENT", 187, 197]]], ["22 In the report of the Wuhan Children's Hospital, 3 of 171 (1.8%) SARS-CoV-2-positive children required intubation.", [["SARS", "DISEASE", 67, 71], ["SARS-CoV-2", "ORGANISM", 67, 77], ["children", "ORGANISM", 87, 95], ["Children", "SPECIES", 30, 38], ["children", "SPECIES", 87, 95], ["SARS", "TEST", 67, 71], ["CoV", "TEST", 72, 75], ["intubation", "TREATMENT", 105, 115]]], ["20 These three children were described in detail together with five other severe cases aged 2 months to 15 years.", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23]]], ["23 Septic shock and multiorgan dysfunctions were found in these critically ill children and infants, including the nervous, blood, urinary, and cardiac systems.", [["multiorgan", "ANATOMY", 20, 30], ["nervous", "ANATOMY", 115, 122], ["blood", "ANATOMY", 124, 129], ["urinary", "ANATOMY", 131, 138], ["cardiac systems", "ANATOMY", 144, 159], ["Septic shock", "DISEASE", 3, 15], ["multiorgan dysfunctions", "DISEASE", 20, 43], ["critically ill", "DISEASE", 64, 78], ["multiorgan", "ORGAN", 20, 30], ["children", "ORGANISM", 79, 87], ["infants", "ORGANISM", 92, 99], ["nervous", "ANATOMICAL_SYSTEM", 115, 122], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["urinary", "ORGANISM_SUBDIVISION", 131, 138], ["cardiac", "ORGAN", 144, 151], ["children", "SPECIES", 79, 87], ["infants", "SPECIES", 92, 99], ["Septic shock", "PROBLEM", 3, 15], ["multiorgan dysfunctions", "PROBLEM", 20, 43], ["the nervous, blood, urinary, and cardiac systems", "PROBLEM", 111, 159], ["Septic", "OBSERVATION_MODIFIER", 3, 9], ["shock", "OBSERVATION", 10, 15], ["multiorgan dysfunctions", "OBSERVATION", 20, 43], ["urinary", "ANATOMY", 131, 138], ["cardiac systems", "ANATOMY", 144, 159]]], ["23 All of above-mentioned children or infants had underlying diseases.", [["children", "ORGANISM", 26, 34], ["infants", "ORGANISM", 38, 45], ["children", "SPECIES", 26, 34], ["infants", "SPECIES", 38, 45], ["underlying diseases", "PROBLEM", 50, 69], ["diseases", "OBSERVATION", 61, 69]]], ["Among them, one 10-month-old female infant died of multiorgan failure.", [["multiorgan", "ANATOMY", 51, 61], ["multiorgan failure", "DISEASE", 51, 69], ["female", "ORGANISM", 29, 35], ["infant", "ORGANISM", 36, 42], ["multiorgan", "ORGAN", 51, 61], ["infant", "SPECIES", 36, 42], ["multiorgan failure", "PROBLEM", 51, 69], ["multiorgan failure", "OBSERVATION", 51, 69]]], ["23 Additionally in China, one 14-year-old boy with COVID-19 who died on February 7, 2020, was mentioned among 731 confirmed children (CFR = 0.14%), but there was no detail description.", [["boy", "ORGANISM", 42, 45], ["children", "ORGANISM", 124, 132], ["boy", "SPECIES", 42, 45], ["children", "SPECIES", 124, 132], ["CFR", "TEST", 134, 137]]], ["12 To summarize this information, severe or critical cases occurred more often in small children, and the prevalence seemed to be less than 10% among infected children.", [["children", "ORGANISM", 88, 96], ["children", "ORGANISM", 159, 167], ["children", "SPECIES", 88, 96], ["children", "SPECIES", 159, 167], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["small children", "OBSERVATION_MODIFIER", 82, 96]]], ["The CFR was less than 1% in SARS-CoV-positive children and infants according to current reports.CRITICAL CASES AND MORTALITY IN CHILDREN AND INFANTS WITH COVID-19In the end of March and the beginning of April 2020, there was a little unpublished data regarding the death or critical condition of a few children and infants ( Table 2) .", [["SARS-CoV-positive", "DISEASE", 28, 45], ["death", "DISEASE", 265, 270], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["children", "ORGANISM", 46, 54], ["infants", "ORGANISM", 59, 66], ["children", "ORGANISM", 302, 310], ["infants", "ORGANISM", 315, 322], ["children", "SPECIES", 46, 54], ["infants", "SPECIES", 59, 66], ["children", "SPECIES", 302, 310], ["infants", "SPECIES", 315, 322], ["SARS-CoV", "SPECIES", 28, 36], ["The CFR", "TEST", 0, 7], ["the death", "PROBLEM", 261, 270]]], ["[26] [27] [28] [29] [30] In the United States, one 6-week-old infant was brought unresponsive to a hospital and died after resuscitation.", [["[26] [27] [28] [29", "SIMPLE_CHEMICAL", 0, 18], ["infant", "ORGANISM", 62, 68], ["infant", "SPECIES", 62, 68], ["unresponsive", "PROBLEM", 81, 93], ["resuscitation", "TREATMENT", 123, 136]]], ["28 On April 2, 2020, in Japan, one 8-month-old female infant was brought to hospital in out-of-hospital cardiac arrest (OHCA) status.", [["cardiac", "ANATOMY", 104, 111], ["cardiac arrest", "DISEASE", 104, 118], ["OHCA", "DISEASE", 120, 124], ["female", "ORGANISM", 47, 53], ["infant", "ORGANISM", 54, 60], ["infant", "SPECIES", 54, 60], ["cardiac arrest", "PROBLEM", 104, 118], ["cardiac", "ANATOMY", 104, 111], ["arrest", "OBSERVATION", 112, 118]]], ["29 Both of them were thereafter identified as SARS-CoV-2-positive cases according to the news.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54]]], ["These cases remind first-line physicians to take strong precautions while resuscitating any children, especially those with sudden collapse or OCHA.", [["sudden collapse", "DISEASE", 124, 139], ["OCHA", "DISEASE", 143, 147], ["children", "ORGANISM", 92, 100], ["children", "SPECIES", 92, 100], ["strong precautions", "TREATMENT", 49, 67], ["sudden collapse", "PROBLEM", 124, 139], ["OCHA", "PROBLEM", 143, 147], ["collapse", "OBSERVATION", 131, 139]]], ["Additionally, four other SARS-CoV-2-positive children's deaths appeared on the news, including those of three teenagers (Table 2) .", [["deaths", "DISEASE", 56, 62], ["SARS-CoV-2", "ORGANISM", 25, 35], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["four other SARS", "TEST", 14, 29], ["CoV", "TEST", 30, 33]]], ["26, 27, 30 Official reports should be obtained soon to confirm this information.SARS-COV-2-POSITIVE CHILDREN IN CHINAThe Chinese Center for Disease Control and Prevention (China CDC) recently published the largest case series of COVID-19 up to February 11, 2020, in mainland China.", [["SARS", "DISEASE", 80, 84], ["Disease Control", "TREATMENT", 140, 155], ["COVID", "TEST", 229, 234]]], ["2 Of the confirmed 44 672 SARS-CoV-2-positive cases, 549 (1.2%) cases were aged 0-19 years (549 cases), and 416 (0.9%) cases were younger than 10 years of age.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 31, 36], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["cases", "TEST", 64, 69]]], ["2 Thus, the overall proportion of children among SARS-CoV-2-positive cases was 2.2%.SARS-COV-2-POSITIVE CHILDREN IN CHINADong et al 12 reported 2143 suspected COVID-19 children younger than 18 years of age by analyzing data from the China CDC by February 8, 2020.", [["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 84, 88], ["children", "ORGANISM", 34, 42], ["SARS-CoV-2", "ORGANISM", 49, 59], ["children", "ORGANISM", 168, 176], ["children", "SPECIES", 34, 42], ["children", "SPECIES", 168, 176], ["SARS-CoV", "SPECIES", 49, 57], ["CoV", "TEST", 54, 57]]], ["One third (n = 731) of them were SARS-CoV-2 positive, and all ages could be susceptible to COVID-19.", [["SARS", "DISEASE", 33, 37], ["COVID-19", "CHEMICAL", 91, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["COVID", "TEST", 91, 96]]], ["12 The authors mentioned that the clinical manifestations of pediatric patients were relatively less severe than those of adult patients.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 128, 136]]], ["Infants accounted for 11.8% of confirmed children.", [["Infants", "ORGANISM", 0, 7], ["children", "ORGANISM", 41, 49], ["Infants", "SPECIES", 0, 7], ["children", "SPECIES", 41, 49]]], ["12 Among these 731 confirmed cases, three kids progressed critical condition, and one 14-year-old boy died.", [["boy", "ORGANISM", 98, 101], ["boy", "SPECIES", 98, 101]]], ["12 The proportion of critical deterioration or mortality in SARS-CoV-2-positive case was 0.5%.SARS-COV-2-POSITIVE CHILDREN IN CHINALu et al 20 summarized 171 SARS-CoV-2-positive children (0-15 years old) who were identified in Wuhan Children's Hospital up to February 26, 2020.", [["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 94, 98], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["SARS-CoV-2", "ORGANISM", 158, 168], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 178, 186], ["Children", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 60, 68], ["critical deterioration", "PROBLEM", 21, 43], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68], ["critical", "OBSERVATION_MODIFIER", 21, 29], ["deterioration", "OBSERVATION", 30, 43]]], ["Among them, 111 Table 1 Published reports on SARS-CoV-2-positive children and infants up to April 6, 2020 (Table 1) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["children", "ORGANISM", 65, 73], ["infants", "ORGANISM", 78, 85], ["children", "SPECIES", 65, 73], ["infants", "SPECIES", 78, 85], ["SARS-CoV", "SPECIES", 45, 53]]], ["18, 19, 22, 23 Summarizing these reports, the top common initial symptoms of SARS-CoV-2-positive children were fever and cough, especially dry cough.", [["SARS", "DISEASE", 77, 81], ["fever", "DISEASE", 111, 116], ["cough", "DISEASE", 121, 126], ["dry cough", "DISEASE", 139, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["fever", "PROBLEM", 111, 116], ["cough", "PROBLEM", 121, 126], ["dry cough", "PROBLEM", 139, 148], ["cough", "OBSERVATION", 121, 126], ["cough", "OBSERVATION", 143, 148]]], ["None of these publications mentioned the symptom of loss of smell or taste.", [["loss of smell", "DISEASE", 52, 65], ["loss of smell or taste", "PROBLEM", 52, 74]]], ["5 Their first SARS-CoV-2-positive child was announced on February 19, 2020.", [["SARS-CoV-2", "ORGANISM", 14, 24], ["child", "ORGANISM", 34, 39], ["CoV", "TEST", 19, 22]]], ["The 10-year-old girl had close contact history with her mother and uncle, who were SARS-CoV-2-positive cases.", [["girl", "ORGANISM", 16, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["girl", "SPECIES", 16, 20], ["SARS-CoV", "SPECIES", 83, 91], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91]]], ["The girl only had mild pneumonia without the need for specific management.", [["pneumonia", "DISEASE", 23, 32], ["girl", "ORGANISM", 4, 8], ["girl", "SPECIES", 4, 8], ["mild pneumonia", "PROBLEM", 18, 32], ["specific management", "TREATMENT", 54, 73], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["pneumonia", "OBSERVATION", 23, 32]]], ["5,31 A 45-day-old male infant, the youngest case in Korea, was identified on March 2.", [["infant", "ORGANISM", 23, 29], ["infant", "SPECIES", 23, 29]]], ["He had close contact with his SARS-CoV-2-positive father.", [["SARS", "DISEASE", 30, 34], ["He", "ORGANISM", 0, 2], ["CoV-2", "GENE_OR_GENE_PRODUCT", 35, 40], ["father", "ORGANISM", 50, 56]]], ["5 Up to March 10, 2020, based on published reports, no critical complications or mortality in pediatric patients was reported in the Republic of Korea.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["critical complications", "PROBLEM", 55, 77], ["no", "UNCERTAINTY", 52, 54], ["critical", "OBSERVATION_MODIFIER", 55, 63], ["complications", "OBSERVATION", 64, 77]]], ["24 According to the early published report enrolling data From February 12 to March 16, 2020 in the United States, a total of 4226 COVID-19-confirmed cases were reported.", [["COVID", "TEST", 131, 136]]], ["Among 2449 hospitalized patients with known age, only 5% of them aged 0-19 years, and no ICU admissions or deaths were reported in this aged group during that period of time.", [["deaths", "DISEASE", 107, 113], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["deaths", "PROBLEM", 107, 113]]], ["16 Since the number of confirmed COVID-19 cases in the United States has risen rapidly since mid-March 2020, the \"CDC COVID-19 Response Team\" recently further reported 2572 (1.7%) laboratory positive children (<18 years old) among 149 080 confirmed cases from February 12 to April 2, 2020, in the United States.", [["COVID", "DISEASE", 33, 38], ["children", "ORGANISM", 200, 208], ["children", "SPECIES", 200, 208], ["COVID", "TEST", 33, 38]]], ["Among them, more than 90% had an exposure history to other confirmed COVID-19 cases.", [["COVID", "TEST", 69, 74]]], ["24 Characteristic COVID-19 symptoms of fever, cough, or shortness of breath were observed in 73% of infected children.", [["fever", "DISEASE", 39, 44], ["cough", "DISEASE", 46, 51], ["shortness of breath", "DISEASE", 56, 75], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["Characteristic COVID", "TEST", 3, 23], ["symptoms", "PROBLEM", 27, 35], ["fever", "PROBLEM", 39, 44], ["cough", "PROBLEM", 46, 51], ["shortness of breath", "PROBLEM", 56, 75]]], ["The hospitalization rate was 19.7% (147/745), and ICU admission rate was 2% (15/745) among COVID-19 children in the United States.", [["children", "ORGANISM", 100, 108], ["children", "SPECIES", 100, 108], ["The hospitalization rate", "TEST", 0, 24], ["ICU admission rate", "TEST", 50, 68]]], ["Infants (<1 year old) accounted for the highest percentage (59/95, 62%) of hospitalizations and ICU (5/59, 8.5%) admissions.", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7]]], ["Additionally, 77% (28/37) hospitalized COVID-19 children had underlying conditions, and there was a total of three deaths (0.4%) in COVID-19 children in the United States up to April 2, 2020.", [["deaths", "DISEASE", 115, 121], ["children", "ORGANISM", 48, 56], ["children", "ORGANISM", 141, 149], ["children", "SPECIES", 48, 56], ["children", "SPECIES", 141, 149], ["hospitalized COVID", "TEST", 26, 44], ["underlying conditions", "PROBLEM", 61, 82]]], ["Most of the children and teenagers (20, 83 .3% of infected children) had travel history to European or American locations (Table 3) .", [["children", "ORGANISM", 12, 20], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 12, 20], ["children", "SPECIES", 59, 67]]], ["Four other children all had definite direct or indirect contact histories with someone who had travelled back from other countries.SARS-COV-2-POSITIVE CHILDREN IN TAIWANAmong the 24 children and teenagers, only one 11-year-old boy (4.2%) was completely asymptomatic (Table 3) .", [["SARS", "DISEASE", 131, 135], ["children", "ORGANISM", 11, 19], ["children", "ORGANISM", 182, 190], ["boy", "ORGANISM", 227, 230], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 182, 190], ["boy", "SPECIES", 227, 230]]], ["Fever (n = 17, 70.8%), cough (n = 9, 37.5%), and headache (n = 6, 25.0%) were the top three symptoms, especially in teenagers.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 23, 28], ["headache", "DISEASE", 49, 57], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 23, 28], ["headache", "PROBLEM", 49, 57], ["the top three symptoms", "PROBLEM", 78, 100]]], ["Loss of smell and/or taste were found in three (12.5%) teenagers.", [["Loss of smell", "DISEASE", 0, 13], ["Loss of smell and/or taste", "PROBLEM", 0, 26], ["smell", "OBSERVATION", 8, 13]]], ["In the four reported preschool children, fever was the only presentation when they were diagnosed.", [["fever", "DISEASE", 41, 46], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["fever", "PROBLEM", 41, 46]]], ["According to the statement of the TCDC, there was no mortality among these children and teenagers.SARS-COV-2-POSITIVE CHILDREN IN TAIWANAll information on these SARS-CoV-2-positive children listed in Table 3 were obtained from the daily announcement of the TCDC.", [["TCDC", "CANCER", 34, 38], ["children", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 161, 171], ["children", "ORGANISM", 181, 189], ["TCDC", "CANCER", 257, 261], ["children", "SPECIES", 75, 83], ["children", "SPECIES", 181, 189], ["these SARS", "TEST", 155, 165], ["CoV", "TEST", 166, 169], ["no", "UNCERTAINTY", 50, 52]]], ["10,34 Until April 7, 2020, no infants or neonates had been identified in Taiwan.SARS-COV-2-POSITIVE NEWBORNSDuring infectious disease outbreaks, fetuses and newborn infants are the most susceptible.", [["fetuses", "ANATOMY", 145, 152], ["infectious disease outbreaks", "DISEASE", 115, 143], ["infants", "ORGANISM", 30, 37], ["neonates", "ORGANISM", 41, 49], ["fetuses", "ORGANISM", 145, 152], ["infants", "ORGANISM", 165, 172], ["infants", "SPECIES", 30, 37], ["infants", "SPECIES", 165, 172], ["POSITIVE", "OBSERVATION_MODIFIER", 91, 99], ["NEWBORNSDuring", "OBSERVATION_MODIFIER", 100, 114], ["infectious", "OBSERVATION_MODIFIER", 115, 125]]], ["Perinatal SARS-CoV-2 infection may induce fetal distress, premature labor, and neonatal illness, such as respiratory distress, viral sepsis, multiorgan involvement, and even death.", [["fetal", "ANATOMY", 42, 47], ["respiratory", "ANATOMY", 105, 116], ["multiorgan", "ANATOMY", 141, 151], ["SARS-CoV-2 infection", "DISEASE", 10, 30], ["fetal distress", "DISEASE", 42, 56], ["premature labor", "DISEASE", 58, 73], ["neonatal illness", "DISEASE", 79, 95], ["respiratory distress", "DISEASE", 105, 125], ["viral sepsis", "DISEASE", 127, 139], ["multiorgan involvement", "DISEASE", 141, 163], ["death", "DISEASE", 174, 179], ["SARS-CoV-2", "ORGANISM", 10, 20], ["fetal", "ORGAN", 42, 47], ["CoV-", "SPECIES", 15, 19], ["SARS-CoV-2", "SPECIES", 10, 20], ["Perinatal SARS", "PROBLEM", 0, 14], ["CoV", "PROBLEM", 15, 18], ["2 infection", "PROBLEM", 19, 30], ["fetal distress", "PROBLEM", 42, 56], ["premature labor", "PROBLEM", 58, 73], ["neonatal illness", "PROBLEM", 79, 95], ["respiratory distress", "PROBLEM", 105, 125], ["viral sepsis", "PROBLEM", 127, 139], ["multiorgan involvement", "PROBLEM", 141, 163], ["even death", "PROBLEM", 169, 179], ["viral sepsis", "OBSERVATION", 127, 139]]], ["However, there is still no definite evidence of vertical transmission from a SARS-CoV-2-infected pregnant mother to her fetus or newborn infants to date.SARS-COV-2-POSITIVE NEWBORNSSome investigators have reported on their experiences with SARS-CoV-2-positive pregnant mothers and their newborn infants.", [["fetus", "ANATOMY", 120, 125], ["SARS-CoV-2-infected", "DISEASE", 77, 96], ["SARS-CoV-2", "ORGANISM", 77, 87], ["fetus", "ORGANISM", 120, 125], ["infants", "ORGANISM", 137, 144], ["SARS-CoV-2", "ORGANISM", 240, 250], ["mothers", "ORGANISM", 269, 276], ["infants", "ORGANISM", 295, 302], ["CoV-2", "SPECIES", 82, 87], ["infants", "SPECIES", 137, 144], ["infants", "SPECIES", 295, 302], ["SARS-CoV", "SPECIES", 77, 85], ["vertical transmission", "PROBLEM", 48, 69], ["a SARS", "TEST", 75, 81], ["no definite evidence of", "UNCERTAINTY", 24, 47], ["vertical transmission", "OBSERVATION", 48, 69]]], ["[35] [36] [37] [38] [39] According to these publications, cesarean sections are usually the delivery method of choice when the mother has symptomatic COVID-19.", [["sections", "ANATOMY", 67, 75], ["[35] [36] [37] [38", "SIMPLE_CHEMICAL", 0, 18], ["cesarean sections", "TREATMENT", 58, 75], ["symptomatic COVID", "PROBLEM", 138, 155]]], ["Most of the reports regarding specimens collected from amniotic fluid, cord blood, neonatal throat swabs, or breastmilk samples revealed that nearly all were negative for SARS-CoV-2.", [["specimens", "ANATOMY", 30, 39], ["amniotic fluid", "ANATOMY", 55, 69], ["cord blood", "ANATOMY", 71, 81], ["throat swabs", "ANATOMY", 92, 104], ["breastmilk samples", "ANATOMY", 109, 127], ["SARS", "DISEASE", 171, 175], ["specimens", "CANCER", 30, 39], ["amniotic fluid", "ORGANISM_SUBSTANCE", 55, 69], ["cord blood", "ORGANISM_SUBSTANCE", 71, 81], ["throat", "ORGANISM_SUBDIVISION", 92, 98], ["swabs", "ORGANISM_SUBSTANCE", 99, 104], ["breastmilk samples", "ORGANISM_SUBSTANCE", 109, 127], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 171, 181], ["SARS-CoV", "SPECIES", 171, 179], ["specimens", "TEST", 30, 39], ["amniotic fluid", "TEST", 55, 69], ["cord blood", "TEST", 71, 81], ["neonatal throat swabs", "TEST", 83, 104], ["breastmilk samples", "TEST", 109, 127], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["amniotic fluid", "OBSERVATION", 55, 69], ["cord", "ANATOMY", 71, 75]]], ["[36] [37] [38] [39] [40] However, early-onset (<7 days) neonatal COVID-19 was found in a few neonates born to SARS-CoV-2-positive mothers ( Table 4 ).", [["SARS", "DISEASE", 110, 114], ["[36] [37] [38] [39", "SIMPLE_CHEMICAL", 0, 18], ["neonates", "ORGANISM", 93, 101], ["SARS-CoV-2", "ORGANISM", 110, 120], ["mothers", "ORGANISM", 130, 137], ["SARS-CoV", "SPECIES", 110, 118], ["neonatal COVID", "TEST", 56, 70], ["CoV", "TEST", 115, 118]]], ["Zeng et al 35 reported three SARS-CoV-2-positive neonates born to mothers with confirmed COVID-19 (Table 4 ).", [["SARS-CoV-2", "ORGANISM", 29, 39], ["neonates", "ORGANISM", 49, 57], ["mothers", "ORGANISM", 66, 73], ["CoV", "TEST", 34, 37], ["COVID", "TEST", 89, 94]]], ["34 All three of these confirmed babies were symptomatic, including fever, lethargy, respiratory distress, and pneumonia on chest images.", [["respiratory", "ANATOMY", 84, 95], ["chest", "ANATOMY", 123, 128], ["fever", "DISEASE", 67, 72], ["lethargy", "DISEASE", 74, 82], ["respiratory distress", "DISEASE", 84, 104], ["pneumonia", "DISEASE", 110, 119], ["babies", "ORGANISM", 32, 38], ["chest", "ORGANISM_SUBDIVISION", 123, 128], ["symptomatic", "PROBLEM", 44, 55], ["fever", "PROBLEM", 67, 72], ["lethargy", "PROBLEM", 74, 82], ["respiratory distress", "PROBLEM", 84, 104], ["pneumonia", "PROBLEM", 110, 119], ["chest images", "TEST", 123, 135], ["symptomatic", "OBSERVATION_MODIFIER", 44, 55], ["respiratory distress", "OBSERVATION", 84, 104], ["pneumonia", "OBSERVATION", 110, 119], ["chest", "ANATOMY", 123, 128]]], ["Their nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 and negative on day 6 or 7.", [["nasopharyngeal", "ANATOMY", 6, 20], ["anal swabs", "ANATOMY", 25, 35], ["nasopharyngeal", "CANCER", 6, 20], ["anal swabs", "CANCER", 25, 35], ["SARS-CoV", "SPECIES", 54, 62], ["Their nasopharyngeal and anal swabs", "TEST", 0, 35], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["nasopharyngeal", "ANATOMY", 6, 20], ["anal swabs", "ANATOMY", 25, 35]]], ["Additionally, both Lu and Shi 17 and Yu et al 41 also reported a total of three infected neonates born from infected mothers, and they were positive for SARS-CoV-2 tests at the ages of 30 hours, 36 hours, and 5 days after birth.", [["neonates", "ORGANISM", 89, 97], ["mothers", "ORGANISM", 117, 124], ["SARS-CoV", "SPECIES", 153, 161], ["three infected neonates", "PROBLEM", 74, 97], ["SARS", "PROBLEM", 153, 157], ["CoV", "TEST", 158, 161]]], ["Therefore, the possibility of vertical transmission from an infected mother cannot be completely excluded.", [["vertical transmission", "PROBLEM", 30, 51], ["infected", "OBSERVATION", 60, 68], ["cannot be completely excluded", "UNCERTAINTY", 76, 105]]], ["Additionally, late-onset (\u22657 days) neonatal COVID-19 was reported in three neonates between the ages of 15 and 19 days.", [["neonates", "ORGANISM", 75, 83], ["neonatal COVID", "TEST", 35, 49], ["late", "OBSERVATION_MODIFIER", 14, 18], ["-onset", "OBSERVATION_MODIFIER", 18, 24]]], ["The infectious sources included their infected mothers (n = 2) and a housemaid (Table 4) .", [["infectious", "OBSERVATION", 4, 14]]], ["[42] [43] [44] Close contact with infected persons after birth is the most probable transmission route of these late-onset neonatal COVID-19 cases.", [["persons", "ORGANISM", 43, 50], ["persons", "SPECIES", 43, 50], ["neonatal COVID", "TEST", 123, 137]]], ["All of these reported SARS-CoV-2-positive neonates recovered after management.", [["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "ORGANISM", 22, 32], ["neonates", "ORGANISM", 42, 50], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["positive neonates", "PROBLEM", 33, 50], ["management", "TREATMENT", 67, 77]]], ["Although current published reports reveal that children develop Table 3 SARS-CoV-2-positive children and teenagers younger than 20 years old in Taiwan from January 10 to April 7, 2020 10 less severe cases of COVID-19 than adults, critical deterioration or death did occur.", [["SARS", "DISEASE", 72, 76], ["COVID", "DISEASE", 208, 213], ["death", "DISEASE", 256, 261], ["children", "ORGANISM", 47, 55], ["SARS-CoV-2", "ORGANISM", 72, 82], ["children", "ORGANISM", 92, 100], ["children", "SPECIES", 47, 55], ["children", "SPECIES", 92, 100], ["COVID", "TEST", 208, 213], ["critical deterioration", "PROBLEM", 230, 252], ["death", "PROBLEM", 256, 261], ["deterioration", "OBSERVATION", 239, 252]]], ["Asymptomatic children are not tested usually for SARS-CoV-2 in many countries, so the prevalence of infected children is underestimated in the current reported data.SARS-COV-2-POSITIVE NEWBORNSUsually, younger children take part in fewer daily social activities than teenagers, and their contact opportunities with carriers or patients should thus be lower, resulting in a lower risk of getting the COVID-19 illness.", [["SARS", "DISEASE", 49, 53], ["children", "ORGANISM", 13, 21], ["SARS-CoV-2", "ORGANISM", 49, 59], ["children", "ORGANISM", 109, 117], ["children", "ORGANISM", 210, 218], ["patients", "ORGANISM", 327, 335], ["children", "SPECIES", 13, 21], ["children", "SPECIES", 109, 117], ["children", "SPECIES", 210, 218], ["patients", "SPECIES", 327, 335], ["SARS-CoV", "SPECIES", 49, 57], ["infected", "OBSERVATION", 100, 108]]], ["Although not as prevalent as those of 20-to 30-year-old adults, the social activities of teenagers, including international travelling, are still eventful.", [["adults", "ORGANISM", 56, 62]]], ["That may partly explain why the number of confirmed COVID-19 cases in teenagers is much higher than that in small children, according to data from the TCDC.", [["COVID", "DISEASE", 52, 57], ["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["COVID", "TEST", 52, 57], ["may partly explain", "UNCERTAINTY", 5, 23]]], ["In infanthood and toddlerhood, the major contacts of small children are further narrowed to their family and caregivers, and thus their COVID-19 incidence seems to be the lowest.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]], ["Nevertheless, we still need to monitor all children carefully when the COVID-19 pandemic is under today's explosive outbreak in many countries.SARS-COV-2-POSITIVE NEWBORNSIn comparison with adults, children with COVID-19 were deemed to have milder illness and a better prognosis.", [["illness", "DISEASE", 248, 255], ["children", "ORGANISM", 43, 51], ["children", "ORGANISM", 198, 206], ["children", "SPECIES", 43, 51], ["children", "SPECIES", 198, 206], ["milder illness", "PROBLEM", 241, 255]]], ["45 Although most of the originally healthy children with COVID-19 are mild, critical cases did occur.", [["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["COVID", "TEST", 57, 62], ["mild", "OBSERVATION_MODIFIER", 70, 74]]], ["When children had a chronic underlying disease, the risk of critical illness, or even mortality, rose.", [["illness", "DISEASE", 69, 76], ["children", "ORGANISM", 5, 13], ["children", "SPECIES", 5, 13], ["a chronic underlying disease", "PROBLEM", 18, 46], ["critical illness", "PROBLEM", 60, 76], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["disease", "OBSERVATION", 39, 46]]], ["Investigations into the susceptibility of children of different ages and the mechanisms of disease severity are necessary for future care of pediatric patients and disease prevention.SARS-COV-2-POSITIVE NEWBORNSSmell and/or taste disturbance is a specific symptom in some COVID-19 patients, and that require further investigations.", [["SARS", "DISEASE", 183, 187], ["taste disturbance", "DISEASE", 224, 241], ["children", "ORGANISM", 42, 50], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 281, 289], ["children", "SPECIES", 42, 50], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 281, 289], ["disease severity", "PROBLEM", 91, 107], ["disease prevention", "TREATMENT", 164, 182], ["taste disturbance", "PROBLEM", 224, 241], ["a specific symptom", "PROBLEM", 245, 263], ["further investigations", "TEST", 308, 330]]], ["In a multicenter European study among 417 mild-to-moderate COVID-19 patients, 85.6% and 88.0% of patients had olfactory and/or gustatory dysfunctions, respectively.", [["olfactory", "ANATOMY", 110, 119], ["gustatory", "ANATOMY", 127, 136], ["olfactory and/or gustatory dysfunctions", "DISEASE", 110, 149], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 97, 105], ["olfactory", "ORGAN", 110, 119], ["gustatory", "ORGANISM_SUBDIVISION", 127, 136], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 97, 105], ["a multicenter European study", "TEST", 3, 31], ["COVID", "TEST", 59, 64], ["olfactory", "PROBLEM", 110, 119], ["gustatory dysfunctions", "PROBLEM", 127, 149]]], ["46 The authors suggest that olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, and the sudden anosmia or ageusia need to be recognized as important symptoms of the COVID-19 infection.", [["olfactory", "ANATOMY", 28, 37], ["gustatory", "ANATOMY", 42, 51], ["olfactory and gustatory disorders", "DISEASE", 28, 61], ["anosmia", "DISEASE", 131, 138], ["ageusia", "DISEASE", 142, 149], ["infection", "DISEASE", 210, 219], ["olfactory", "ORGAN", 28, 37], ["patients", "ORGANISM", 106, 114], ["COVID-19", "ORGANISM", 201, 209], ["patients", "SPECIES", 106, 114], ["olfactory and gustatory disorders", "PROBLEM", 28, 61], ["prevalent symptoms", "PROBLEM", 66, 84], ["the sudden anosmia", "PROBLEM", 120, 138], ["ageusia", "PROBLEM", 142, 149], ["the COVID-19 infection", "PROBLEM", 197, 219], ["infection", "OBSERVATION", 210, 219]]], ["46 As shown in Table 3 , all three teenagers who lost smell and/or taste were diagnosed during late March 2020, and they all had a recent history of travel to Europe (Spain or the United Kingdom) in late March.", [["teenagers", "ORGANISM", 35, 44]]], ["Therefore, further researches on European COVID-19 for its special presentation and suspected higher CFR should be done.SARS-COV-2-POSITIVE NEWBORNSIsolation of confirmed or suspected cases with mild illness is also an important way to block viral transmission.", [["European COVID", "TEST", 33, 47], ["higher CFR", "PROBLEM", 94, 104], ["mild illness", "PROBLEM", 195, 207], ["mild", "OBSERVATION_MODIFIER", 195, 199], ["illness", "OBSERVATION", 200, 207]]], ["Therefore, developing accurate and rapid diagnostic techniques to identify SARS-CoV-2 patients or carriers is crucial.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79]]], ["Although real-time reverse transcription polymerase chain reaction assays remain the molecular test of choice for COVID-19 etiologic diagnosis, many new antibody-based techniques are being investigated and tried.", [["chain reaction assays", "TEST", 52, 73], ["COVID", "TEST", 114, 119]]], ["47 We hope and believe that new diagnostic ways to promote the diagnostic speed and accuracy and monitor SARS-CoV-2 viral viability will be applied in clinical situations soon and that they will help control the outbreak of COVID-19.SARS-COV-2-POSITIVE NEWBORNSPrevention is always more important than treatment in infectious diseases, especially for such a very contagious virus as COVID-19.", [["infectious diseases", "DISEASE", 315, 334], ["COVID-19", "CHEMICAL", 224, 232], ["CoV-2", "ORGANISM", 110, 115], ["accuracy", "TEST", 84, 92], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["2 viral viability", "TREATMENT", 114, 131], ["COVID", "TEST", 224, 229], ["a very contagious virus", "PROBLEM", 356, 379], ["COVID", "TEST", 383, 388]]], ["Histories of travelling to COVID-19 epidemic regions or contact with infected subjects are more important than age when judging whether or not to perform further assessments.", [["further assessments", "TEST", 154, 173]]], ["The well-known transmission routes of COVID-19 are droplet and contact transmission.", [["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "CHEMICAL", 38, 46], ["COVID", "TEST", 38, 43]]], ["Therefore, the precautionary measures for recommended for the general population should include hand washing; not touching the mouth, nose, and eyes; maintaining social distance; and wearing masks to cover the mouth and nose in public spaces.", [["hand", "ANATOMY", 96, 100], ["mouth", "ANATOMY", 127, 132], ["nose", "ANATOMY", 134, 138], ["eyes", "ANATOMY", 144, 148], ["mouth", "ANATOMY", 210, 215], ["nose", "ANATOMY", 220, 224], ["hand", "ORGANISM_SUBDIVISION", 96, 100], ["mouth", "ORGANISM_SUBDIVISION", 127, 132], ["nose", "ORGANISM_SUBDIVISION", 134, 138], ["eyes", "ORGAN", 144, 148], ["mouth", "ORGANISM_SUBDIVISION", 210, 215], ["nose", "ORGANISM_SUBDIVISION", 220, 224], ["the precautionary measures", "TREATMENT", 11, 37], ["the general population", "TREATMENT", 58, 80], ["hand washing", "TREATMENT", 96, 108], ["masks", "TREATMENT", 191, 196], ["mouth", "ANATOMY", 127, 132], ["nose", "ANATOMY", 134, 138], ["eyes", "ANATOMY", 144, 148], ["mouth", "ANATOMY", 210, 215], ["nose", "ANATOMY", 220, 224], ["public spaces", "ANATOMY", 228, 241]]], ["For medical personnel, different grades of advanced protective gowns and hats, N95 or surgical masks, goggles, and gloves should be employed liberally to protect these first-line medical providers and save more people from COVID-19.SARS-COV-2-POSITIVE NEWBORNSVaccine development for COVID-19 is the most important measure for future and long-term prevention.", [["people", "ORGANISM", 211, 217], ["people", "SPECIES", 211, 217], ["advanced protective gowns", "TREATMENT", 43, 68], ["N95", "TREATMENT", 79, 82], ["surgical masks", "TREATMENT", 86, 100], ["goggles", "TREATMENT", 102, 109], ["gloves", "TREATMENT", 115, 121], ["COVID", "TEST", 223, 228], ["COVID", "TEST", 284, 289], ["long-term prevention", "TREATMENT", 338, 358], ["advanced", "OBSERVATION_MODIFIER", 43, 51], ["protective gowns", "OBSERVATION", 52, 68], ["surgical masks", "OBSERVATION", 86, 100]]], ["An effective vaccine to rapidly induce potent and long-lasting virus-specific immune responses against SARS-CoV-2 is one of the most urgently needed weapons to fight COVID-19.", [["SARS", "DISEASE", 103, 107], ["SARS-CoV-2", "ORGANISM", 103, 113], ["SARS-CoV", "SPECIES", 103, 111], ["An effective vaccine", "TREATMENT", 0, 20], ["potent and long-lasting virus", "PROBLEM", 39, 68], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111]]], ["The characteristic structural component of the viral envelope, the virus spike (S) protein, is considered a good target for developing vaccines for COVID.", [["COVID", "DISEASE", 148, 153], ["virus spike (S) protein", "PROTEIN", 67, 90], ["the viral envelope", "PROBLEM", 43, 61], ["the virus spike", "PROBLEM", 63, 78], ["developing vaccines", "TREATMENT", 124, 143], ["COVID", "TREATMENT", 148, 153], ["structural", "OBSERVATION_MODIFIER", 19, 29], ["component", "OBSERVATION_MODIFIER", 30, 39], ["viral envelope", "OBSERVATION", 47, 61]]], ["49, 50 Evidence of their efficacy and safety in the near future to help save people's lives is eagerly awaited.SARS-COV-2-POSITIVE NEWBORNSIn conclusion, COVID-19, caused by SARS-CoV-2, has become a global health emergency since December 2019 and has increased explosively since March 2020.", [["SARS", "DISEASE", 111, 115], ["SARS-CoV-2", "CHEMICAL", 174, 184], ["people", "ORGANISM", 77, 83], ["SARS-CoV-2", "ORGANISM", 174, 184], ["people", "SPECIES", 77, 83], ["SARS-CoV", "SPECIES", 174, 182], ["SARS", "TEST", 111, 115], ["COV", "TEST", 116, 119], ["COVID", "TEST", 154, 159]]], ["Although the proportion of children infected by SARS-CoV-2 seems relatively lower, and their symptoms are relatively less severe than those of adults, a few infected children could progress to critical illness.", [["SARS", "DISEASE", 48, 52], ["children", "ORGANISM", 27, 35], ["SARS-CoV-2", "ORGANISM", 48, 58], ["children", "ORGANISM", 166, 174], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 166, 174], ["SARS-CoV", "SPECIES", 48, 56], ["their symptoms", "PROBLEM", 87, 101], ["critical illness", "PROBLEM", 193, 209], ["infected", "OBSERVATION", 36, 44]]], ["Vertical transmission from the mother to her fetus or neonate has yet to be proven, but case reports of sick neonates exist.", [["fetus", "ANATOMY", 45, 50], ["fetus", "ORGANISM", 45, 50], ["neonates", "ORGANISM", 109, 117], ["sick neonates", "PROBLEM", 104, 117]]], ["Early identification and isolation, adequate management, prevention, and vaccine development are the keys to controlling disease spread.", [["Early identification", "TEST", 0, 20], ["isolation", "TREATMENT", 25, 34], ["adequate management", "TREATMENT", 36, 55], ["prevention", "TREATMENT", 57, 67], ["vaccine", "TREATMENT", 73, 80], ["controlling disease spread", "PROBLEM", 109, 135]]], ["Further studies on the different faces of COVID-19 are required to fight this viral pandemic.", [["Further studies", "TEST", 0, 15], ["COVID", "TEST", 42, 47], ["this viral pandemic", "PROBLEM", 73, 92]]]]}